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Abstract
Methods for genetically and synthetically manipulating protein composition enable a greater flexibility in the
study of protein dynamics and function. However, current techniques for incorporating biophysical probes in
the form of unnatural amino acids (Uaas) can suffer from poor yield, limited selectivity for the desired probe,
and an insufficient understanding of the impact that the probe has on protein structure and function. Each of
the studies discussed herein addresses one or more of these shortcomings in an effort to improve the usage of
Uaas in biochemistry. We have shown that using inteins as traceless, cleavable purification tags enables the
separation of full length Uaa containing proteins from their corresponding truncation products. This method
has been used to incorporate Uaas in previously unattainable positions in a variety of proteins using a myriad
of Uaas, inteins, and purification tags. In other applications, we have used E. coli aminoacyl transferase (AaT)
to selectively modify the N-termini of proteins with Uaas to be used in native chemical ligation or “click”
chemistry reactions. Finally, we have previously used backbone thioamide modifications to enable biophysical
studies of proteins by taking advantage of their properties as fluorescence quenchers. However, the impact of
thioamides on the stability of proteins rich in secondary and tertiary structure has yet to be understood in
detail. In this work, we have conducted the most comprehensive studies to date on the effect of thioamides on
the structure and thermostability of the full-length proteins, using calmodulin and the B1 domain of protein
G. We have found that the thioamide can have destabilizing, neutral, or even stabilizing effects depending on
the position of substitution within alpha-helical and beta-sheet folds. Moreover, the advances we have made in
thioamide peptide synthesis and protein ligation will enable us to install thioamides with increased efficiency,
permitting the first syntheses of proteins with multiple thioamides. In general, by working at the interface of
several protein modification technologies, we have developed rigorous methodologies for the incorporation of
side chain and backbone modifications while scrutinizing the effects that these modifications may have on
protein structure and stability.
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ABSTRACT 
 
IMPROVING THE USAGE OF UNNATURAL AMINO ACIDS IN PROTEINS: THIOAMIDES AND 
OTHER BIOPHYSICAL PROBES 
Christopher R. Walters 
E. James Petersson 
 
Methods for genetically and synthetically manipulating protein composition enable 
a greater flexibility in the study of protein dynamics and function. However, current 
techniques for incorporating biophysical probes in the form of unnatural amino acids 
(Uaas) can suffer from poor yield, limited selectivity for the desired probe, and an 
insufficient understanding of the impact that the probe has on protein structure and 
function. Each of the studies discussed herein addresses one or more of these 
shortcomings in an effort to improve the usage of Uaas in biochemistry. We have shown 
that using inteins as traceless, cleavable purification tags enables the separation of full 
length Uaa containing proteins from their corresponding truncation products. This method 
has been used to incorporate Uaas in previously unattainable positions in a variety of 
proteins using a myriad of Uaas, inteins, and purification tags. In other applications, we 
have used E. coli aminoacyl transferase (AaT) to selectively modify the N-termini of 
proteins with Uaas to be used in native chemical ligation or “click” chemistry reactions. 
Finally, we have previously used backbone thioamide modifications to enable biophysical 
studies of proteins by taking advantage of their properties as fluorescence quenchers. 
However, the impact of thioamides on the stability of proteins rich in secondary and tertiary 
structure has yet to be understood in detail. In this work, we have conducted the most 
comprehensive studies to date on the effect of thioamides on the structure and 
viii	
	
thermostability of the full-length proteins, using calmodulin and the B1 domain of protein 
G. We have found that the thioamide can have destabilizing, neutral, or even stabilizing 
effects depending on the position of substitution within alpha-helical and beta-sheet folds. 
Moreover, the advances we have made in thioamide peptide synthesis and protein ligation 
will enable us to install thioamides with increased efficiency, permitting the first syntheses 
of proteins with multiple thioamides. In general, by working at the interface of several 
protein modification technologies, we have developed rigorous methodologies for the 
incorporation of side chain and backbone modifications while scrutinizing the effects that 
these modifications may have on protein structure and stability. 
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Section 1.1 -  Introduction to Protein Structure and Function 
The structural and functional characterization of macromolecules such as 
DNA, RNA, and proteins has vastly expanded our understanding of fundamental 
cellular processes in biology. Genetic information is stored and transmitted by DNA 
and RNA, whereas proteins carry out nearly all of the chemical transformations 
and functional tasks necessary for cells to maintain homeostasis.1, 2 Proteins are 
sequences of amino acids strung together linearly, which can arrange into larger, 
complex structural motifs. According to the Anfinsen hypothesis3, protein 
architectures (i.e. folds or conformations), are encoded by the identity of the amino 
acids in the protein sequence. The amino acid sequence can drive this folding 
event through local and global amino acid interactions in the form of intricate 
hydrogen bonding networks, removal of hydrophobic groups from bulk solvent 
(water), van der Waals forces, salt bridges, covalent bonds (e.g. disulfide bonds), 
and even weak electronic interactions (nàπ*).4-6 Helical and sheet-like motifs, 
(dubbed secondary structure) resulting from these interactions can arrange into a 
vast array of architectures (tertiary and quaternary structure) that enable a 
functional task or chemical reaction to be carried out by the protein. The folding 
process itself is fast (microseconds to hours in vitro) due to the low free-energy 
changes and small activation barriers often associated with individual folding 
steps.7, 8 Additionally, local interactions of amino acids essentially limit the 
conformational space a protein can explore. These two factors enable small 
thermodynamically favorable folding events to “funnel” the protein to a global 
energy minimum generally corresponding to its folded state (Figure 1-1). 
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Figure	1-1:	Global	protein	 folding	 landscape	depicting	 the	distinct	 intermediate	states	 that	occur	as	 the	
protein	is	‘funneled’	to	its	native	conformation.	Figure	adapted	from	work	by	Splettstoesser.9	
 
Although the widely accepted dogma from Anfinsen postulated that a single 
sequence specified a single fold for a protein, many proteins that toggle between 
multiple folded structures have been described in the literature.5, 10-12 This 
discrepancy, along with the general complexity of protein structure, makes 
predicting the structure and function of proteins based upon sequence alone a 
complex task. One must also consider that proteins are dynamic macromolecules 
that change their conformations based upon their bulk chemical environment 
(cellular environment or in vitro buffer conditions) or ligands to which they are 
covalently or electrostatically bound. These factors make mapping the dynamic 
processes and nano-scale movements of proteins, a challenging problem in 
biology and chemistry.  
There are a nearly unfathomable number of proteins that exist in nature. 
Yet, for the proteins that have been isolated, structural and dynamic details are 
constantly in flux, largely due to the continual advancements in methods used to 
study macromolecules. These studies have implications for human health, as 
Generic Protein 
Folding Landscape
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misfolded and aggregated proteins are the underlying cause of many inherited, 
neurodegenerative, and infectious diseases. These diseases include, but are not 
limited to: Cruzfeldt-Jakob disease, Alzheimer’s disease, Parkinson’s disease, 
Bovine spongiform encephalopathy (mad cow disease) and Amyotrophic lateral 
sclerosis.13  
 
Figure	 1-2:	 The	 folding	 and	 misfolding	 landscape	 that	 can	 lead	 to	 disease	 state	 aggregated	 protein	
structures	in	the	diseases	described	above.	Figure	adapted	from	work	by	Stefani.14	
 
Understanding the structural and dynamic characteristics of proteins can 
not only provide understanding as to how proteins misfold, but also insight into the 
design of therapeutic molecules for disease treatment and prevention. Additionally, 
protein targets in cancers and pathogenic diseases require a detailed 
understanding of the protein’s architecture to design molecules with high-
specificity to only that protein target. Finally, understanding the link between 
sequence, structure, dynamics, and function will allow scientists to engineer 
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proteins for biocatalysis in synthetic applications, and in the future design de novo 
proteins for applications of their choosing. 
Section 1.2 - Techniques to Observe Protein Structure, Function, and 
Dynamics 
 
 As mentioned previously, a protein’s fold can vary with chemical 
environment. Therefore, techniques for studying protein structure and dynamics 
should allow for mimicry of the native cellular environment as much as possible. 
Small disruptions to the chemical environment such as changes in salt 
concentration, solvent, pH, and concentration of the protein itself may induce non-
native folds.6 To achieve atomic resolution of protein structures, X-ray 
crystallography and nuclear magnetic resonance (NMR) spectroscopy have been 
used to great effect. Indeed, as of 2017, more than 130,000 high-resolution 
structures of proteins have been deposited online in the protein data bank (PDB).15 
Yet, only proteins that can effectively crystallize can be studied by X-ray diffraction, 
making it difficult to obtain structures of proteins that contain highly flexible, 
dynamic regions. Crystallography also inherently limits these studies to static 
snapshots of the protein that lack dynamic information and implicit hydrogen atom 
assignments.16 However, NMR can often be used in the determination of structural 
and dynamic information of an ensemble of protein conformations in solution, 
without the need for crystal lattices. For precise structure determination, NMR 
requires the isotopic labeling of proteins with 13C and 15N isotopes, which can be 
impractical on large scales.17, 18 NMR also generally has limitations in the 
molecular weight of proteins that can be studied in solution (<40 kilodaltons), as 
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large isotopically labeled proteins lead to distorted signals due to long rotational 
tumbling times, thereby making the reconstitution of protein structures difficult.19 
For higher molecular weight structures and protein complexes, electron 
microscopy (EM) could also theoretically be used to determine protein structure.20-
22 Yet, atomic resolution in EM is still difficult to achieve, with technical limitations 
enabling a threshold of 3-4 Å resolution.23 
 In vitro studies are empowering in understanding protein function, structure, 
and dynamics. However, developing in vitro methods that can be recapitulated in 
vivo may provide even more valuable tools for studying protein folding and 
dynamics in more meaningful contexts.24 Most notably, fluorescence studies of 
proteins can enable an array of biophysical experiments not accessible by X-ray 
crystallography, NMR, or EM. These experiments are at the sacrifice of lower 
structural resolution, but can be performed on much lower concentrations of 
protein (≤ 1 µM), giving them a distinct advantage over X-ray diffraction and NMR. 
Only three naturally occurring amino acids are fluorescent: Phe, Tyr, and 
Trp. However, the low quantum yield and near-UV absorbance properties of these 
amino acids makes them of limited utility in studying proteins in cells.25, 26 One 
major class of fluorescent probes are fluorescent proteins, established with the 
isolation of green fluorescent protein (GFP) from the jellyfish Aequorea Victoria.27 
The protein is 240 amino acids in length and forms an 11-strand β-barrell that 
contains the chromophore 4-(p-hydroxybenzylidene)-imidazolidin-5-one. This 
chromophore forms post-translationally from a Ser-Tyr-Gly tripeptide motif that is 
only fluorescent within the folded core of GFP. As a fluorescent probe for 
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biophysical studies, GFP can be genetically encoded at the C- or N-terminus of 
any protein without the need for specialized translational machinery or additional 
reagents. GFP was first recombinantly expressed in E. coli in 1992 and saw its first 
in vivo use in the female germ cells of Drosophila to study the role of the exu protein 
in oogenesis in 1994.28, 29  
 
Figure	1-3:	GFP	(left)	showing	 its	characteristic	β-barrel	structure	and	chromophore	(right)	formed	from	
Ser65,	Tyr66	and		Gly67.	
 
Since then, GFP has seen remarkable improvements and modifications 
including different emission and excitation wavelengths, enhanced brightness, pH 
resistance, and photoactivatable variants.30-33 There have even been split GFP 
tags attached to two protein targets where assembly of the chromophore 
containing β-barrel only occurs when two proteins of interest (POIs) bearing the 
tag come into contact with one another.34 This has been used to great effect in 
mapping neuronal networks in response to stimuli in Drosophila.35 As an in vitro 
probe, GFP has been used in a variety of techniques that include Förster 
resonance energy transfer (FRET) with other GFP variants, fluorescence 
correlation spectroscopy, fluorescence recovery after photobleaching, and even 
super-resolution techniques, such as stimulated emission depletion microscopy 
4 
is often constrained by the chemistry necessary to install a fluorescent probe, the size of 
the probe, or the location of the probe’s installation on the protein.  Development of 
fluorescent modifications for proteins has yielded a broad suite of probes and methods 
that are as structurally and spectroscopically diverse as the applications for which they 
were designed.  
 
FLUORESCENCE AS A MINIMALLY PERTURBING METHOD FOR 
MONITORING PROTEIN DYNAMICS 
 
Figure 1.1: Chromophore Size. Space-filling renderings of several chromophores, based on either crystal 
structures or ab initio calculations. The green fluorescent protein (GFP) was rendered from PDB ID 1GFL9. 
The benzylated SNAP tag protein was rendered from PDB ID 3L00 (S. Schmitt, B. Mollwitz, F. Pojer, M. 
Green Fluorescent 
Protein
HO N
N
OO
N
H OH
Tyr66
Gly67
Ser65
4-(p-hydroxybenzylidene)-
imidazolidin-5-one	
chromophore
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and photoactivated localization microscopy.36-38 For all the gains in understanding 
of biological processes GFP has provided, its usage is inherently limited by its size. 
Fusing GFP to a protein of interest could disrupt the processes one wishes to 
observe, especially when the protein is of similar or smaller in size than the GFP. 
This size also makes it difficult to monitor smaller dynamic movements of the 
protein that may be captured in high-resolution techniques like NMR. Additionally, 
photostability of GFP is an issue; GFP readily photobleaches, making small 
molecule fluorophores that have better photostability more desirable.  
 Genetically encoded proteins that can be covalently linked with fluorescent 
small molecules can provide an alternative to fluorescent proteins. Several 
modified enzymatic tags have been developed to this end, with SNAP-tag, CLIP-
tag, and HALO-tag being the most widely used. SNAP-tag is a mutant of the 
enzyme O6-alkylguanine-DNA alkyltransferase that can recognize and covalently 
link to benzylguanine groups with high specificity.39 Similarly, CLIP-tag uses a 
modified enzyme to covalently bond with benzylcytosine substrates.39 HALO-tag 
utilizes a mutant haloalkane dehalogenase to covalently link to an alkyl chloride 
substrate.40  Here, any synthetic, small molecule fluorophore can be chosen by the 
user, provided that they can be synthesized as benzylguanine, benzylcytosine, or 
alkyl chloride derivatives. This allows for fluorescently tagged proteins with a larger 
range of spectrochemical properties, but these proteins are again large in size (~20 
kDa) and may influence the dynamics, fold, and function of the proteins they are 
attached to.  
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Figure	1-4:	SNAP-Tag	(left)	and	CLIP-Tag	(right)	attached	to	a	protein	of	interest	(POI).	Labeling	reactions	
proceed	 through	 covalent	 modification	 of	 a	 Cys	 residue	 with	 fluorescently	 tagged	 (red	 stars)	
benzylguanosine	and	benzylcytosine	substrates,	respectively.		
 
 The restrictions of these fluorescent and taggable proteins that arise from 
their size can be overcome by finding methods to modify single or multiple amino 
acids as local “tags” to enable tracking of smaller dynamic movements. By making 
changes at specified amino acid locations, one can potentially minimize the non-
native perturbations these probes have on protein structure. Modifications at amino 
acids also enable site-specific molecular contacts to be mapped in protein-ligand, 
intermolecular protein-protein, and intramolecular protein domain interactions.41 
The remaining portion of this introduction will focus on the site-specific 
incorporation of canonical and non-canonical mutations to proteins and how these 
modifications have enabled a wide array of protein engineering, therapeutic 
development, and biophysical structure/function studies of POIs.  
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Section 1.3 – Amino Acid Modifications and Chemoselective Reactions for 
the Labeling and Biophysical Studies of Proteins  
 
 Modifications to the side chains and backbones of amino acids is one of the 
most powerful and widely used strategies available to protein scientists. 
Technologies enabling chemical changes to side chains give access to site-
specifically installed post-translational modifications (PTMs), biophysical probes, 
affinity tags, and many other modifications.24 These changes can enable the study 
of protein folding as it relates to disease, protein-protein interactions in proteomics 
applications, protein engineering, and various other applications. This section 
briefly summarizes the types of side chain modifications that are of use to the 
biochemical community, with a focus on those that enable biophysical studies of 
protein folding and misfolding phenomena. 
Post-translational Modifications 
 PTMs are modifications that can be transferred to side chains containing 
functional groups either co-translationally or after the protein is released from the 
ribosome. These modifications can be as small as methyl groups or as large as 
small proteins and have been found to occur on the side-chains Arg, Asn, Cys, 
Gln, Glu, His, Lys, Pro, Ser, Thr, Trp, and Tyr.42 The most common PTMs are (in 
order of occurrence) phosphorylation (Ser, Thr, Tyr, His, Lys, and Arg), acetylation 
(N-terminus, Lys), N-linked glycosylation (Asn), amidation (N-terminus, Asp, Glu, 
and Cys), hydroxylation (Lys or Pro), methylation (Arg or Lys), O-linked 
glycosylation (Ser or Thr), ubiquitylation (Lys), and sulfation (Tyr).42 These 
modifications often control the enzymatic activity of central metabolic enzymes, 
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highlighting their functional importance in regular cellular processes. The 
installation of site-specific PTMs both in vitro and in vivo has enabled researchers 
to map the functional relevance of single or multiply modified proteins without 
complications from undesired off-target PTMs. These studies include the 
interactions of histones with chromatin, nuclear transport processes via GTPase 
acetylation, and the ubiquitylation processes of many other proteins, along with a 
myriad of other studies.43 Additionally, amino acids bearing non-hydrolyzable 
mimics of PTMs have been used to decipher cell signaling pathways.44 PTMs are 
naturally occurring modifications that can inform about enzymatic and cellular 
processes in general, but an additional repertoire of amino acid side chain variants 
are necessary if one wishes to deconvolute specific, complex biochemical 
interactions in detail. 
Fluorescent Amino Acids 
 One class of Uaas that can assist in the tracking of protein trafficking and 
protein-protein interactions are fluorescent amino acids. These amino acids 
contain, in general, polyaromatic side chains with varying fluorescent properties. 
To date, several classes of fluorescent molecule cores have been synthesized as 
amino acids and incorporated into proteins such as: coumarins, phenylalanine 
derivatives, acridones, naphthalenes, dansyls, and others.24 Fluorescent amino 
acid scaffolds can be chemically modified to enhance the properties desired for a 
chosen experimental technique. Properties of interest are the wavelength of 
excitation and emission maxima, extinction coefficient (ε), quantum yield (Φ), 
12	
	
fluorescence lifetime, pH dependent fluorescence and in the case of dansyl and 
naphthalene derived scaffolds, solvatochromatic shift.45-47  
 
Figure	 1-5:	 Top:	 Fluorescent	 canonical	 amino	 acid	 side	 chains	 phenylalanine	 (Phe),	 tyrosine	 (Tyr),	 and	
tryptophan	(Trp).	Bottom:	A	non-exhaustive	list	of	example	fluorescent	unnatural	amino	acids	including	(7-
methoxy-coumarin-4-yl)-alanine	 (Mcm),	 dansyl	 alanine	 (DansA),	 6-propionyl-2-(N,N-dimethyl)-
aminonapthalene	(Anap),	acridon-2-ylalanine	(Acd),	4-cyano-phenylalanine	(Cnf),	and	5-cyano-tryptophan	
(TRPCN).	
 
Fluorescent Uaas generally have more ideal properties for biophysical 
studies than the naturally occurring fluorescent amino acids Phe, Tyr, or Trp. 
Furthermore, the sidechains are often small enough that it is unlikely they will 
provide the perturbations to protein structure that are more commonly associated 
with fluorescent proteins. One can use fluorescence quenching studies such as 
Förster resonance energy transfer (FRET) or photoinduced electron transfer (PeT) 
to obtain distance dependent measurements between side-chains, enabling 
intramolecular and intermolecular contacts to be deconvoluted using minimal 
modifications to the protein.48 Other applications of fluorescent amino acids include 
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metal-binding studies and cellular and subcellular localization studies through the 
use of fluorescence microscopy.49 However, many of these fluorescent Uaas have 
short excitation wavelengths, making them non-ideal for uses in vivo as UV 
irradiation can damage cells.50 Yet, derivatization of fluorescent amino acid cores 
and improved rational design of fluorescent molecules means there is sufficient 
variety such that one can often choose an amino acid with properties appropriate 
for the application at hand. 
 
Photocrosslinking Amino Acids 
 Sidechains bearing UV-activatable photocrosslinkers may be valuable in 
identifying protein binding partners and determining a residue’s role in protein-
protein or protein-ligand interactions.  In total, cohorts of UV-crosslinking studies 
can generally inform on the global topographical positioning of protein-protein 
interactions. The light triggered reaction allows for temporal and spatial control of 
the reaction, providing several advantages over chemical crosslinking methods.41 
Several classes of photocrosslinkers are available, with the most common being 
p-benzoyl-phenylalanine (Bpa), which can trap protein-protein or protein-ligand 
interactions through insertion of the benzophenone diradical into C-H bonds in both 
proteins and DNA.51, 52 Additionally, aziridine containing lysine, phenylalanine, and 
methionine-like residues, along with p-azidophenylalanine (Azf), can eliminate 
nitrogen in a phototriggered process to form a carbene or nitrene intermediate, 
which can insert into C-H, N-H, or O-H bonds.41 These photocrosslinking amino 
acids have been used in detailing protein-DNA binding sites in chromatin-histone 
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interactions, showing contacts between the active mitochondrial protein 
translocation gate (TOM complex) and its translocating substrates, as well as 
giving quantitative readouts on a host of histone modifications that controlled 
chromosome hypercondensation during mitosis.53-55 The broad usage of 
photocrosslinking amino acids amongst varied protein-protein and protein-DNA 
substrates shows their versatility in biochemical studies. However, the resulting 
covalent linkage between the two interacting molecules is irreversible, making 
binding-dissociation studies unfeasible. As with many of the fluorescent probes, 
these amino acids require near-UV light to generate the radical crosslinking 
species, making them difficult to use in vivo due to cellular toxicity. Despite this 
limitation, there have still been several studies performed where 
photocrosslinkning has been done in vivo using short irradiation times.56, 57 
 
Figure	 1-7:	 Commonly	 used	 photocrosslinking	 amino	 acids	 for	 covalently	 linking	 intermolecular	 or	
intramolecular	contacts	of	proteins.	From	left	to	right:	p-benzoyl-phenylalnine	(Bpa),	p-azidophenylalanine	
(Azf),	 4’-(3-trifluoromethyl)-3H-diazirin-3-ylphenylalanine	 (TmdPhe),	 photo-methionine	 (PhotoMet),	 and	
photo-lysine	(PhotoLys).	
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Each of the aforementioned amino acid derivatives (PTMs, fluorophores, 
and photocrosslinkers) have stand-alone functional groups enabling the probing of 
biochemical phenomena. However, size and functional group identity may make 
the cotranslational introduction of these amino acids difficult (see Section 1.3 on 
genetic code expansion). Additionally, it may be useful to temporally or spatially 
control the addition of a modification to the side-chain of an amino acid embedded 
in a protein to capture a desired process or biomolecular interaction. The 
burgeoning field of chemoselective reactions for protein labeling has provided a 
host of new techniques enabling the post-translational insertion of virtually any 
probe for these types of applications. 
Cysteine Mediated Labeling of Proteins 
One strategy for installing unnatural functionalities on side-chains of amino 
acids is cysteine (Cys) mediated conjugation. Site-selective modification can be 
achieved by genetically encoding a Cys residue at virtually any position within a 
protein. Linkages to the Cys sulfur can be performed by disulfide formation with 
the target modification or through simple alkylation via a SN2 reaction with an alkyl 
halide.58 However, these reactions may be difficult to control and may lead to off 
target labeling of protein substrates, especially when a protein contains multiple 
Cys residues. Cys can also be converted to dehydroalanine through treatment with 
α,α’-dibromo-adipyl(bis)amide.59 This dehydroalanine can then be selectively 
labeled with alkyl halides through a radical initiated process.60 This is a versatile 
method for post-translationally modifying the protein but leads to racemization of 
the target amino acid site.  
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Figure	1-8:	Site	selective	modifications	of	cysteine	residues	as	discussed	in	the	text.	The	modification	(red	
star)	 can	 be	 an	 array	 of	 fluorophores,	 affinity	 handles	 (e.g.	 biotin),	 and	 in	 alkylation,	 disulfide,	 and	
dehydroalanine	labeling	reactions,	post-translational	modification	mimics.	
 
Cys residues are sufficiently ‘soft’ nucleophiles that they can undergo 1,4-
conjugate addition with α, β-unsaturated carbonyls. The most widely used method 
for labeling Cys is the Michael addition of the Cys sulfur to a maleimide, which can 
contain the desired biochemical or biophysical probe linked to the maleimide 
nitrogen.61 Cys-maleimide reactions have been used in the conjugation of 
therapeutic small molecules to antibodies, fluorescent dyes to proteins for 
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fluorescent tracking, and biotin to proteins of interest for streptavidin pull-down 
studies.61 Additionally, Pentelute and coworkers have devised nucleophilic 
aromatic substitution reactions using polyfluorinated aromatic probe molecules as 
a selective Cys labeling method in Phe-Cys-Pro-Phe labeling tags.62 Buchwald 
and Pentelute have even ambitiously pioneered the palladium based cross-
coupling of the Cys thiol to aryl halides.63 However, in each of these strategies, it 
is difficult to control site-specific Cys conjugation in proteins that contain other 
native Cys residues. Additionally, the Cys residue must be sufficiently solvent 
accessible for an encounter with the target labeling molecule. Since Cys has a low 
natural occurrence in proteins64, may perturb the structure of the protein at point 
mutant insertion points65, or cause unwanted disulfide formation, other more 
selective protein conjugation reactions have been developed.  
Chemoselective Reactions Using Non-native Functional Groups 
Chemoselective reactions using Uaas must meet the following criteria: 1) 
the functionality installed in the protein and the probe must react with one another 
selectively in the presence of all other chemical functionalities observed under 
physiological conditions, 2) the reaction products contain a covalent linkage that is 
stable, and 3) byproducts or reagents used in the reaction must not interfere with 
the function of the biomolecule or the processes to be studied.24 If these criteria 
are met, a single chemical reaction can theoretically be used for labeling a diverse 
set of biomolecules with virtually any probe both in vitro and in vivo.58 Additional 
criteria that may be desired for individual applications are fast kinetic rates of the 
labeling reaction, low cytotoxicity for in cellulo studies, and few equivalents of 
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probe molecule necessary for complete labeling, among others. Owing to their high 
chemoselectivity in the presence of all other biologically relevant functional groups, 
these reactions are more colloquially referred to as ‘click’ chemistry reactions, a 
term coined by B. Sharpless in 1998.66 
Perhaps the most powerful and popular development in chemoselective 
reactions came when azide-alkyne [3+2] cycloadditions were first applied to 
biological systems (see Figure 1-9). First described in the mid-20th century, this 
cycloaddition required high temperature and pressure to form the triazole 
product.67, 68 However, in 2002, the catalysis of this reaction by copper(I) salts 
using terminal alkynes and azides was first described for the selective formation 
of 1,4-disubstituted 1,2,3-triazoles.69-71 Azides and alkynes are generally stable 
under physiological conditions, are not found in biochemical systems, and are 
synthetically accessible when functionalizing probe molecules. The Cu(I) 
catalyzed reaction is also faster in water than in organic solvents, however for 
cellular applications, Cu(I) has shown high cytotoxicity in both mammalian and 
bacterial cells due to the copper mediated generation of reactive oxygen 
species.72, 73 Unfortunately, azide-alkyne cycloaddition rates decrease to unusable 
levels when limiting the amount of copper catalyst, making the reduction of Cu(I) 
species not a viable strategy for limiting toxicity when labeling proteins in cellulo.74 
However, many water soluble Cu(I) ligands, such as tris[(1-hydroxypropyl-1H-
1,2,3-triazol-4-yl)methyl]amine (THPTA), have been applied to this methodology 
to increase reaction rates and limit the amount of free copper necessary for the 
reaction to occur.75 In fact, routine Cu(I) mediated ‘click’ reactions often have rate 
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constants of the magnitude of 105 M-1 s-1. However, in many cases cytotoxicity is 
still an issue and the copper salt may also induce off target pathway activation that 
may interfere with physiologically relevant studies. Nonetheless, the landmark 
development in the use of Huisgen cycloaddition reactions is one of the most 
effective chemoselective reactions for the in vitro labeling of biomolecules, where 
toxicity is not a factor. Indeed, these labeling reactions have spanned a variety of 
substrates on viruses, proteins, lipid membranes, and nucleic acids.24  
To circumvent the need for copper in ‘click’ chemistry reactions, Bertozzi 
and coworkers used a strained alkyne (difluorooctyne) to chemoselectively react 
with a terminal azide.76, 77 The destabilization of the alkyne through ring-strain and 
the electronic induction of the geminal difluorine motif provide the driving force for 
the reaction. Other octynes, including dibenzocyclooctynes (DBCO) and 
biarylazacyclooctynes (BARAC), have been used in these “strain promoted 
alkyne-azide cycloadditions (SPAAC).” However, these reactions are generally 
slower than the Cu(I) mediated reactions by several orders of magnitude (k = ~0.2 
M-1 s-1) and the synthesis of octyne containing probes for labeling proteins can 
often be challenging.78, 79 Thus, alternative cycloaddition reactions have been 
investigated for their use in ‘click’ chemistry. 
Although many other variations on these cycloaddition reactions have been 
used for chemoselective labeling of biomolecules, the fastest strain-promoted, 
metal free reaction to date is the strained alkene/alkyne-tetrazine reaction. These 
inverse-electron-demand Diels-Alder [4+2] cycloadditions can have rate constants 
on the order of 103-104 M-1 s-1 in the cases of substrates such as norborenes and 
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trans-cyclooctenes. They produce a stable 1,4-dihydropyridizine and are 
‘bioorthogonal’ to physiological alkenes.80-82 These versatile probes have now 
been used to both image and modify proteins in bacteria and mammalian cells with 
no apparent cytotoxicity.83, 84 Indeed, other smaller, strained alkenes, such as 
methylcyclopropene derivatives, have also been used in tetrazine Diels-Alder 
reactions.85 The development of faster cycloadditions that are biocompatible will 
enable the usage of these probes in even more diverse settings in the future. 
 
Figure	 1-9:	 Selected	 ‘click’	 chemistry	 reactions.	 Top:	 Copper	 catalyzed	 Huisgen	 cycloaddition	 between	
protein	 containing	 an	 azide	 and	 an	 alkyne	 containing	 probe	 molecule.	 Tris[(1-hydroxypropyl-1H-1,2,3-
triazol-4-yl)methyl]amine	(THPTA)	is	used	as	a	water	soluble	ligand	to	for	the	copper	catalyst.	Middle:	Strain	
promoted	alkyne-azide	cycloaddition	(SPAAC)	between	a	protein-azide	and	biarylazacyclooctyne	(BARAC).	
Bottom:	 Inverse-electron-demand	 Diels-Alder	 cycloaddition	 between	 a	 protein	 containing	 a	 trans-
cyclooctene	modified	side	chain	and	a	tetrazine	containing	probe	molecule.	
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Although the focus of this section was the use of cycloaddition reactions as 
chemoselective labeling methods, there have been a host of other reactions 
suitable for bioconjugation. Aldehydes and ketones have been used in conjunction 
with amines and hydroxylamines for reversible labeling of proteins through imine 
and oxime formation.86 Additionally, aldehydes have also been used in Pictet-
Spengler rearrangements with tryptamine bearing probes.87, 88 The aldehyde 
moiety has even found use in linking proteins to phosphonium ylide containing 
probes through Wittig reactions.89 In another vein, terminal azides, a functionality 
that has most often been used in cycloaddition reactions, can also be treated with 
phosphine reagents to undergo Staudinger reactions. The most effective example 
is when the azide is treated with a phosphine reagent to form an aza-ylide, which 
can subsequently rearrange to give an amide-linked bioconjugation that is free 
from the phosphine-oxide byproduct.90 This reaction has been dubbed the 
“traceless” Staudinger ligation. Finally, even organometallic cross coupling has 
found use in the labeling of proteins with probe molecules.91 In one such example, 
a protein containing a p-iodophenylalanine was reacted with a fluorescent boronic 
acid derivative to label proteins on the surface of E. coli. This Suzuki-Miyaura 
reaction can be performed in aqueous buffer at pH 8.0 with Pd(OAc)2 or Pd(NO3)2 
as a catalyst. With the usage of Pd(NO3)2, these cross couplings have even shown 
limited toxicity to cells.92 
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Figure1-10:	Wittig	 labeling	of	 a	 protein	with	 an	 alkene	 containing	phosphonium	ylide	 (Top)	 and	Pictet-
Spengler	type	rearrangement	with	a	fluorophore	(blue	star)	containing	tryptamine	derivative	(Bottom).	
 
With the ever-growing need to label biomolecules, it is no surprise to see 
the imaginative and ingenuitive array of chemical reactions that have been 
optimized for chemoselectivity in the aqueous and chemically rich environment of 
proteins, cells, and even entire animal hosts. These tools are constantly improving 
and with their development, protein scientists will continue to expand the 
knowledge landscape of biophysics, biochemistry, and medicine at a rapidly 
increasing pace.  
Backbone Modifications to Amino Acids 
 Side chain alteration is not the only tool available for changing a peptide or 
protein’s amino acid composition in order to engineer new conformations, study 
folding properties, or monitor biomolecule interactions. Modifications to the protein 
backbone in the form of amide isosteres or amino acids containing additional 
O O
O
O
PPh3H
O
O
O
H2O/t-BuOH
O O
H
O
N
O NH
NHO
ON
N
O
H
N
Wittig Labeling
Pictet-Spengler
Labeling
23	
	
methylene units have been studied in detail for their propensities to fold into 
ordered secondary and tertiary structures found in proteins (e.g. arranged sheets 
and helices). Any set of polymers, including those which contain amino acid 
backbone modifications, which have the propensity to fold into a specific compact 
conformation were dubbed  “foldamers” by Gelman in 1998.93  
 Early exploration into the design of foldamers centered around β-amino 
acids, which have similar architecture to α-amino acids but contain one extra 
methylene unit in the backbone. Seebach and Gelman simultaneously published 
reports of β-amino acid peptides adopting helical structures in 1996.94, 95 Following 
this report, substitution patterns of β-amino acids (β3, β2, and β2,3) have been 
explored to gain a more comprehensive understanding of how β-amino acids affect 
the folding of helical structures.96, 97 Even though they are less synthetically 
accessible than their α and β counterparts, γ-amino acids have even been used in 
combination with α- and β-amino acids to yield folded, stable helices.98 New 
classes of cyclic β-amino acids have also been developed and can lead to distinct 
changes in folding propensities depending on the site of incorporation.94, 97, 99 The 
applications of foldamers are numerous, but have recently been emphasized as 
possible therapeutics, due to enhanced resistance to proteolysis.100 This is clear 
in the design of hormone therapeutics that have an increased half-life in vivo. A 
prime example is the peptide hormone GLP-1, which can be used to treat type-II 
diabetes.101, 102 In this case, αααβ substitution patterns with cyclic β-amino acids 
enabled the foldamer to adopt the appropriate conformation for activity and 
increased the hormone’s resistance to proteolysis. 
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Figure	 1-11:	 Selected	 backbone	modifications	 as	 found	 in	 Reinert	et	 al.	 and	Gopalakrishnan	et	 al.98,	 103	
Backbone	modifications	can	be	used	to	probe	the	structure	and	function	of	proteins	as	well	as	mimic	protein	
structure	in	polymer/foldamer	formation.	
	
Although β- and γ-amino acids are useful backbone alterations, additional 
work has been performed by modifying α-amino acids or using amide bond 
isosteres. In the former, aminoisobutyric acid (Aib), D-amino acids, N-methyl 
modified, or α-peptoids have all been used to confer different folding properties to 
polypeptide foldamers (see Figure 1-11). Amide isosteres such as oxoesters and 
thioamides have also been used in biophysical studies as α-amino acid 
replacements. More exotic isosteres including alkene, thioether, α-aza, and 
triazole linkages have also found usage in foldamers as backbone amide 
replacements.98 Each of these linkages have different conformational preferences, 
size, chemical stabilities, and physical properties. 
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Having a wide array of chemical functionalities as backbone replacements 
allows the user to tailor the substitution to the desired conformation and properties 
of the envisioned foldamer for applications to an array of biochemical processes. 
However, there is much still to be uncovered in translating predicted and 
theoretical folding properties into practical usage. αβ-mixed folds (among others, 
see review from Reinert and Horne)98 have been reported by mixing canonical 
amino acids with a variety of α- and β-amino acid backbone modifications. Yet, 
there is still a vast amount of work to be performed before partially, or even 
completely ‘synthetic’, functional proteins can be designed and engineered. For 
the time being however, these backbone replacements can still be powerful tools 
in studying the hydrogen bonding networks and functional importance of individual 
amino acids within protein structures.  
Section 1.3 – Cellular Incorporation of Unnatural Amino Acids 
 In order to reap the benefits of the chemoselective reactions (discussed in 
Section 1.3) and apply them to protein labeling, techniques have been developed 
to use endogenous cellular machinery to cotranslationally insert Uaas into growing 
peptide chains. This requires that the Uaa can be recognized and faithfully 
incorporated by the translational machinery. If it cannot, then extensive 
engineering may be required to enable cellular incorporation in a site-specific 
manner. Currently, two distinct strategies exist to accomplish cellular incorporation 
of Uaas: 1) incorporation through selective pressure and 2) genetic code 
expansion.  
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Selective Pressure Incorporation 
 Selective pressure was first demonstrated in the 1950s, where total 
replacement of methionine with selenomethionine was accomplished in E. coli.104 
In selective pressure incorporation, the substitute amino acid (generally a Uaa) 
globally replaces a natural amino acid through genetic incorporation. Additionally, 
the Uaa must be a substrate of the aminoacyl-tRNA-synthetase (aaRS) that is 
used for the natural amino acid’s incorporation. During expression of the protein, 
the Uaa must be present within the cell at high levels to achieve quantitative 
incorporation.105 Auxotrophic bacteria, which lack the components necessary for 
the target amino acid synthesis, are grown in the presence of Uaa enriched media 
to achieve incorporation. Auxotrophic strains of E. coli have been used in the 
reassignment of Ile, Leu, Met, Phe, Pro, and Trp.24 As previously discussed, azides 
and alkynes are functional groups that are desirable for ‘click’ chemistry reactions. 
Selective pressure incorporation has been used to incorporate these functionalities 
in place of Met, as well as Leu and Phe. Uaas with ‘click’ chemistry handles used 
for incorporation at Met can be azidohomoalanine (Aha), homopropargylglycine 
(Hpg), and homoallylglycine (Hag).106-108 However, there are several amino acids 
that are not tolerated for replacement by cellular machinery; mutations to the aaRS 
must be made to increase the scope of Uaas that can be incorporated by selective 
pressure. An excellent example of this was in the mutational screening of the Phe 
aaRS (PheRS) from E. coli. Here a single mutation can be made (A294G) to make 
the PheRS more permissive. Overexpression of a plasmid encoding this mutant 
PheRS can allow for faithful incorporation of a number of Phe cognates, such as 
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p-ethynylphenylalanine and p-azidophenylalanine, each of which can be used in 
the labeling of proteins via ‘click’ chemistry.109 Although used to great effect for the 
substitution of canonical amino acids, site-specific changes that don’t involve 
global replacement are nearly impossible to achieve with this technology. Thus, 
recent efforts have been focused on the expansion of the genetic code for single 
and, in some cases, multiple site-specific substitutions, while retaining all other 
canonical amino acids. 
Genetic Code Expansion 
To expand the genetic code, one must envision the reassignment or 
insertion of codons that can be translated using reconstituted translational 
machinery in vitro or even in concert with canonical translation in cellulo or in vivo.  
According to Lang and Chin, the three requisites of expanding the genetic code 
are the generation of an aaRS/tRNA pair that can operate orthogonally to cellular 
aaRS/tRNA pairs, a “blank” codon that encodes for insertion of the Uaa into the 
growing peptide chain, and specificity of the aaRS/tRNA to ensure that no 
canonical amino acid cognates are aberrantly incorporated.24  To achieve these 
lofty goals in living cells, Peter Schultz and coworkers developed an initial method 
for Uaa incorporation into proteins translated by E. coli through stop-codon 
suppression in 2001.110 Here, a TyrRS/tRNATyr pair from Methanocaldococcus 
jannaschii was modified to allow for the incorporation of O-methyl-tyrosine into the 
β-lactamase enzyme at the site of an amber stop codon (UAG) that was inserted 
in place of a codon coding for a non-essential Ala residue. The ribosome can ‘read 
through’ the stop codon on the basis that the aminoacylated tRNA containing the 
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Uaa has high affinity for the UAG codon even though it must compete with 
termination machinery such as release factors (see Chapter 2). A number of 
aaRS/tRNA pairs have now been described for this process, with the most popular 
systems being the aforementioned M. jannaschii TyrRS/tRNACUA pair, the E. coli 
TyrRS/tRNACUA and LeuRS/tRNACUA pairs, as well as the pyrolysylRS/tRNACUA 
pair from Methanosarcinae.111  
 
Figure	 1-12:	 Amber	 stop	 codon	 suppression.	 An	 orthogonal	 aminoacyl	 synthetase-tRNA	 pair	 directs	
insertion	of	an	Acd	unnatural	amino	acid	within	the	protein	of	interest	at	the	site	of	the	amber	termination	
codon.	Figure	courtesy	of	Itthipol	Sungwienwong.	
 
Several systems now exist to allow for the evolution of these aaRS/tRNA 
pairs to ensure specificity for the desired Uaa. This has enabled the incorporation 
of Uaas bearing ‘click’ chemistry handles, PTMs, fluorescent side chains, 
photocrosslinker side chains, and other moieties of interest for the system to be 
studied. However, not every aaRS/tRNA pair can be ubiquitously used across cell 
types. In point of fact, pyrolysylRS/tRNACUA is the only aaRS/tRNA pair that is 
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orthogonal to cellular processes in bacterial and eukaryotic cells.112 However, in 
eukaryotic and mammalian cells, transcriptional machinery is often much more 
complicated than in bacterial cells and can lead to inefficient usage of stop codon 
suppression. To improve and optimize the genetic code expansion methodology, 
it is important that additional read through codons are developed. To this end, there 
have been preliminary reports demonstrating the feasibility of using opal and ochre 
codons (UGA and UAA, respectively) to direct insertion of Uaas into proteins in 
cellulo.113 In an even more ambitious venture, Guo and Schultz have even shown 
that four base (quadruplet) frameshift codons can be used in place of stop 
codons.114 
 Other equally ambitious ventures using orthogonal ribosomes in E. coli have 
yielded remarkable results in advancing genetic code expansion technology.115 
These ribosomes can function independently to translate an orthogonal set of 
genetic sequences as they are not involved in the translation of the cellular 
proteome. The important application of this technology is not only the ability of this 
ribosome to read through amber stop codons, but also the ability to read 
quadruplet codons using an extended anti-codon system that cannot be read 
efficiently by the native ribosome.  
 The blossoming of genetic code expansion in the last fifteen years has 
enabled selective incorporation of over 100 Uaas into virtually any protein system 
in a myriad of organisms for applied biochemical and biophysical studies.41 
Although revolutionary in the quest for efficient Uaa incorporation methodologies, 
genetic code expansion can still be difficult to use. In stop codon read through, the 
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endogenous host machinery is constantly competing for termination of protein 
synthesis at the stop codon site.116, 117 Truncated protein byproducts and the 
aberrant insertion of Uaas at other stop codon sites within the cell may compromise 
cell-health or lead to diminished protein yield. Indeed, these challenges have still 
been a major roadblock for scalable Uaa incorporation by E. coli in bioreactors for 
industrial applications (e.g. Uaa containing therapeutics).118 This is especially true 
for proteins where it may be advantageous to include multiple Uaas through 
multiple stop codon read through events. For mammalian cells, additional 
accommodations must be made when considering the delivery of genetic material 
to these cells and expression levels of the aaRS/tRNA pair.119 Genetic code 
expansion is becoming a more ubiquitous technology in chemical biology, 
necessitating quick progress towards solutions to these problems. Additionally, as 
progress in other fields of Uaa incorporation is made (e.g. protein synthesis and in 
vitro enzymatic Uaa insertion), combinatorial Uaa incorporation may be possible 
for systems that suffer from the few, yet important, issues that have yet to be 
completely solved in genetic code expansion. 
 
Section 1.4 – Chemical Ligation for the Synthesis of Proteins 
Chemical reactions used for the formation of amide bonds or amide bond 
surrogates between long protein or peptide fragments have enabled a surge in the 
total chemical synthesis or semisynthesis of proteins containing synthetic 
modifications that may be unachievable by other Uaa incorporation methods. 
Although solid phase peptide synthesis (SPPS) has been used in many classical 
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examples to synthesize a variety of proteins in their entirety120-122, it commonly 
suffers from low isolated yields in targets greater than 50 amino acids in length 
due to low coupling efficiencies from on-resin aggregation and sequence specific 
steric interference. The development of chemoselective condensation reactions for 
the ligation of peptide fragments can overcome these issues by keeping the length 
of peptides generated in SPPS shorter, thereby increasing the yields of the total 
synthetic process. In the following section, the scope, limitations, and 
improvements of chemical ligation strategies for the synthesis of proteins will be 
discussed in detail to establish a basis by which Uaas can be incorporated into 
proteins through synthetic means. A thorough review of strategies for the synthesis 
of proteins that do not use thiol-thioester based capture reactions (keto-acid, 
Staudinger, alkyne-azide, thioether, oxime ligations, and Ser/Thr ligations, among 
others) can be found in detail elsewhere.123, 124 
 
Native Chemical Ligation (NCL) 
Native chemical ligation (NCL) specifically refers to a ligation reaction in 
which two protein fragments are linked together by an amide bond (i.e. a “native” 
peptide bond). The ideal reaction would be performed under mild conditions, such 
as low temperature, aqueous buffer, and few chemical additives. These conditions 
would potentially avoid degradation of the target protein product. Because this 
technique often employs protein fragments made by SPPS, any number of Uaas 
may be incorporated, thereby avoiding the potential pitfalls of Uaa mutagenesis 
(see Section 1.3). This methodology was first realized in a study by Kent and 
32	
	
coworkers in 1994, wherein they synthesized the 72 amino acid protein target 
interleukin-8 (IL-8).125 The pioneers of this technique utilized a C-terminal peptide 
containing a N-terminal Cys residue as a nucleophile and a N-terminal peptide 
fragment containing a C-terminal thioester as an electrophilic site. As shown in 
Figure 1-13, the Cys thiol group attacks the thioester in a transthioesterification 
step, liberating a free thiol. This is followed by an intramolecular SàN acyl shift to 
reveal the native amide bond between the Cys residue (C-terminal fragment) and 
the C-terminal residue of the N-terminal fragment. These reactions are typically 
performed in high concentrations of denaturant to prevent aggregation of the 
peptide fragments. A particular advantage of this method is that it can be 
performed on unprotected peptides, with neither the nucleophile nor electrophile 
requiring any orthogonal protecting chemistry. Additionally, thiol additives can be 
used as catalysts to increase the reactivity of the thioester by exchange of the thiol 
and therefore increase the yield of the reaction. Aryl thiols such as thiophenol and 
4-mercaptophenylacetic acid (MPAA), are most commonly used in this capacity 
however, alkyl thiols such as benzyl mercaptan, sodium 2-
mercaptoehtanesulfonate (MESNa), and even 2,2,2-trifluoroethanethiol have also 
been used.126-128 
Since its advent, this powerful technique has been used in a myriad of 
syntheses of site-specifically modified proteins for use in biophysical and 
biochemical studies. Notable examples include the synthesis of phosphorylated 
proteins (TGF-β)129, lipoproteins (Rab GTPase)129, acetylated and ubiquitinated 
proteins (histones)130, and sulfated proteins (Madanin-1 and chimadanin)131 used 
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for biochemical studies and fluorescently labeled proteins for biophysical studies 
(α-synuclein).132 In even more advanced efforts, an ester bond was substituted for 
an amide backbone in the bacterial KcsA potassium channel to study its effects on 
ion selectivity.133 Surprisingly, this membrane protein can easily refold once 
introduced to reconstituted lipid vesicles, showcasing the ability of chemically 
synthesized proteins to refold under optimized induction conditions. Furthermore, 
NCL has enabled the synthesis of several modified protein therapeutics, such as 
a human glycosyl-interferon-β134, which may offer better homogeneity and purity 
when compared to their recombinant or extracted counterparts.135, 136 NCL has 
even been used in the production of functional enzymes, such as barnase first 
synthesized by Dawson et al.126 However, these syntheses would not have been 
possible without advances in the scope and chemical reactivity of NCL peptide  
fragments, which helped to overcome the initial limitations of the NCL 
methodology. For example, many proteins do not contain a Cys residue to enable 
NCL. Additionally, if the protein target is large (>100 amino acids), more than one 
ligation may be necessary. This requires the development of mild, orthogonal 
protecting reagents for either the thiol or thioester bearing peptides. Additionally, 
creation of methods that enable the production of large (>70 amino acid) protein 
fragments may be necessary. Each of these limitations, and the methods that have 
been developed to overcome them, are discussed in detail in the following 
sections. 
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Figure	 1-13:	 Scheme	 for	 native	 chemical	 ligation.	 The	 C-terminal	 fragment	 (magenta)	 captures	 the	 N-
terminal	 fragment	 (blue)	 in	 a	 transthioesterification	 step,	 followed	 by	 an	 irreversible	 SàN	 acyl	
rearrangement	to	give	the	native	peptide	bond	(bottom).	
 
Expressed Protein Ligation 
Expressed Protein Ligation (EPL) is the synthesis of a protein by NCL where 
at least one of the fragments is produced by recombinant expression. By taking 
advantage of cellular expression systems, one can reduce the number and length 
of peptides synthesized by SPPS. Often, the yield of long polypeptides (>30 amino 
acids) can be a limiting factor in the scale of NCL reactions, especially if milligram 
quantities are needed for high resolution biophysical studies or in vivo use. The 
use of EPL requires the generation of either protein thioesters or protein fragments 
containing an N-terminal Cys residue. To generate protein thioesters, an elegant 
strategy involving engineered intein proteins was put forth by Muir and coworkers 
in 1998.137, 138 Inteins (abbreviated from intervening proteins) are auto-processing, 
self-splicing proteins that were first found in the ATPase gene of Saccharomyces 
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cerevisiae and later discovered in bacteria, archaea, and other single celled 
eukaryotes.139-141 Inteins are often expressed with two flanking exteins (N-terminal 
and C-terminal) that are fragments of the desired protein splicing product. To 
cleave the intein and join the extein sequences, a series of acyl transfer reactions 
takes place (outlined in Figure 1-14).142 In short, the N-terminal residue (Cys or 
Ser) of the intein undergoes a NàS acyl shift with the amide backbone carbonyl. 
This is followed by a transesterification rearrangement by nucleophilic attack from 
the C-terminal extein (Cys, Ser, or Thr residue). Finally, the intein is removed 
through formation of a succinimide by nucleophilic attack of the C-terminal intein 
Asn to the backbone amide carbonyl. The resulting spliced extein ester undergoes 
a O/SàN acyl shift to form the final ligated protein product.  
The N-terminal thioester formation in the first step of intein cleavage 
attracted attention for use as an intermediate in C-terminal protein thioester 
formation through the nucleophilic attack of exogenous thiols.137 Most commonly, 
alkyl thiols such as MESNa are used at high concentrations to produce 
hydrolytically stable protein thioesters (Figure 1-15, left).143, 144 Indeed, there have 
been several engineered contiguous inteins derived from Nostoc punctiforme (Npu 
DnaE)145 and Myobacterium xenopi (Mxe GyrA intein)146 that are now used as 
“gold standards” for the generation of protein thioesters in EPL. More recently, 
these inteins have been expressed with purification tags (His6, chitin binding 
domain, etc.) for affinity chromatography, allowing for the removal of the spliced 
intein after thiol cleavage. By genetically encoding an intein at the C-terminus of 
an expressed protein fragment, one can create virtually any protein thioester for 
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use in NCL synthesis, regardless of length and amino acid sequence. With the 
emergence of intein usage in EPL, engineered contiguous and split inteins have 
been utilized in a variety of other biotechnology functions, such as the generation 
of segmentally isotopically labeled proteins147, protein and peptide cyclization148, 
in vivo protein splicing149, and purification tags150, among others. For more details 
on these uses, please refer to Section 2.1, or the exceptional reviews by Muir and 
Camarero.141, 151, 152 
 
 
Figure	1-14:	An	example	mechanism	of	extein	trans-protein	splicing	mediated	by	an	intein	and	using	a	Cys	
residue	for	each	nucleophilic	capture	step.	This	figure	is	adapted	from	Muir	and	coworkers.141		
  
Protein thioesters are not the only protein fragment desired for EPL. The 
generation of recombinantly expressed protein fragments bearing N-terminal Cys 
residues have also been reported. Due to the necessity of a N-terminal Met residue 
for translation to occur, a Cys residue cannot be directly placed at the N-terminus. 
POI
N
H
O
O
HS
N
H
O
H
N
O
HS
O
NH2
Intein C-exteinN-extein
N to S 
Acyl Shift
O
O
S
N
H
O
H
N
O
HS
O
NH2
Intein C-extein
N-extein
H2N
Trans-thioesterification
O
O
N
H
O
H
N
O
S
O
NH2
Intein C-extein
N-extein
H2N
HSSuccinimide
Formation
O
H2N
O
S
C-extein
N-extein
O
InteinH2N
HS
H
N
NH
O
O
+
OH
Succinimide
Hydrolysis
S to N
Acyl Shift
N
H
O
C-exteinN-extein
O
HS
Spliced Product
O
InteinH2N
HS
H
N
O
OH
NH2
O
Hydrolyzed Succinimide
37	
	
However, masking the N-terminus through two methods can lead to the desired N-
terminal Cys protein fragment.151 In one such method, the N-terminal Cys residue 
of the protein fragment is preceded by an amino acid sequence recognized by a 
protease, followed by a purification tag and the necessary N-terminal Met residue. 
After affinity purification, this short leader sequence can be removed by treatment 
with a protease specific to the recognition sequence. Often this recognition 
element is an Ile-Glu-Gly-Arg-Xxx sequence, which the protease factor Xa 
identifies and subsequently hydrolyzes the amide bond C-terminal to the Arg 
residue.153 Another method for N-terminal Cys expression is to encode Cys as the 
second residue following the initial Met (fMet-Cys-protein fragment, where f is 
formyl) and express the protein in Escherichia coli as a host organism. After 
translation of the protein fragment, an endogenous methionine aminopeptidase will 
remove the Met residue and cyclize the Cys into a thiazolidine (Thz) ring using 
cellular sources of formaldehyde.154 This thiazolidine can be converted back to Cys 
by treatment with methoxylamine in aqueous buffer at pH 4.155, 156 This Thz 
“protecting group” can be useful in controlling the Cys ligation site reactivity in more 
complicated, multi-component, one-pot NCL reactions, such as the example 
synthesis of the 148 amino acid protein α-synuclein (a protein implicated in 
Parkinson’s disease) discussed in more detail in the following section on peptide 
thioesters.157 
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Figure	1-15:	Scheme	for	the	formation	of	protein	fragments	for	EPL.	Left:	C-terminal	protein	thioesters	are	
formed	from	the	cleavage	of	an	intein	by	2-mercaptoethanesulfonate	(MES).	The	protein	of	interest	(POI)	
is	 the	 fragment	 used	 in	 a	 subsequent	 NCL	 reaction.	 Right:	 N-terminal	 Cys	 residue	 unmasking	 through	
proteolysis.	Factor	Xa	protease	recognizes	the	sequence	IEGR,	cleaving	the	amide	bond	C-terminal	to	the	
Arg	in	the	recognition	sequence.		
 
The preceding techniques enable the generation of large C- or N-terminal 
protein fragments to be used in NCL. This combinatorial, semisynthesis strategy 
can reduce the labor intensive SPPS steps necessary for multiple, iterative NCL 
reactions in the synthesis of large protein targets. However, these large fragment 
ligation reactions are not without drawbacks. Large fragments may lead to low 
ligation efficiency due to steric occlusion of the reactive sites or accelerated 
thioester hydrolysis in certain C-terminal sequences of the protein thioester 
(generally sequences rich in Asp, Asn, Glu, or Gln).150 The optimal usage of this 
technology lies at the generation of protein fragments that minimize these pitfalls, 
while keeping synthetic fragments at an appropriate length to maximize yield, and 
therefore incorporation of synthetically installed Uaas. 
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Generation of Peptide Thioesters 
For N-terminal fragments generated by SPPS, a variety of methods have 
been developed to form C-terminal thioesters during cleavage from solid phase 
supports. Moreover, solution phase thioesterification of the free peptide carboxy 
terminus is possible after the removal of the peptide from solid support. The use 
of chemical auxiliaries has even enabled the chemoselective deprotection of the 
C-terminus in unprotected peptides to reveal thioesters for temporally controlled 
NCL reactions involving more than two peptide fragments.123 At the confluence of 
these chemical advances is the ability to synthesize increasing complex protein 
targets containing “post-translational” or unnatural amino acid modifications at any 
site throughout the protein sequence. 
 Traditionally, peptide thioesters were generated through a thioester linkage 
to the resin in tert-butyloxycarbonyl (Boc)-based SPPS. However, this requires 
cleavage from resin using HF, a dangerous, highly acidic reagent that requires 
special equipment to handle and distill.125 Therefore, other methods using 
fluorenylmethyloxycarbonyl (Fmoc)-based SPPS were developed to circumvent 
the use of HF, yet, thioesters are unstable to the basic conditions needed for Fmoc 
protecting group removal during elongation (e.g. piperidine). One solution is to use 
resins which permit cleavage of the peptide from solid support while the N-terminus 
and side-chains remain protected. The free carboxy-terminus is then treated with 
a peptide coupling reagent and a free thiol in the presence of a mild base. In a 
comprehensive study, reaction optimization showed that benzotriazol-1-yl-
oxytripyrrolidinophosphonium (PyBOP), diisopropylethylamine (DIPEA) and 
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methyl 3-mercaptopropionate gave high thioester yields, limited C-terminal 
epimerization, and an alkyl thioester stable to hydrolysis during removal of the 
side-chain and N-terminal protecting groups with trifluoroacetic acid (TFA).158 
However, protected peptides may be insoluble due to a combination of polar amide 
backbone and hydrophobic protecting groups and, depending on the C-terminal 
amino acid identity, epimerization at this site may persist, thereby limiting the yield 
of peptide thioester.  
 Alternative strategies are to use chemical auxiliaries connected to solid 
support, which allow for peptide thioesters to be introduced after the peptide chain 
is fully elongated. In some cases, a thiol nucleophile can be used to cleave the 
peptide from resin, directly yielding the desired thioester, as is the case with 
Kenner’s sulfonamide safety-catch linker (Figure 1-16).159 Perhaps even more 
useful are C-terminal auxiliaries that can be removed from solid support in an 
inactive form with normal TFA conditions. The removal of these auxiliaries can 
then be chemically induced post-cleavage to “unmask” a thioester.  Several studies 
using this strategy have been published including: N-acyl-benzimidazolinones160, 
NàS and OàS acyl-transfer auxiliaries161-163, o-aminoanilides164, and acyl 
hydrazides165, as well as others.166 
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Figure	1-16:	SPPS	chemical	auxiliaries	for	use	in	generating	peptide	thioesters.		
 
 Recently, acyl hydrazides have been widely adopted as peptide thioester 
surrogates due to their ease of installation. Hydrazide based solid supports for the 
generation of C-terminal hydrazides can be generated by treating commercially 
available 2-chlorotrityl chloride resin with an aqueous solution of 5% hydrazine for 
short periods at room temperature.165 Furthermore, peptide hydrazides are 
compatible with Fmoc-based SPPS and can be cleaved from solid support with a 
TFA cocktail, purified by reverse phase HPLC and kept stably as dried solids for 
long term storage. Perhaps most importantly, peptide hydrazides can be activated 
selectively in unprotected peptides in situ by treatment with NaNO2 at acidic pH. 
The resulting electrophilic acyl azide can be attacked by virtually any nucleophilic 
thiol (most commonly 4-mercaptophenylacetic acid, MPAA) to generate a peptide 
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thioester, which can be directly treated with a Cys containing peptide fragment to 
initiate NCL. Peptide hydrazides have now been used in the synthesis of several 
protein products such as α-synuclein and histone H2B, each of which contained 
one or several site-specific post-translational modifications.167, 168 A key advantage 
of these multi-component syntheses is that Cys residues do not need to be 
protected, as synthesis proceeds from the N- to C-terminus. Zheng et al. have 
used four synthetic fragments, each no longer than 36 amino acids in length, to 
assemble the 148 amino acid protein α-synuclein in 54 % yield in three total NCL 
reactions.165 The previously published C- to N-terminal synthesis from Fauvet et 
al., which utilized a Thz based Cys protection and N-acyl-benzimidazolinone 
mediated thioester formation, had a lower isolated yield (21%).157  
 With a large repertoire of reactions for forming peptide thioesters, one may 
be able to screen many C-terminal ligation sites and thioester reactions to optimize 
a particular NCL synthesis. It is also important to note that inteins can be cleaved 
from expressed protein fragments using hydrazine to create protein hydrazide 
fragments.169 The increased size of these fragments may also enable synthesis of 
larger proteins in an N- to C-terminal direction, as Liu notes that syntheses using 
only SPPS generated peptides may be limited to proteins that are, at maximum, 
200 amino acids in length.165 Nonetheless, the scope of peptide thioester forming 
reactions is sufficiently large that a user should be able to generate the necessary 
component peptide for NCL with relative ease. 
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Figure	1-17:	Convergent	syntheses	of	the	same	protein	product	using	two	consecutive	NCL	reactions.	Left:	
Peptide	hydrazides	used	for	a	N-	to	C-terminal	synthesis	with	unprotected	cysteine	residues.	MPAA	is	4-
mercaptophenylacetic	acid.	Right:	NCL	using	peptide	thioesters	and	a	protected	cysteine	as	a	thiazolidine	
(Thz)	on	peptide	2.	The	Thz	group	is	removed	after	NCL	with	peptide	3	by	treatment	with	methoxylamine	
at	pH	4.0.	
 
Ligation Masking 
As previously discussed, not all proteins naturally contain the Cys residue 
necessary for NCL (Cys is the least abundant amino acid in the human proteome 
at 2.4 %).64 If NCL is to be used effectively, the protein to be synthesized should 
be free of any “scar” sequences, such as a non-native Cys, after the ligation is 
complete. Three main strategies have been employed in this regard: 1) alkylation 
of the free thiol to mimic the native residue at the chosen ligation site, 2) use of a 
thiol containing auxiliary that can be removed after ligation, and 3) removal of the 
thiol to yield a free alkyl chain (e.g. a CysàAla transformation) using a radical 
initiated desulfurization reaction. 
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Owing to the nucleophilicity and pKa (~8) of the Cys thiol, this residue can 
be selectively alkylated at neutral or slightly basic pH in the presence of all other 
amino acid side chains. Transformation of Cys to Glu, Gln, and Lys mimics have 
been accomplished by using iodoacetic acid, iodoacetamide, and 2-
bromoethylamine, respectively (Figure 1-18).170-172 A more “traceless” ligation 
reaction can be achieved by using a homocysteine (Hcs) residue as the thiol donor 
in the NCL reaction and alkylating it with methyl iodide to yield a native Met 
residue.173, 174 However, homocysteine ligations have decreased rates due to the 
six-membered ring intermediate that occurs during the SàN acyl shift. 
Nonetheless, these alkylating procedures are generally simple and result in a 
quantitative conversion of free thiol to thioether. Yet, in the three former cases, a 
non-native residue remains and the subtle differences in amino acid identity may 
perturb the protein’s secondary and tertiary structure. Therefore, alternative 
methodologies are needed to enable truly traceless NCL reactions. 
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Figure	1-18:	Alkylation	strategies	for	the	masking	of	thiol	residues	after	NCL.	Left:	Cys	can	be	alkylated	by	
2-bromoethylamine,	iodoacetamide,	or	iodoacetic	acid	to	give	Lys	(CysK),	Gln	(CysQ),	or	Glu	(CysE)	mimics,	
respectively.	Right:	Homocysteine	(Hcs)	is	alkylated	with	methyl	iodide	to	give	a	native	Met	residue.	
 
Thiol auxiliaries or surrogates may be used as a ligation site and removed 
through mild conditions. One such chemical auxiliary is a photocleavable 
nitrobenzyl Cys surrogate that is attached through N-alkylation of a chemically 
installed bromoacetamide functionality linked to a Lys side chain.175, 176 After 
undergoing NCL, the photocleavage of this auxiliary is initiated with UV light to 
reveal a Gly residue at the ligation site. Although the conditions for auxiliary 
removal are mild and “traceless,” the installation of these auxiliaries may provide 
difficult synthetic targets for SPPS. Consequently, other methods which use 
selenocysteine (Sec) as a ligation site provide a nucleophilic selenol for the initial 
capture step and facile post-ligation deselenization to Ala through the use tris(2-
carboxyethyl) phosphine (TCEP), a water soluble reducing reagent and radical 
initiator.177, 178 The conditions of this reaction have even been optimized to avoid 
unselective Cys desulfurization in peptides and proteins containing native Cys 
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residues at non-ligation sites. Even more intriguing is the transformation of Sec to 
Ser that can be leveraged in aerobic “deselenization” reactions.179 In a recent 
study, Sec has even been used in an expressed protein fragment as a ligation site 
using an optimized cysteinyl-tRNA misloading procedure.180 However, the 
expressed fragment cannot contain any structurally critical Cys residues and the 
maximum SecàCys substitution rate is 90%. Furthermore, incorporation into 
peptide fragments by SPPS may require special protecting groups and selenol 
containing amino acid synthesis may require the use of dangerous selenium 
reagents. Therefore, thiol containing residues that can be selectively desulfurized 
may provide a more practical approach for traceless ligations. 
 The desulfurization of Cys in a NCL synthesis, resulting in an Ala residue at 
the site of ligation, was first described by Dawson and coworkers in 2001.181 The 
authors used Raney Nickel hydrogenation of the C-S bond to achieve this 
transformation. Alanine is significantly more abundant in proteins than Cys, making 
it a favorable ligation site residue.64 In 2007, Chen et al. used the water soluble 
radical initiator 2,2’-azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (VA-044), 
in conjunction with TCEP, to achieve desulfurization without the use of harsh 
hydrogenating reagents such as Raney Ni or palladium, which may not be 
compatible with Uaa or post-translationally modified residues in peptide 
fragments.182, 183 Since this initial study, VA-044 mediated desulfurization has 
become the standard in the field for removal of thiol groups after ligation. This has 
generated interest in a number of other thiol residues that contain a thiol at the β- 
or γ-carbon of a canonical amino acid (see Figure 1-19). β-thiophenylalanine 
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and  β-thiovaline (penicillamine) were among the first β-thiol amino acids to be 
synthesized, integrated into peptides, used in NCL, and desulfurized to reveal a 
native residue (Phe and Val, respectively).184, 185 To date many other thiol 
containing amino acids have been synthesized for this use, such as: γ-thiol valine, 
γ- and δ-thiol lysine, γ-thiol threonine, and β-thiol leucine, as well as others (see 
review from Payne and Malins).186  
 
Figure	1-19:	Radical	deselnization	and	desulfurization	reactions	for	selenol	and	thiol	containing	residues.	
Left:	 Sec	 can	 be	 deselenized	 to	 Ala	 or	 Ser	 using	 a	 phosphine	 reagent	 (TCEP).	 Middle	 and	 Right:	 Thiol	
containing	residues	can	be	selectively	desulfurized	using	VA-044	as	a	radical	based	initiator.	
 
Ligation masking has become perhaps the most important consideration in 
the semisynthesis of proteins, especially when carrying out biophysical studies or 
in vivo experiments using the NCL product. Using the most “native-like” structure 
ensures that the only relevant differences between the synthetic product and wild 
type protein are the sites of modification installed by the user. Although there have 
been an abundance of studies performed to improve its usage, NCL still has 
limitations. For example, the synthesis β- and γ-thiol amino acids often requires 
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several steps and total isolated yields are often low.186 Additionally, very few of 
these amino acids are commercially available. Another consideration is the 
applicability of β- and γ-thiol amino acids to EPL, as only C-terminal expressed 
protein fragments bearing Cys, Hcs, and Sec, have been used in EPL.151, 177, 180, 
187 Increasing the repertoire of thiol-bearing amino acids that can be integrated into 
the N-terminal residue of proteins through Uaa mutagenesis or other methods 
remains an important consideration in increasing the scope of EPL for use in the 
semisynthesis of protein targets. 
Section 1.5 – Chemoenzymatic Labeling of Proteins 
 Enzymatic labeling provides a post-translational means of site specifically 
tagging a POI with a chemical functionality that can be a stand-alone probe or 
chemoselectively modified in a secondary reaction. Generally, this method uses 
an engineered enzyme that recognizes a sequence within a protein for transfer of 
a functional group or whole amino acid. These recognition elements can be 
genetically encoded as short peptides at the termini of proteins.188 An advantage 
of this technique is the high specificity of enzymes for their recognition sequences 
and the mild conditions under which labeling can be achieved. Typically, labeling 
reactions are performed on isolated target proteins in vitro or on live cell surfaces, 
but they have also been used in unique applications for biotin labeling in transgenic 
mice.189, 190 A notable example of an enzymatic labeling technology is Biotin ligase 
(BirA), which transfers biotin to a Lys embedded in a 15 amino acid peptide tag. 
This biotin group can be recognized with high specificity by fluorescent streptavidin 
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reporters for protein trafficking studies.191 Other enzymes, such as lipoic acid 
ligase, tubulin tyrosine ligase, phosphopantetheinyl transferase, formylglycine 
generating enzyme, and sortase A (SrtA) have been used to transfer a variety of 
functional groups or stand-alone probes to proteins for imaging or pull-down 
assays. More detailed information for these enzymes can be found in a review by 
Seitz and Beck-Sickinger.189 However, of the aforementioned enzymes, it is 
important to note that the recognition element of SrtA is the shortest, with a 
sequence identity of LPxTG (where x can be any amino acid).192 Shorter 
recognition elements are desirable, as they are likely to have less effect on the 
function or structure of the POI. However, shorter recognition sequences may also 
lead to a greater possibility of off-target labeling in certain enzyme systems. If a 
single amino acid could be recognized at the N- or C-terminus of a protein, then 
modification could proceed with high specificity, and with little change to the POI 
sequence and structure/function. To this end, leucyl/phenalanyl 
aminoacyltransferase (AaT) from E. coli has been developed as an additional 
enzymatic labeling strategy. 
 Endogenously, AaT functions in the N-end rule protein degradation pathway 
by adding Phe or Leu to the positively charged N-terminal Lys or Arg residues of 
a protein via a phenylalanyl- or leucyl-tRNA substrate that is generated by an 
aaRS.193 AaT has strict fidelity to the N-terminal residues of a protein as it has not 
been observed to modify internal amino acids. Recent work has demonstrated that 
a chemoenzymatic protocol with a simple aminoacyl adenosine analogue of tRNA 
can be efficiently used as a minimalist substrate for AaT (see Figure 1-20).194 
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Using either enzymatic (aaRS/tRNA) or chemoenzymatic transfer, AaT can 
conveniently modify the N-termini of peptides and proteins with residues useful for 
chemoselective labeling or as reactive chemical handles in NCL reactions. For 
example, homocysteine (Hcs) was transferred to the N-terminal Lys of a fragment 
of the protein α-synuclein, used in a NCL reaction to generate labeled α-synuclein, 
and methylated, leaving Met at the ligation site.195 This “traceless” ligation allows 
for the inclusion of a synthetic probe without the need to introduce a Cys into the 
protein sequence, thereby enabling studies of the protein in a near-native state. 
Additionally, click chemistry substrates such as Hpg, Aha, and Azf have all been 
transferred by the WT enzyme, showcasing its versatility in substrate scope.194, 196 
However, polyaromatic and β-branched amino acids, which could be used as 
fluorescent probes and NCL handles (β-thiols), respectively, lie outside the current 
substrate scope of the enzyme.197 
 
Figure	1-20:	Transfer	of	amino	acid	Z	to	a	protein	bearing	an	N-terminal	amino	acid	X	(Lys	or	Arg)	by	AaT.	
The	AaT	enzyme	can	use	an	aminoacylated	tRNA	substrate	generated	by	an	aminoacyl	tRNA	synthetase	
(aaRS)	in	the	fully	enzymatic	method	(bottom)	or	a	minimal	aminoacyl	adenosine	donor	molecule	in	the	
chemoenzymatic	method	(Top).	
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Figure	1-21:	Substrate	scope	of	the	WT	AaT	enzyme.	Canonical	substrates	are	leucine,	phenylalanine,	and	
methionine.	Non-canonical	substrates	are	amino	acids	bearing	‘click’	chemistry	handles	(Azf,	Aha,	and	Hpg),	
masked	thiols	for	NCL	(Hcm)	and	polyaromatic	groups	for	the	exploration	of	fluorescent	amino	acid	transfer	
(Nap).	
 
Although some mutagenesis has been attempted with AaT, very little work 
has been done to expand the scope of the N-terminal amino acids that AaT can 
recognize as substrates.198 Enabling AaT to accept N-terminal residues other than 
Arg or Lys could create a versatile chemoenzymatic technology for the installation 
of NCL-capable residues onto expressed proteins. In addition to expanding the 
scope of EPL sites, AaT could be used to selectively label the N-termini of proteins 
with fluorescent amino acids. However, large fluorophores like β-(7-methoxy-
coumarin-4-yl)-alanine or acridon-2-ylalanine are unable to be transferred in high 
yields via WT AaT and the enzyme will likely require extensive mutagenesis to 
transfer these substrates. 
Enzymatic methods such as AaT and SrtA can provide methods to post-
translationally modify a POI at a single site, without the need for bioorthoganality 
that is generally necessary for genetic code expansion. The mild conditions used 
Current Substrate Scope (Z)
S
Canonical	Substrates
Non-Canonical	Substrates
PheLeu Met
Azf Nap Hcm Aha Hpg
N3 S S N3
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during these reactions enable labeling of folded substrate proteins, generally 
without the need for denaturants and refolding as with many chemical ligation 
methods. By expanding the recognition elements of AaT and using short 
recognition sequences in other enzymatic transfer methods, these enzymes can 
provide alternative methods for installing Uaas for biophysical and biochemical 
studies both in vitro and in vivo.  
 
The following section contains reprinted (adapted) passages with permission from 
(Christopher R. Walters, John J. Ferrie, and E. James Petersson) John Wiley and 
Sons Publication Company (Chemical Ligation: Tools for Biomolecule Synthesis 
and Modification). Copyright (2017) John Wiley and Sons.199 
Section 1.6 – Introduction to Thioamides 
Modification of the peptide backbone has long held the interest of biological 
chemists. Several modifications including esters, thioesters, thioamides, 
selenoamides, telluroamides, alkenes, and fluoroalkenes, among others, have 
been documented as potential backbone replacements for biophysical studies.200 
The chalcogen amide functionalities are of particular interest as they are nearly 
isosteric replacements of the amide oxygen with sulfur, selenium, or tellurium, and 
preserve the hydrogen donor and acceptor capabilities of the native amide bond. 
However, owing to the instability of selenoamides and telluroamides, the 
incorporation of thioamides may hold the most promise as isosteric replacements 
of the peptide backbone linkage.  
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Figure	 1-22:	 Top:	 The	 structure	 of	 an	 oxoamide	 and	 thioamide	 along	 with	 van	 der	 Waal’s	 surface	
representation.	 Bottom:	 Relative	 size	 of	 other	 common	biophysical	 probes	 compared	 to	 the	 thioamide	
including:	green	fluorescent	protein	(GFP),	FlAsH	tetracysteine	coordinated	fluorescein	arsenical	hairpin,	7-
hydroxycoumarin	(Hco),	tryptophan	(Trp),	and	acridon-2-ylalanine	(Acd).	
	
Thioamides have different properties compared to oxoamides such as: a 
larger van der Waals radius, a red shifted π-π* absorption, lower oxidation 
potential, lower infrared stretching frequency, and lower N-H pKa (see review from 
Wang et al. and Table 1-1).201 The differing physical properties with respect to 
oxoamides make the thioamide an attractive minimalist probe for a host of 
biophysical techniques to study protein structure and dynamics. In this section, 
thioamide incorporation will be discussed in the context of natural products, 
peptides, and proteins. Each of these settings will showcase the versatility of this 
functional group in nature and in laboratory based experiments. Specifically, a 
review of thioamide installation in peptides and proteins, and the biophysical 
studies that synthetic gains have enabled, will establish the basis by which 
thioamides can be used as versatile probes in new protein systems. This will set 
the stage for what additional information is still needed to inspire a broader usage 
 
52 
§ 1.4 The Thioamide Functional Group. 
Chemical and Physical Properties.  Physically and chemically thioamides are 
somewhat similar to oxoamides.  Chemical structures and space filling models are shown 
in Figure 1.23.  The thioamide carbon-sulfur bond length is 1.54 – 1.68 Å, which is 
slightly longer than the 1.24 Å carbon-oxygen bond length in an amide.210  The carbon-
nitrogen bond is slightly longer in formamide (1.35 Å) than in thioformamide (1.32 Å).211  
The covalent radius of oxygen (0.73 Å) is slightly smaller than that of sulfur (1.02 Å).128   
The van der Waals radius of sulfur (1.85 Å) is slightly larger than that of oxygen (1.40 
Å).212  Oxygen is more electronegative (3.50) than sulfur (2.44).212  Thioamides tend to 
have larger dipole moments (~ 5 D) than corresponding oxoamides (~ 3.8 D), but these 
values can be affected by neighboring groups.213  The amide carbon-oxygen bond (~170 
kcal•mol-1) is stronger than the thioamide carbon-sulfur bond (~130 kcal•mol-1).128  The 
amide functional group can be described by three resonance structures, but the thioamide 
functional group is more well-represented by only two, as shown in Figure 1.24. 
 
 
Figure 1.23.  Chemical Structures of an Amide and Thioamide.  Space-filling models rendered in 
PyMOL (Schrödinger; Portland, OR).  
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is often constrained by the chemistry nec ssary to install a fluorescent probe, the size of 
the probe, or the location of the probe’s installation on the protein.  Development of 
fluorescent modifications for proteins has yielded a broad suite of probes and methods 
that are as structurally and spectroscopically diverse as the applications for which they 
were designed.  
 
FLUORESCENCE AS A MINIMALLY PERTURBING METHOD FOR 
MONITORING PROTEIN DYNAMICS 
 
Figure 1.1: Chromophore Size. Space-filling renderings of several chromophores, based on either crystal 
structures or ab initio calculations. The green fluorescent protein (GFP) was rendered from PDB ID 1GFL9. 
The benzylated SNAP tag protein was rendered from PDB ID 3L00 (S. Schmitt, B. Mollwitz, F. Pojer, M. 
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of the probe in the biochemical community (See Chapters 3, 4, and 5). 
Table	1-1:	Physical	properties	of	oxoamides	and	thioamides	and	their	applications	to	biological	systems.	
	
 
Thioamide Synthesis 
In the literature, the thioamide functional group has historically been 
referred to as a thionoamide, thioxoamide, endothiopeptide, mercaptoamide, 
thiopeptide unit, thiodepsipeptide, and thiocarboxamide. For clarity, and in 
agreement with most current Organic Chemistry literature, here it will be referred 
to by the single name, the thioamide (as denoted by superscript S throughout). 
Additionally, in the context of biologically relevant peptides, thiopeptide has been 
used to describe thiazole- and thiazolene-containing natural products, but will be 
used in the single context of thioamide containing peptides for the remainder of 
this work. 
 The first reported synthesis of a thioamide was performed in 1815 by Gay-
Lussac and was synthesized through the combination of cyanogen and hydrogen 
sulfide to form cyanothioformate and dithiooxoamide.202 This reaction yielded 
thioamide products with little utility. However, this ignited a sustained interest in 
Property Oxo Thio Application
vdW radius	(Å) 1.40 1.85 ---
C=X	bond	 length	(Å) 1.23 1.71 ---
Electronegativity 3.44 2.58 Metal-substrate,	n-π*	interactions
C=X•••H-N	BDE	(kcal	mol -1) 6.10 4.80 Peptide	folding
N-H	pKa 17 13 Hydrogen bonding	probe
π-π*	absorption	(nm) 200 270 Photoswitch,	FRET-based	quencher
EOx (V	vs.	S.H.E.) 3.29 1.21 PeT-based	quencher
vdW =	van	der	Waals,	BDE	=	bond	dissociation	energy,	FRET	=	Förster resonance	energy	transfer;	PeT =	photoinduced
electron	transfer,	S.H.E.	=	standard	hydrogen	electrode
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the discovery of additional chemical syntheses of the thioamide functionality. 
Several thioamide forming reactions, from a multitude of functional groups 
(ketones, aldehydes, isothiocyanates, and amides to name a few), have been 
reported in the literature. Most notably the Wilgerodt-Kindler reaction, 2,4-Bis(4-
methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-dithione (Lawesson’s reagent), 
and tetraphosphorus decasulfide (P4S10), have become standard reactions for the 
installation of thioamides.203-205 As this functional group has transitioned to broader 
usage in medicinal chemistry scaffolds, metal coordination frameworks, and 
biological systems, a concomitant expansion of the processes to achieve these 
chemical transformations has occurred. Increased scope of both the starting 
material (now thioamides can be formed from acids, thiols, alkynyl bromides, 
oximes, and azides) and the reaction conditions (e.g. safer temperatures, safer 
chemicals, and easier product separation) have made thioamides accessible in 
virtually any synthetic system. Yet, biological systems (peptides and proteins), 
which often contain multiple functional groups primed for thioamidation, present 
more extreme technical challenges when attempting to broaden the usage of this 
probe. For individual applications in biophysics (vide infra) and medicinal 
chemistry, the methodology used to incorporate thioamides must be adapted to 
the context of the molecule. 
Thioamide Incorporation into Natural Products, Peptides, and Proteins. 
 Thioamides are a motif engineered into many medicinally relevant 
compounds such as ethionamide and prothionamide (Figure 1-23).206 Although 
these products are designer small molecules, the thioamide motif has been 
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observed in many small molecule natural products, such as ammosamide A, a 
potent anti-cancer molecule against colon carcinomas.207 Here, the thioamide is 
locked within a polycyclic iminoquinone scaffold, whereas other classes of natural 
products contain more peptidic-like linkages. These polypepties are ribosomally 
translated and post-translationally modified to site-specifically install the thioamide. 
The mechanisms of these installations are currently being elucidated through the 
study of thiazole producing enzymes from gene clusters found in a variety of 
aerobic and anaerobic microbes.208  
 
Figure	1-23:	Selected	thioamide	containing	natural	products	isolated	from	bacteria	and	archaea.	
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Some notable peptide products include methanobactin (a copper binding 
metabolite)209, closthioamide (an anti-biotic against methicillin-resistant 
Staphylococcus aureus)210, and thioviridamide (an apoptosis inducing peptide for 
anti-cancer applications).211 It is likely that, as natural product discovery continues, 
the thioamide will be found in additional peptides showing therapeutic properties. 
This makes site selective incorporations of thioamides in laboratory based 
syntheses an important factor in the mass production of thioamide containing 
natural products, as many of the microbes in these studies produce minimal 
quantities of these products.  
In addition to their prevalence in the medicinal chemistry globe, thioamides 
have also recently been used as spectroscopic probes in peptides and proteins. 
This adds to the need for synthetic strategies to thionate amino acids and peptides 
at selective positions. The first amino acid derivative containing a thioamide was 
phenyl thioglycine, synthesized by Gatewood and Johnson in 1926.212 A more 
complicated synthesis of the thioamide containing cyclic peptide hormone 
analogue thio-oxytocin was synthesized by Du Vigneaud and coworkers.213 Direct 
thionation of a N-benzoyl-Gly-NH2 with P4S10, followed by a series of solution 
phase couplings and a final coupling to the core of oxytocin, provided a novel 
synthetic approach. Direct thionation of short peptides containing α-
aminoisobutyric acid (Aib) or β-amino acids has also been demonstrated as an 
alternative approach. In each of these examples, Lawesson’s reagent was used to 
yield efficient conversion of backbone amides to thioamides; however, a mixture 
of different thionated positions was observed. Extensive purification and 
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separation of these various thioamide analogues is time consuming and often 
difficult, leading to a major drawback of this approach.  
A variety of thioamide surrogate residues have been also been used in an 
‘azirine/thiazolone’ method, yet this approach can lead to significant epimerization 
of the α-carbon stereocenter at the site of thioamide incorporation.214 With the 
popularization of solid phase peptide synthesis (SPPS), the development of 
thioamino acid monomer building blocks would enable more diverse sets of 
thiopeptides to be produced. At the forefront of this chemistry were Belleau and 
coworkes, who established thiobenzimidazolones as chemoselective 
aminothioacylating reagents (see Figure 1-24).215 Following this report, a myriad 
of other thioacylating reagents were prepared such as fluorobenzimidazolone, 
thioacyl-N-pthalimide, and nitrobenzotriazolide derivatives aimed at improving 
small molecule yields, thioacylating efficiency, and enantiopurity of the thiopeptide 
product.216 The nitrobenzotriazolide thioacylating derivatives from Rappaport are 
by far the most widely used as the synthetic route is often high yielding (the original 
report lists yields of 80-85%), amino acid monomers can be stored without 
appreciable degradation, and couplings proceed with no observable 
epimerization.217 
 Several Fmoc-protected benzotriazolide amino acid monomers have been 
prepared using N-boc-1,2-phenylenediamine and para-deactivated 4-nitro-1,2-
phenylenediamine (Ala, Asp, Arg, Glu, Cys, Gly, Ile, Leu, Lys, Phe, Pro, Trp, Tyr, 
and Ser) as amidating reagents.218 These monomers have been used in the 
synthesis of several peptides, such as the Villin Head Piece variant HP35, the 
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yeast transcription factor GCN4, and various β-hairpins.219-221 However, the 
successful incorporation of a thioamide via thioacylating monomer can be largely 
sequence dependent. Nucleophilic residues proximal to the thioamide may lead to 
cyclic intermediates that can cleave the peptide or cause oxygen-sulfur exchange 
during TFA cleavage of the peptide from resin. Moreover extended treatment with 
TFA may lead to fragmentation of the peptide at the n+1 position through an 
Edman degradation-like mechanism.153  
 
Figure	 1-24:	 Synthesis	 of	 thioacylating	 monomers	 from	 commercially	 available	 Fmoc-protected	 amino	
acids.	a)	IBCF,	NMM,	THF,	0	°C,	15	min;	N-Boc-OPD	or	4-nitro-OPD	b)	Lawesson’s	Reagent	or	P4S10,	CH2Cl2	
or	THF,	2-18	hours;	c)	R2=F,	R3=H;	phosgene	or	triphosgene,	CH2Cl2	d)	R2=NO2,	R3=H;	NaNO2,	95:5	AcOH/H2O,	
30	min	e)	R2=H,	R3=Boc;	50:50	TFA/CH2Cl2,	0	°C,	2	h;	Then	NaNO2,	95:5	AcOH/H2O,	30	min.	IBCF	=	isobutyl	
chloroformate.	
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Recently, several improvements to the usage of these thioacylating 
monomers have been published. One notable example is the use of anhydrous 
dichloromethane (DCM) and short reaction times during the coupling reaction with 
the free amino terminus of the resin-bound peptide.153, 222 This has increased the 
coupling efficiency of the reaction when compared to N,N-dimethylformamide 
(DMF) and solvents that may have water as an impurity, which can act as a 
competing nucleophile with the free amine. Epimerization of the α-carbon of the 
thioamino acid during Fmoc removal can also hinder the enantiopurity of the 
peptide. Most commonly, piperidine is used to achieve this deprotection, yet these 
basic conditions can lead to epimerization. Preliminary studies indicated that this 
epimerizartion may be suppressed by using a lower concentration of piperidine (1 
% vs 20 % in DMF) for shorter reaction times.223 Evidence supporting the benefits 
of these conditions applied to thiopeptides is not fully delineated, but other 
deprotection reagents may provide cleaner, high-yielding thiopeptide syntheses in 
the future (see Chapter 5). 
 Although thioacylating amino acid derivatives provide a powerful tool for the 
incorporation of backbone thioamides in synthetic peptides, their use is limited by 
the inherent length constraints of SPPS. Thus, other procedures that circumvent 
the size limitations of SPPS must be developed. To incorporate the thioamide into 
proteins beyond the size constraints of SPPS, NCL can be used. However, 
because of the thioamide’s enhanced carbonyl electrophilicity and sulfur 
nucleophilicity, routine thioester formation and NCL reaction conditions needed to 
be established. Our laboratory has recently undertaken the synthesis of a series 
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of short peptides with the thioamide proximal to an N-terminal Cys or C-terminal 
thioester.153 Each of these peptides contained a LeuS amino acid at varying 
positions and were tested for compatibility with the necessary reagents used in 
common NCL schemes such as: guanidinium•HCl, TCEP, thiophenol, MPAA, 
MESNa, and MeONH2 (for Thz deprotection). One noticeable competing reaction 
was the cyclization of the thioamide sulfur with the β-carbon of a thiophosphonium 
intermediate during the reduction of disulfide species via TCEP. However, these 
byproducts can be avoided if disulfide formation is prevented through sparging 
reaction buffers with argon. Cyclization is also possible via nucleophilic attack of 
the thioamide sulfur at the C-terminal thioester. This can again be avoided if one 
can design a NCL scheme that places the thioamide at positions other than the n-
2 position, where cyclization was observed to be most prevalent. These sequence-
specific effects notwithstanding, thioamides were found to be generally well-
tolerated in either thioester or N-terminal Cys peptides during NCL, with 
conversions raging from 55-77 % and crude purities of 54-71%, as confirmed by 
HPLC analysis. In subsequent studies, thioamides were also found to be 
compatible with a variety of thioester forming auxiliaries (see Section 1.4) such as 
Kawakami and MacMillan’s intrapeptide cyclization Csb-Pro-Gla linker (Csb is a t-
butyl disulfide protected Cys and Gla is glycolic acid).153 Additional studies also 
provided evidence for the compatibility of thioamides with Dawson’s N-acyl-
benzimidazolone method for thioester formation.224 However, any auxiliary method 
requiring the removal of an allyloxycarbonate (Alloc) protecting group via catalytic 
Pd0 should be avoided, as desulfurization of the thioamide has been observed.  
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 In a series of final tests, thioamide containing variants of α-synuclein have 
been synthesized to establish, for the first time, a thioamide in a full-length protein 
formed by EPL. This reaction was performed with yields greater than 50% and 
99% retention of the thioamide. In the pilot study, ValS was incorporated as a proof 
of concept, however the long-term interest of thioamides as fluorescence 
quenchers to monitor protein conformations demands dual labeling strategies of a 
protein. Therefore, the Uaa p-cyanophenylalanine (Cnf) was integrated into αS9-
140 through Uaa mutagenesis in E. Coli. This expressed fragment was purified and 
treated with a protease to reveal a N-terminal Cys residue for NCL (see Section 
1.4). NCL was then then performed with a peptide fragment αS1-8 containing a 
PheS thioamide and a C-terminal thioester.132 Double labeled protein is purified 
with yields ranging from 60 to 70 %. Yet, the remaining Cys residue may be 
perturbing to protein structure as WT αS does not contain a Cys residue at the 
ligation site. To mask the Cys residue, both alkylation and desulfurization of the 
ligation site Cys or Hcy residue were tested for compatibility with the thioamide. 
Alkylation of an Hcy residue with methyl iodide in a thioamide containing αS variant 
yielded a native Met residue at a new ligation site.225 This alkylation is selective for 
the Hcy residue, without alkylation of the thioamide sulfur, provided that the 
reaction time is short (5 min) and the protein is treated with excess alkylating 
reagent (5,000 equivalents). Additionally, one may wish to desulfurize the ligation 
site Cys to Ala in the presence of thioamide. A recent study has applied and 
adjusted Danishefsky’s VA-044 radical desulfurization method to enable this 
strategy. An obvious byproduct during the use of radical desulfurization methods 
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is the removal of the thioamide sulfur. However, this can be avoided when 
thioacetamide is used as a ‘suicide scavenger’ in the reaction.218 These conditions 
allow for selective desulfurization of the Cys residue while the thioamide remains 
intact. This strategy has even been implemented in the total synthesis of a 
thioamide containing variant (LeuS6) of the protein G, B1 domain (GB1) from 
Streptococcus.   
 
Figure	1-25:	Synthesis	of	doubly	labeled	thioproteins.	Top:	Expressed	protein	fragment	containing	Cnf	from	
Uaa	 mutagenesis	 and	 an	 N-terminal	 Cys.	 Ligation	 with	 a	 thiopeptide	 yields	 double	 labeled	 protein	
containing	a	free	cysteine.	Middle:	After	 ligation,	selective	desulfurization	of	Cys	to	Ala	can	be	achieved	
through	 the	 use	 of	 VA-044	 in	 the	 presence	 of	 the	 thioamide.	 Bottom:	 Expressed	 protein	 fragment	
containing	Cnf	as	an	Uaa	and	a	N-terminal	Lys	or	Arg.	Hcm	is	transferred	to	the	N-terminal	residue	via	AaT.	
The	 resulting	protein	 can	undergo	NCL	with	 a	 thiopeptide	 and	 subsequent	methylation	 to	 yield	double	
labeled	protein	with	a	native	methionine	at	the	ligation	site.	Figure	adapted	from	Walters	et	al.199	
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It is important to note that thioamides have even been detected in full-length 
proteins in nature. The nickel dependent methyl-coenzyme M reductase (MCR), 
which catalyzes methane formation in all methanogenic archaea, contains a 
thioglycine residue.226 Although this residue’s incorporation and function within the 
enzyme remain undetermined, it has prompted an investigation into alternative 
methods for thioamide installation in proteins.  
New technology developed by Mitchell and coworkers in 2013, utilizes a 
thiazole/oxazole-modified microcin (TOMM) cyclodehydratase enzyme to 
generate backbone azoline heterocycles at positions flanking the nucleophilic 
residues Thr, Ser, and Cys.227 Following azoline formation, the peptide or protein 
is treated with potassium hydrosulfide (KHS), resulting in ring-opening of the 
azoline to reveal a thioamide at the n+1 position of the Thr/Ser/Cys residue. 
Although this is not the first enzymatic method for installing thioamides, it has the 
most potential for use on large proteins. However, despite the promise that this 
method displays, there are some restrictions that must be noted. Firstly, any 
additional Ser, Thr, or Cys residues in the protein of interest must be deleted in 
order to avoid off-target azoline formation. Furthermore, the largest peptide 
substrate used in the initial report is approximately 60 amino acids in length. 
Thionation by the incorporation of benzotriazolide monomers in SPPS could also 
conceivably be used to generate peptides of this length, although yields may vary 
depending on sequence identity. Even in the case of this enzymatic method, 
sequence specificity can be limiting and a leader sequence is often used for 
recognition of the substrate by the cyclodehydratase. Suga and coworkers have 
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shown that such leader sequences can be manipulated to some degree, but such 
methods do not currently allow one to install thioamides into large proteins.228 
Engineering of TOMM synthetases may serve as a solution to this shortcoming. 
Additionally, as more is learned about the cellular pathways and enzymes that 
generate azoline rings and other masked thioamides (thioviridamide, 
closthioamide, and thiobactin pathways, among others), other enzyme clusters 
may be discovered, leading to new enzymatic, ‘post-translational’ methods for 
thioamide installation into a peptide or protein backbone (see review by Dunbar 
and Mitchell).208 
 Another strategy for thioamide incorporation into longer polypeptides, and 
even proteins, is to genetically incorporate the thioamide through translational 
machinery. In 2015, a mutant 23 rRNA, reconstituted ribosome from E. coli was 
used to direct the translational insertion of dipeptides into the enzyme dihydrofolate 
reductase (DHFR).229 This included a PheS-Gly dipeptide, showing for the first time 
a backbone thioamide ribosomally incorporated into a protein. However, this 
system has not yet been used for in cellulo translation. Furthermore, a particular 
sequence is likely required to allow for the dipeptide to bind in the ribosome as 
these mutants are based off of a puromycin permissive ribosome. As genetic 
expansion technologies advance, thioamide mutations in proteins may become 
more accessible. Yet, it appears that, contemporary thioamide incorporation for 
biophysical applications is likely still limited to NCL, as it is the most robustly tested 
and widely applied methodology. 
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Thioamide Applications to Biophysical Studies 
Thioamides have a wide array of applications when studying biomolecule 
interactions and properties (as mentioned above). To establish their usage in 
proteins, several groups have investigated if the thioamide can be incorporated 
into secondary structural elements in short peptide fragments. The steric bulk of 
(1.85 Å vs. 1.40 Å) the thioamide and the longer C=S bond (1.71 Å vs 1.23 Å), 
when compared to oxoamides, makes the thioamide a weaker hydrogen bond 
acceptor. Yet, the lower pKa of the N-H proton (13 vs. 17) makes the thioamide a 
stronger hydrogen bond donor.201 These small, but important changes, are likely 
to make the thioamide’s incorporation into helical and β-sheet structural elements 
dependent upon the surrounding amino acid sequence and position of 
incorporation.  
Pilot computational studies monitoring the potential energy surfaces of 
torsional backbone bond angles of thioamide containing dipeptides suggested that 
they could be accommodated in the C-termini of α-helices and β-sheets.230 
However, if incorporated in highly structured hydrogen bonding networks, the 
conformational restrictions of the thioamide would likely interfere with these 
networks, thus hindering the folding process of these motifs. Putting this 
information into practice, Reiner et al. used circular dichroism (CD) and nuclear 
magnetic resonance (NMR) spectroscopy to study a 16 residue polyalanine based 
helix.231 Indeed, they found that the placement of the thioamide in the N-terminal 
or central region of the helix was destabilizing (~1.7 kcal mol-1), likely due to the 
disruption of the hydrogen bonding network. However, in a competing study, Miwa 
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et al. described more nuanced effects of thioamide substitutions in a 35 amino acid 
segment of a yeast derived GCN4 sequence.221 With thioamide substitutions at 
central and C-terminal positions, they did not observe a significant change in the 
helicity of the peptide. In fact, the placement of a central LeuS substitution 
increased the thermal stability of the helical structure by ~10 °C. The discrepancies 
laid out by these pilot studies has sparked a host of additional structural studies of 
the thioamide in α-helical folding, β-sheet TrpZip peptides, type II’ β-hairpins, and 
polyproline type II helices (discussed in more details in Section 4.1).220, 232, 233 
However, each of these studies was performed on short, isolated structural motifs 
without the comprehensive substitutional studies of a thioamide at each position. 
This shortcoming elicits the need for studies of the impact of thioamide backbone 
substitutions on the secondary and tertiary structure of folded, full-length proteins. 
The details of initial studies of thioamides in folded protein structures is the basis 
of Chapter 4 discussed herein. 
 There is also interest in applying the redshifted πàπ* absorption property 
of the thioamide (270 nm vs 200 nm for oxoamide) to the study of biological 
systems. This property allows the thioamide to undergo photoisomerization from 
trans to cis and has been used to study the secondary structure of the RNase S 
peptide-complex during the cleavage of a cyclic monophosphate nucleotide.234 
Additionally, the absorbance in this region has enabled the tracking of the chiral, 
and therefore structural, environment of the thioamide by CD spectroscopy. More 
importantly, the red shifted absorbance properties of the thioamide could be used 
in the fluorescence quenching of fluorophores via a FRET process in the study of 
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biomolecule interactions. In this regard, the Petersson laboratory has clearly 
demonstrated that the quenching of p-cyanophenylalanine (Cnf) is achieved 
through the FRET mechanism.235 Although, fluorescence quenching of tryptophan 
by a thioamide was first observed by Wiczk et al.236, the first assignable FRET 
interaction of a thioamide with a fluorophore was with Cnf as described above. 
Since FRET requires the spectral overlap between donor emission and acceptor 
absorption, Cnf provides an excellent working range for this process with an 
excitation range (230-240 nm) that avoids direct thioamide excitation and emission 
range (centered at 295 nm) that provides sufficient spectral overlap for FRET. A 
sigmoidal distance dependence of Cnf-thioamide quenching interaction was 
observed in polyproline peptides, indicating that the interaction can effectively be 
modeled by FRET with a working distance range of 8-30 Å.235 This initial study 
highlights the use of thioamides in monitoring conformational changes of proteins 
via distance dependent thioamide-fluorophore interactions.  
Within the same study, the quenching of Cnf was used in tandem with CD 
spectroscopy to monitor the thermal denaturation of a short helix-loop-helix 
segment (35 amino acids) villin headpiece (Villin HP35). Additionally, Tyr can 
provide a canonical fluorescent amino acid that is quenched by the thioamide. 
Although the mechanism of this quenching interaction is not yet fully understood, 
a proof of principle experiment involving the quenching of intrinsic protein Tyr 
fluorescence by a thiopeptide binding partner has also been performed.237 This 
study allowed for quantification of the protein-peptide interaction via intermolecular 
quenching (vs intramolecular quenching in the prior Cnf example). In a separate, 
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seminal example, a Cnf/thioamide containing α-synuclein was produced by EPL 
and used for the study of α-synuclein misfolding as it relates to Parkinson’s disease 
and protein compaction in the osmolyte trimethylamine N-oxide (TMAO).132  
 
Figure	 1-26:	 Fluorescence	 quenching	 of	 Cnf	 by	 LeuS	 during	 thermal	 denaturation	 of	 Villin	 HP35.	 Figure	
adapted	from	Goldberg	et	al.235	
	
Additionally, the thioamide has been observed to quench a host of 
fluorophores that do not have spectral overlap with thioamide absorbance. These 
fluorophores include carboxyfluorescein, 7-methoxycoumarin, Alexa Fluor 488, 
boron-dipyrromethane (BODIPY), and rhodamine R6G. The lower oxidation 
potential of the thioamide (1.21 V vs. 3.29 V for an oxoamide) allows for this 
quenching to proceed by PeT.238 In a PeT based mechanism, the oxidation and 
reduction potentials of the donor excited state and the acceptor ground state must 
have a favorable free energy of electron transfer (ΔGET) to allow for quenching. 
Unlike FRET quenching, PeT requires van der Waals contact for quenching, 
thereby necessitating the thioamide to come into close proximity with the 
fluorescent probe. Thioamide PeT quenching has now been used in a variety of 
spectra of 12 µM solutions of these peptides in phosphate buffer
and observed a strong dependence of the fluorescence intensity on
the number of intervening Pro residues. To correlate the fluores-
cence intensity with interchromophore distance, we carried out a
series of 10 ns molecular dynamics (MD) simulations of Leu-Pron-
Phe (n ) 2-10) in explicit water boxes. The distances between
the thioamide (using the Leu amide as a proxy) and Cnf (using
Phe as a proxy) were time-averaged over the unrestrained portions
of the simulations (see the Supporting Information). Normalizing
the fluorescence emission (F) across the proline series to the
emission of Cnf in an oxoamide control peptide (F0), we computed
the efficiency of fluorescence quenching as EQ ) 1 - F/F0. This
allowed us to plot EQ as a function of distance for the proline series
and compute an R0 value of 16.5 Å by fitting the data to a 1/R6
function (Figure 2, solid line), in reasonable agreement with the
value determined from spectroscopic data alone.
Several observations regarding this result are worth noting. First,
although the distance dependence is comparable to the prediction
from Fo¨rster theory, for such short distances one must also consider
Dexter energy transfer via direct orbital overlap.12 Dexter transfer
has a 1/eR distance dependence, which provided a slightly better
fit to the Pro series data (Figure 2, dashed line). In fact, both
mechanisms probably contribute to thioamide quenching and may
be difficult to deconvolute. Second, as thioamides have previously
been used in photoisomerization experiments,4,5 we investigated
the possibility that energy transfer might cause cis/trans isomer-
ization. After 1 h of irradiation, our most efficient energy transfer
peptide, Leu′-Pro2-Cnf, showed no significant change in HPLC,
UV-vis, or circular dichroism (CD) assays (see the Supporting
Information). The lack of isomerization seems to be inconsistent
with either energy transfer mechanism and will be investigated
further. Regardless of the mechanism, our data confirm that the
working distance for the Cnf/thioamide pair is 8-30 Å, comple-
menting longer-range pairs like Trp/dansyl (R0 ≈ 22 Å) and
fluorescein/tetramethylrhodamine (R0 ≈ 50 Å).14 Finally, although
a proximal N-terminal amine can quench Cnf fluorescence,15
acetylation of Leu-Pro2-Cnf and Leu′-Pro2-Cnf had no effect on
the fluorescence at pH 7.0 (see the Supporting Information). This
gives us confidence that the quenching (relative to the parent
oxoamide) is due to the O-to-S substitution alone.
We also carried out one proof-of-principle experiment to
demonstrate the utility of the thioamide/Cnf pair in monitoring a
conformational change. We incorporated Leu′ at the N-terminus
and Cnf at the C-terminus of the villin headpiece HP35 variant,
which was originally described by Kim and co-workers.16 The
fraction folded (ff) as a function of temperature was determined
for the thioamide version HP35-Leu′1Cnf35 and the corresponding
oxoamide control protein HP35-Cnf35 using CD spectroscopy
(Figure 3). The two proteins had comparable Tm values (i.e.,
temperatures at which ff ) 0.5), indicating that incorporating the
thioamide at this position had no dramatic effect on protein
unfolding. The quenching efficiency was determined by comparing
the fluorescence of the thioamide to that of the oxoamide. Since
Cnf fluorescence has been shown to vary strongly with temperature
and local environment,10,17 determining EQ by comparison to the
oxoamide HP35-Cnf35 was essential to control for effects on Cnf
emission that are independent of the thioamide interaction. EQ
ranged from 0.19 at 5 °C to <0.02 at 75 °C.18 The change in EQ
implies a distance change from 20-21 Å in the folded state (19.2
Å observed in 10 ns MD simulations) to greater than the detectable
range of our probe pair (32 Å) in the unfolded state. As Figure 3
shows, converting EQ to distance using the Fo¨rster and Dexter
interpretations gave comparable results (root-mean-square deviations
of 0.8 Å over the 70 °C temperature range). The data show that
Leu′1/Cnf35 dissociation is coupled to global unfolding even though
it is found on the periphery of HP35.
In summary, we have identified a novel fluorophore/quencher
pair and demonstrated its distance dependence and application to
monitoring of the unfolding of a small prot in. Since one can
conceivably replace any amino acid in a synthetically accessible
protein by its thioamide analogue, this quencher could be applied
anywhere in a protein sequence. We are currently exploring the
use of the Cnf/thioamide system in proteins containing Trp or Tyr
to determine its generality and further studying the mechanism of
fluorescence quenching by thioamides.
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Figure 2. Fluorescence emission as a function of chromophore spacing.
The fluorescence emission of Leu′-Pron-Cnf (n) 2-10) at 293 nm is shown
(three trials per peptide, bars represent standard errors). The “∞” data point
indicates the fluorescence of Leu-Pro2-Cnf. The solid line indicates the
distance dependence predicted by Fo¨rster theory with R0 ) 15.6 Å (∼5.1
prolines). The inset shows EQ as a function of the computed Leu′-Cnf
interchromophore distance for the proline series. The data were fit to Fo¨rster
(solid line, r2 ) 0.973) and Dexter (dashed line, r2 ) 0.986) distance
dependences.
Figure 3. Villin HP35 unfolding monitored by Cnf/thioamide FRET. (left)
Villin HP35 structure taken from PDB entry 1VII19 modified with the Cnf
nitrile on Phe35 [image rendered in PyMOL (Delano Scientific, LLC, South
San Francisco, CA)]. (right) Fraction folded as determined from temperature-
dependent CD spectroscopy for HP35-Leu′1Cnf35 (b) and HP35-Cnf35 (O)
and temperature dependence of the Leu′1/Cnf35 separation determined by
comparison of EQ computed from the HP35-Leu′1Cnf35/HP35-Cnf35 fluo-
rescence ratio with the proline series distance dependence co puted using
either the Fo¨rster ([) or Dexter (]) equation.
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contexts, most notably for real time monitoring of proteolysis and again in the study 
of αS compaction by TMAO.239  
 
 
Figure	 1-27:	 FRET/PET	 quenching	 during	 α-synuclein	 compaction.	 In	 the	 presence	 of	 increasing	
concentration	of	TMAO,	α-synuclein	undergoes	successive	compaction.	During	this	process,	changes	in	the	
distance	between	two	regions	of	the	protein	have	been	monitored	by	FRET	(Top),	where	quenching	of	Cnf	
fluorescence	by	the	thioamide	occurs	in	a	distance	dependent	fashion	and	PET	(Bottom),	where	van	der	
Waals	contact	between	fluorescein	and	thioamide	is	required	for	quenching.	Figure	adapted	from	Walters	
et	al.199	
 
The thioamide’s size and ability to quench a wide array of fluorophores 
makes it an attractive probe to study intramolecular and intermolecular protein 
dynamics. This is especially true when larger probes, such as Texas Red, 
fluorescein, and rhodamine, have been demonstrated to disrupt the fold and 
function of proteins when applied to fluorescence studies.240 Although some 
studies have suggested that the thioamide may be accommodated in secondary 
structure elements, further work must be done in full-length proteins to ensure that 
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the thioamide is indeed minimally perturbing in comparison to larger probes. As 
this technology evolves, it will also be important to demonstrate that the thioamide 
can still effectively quench fluorescence when embedded within a minimally 
perturbing position in a structured element (e.g. α-helix or β-sheet). 
Section 1.7 - Conspectus 
In total, there are many technologies that can be employed to effectively 
label proteins for the tracking of structural changes and dynamic movements. 
However, improving the accessibility of these technologies to the biochemical 
community is of the upmost importance to enable a broader usage of chemical 
probes, specifically in the context of site-specific amino acid modifications. In this 
thesis, I describe several improvements to current methodologies for site-specific 
backbone and side chain amino acid modifications. In one study, genetic code 
expansion is improved by eliminating truncation byproducts through the use of self-
splicing intein purification tags. In other efforts, I examine the effects of thioamide 
backbone substitutions in the secondary and tertiary structure of full-length 
proteins synthesized by native chemical ligation. Understanding the effects of 
these substitutions permits the user to more effectively use thioamides as 
fluorescence quenching probes or as structural modulators in protein engineering 
applications. Additionally, I have established more effective methods for thioamide 
incorporation into peptides in solid phase synthesis. I have leveraged these gains 
to install multiple thioamides into the protein calmodulin to assess their additive 
thermodynamic effects on protein stability and for use in intermolecular 
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fluorescence quenching experiments. Finally, I explored the substrate scope of the 
enzyme AaT for application in modifying the N-termini of proteins with Uaas for 
‘click’ chemistry and NCL reactions. By studying the effects of specific protein 
modifications on protein structure and function, as well as improving the general 
methodologies for Uaa incorporation, I have provided opportunities for the 
biochemical community to enhance their usage of Uaas for the study of proteins in 
a range of contexts.  
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CHAPTER 2: 
 
INTEINS AS TRACELESS PURIFICATION TAGS FOR UNNATURAL AMINO 
ACID PROTEINS 
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Reprinted (adapted) with permission from (Solongo Batjargal, Christopher R. 
Walters, and E. James Petersson) the Journal of the American Chemical Society 
(J. Am. Chem. Soc., 2015, 137 (5), 1734–1737). Copyright (2015) American 
Chemical Society. 
 
Section 2.1 - Introduction 
 Genetic incorporation of unnatural amino acids (Uaas) into proteins has 
provided the ability to probe and control protein structure and function with 
extraordinary precision.241, 242 To accomplish site-specific incorporation, an 
orthogonal tRNA is selectively charged with a Uaa by its aminoacyl-tRNA 
synthetase (RS) and directs the insertion of the Uaa into the nascent polypeptide 
chain in response to nonsense (i.e., premature stop) or quadruplet codons during 
translation.110, 243 The “suppressor” tRNA has an anticodon that recognizes the 
nonsense codon; for example, tRNACUA pairs with the UAG stop codon. One of the 
major limitations of this method is the competition of tRNACUA with release factor 1 
(RF1) at the UAG codon, leading to protein truncation. Purification of the full-length 
protein can be difficult, if not impossible, when the UAG codon is located near the 
C-terminus. The use of C-terminal tags such as His6 can alter the native properties 
of some proteins, and cleavage of the tags by proteases may not always be 
specific. Other efforts to solve the “truncation problem” have centered on nontrivial 
manipulations of the E. coli translation system, including genetic deletion of RF1 
or reassignment of all the UAG stop codons in the bacterium.116, 117 These 
75	
	
manipulations may lead to compromised cell health and lower levels of protein 
production.  
Here, we report a simple and efficient method for isolating full-length 
proteins containing a Uaa in a traceless manner by exploiting the self-excising 
property of inteins. Engineered inteins have been leveraged for the preparation of 
protein thioesters, polypeptide cyclization, and the regulation of protein 
functions.151 In our own laboratory, we have used inteins to prepare Uaa-
containing protein fragments for ligation to synthetic peptides to label proteins with 
both side chain and backbone modifications.132 This line of investigation led us to 
develop a traceless intein tagging method for full-length Uaa proteins (Figure 2-1).  
Section 2.2 - Results and Discussion 
The C-terminal His-tagged Mxe GyrA intein provides an affinity purification 
tool that, by virtue of its placement, can exist only in full-length Uaa protein 2-2 and 
not in truncated protein 2-1 (Figure 2-1).  Subsequent removal of the intein tag (2-
3) in a β-mercaptoethanol (βME) triggered process yields the Uaa-labeled protein 
with a C-terminal carboxylate (2-7) via intermediates 2-4 and 2-5. We demonstrate 
the generality of this approach with three test proteins: an intrinsically disordered 
protein, α-synuclein (αS), a small Ca2+ binding protein, calmodulin (CaM), and a 
larger globular protein, maltose binding protein (MBP). In addition, we examine a 
broad spectrum of Uaas including the spectroscopic probes p-cyanophenylalanine 
(Cnf or F*)244, 245 and acridon-2-ylalanine (Acd or δ),246 the “click” chemistry 
handles propargyltyrosine (Ppy or π) and p-azidophenylalanine (Azf or Z),247 and 
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the photocrosslinker p-benzoyl-phenylalanine (Bzf or B).248 This technique should 
be of general use to the Uaa mutagenesis community as it provides a 
straightforward solution to the truncation problem. 
We began our investigation with the expression of αS (140 amino acids) 
containing Cnf at position 136, fused to Mxe GyrA intein followed by a C-terminal 
His6 tag (αS-F*136-MxeH6, 2-2a). To incorporate Cnf, we transformed BL21(DE3) 
cells with a pTXB1-αS-TAG136-MxeH6 plasmid and a plasmid encoding a 
Methanocaldococcus jannaschii (Mj) mutant TyrRS/tRNACUA pair previously 
selected for Cnf incorporation (pDULE2-pXF).249 After lysing the cells, both 
truncation product αS1−135 (2-1a) and mature fusion protein (2-2a) were observed. 
Only the mature protein with the Uaa was obtained from Ni-nitrilotriacetic acid (Ni-
NTA) purification by elution with imidazole, leaving the truncation product in the 
flow- through (Figure 2-1). Matrix-assisted laser desorption/ionization (MALDI) 
mass spectrometry (MS) and polyacrylamide gel electrophoresis (PAGE) analyses 
of the Ni-NTA purified αS-F*136-MxeH6 2-2a showed no evidence of the truncation 
product.  
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Figure	2-1:	Purification	of	Unnatural	Amino	Acid	Proteins	Using	a	C-terminal	Intein	Tag.	Unnatural	amino	
acid	(Uaa;	e.g.,	p-cyanophenylalanine,	Cnf)	proteins	are	expressed	using	a	plasmid	encoding	the	protein	of	
interest	with	a	TAG	stop	codon	(e.g.,	α-synuclein	mutant	at	position	136,	αS-TAG136)	and	a	plasmid	encoding	
an	evolved	tRNA	synthetase	(UaaRS).	The	full	length	intein	fusion	protein	containing	the	Uaa	(2-2)	is	purified	
away	from	the	protein	truncated	at	the	stop	codon	(2-1)	using	Ni-NTA	resin.	Hydrolysis	resulting	from	β-
mercaptoethanol	(βME)	treatment	generates	purified	Uaa	protein	2-7	via	intermediates	2-4	and	2-5.	Intein	
cleavage	with	βME	 can	be	 carried	out	on	or	off	 of	 the	Ni-NTA	 column.	 Inset:	A	 sample	expression	 and	
purification	of	αS-Cnf136	with	either	off-	or	on-column	hydrolysis.	Off:	Crude	cell	lysate,	flow	through	from	
Ni-NTA	column	(FT),	elution	of	Ni-NTA	column	with	300	mM	imidazole,	cleavage	of	eluted	intein	fusion	with	
200	mM	βME	for	24	h,	and	removal	of	intein	and	uncleaved	fusion	protein	by	incubation	with	Ni-NTA	beads.	
On:	Crude	cell	lysate,	FT,	elution	of	Ni-NTA	column	with	200	mM	βME	after	incubation	for	24	h,	and	elution	
of	cleaved	intein	from	Ni-NTA	column	with	300	mM	imidazole:	2-1a,	truncated	αS1−135;	2-2a,	Uaa	protein	
fusion	αS-F*136-MxeH6;	2-3a,	cleaved	MxeH6	intein;	2-7a,	pure	full	length	Uaa	protein	αS-F*136,	molecular	
weight	(MW)	markers	17,	25,	30,	46,	58,	80,	and	175	kDa.		
 
 
Next, we carried out an in-depth analysis of hydrolysis of the fusion protein 
by βME. A study carried out by New England Biolabs reported that dithiothreitol 
(DTT) induced faster intein cleavage than βME.250 However, Kent and co-workers 
showed that the conversion rate from peptide-thioesters (−COSR) to peptide-
carboxylates (−CO2H) with DTT was significantly slower in comparison to βME in 
6 M guanidinium.251 To test βME as a traceless cleaving reagent, we treated αS-
F*136-MxeH6 2-2a with 200 mM βME in HEPES buffer at pH 7.5 at room 
2-1 2-2
2-2
2-3
2-4 2-5
2-6
2-7
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temperature (RT, 22 °C) and monitored the cleavage periodically using SDS PAGE 
and MALDI MS. The fusion protein was >90% cleaved to give the protein−CO2H 
after 8 h incubation. The intermediate product(s), presumably a mixture of αS-F*136 
βME-thioester (2-4a) and βME-oxoester (2-5a), were observed at the 2 h time point 
by MALDI MS. This mixture disappeared over time to form C-terminal carboxylate 
2-7a, expelling ethylene sulfide (2-6). Similar analyses with DTT, performed by 
colleague Dr. Solongo Batjargal, resulted in slightly faster splicing than βME, but 
the formation of the desired C-terminal carboxylate was significantly slower with 
DTT. MALDI MS analyses of full-length and trypsin-digested protein were used to 
ensure the completion of carboxylate formation and the fidelity of Cnf insertion.  
To optimize intein hydrolysis with βME, I incubated αS- F*136-MxeH6 2-2a 
while varying conditions including temperature, βME concentration, and pH. As 
expected, I observed a faster splicing rate as I increased the temperature or βME 
concentration (Ea = 10.6 kcal·mol−1, k = 5.79 × 10−4 M−1 s−1). In contrast, the 
splicing reactivity was not significantly influenced by pH, probably due to a balance 
of acid- and base-catalyzed steps in transthioesterification, S−O rearrangement, 
and hydrolysis. Based on these analyses, I carried out the rest of the hydrolysis 
reactions with 200 mM βME at pH 7.5, 22 °C; conditions under which hydrolysis of 
2-2a was >90% complete in 8 h, giving 2-7a in yields of 6 mg per L of cell culture. 
However, hydrolysis conditions, including βME concentration, may need to be 
optimized for a protein of interest depending on factors such as stability and the 
identity of the C-terminal residue forming the intein thioester.  
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Instead of eluting the protein from the Ni-affinity column (off-column), 
hydrolysis can be carried out when the protein is still bound to the column (on-
column). After removing cellular proteins by washing, resin-bound αS-F*136-MxeH6 
2-2a was either retained on the beads or eluted from the column with imidazole. 
The on- and off-column approaches were both hydrolyzed in >95% yield (Figure 
2-1). For on-column hydrolysis, βME treatment inherently led to elution of pure 
product. For off-column hydrolysis, incubation with Ni-NTA resin allowed for easy 
removal of cleaved intein 2-3a and unhydrolyzed fusion protein 2-2a. It should be 
noted that some reduction of the Ni2+ resin can occur with on-column hydrolysis, 
and the resin should be regenerated with fresh NiSO4 if discoloration is observed.  
It is important that the use of the intein fusion does not disrupt the native 
fold of the protein of interest. Since αS is a disordered protein, we chose to 
evaluate the impact of the intein on folding using CaM (work by Solongo Batjargal). 
Previous attempts to express CaMF-F*139 (2-7b) using standard stop codon 
suppression methods resulted in ∼70% truncation. In contrast, when we expressed 
CaMF-F*139-MxeH6 (2-2b) and carried out off-column hydrolysis, we obtained 2-7b 
in 8 mg/L yield. Through the use of circular dichroism spectroscopy and peptide 
binding assays, Dr. Solongo Batjargal confirmed that the CaMF-F*139 structure was 
not perturbed by fusion to the intein. However, it must be noted that the use of high 
concentrations of βME may compromise the folding or activity of some proteins 
that rely on key, labile disulfide bond; a separate activity assay should always be 
used.  
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To test the viability of the intein tag strategy for larger Uaas that are 
incorporated less efficiently, I incorporated Acd in CaM and Bzf in αS and triggered 
hydrolysis with βME to efficiently isolate CaM-δ139-CO2H (2-7c, Figure 2-2) or αS-
B136-CO2H (2-7d, Figure 2-2) in 3−10 mg/L yields, in spite of substantial truncation 
(≥50%). Although the crude on-column hydrolysis products (“+ βME” lanes in 
Figure 2-2) were relatively clean, additional fast protein liquid chromatography 
(FPLC) purification should be used to purify proteins for biophysical assays, as is 
typical of most Ni-NTA purifications. I also tested the compatibility of our method 
with azide amino acids that may be subject to reduction by βME. Azf was 
incorporated into αS as a “click” chemistry handle for reactions with strained 
cyclooctynes. After on-column hydrolysis of αS-Z136-MxeH6 (2-2e), the incubation 
of αS-Z136-CO2H (2-7e) with tetramethylrhodamine dibenzocyclooctyne (Rco) 
resulted in labeling of αS to give αS-ZRco136-CO2H (2-8e, Figure 2-3). Again, at 
least one round of additional purification is typically necessary to remove 
unreacted dye.  
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Figure	2-2:	Application	of	C-terminal	Intein	Tag	Strategy	with	Acd	and	Bzf.	Left:	expression	and	purification	
of	 an	 acridon-2-ylalanine	 (Acd,	 δ)	mutant	 of	 calmodulin	 (CaM-δ139),	 or	 p-benzoylphenylalanine	 (Bzf,	 B)	
mutant	of	α-synuclein	 (αS-B136)	with	on-column	hydrolysis.	Crude	cell	 lysate,	 flow	 through	 from	Ni-NTA	
column	(FT),	elution	of	protein	after	cleavage	with	200	mM	βME	for	16	h,	protein	purified	by	fast	protein	
liquid	 chromatography	 (FPLC)	 are	 shown	 from	 left	 to	 right	 on	 the	 SDS	 PAGE	 gels.	 Left:	2-1c,	 truncated	
CaM1−138;	2-2c,	Uaa	protein	fusion	CaM-δ139-MxeH6;	2-7c,	pure	full	length	Uaa	protein	CaM-δ139,	molecular	
weight	(MW)	markers	11,	17,	22,	25,	32,	46,	58,	75,	and	100	kDa.	Right:	2-1d	(1a),	truncated	αS1−135;	2-2d,	
Uaa	protein	fusion	αS-B136-MxeH6;	2-7d,	Pure	full	length	Uaa	protein	αS-B136,	MW	markers	11,	17,	22,	25,	
32,	46,	58,	75,	and	100	kDa.		
 
 
 
 
 
 
 
 
CO2H (7d, Figure 2) in 3−10 mg/L yields in spite of
substantial truncation (≥50%). Although the crude on-column
hydrolysis products (“+ βME” lanes in Figure 2) were relatively
clean, additional fast protein liquid chromatography (FPLC)
puriﬁcation should be used to purify proteins for biophysical
assays, as is typical of most Ni-NTA puriﬁcations. We also
tested the compatibility of our method with azide amino acids
that may be subject to reduction by βME. Azf was incorporated
into αS as a “click” chemistry handle for reactions with strained
cyclooctynes. After on-column hydrolysis of αS-Z136-MxeH6
(2e), the incubation of αS-Z136-CO2H (7e) with tetramethylr-
hodamine dibenzocyclooctyne (Rco) resulted in labeling of αS
to give αS-ZRco136-CO2H (8e, SI, Figure S9). Again, at least one
round of additional puriﬁcation is typically necessary to remove
unreacted dye.
We also wished to ensure that our methods were applicable
to larger proteins, alternate immobilization tags, and other
inteins. We tested an MBP (367 amino acids) fusion with a C-
terminal Mxe GyrA intein and chitin binding domain (CBD).
We introduced a UAG codon at position 363, four residues
from the normal MBP C-terminus, and expressed the construct
with Ppy. Isolation of the full-length protein MBP-π363-
MxeCBD (2f) by incubation with chitin beads and subsequent
treatment with βME resulted in the liberation of MBP-π363-
CO2H (7f) in an 8 mg/L yield. After additional puriﬁcation via
FPLC, 7f was treated with a ﬂuorescent azide compound
(Rhodamine 110 azide, Faz) under Cu-catalyzed “click”
conditions to give MBP-πFaz363-CO2H (8f). In separate
experiments, we generated fusions of αS and CaM with
DnaE inteins (Ava, Mcht, and Npu) and found that expression
levels were comparable to Mxe GyrA fusions and that oﬀ-
column hydrolysis rates were comparable to or slower than
Mxe GyrA (see SI, Figures S7 and S10).
In conclusion, we have developed a traceless and eﬃcient
strategy for separating desired Uaa proteins from similarly sized
truncation byproducts. We have demonstrated that a variety of
proteins, Uaas, inteins, and aﬃnity tags can be used in our
method. Since Mxe GyrA intein expression systems are already
commercially available, the strategy described here can easily be
adopted by the biochemical community and should be
applicable to a wide array of proteins expressed in E. coli.
Our intein tags should also be useful in combination with
expression systems with reduced RF-1 activity where some
truncation may still take place.4−6 We expect that our method
will expand the applications of suppression-based Uaa method-
ology for labeling near the C-terminus, including protein
therapeutics or studies of protein structure and function.
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Figure 2. Application of C-terminal intein tag strategy with various
amino acids, proteins, and aﬃnity tags. Top: expression and
puriﬁcation of acridon-2-ylalanine (Acd, δ) mutant of calmodulin
(CaM-δ139), or p-benzoylphenylalanine (Bzf, B) mutant of α-synuclein
(αS-B136) with on-column hydrolysis. Crude cell lysate, ﬂow through
from Ni-NTA column (FT), elution of protein after cleavage with 200
mM βME for 16 h, protein puriﬁed by fast protein liquid
chromatography (FPLC). Top Left: 1c, truncated CaM1−138; 2c,
Uaa protein fusion CaM-δ139-MxeH6; 7c, pure full length Uaa protein
CaM-δ139, molecular weight (MW) markers 11, 17, 22, 25, 32, 46, 58,
75, and 100 kDa. Top Right: 1d (1a), truncated αS1−135; 2d, Uaa
protein fusion αS-B136-MxeH6; 7d, Pure full length Uaa protein αS-
B136, MW markers 11, 17, 22, 25, 32, 46, 58, 75, and 100 kDa. Bottom:
expression and puriﬁcation of propargyl tyrosine (Ppy, π) mutant of
maltose binding protein (MBP-π363) with on-column hydrolysis and
labeling with ﬂuorescent azide reagent Rhodamine 110 azide (Faz).
Crude cell lysate, FT, elution of protein after cleavage with 200 mM
βME for 16 h, protein labeled with Faz using Cu catalysis and puriﬁed
by FPLC: 1f, truncated MBP1−362; 2f, Uaa protein fusion MBP-π363,-
MxeH6; 7f, pure full length Uaa protein MBP-π363; 8f, ﬂuorescently
labeled protein MBP-πFaz363, MW markers 17, 22, 25, 30, 46, 58, and
80 kDa.
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Figure	2-3:	Analysis	of	αS-ZRco136	 Expression,	Purification,	 and	 Labeling.	PAGE	 shows	 that	 the	 truncation	
product,	 αS1-135	 (2-1a)	 remained	 in	 the	 flow-through,	 thereby	 allowing	 efficient	 isolation	 of	 the	mature	
protein,	αS-Z136-MxeH6,	(2-2e)	using	Ni-NTA	beads.	The	hydrolysis	of	the	fusion	protein	with	βME	resulted	
in	αS-Z136	(2-7e),	which	was	then	reacted	with	Rco	at	37	°C	for	20	h	to	give	αS-ZRco136	(2-8e).	MALDI	MS	
analyses	confirmed	the	product	mass.		
 
We also wished to ensure that our methods were applicable to larger 
proteins, alternate immobilization tags, and other inteins. Therefore, I tested an 
MBP (367 amino acids) fusion with a C-terminal Mxe GyrA intein and chitin binding 
domain (CBD). I introduced a UAG codon at position 363, four residues from the 
normal MBP C-terminus, and expressed the construct with Ppy. Isolation of the 
full-length protein MBP-π363-MxeCBD (2-2f) by incubation with chitin beads and 
subsequent treatment with βME resulted in the liberation of MBP-π363-CO2H (2-7f) 
in an 8 mg/L yield. After additional purification via FPLC, 2-7f was treated with a 
fluorescent azide compound (Rhodamine 110 azide, Faz) under Cu-catalyzed 
“click” conditions to give MBP-πFaz363-CO2H (2-8f). In additional experiments 
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Figure S9.  Analysis of αS-ZRco136 expression, purification and labeling.  PAGE shows that the truncation 
product, αS1-135 (1a) remained in the flow-through, thereby allowing efficient isolation of the mature 
protein, αS-Z136-MxeH6, (2e) using Ni-NTA beads.  The hydrolysis of the fusion protein with βME resulted 
in αS-Z136 (7e), which was then reacted ith Rco at 37 °C for 20 h to give αS-ZRco136 (8e).  MALDI MS 
analyses confirmed the product ma s. 
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performed by Solongo Batjargal, which are detailed elsewhere, fusions of αS and 
CaM with DnaE inteins (Ava, Mcht, and Npu) were generated and it was found that 
expression levels were comparable to Mxe GyrA fusions and that off-column 
hydrolysis rates were comparable to or slower than Mxe GyrA.252  
 
 
Figure	 2-4:	 Purification	 of	 Maltose	 Binding	 Protein	 Containing	 Ppy	 via	 C-terminal	 Intein	 Tag	 Strategy.	
Expression	and	purification	of	propargyl	 tyrosine	 (Ppy,	π)	mutant	of	maltose	binding	protein	 (MBP-π363)	
with	on-column	hydrolysis	and	labeling	with	fluorescent	azide	reagent	Rhodamine	110	azide	(Faz).	Crude	
cell	lysate,	FT,	elution	of	protein	after	cleavage	with	200	mM	βME	for	16	h,	protein	labeled	with	Faz	using	
Cu	catalysis	and	purified	by	FPLC:	2-1f,	truncated	MBP1−362;	2-2f,	Uaa	protein	fusion	MBP-π363,-MxeH6;	2-7f,	
pure	full	length	Uaa	protein	MBP-π363;	2-8f,	fluorescently	labeled	protein	MBP-πFaz363,	MW	markers	17,	22,	
25,	30,	46,	58,	and	80	kDa.		
 
In conclusion, we have developed a traceless and efficient strategy for 
separating desired Uaa proteins from similarly sized truncation byproducts. We 
have demonstrated that a variety of proteins, Uaas, inteins, and affinity tags can 
be used in our method. Since Mxe GyrA intein expression systems are already 
commercially available, the strategy described here can easily be adopted by the 
biochemical community and should be applicable to a wide array of proteins 
expressed in E. coli. Our intein tags should also be useful in combination with 
expression systems with reduced RF-1 activity where some truncation may still 
CO2H (7d, Figure 2) in 3−10 mg/L yields in spite of
substantial truncation (≥50%). Although the crude on-column
hydrolysis products (“+ βME” lanes in Figure 2) were relatively
clean, additional fast protein liquid chromatography (FPLC)
puriﬁcation should be used to purify proteins for biophysical
assays, as is typical of most Ni-NTA puriﬁcations. We also
tested the compatibility of our method with azide amino acids
that may be subject to reduction by βME. Azf was incorporated
into αS as a “click” chemistry handle for reactions with strained
cyclooctynes. After on-column hydrolysis of αS-Z136-MxeH6
(2e), the incubation of αS-Z136-CO2H (7e) with tetramethylr-
hodamine dibenzocyclooctyne (Rco) resulted in labeling of αS
to give αS-ZRco136-CO2H (8e, SI, Figure S9). Again, at least one
round of additional puriﬁcation is typically necessary to remove
unreacted dye.
We also wished to ensure that our methods were applicable
to larger proteins, alternate immobilization tags, and other
inteins. We tested an MBP (367 amino acids) fusion with a C-
terminal Mxe GyrA intein and chitin binding domain (CBD).
We introduced a UAG codon at position 363, four residues
from the normal MBP C-terminus, and expressed the construct
with Ppy. Isolation of the full-length protein MBP-π363-
MxeCBD (2f) by incubation with chitin beads and subsequent
treatment with βME resulted in the liberation of MBP-π363-
CO2H (7f) in an 8 mg/L yield. After additional puriﬁcation via
FPLC, 7f was treated with a ﬂuorescent azide compound
(Rhodamine 110 azide, Faz) under Cu-catalyzed “click”
conditions to give MBP-πFaz363-CO2H (8f). In separate
experiments, we generated fusions of αS and CaM with
DnaE inteins (Ava, Mcht, and Npu) and found that expression
levels were comparable to Mxe GyrA fusions and that oﬀ-
column hydrolysis rates were comparable to or slower than
Mxe GyrA (see SI, Figures S7 and S10).
In conclusion, we have developed a traceless and eﬃcient
strategy for separating desired Uaa proteins from similarly sized
truncation byproducts. We have demonstrated that a variety of
proteins, Uaas, inteins, and aﬃnity tags can be used in our
method. Since Mxe GyrA intein expression systems are already
commercially available, the strategy described here can easily be
adopted by the biochemical community and should be
applicable to a wide array of proteins expressed in E. coli.
Our intein tags should also be useful in combination with
expression systems with reduced RF-1 activity where some
truncation may still take place.4−6 We expect that our method
will expand the applications of suppression-based Uaa method-
ology for labeling near the C-terminus, including protein
therapeutics or studies of protein structure and function.
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Figure 2. Application of C-terminal intein tag strategy with various
amino acids, proteins, and aﬃnity tags. Top: expression and
puriﬁcation of acridon-2-ylalanine (Acd, δ) mutant of calmodulin
(CaM-δ139), or p-benzoylphenylalanine (Bzf, B) mutant of α-synuclein
(αS-B136) with on-column hydrolysis. Crude cell lysate, ﬂow through
from Ni-NTA column (FT), elution of protein af r cleavage with 200
mM βME for 16 h, protein puriﬁed by fast protein liquid
chromatography (FPLC). Top Left: 1c, truncated CaM1−138; 2c,
Uaa protein fusion CaM-δ139-MxeH6; 7c, pure full length Uaa protein
CaM-δ139, molecular weight (MW) markers 11, 17, 22, 25, 32, 46, 58,
75, and 100 kDa. Top Right: 1d (1a), truncated αS1−135; 2d, Uaa
protein fusion αS-B136-MxeH6; 7d, Pure full length Uaa protein αS-
B136, MW markers 11, 17, 22, 25, 32, 46, 58, 75, and 100 kDa. Bottom:
expression and puriﬁcation of propargyl tyrosine (Ppy, π) mutant of
maltose binding protein (MBP-π363) with on-column hydrolysis and
labeling with ﬂuorescent azide reagent Rhodamine 110 azide (Faz).
Crude cell lysate, FT, elution of protein after cleavage with 200 mM
βME f r 16 h, protein labeled with Faz using Cu catalysis and puriﬁed
by FPLC: 1f, truncated MBP1−362; 2f, Uaa protein fusion MBP-π363,-
MxeH6; 7f, pure full length Uaa protein MBP-π363; 8f, ﬂuorescently
labeled protein MBP-πFaz363, MW markers 17, 22, 25, 30, 46, 58, and
80 kDa.
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take place.116, 117, 243 We expect that our method will expand the applications of 
suppression-based Uaa methodology for labeling near the C-terminus, including 
protein therapeutics or studies of protein structure and function.  
Section 2.3 - Materials and Methods 
2.3.1 – Materials 
 L-4-Azidophenylalanine (Azf, Z), L-4-benzoylphenylalanine (Bzf, B), Boc-L-
thionophenylalanine-1-(6-nitro)benzotriazolide, and L-4-cyanophenylalanine (Cnf, 
F*) were purchased from Bachem (Torrance, CA, USA). Acridon-2-ylalanine (Acd, 
δ) was synthesized following the procedure described previously.246 Propargyl 
tyrosine (Ppy, π) was synthesized following a procedure reported by Zhang et al.253 
Rhodamine 110 azide (Faz) was purchased from Click Chemistry Tools 
(Scottsdale, AZ, USA). Tetramethylrhodamine dibenzocyclooctyne (Rco) was 
synthesized from 5(6) -carboxytetramethylrhodamine (EMD Millipore; Darmstadt, 
Germany) and dibenzocyclooctyne-amine (Click Chemistry Tools) as described 
previously.254 A QuickChange® site-directed mutagenesis kit, E. coli BL21(DE3) 
cells, and all restriction enzymes were purchased from Stratagene (currently 
Agilent Technologies; Santa Clara, CA, USA). Ni-NTA resin and a QIAquick gel 
extraction kit were purchased from Qiagen (Valencia, CA, USA). Protease inhibitor 
cocktail was purchased from Sigma-Aldrich. DNA oligomers were purchased from 
Integrated DNA Technologies, Inc. (Coralville, IA, USA). All other chemical 
reagents were purchased from Fisher Scientific (Pittsburgh, PA, USA). DNA 
sequencing was performed at the University of Pennsylvania DNA sequencing 
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facility. Milli-Q filtered (18 MΩ) water was used for all solutions (currently EMD 
Millipore; Billerica, MA, USA). Matrix-assisted laser desorption ionization (MALDI) 
mass spectra were collected with a Bruker Ultraflex III MALDI-TOF-TOF mass 
spectrometer (Billerica, MA, USA). Protein purification was conducted on an ÄKTA 
fast protein liquid chromatography (FPLC) system (GE Healthcare Life Sciences; 
Piscataway Township, NJ, USA). Gels were imaged using a Typhoon FLA 7000 
(GE Healthcare Life Sciences).  
 
2.3.2 - General Protocol for Expression of Intein-Containing Proteins 
E. coli BL21-Gold (DE3) cells were transformed with a plasmid containing a 
protein of interest with a TAG mutation at the desired site and a plasmid containing 
the UaaRS and tRNACUA pair (see below for specific UaaRS/tRNA pair used). In 
all cases, the plasmid encoding the UaaRS/tRNA pair was streptomycin (Strep) 
resistant, whereas the plasmid encoding the protein of interest was ampicillin 
(Amp) resistant. Thus, cells were selected on the basis of Amp (100 μg/mL) and 
Strep (100 μg/mL) resistance. A starter culture of 4 mL LB media was inoculated 
with a single colony and was grown at 37 °C in the presence of Amp (100 mg/L) 
and Strep (100 mg/L) for approximately 4 h. A secondary culture of 1 L M9 media 
was inoculated with 4 mL of the starter culture and grown at 37 °C with the same 
concentrations of Amp and Strep. M9 minimal media was prepared by adding the 
following autoclaved solutions to 1 L of autoclaved water containing 6 g Na2HPO4, 
3 g KH2PO4, 0.5 g NaCl and 1 g NH4Cl: 1 mL of 2 M MgSO4, 1 mL of 15 mg/mL 
FeCl2 (in 1.0 M HCl), 1 mL of 15 mg/mL ZnCl2 (in acidified H2O), 2 mL of 10% 
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Bacto™ Yeast Extract, 20 mL of 10% glycerol (v/v) and 1 μL of 1 M CaCl2. The 
culture was induced by the addition of the Uaa (0.5 – 1 mM) followed by 0.5 mM 
of IPTG when it reached an OD600 of 0.7 – 1.0 and allowed to grow at 18 °C 
overnight, with shaking at 250 rpm.  
 
Expression of αS-F*136-intein and αS-Z136-intein Fusions 
These protein expressions followed the general protocol for intein-
containing fusions. Each plasmid containing an αS-TAG136-intein (pαS-TAG136-
MxeH6, pαS-TAG136-AvaH6, pαS-TAG136-MchH6, or pαS-TAG136-NpuH6) was 
transformed into pDULE2-pXF (formerly known as pDULE2-pCNF) containing E. 
coli BL21(DE3) cells. Once the secondary culture reached OD600 of 0.8, Cnf or Azf 
(0.6 mM) was added to the culture just before induction with IPTG.  
 
Expression of CaMF-F*139-intein Fusions 
These protein expressions followed the general protocol for intein-
containing fusions. Each plasmid containing CaM-TAG139-intein (pCaMF-TAG139-
MxeH6 or pCaMF-TAG139-MchH6) was transformed into E. coli BL21(DE3) cells 
carrying the pDULE2-pXF plasmid. After the secondary culture reached OD600 of 
0.8, the culture was induced by the addition of 0.6 mM Cnf, followed by the addition 
of IPTG.  
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Expression of CaMF-δ139-MxeH6 Fusion 
This protein expression followed the general protocol for intein-containing 
fusions. The pCaMF-TAG139-MxeH6 plasmid was used to transform E. coli 
BL21(DE3) cells carrying the pDULE2-Acd plasmid.246 When the OD600 reached 
0.8, 70 mg of Acd (for 250 mL expression) was solubilized in 4 mL sterile water 
(with 6 drops 5 M NaOH) and added into the culture, followed by induction with 
IPTG.  
 
Expression of αS-B136-MxeH6 Fusion  
This protein expression followed the general protocol for intein-containing 
fusions. A plasmid encoding pαS-TAG136-MxeH6 was co-transformed with the 
pDULE2-Bzf plasmid255 into E. coli BL21(DE3) cells. Bzf was solubilized in 4 mL 
of sterile water with (4 drops of 10 M NaOH) and added to the culture such that the 
final concentration of Bzf was 0.5 mM. After the addition of Bzf at OD600 of 0.8, 
protein expression was induced with IPTG. Bzf is a light sensitive compound, thus 
the protein expression and the following purification were carried out in a dark 
room.  
 
 
Expression of MBP-π363-MxeCBD Fusion 
This protein expression followed the general protocol for intein-containing 
fusions. A plasmid encoding pTXB10-MBP-TAG363-MxeCBD was co-transformed 
with the pDULE2-pXF plasmid into E. coli BL21(DE3) cells. When OD600 of the 
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protein expression culture reached 0.8, Ppy (1 mM) was added, followed by IPTG 
induction.  
 
Expression of pET15b-CaM Mutant 
 A pET15b plasmid encoding CaMF-TAG139 was transformed into E. coli BL 
21(DE3) cells carrying the pDULE2-pXF plasmid. This protein expression followed 
the protocol for intein-containing fusions except that the culture was induced with 
1.0 mM IPTG when it reached an OD600 of 0.8 and allowed to grow at 37 °C 
overnight, shaking at 250 rpm.  
 
2.3.3 - General Procedure for Purification of Proteins with His6 Tags 
Cells (1 L expression) were harvested at 5,000 RPM using a GS3 rotor and 
Sorvall RC-5 centrifuge for 15 min at 4 °C. After discarding the supernatant, the 
pellet was resuspended in 30 mL of resuspension buffer: 40 mM Tris, 5 mM EDTA, 
pH 8.3, protease inhibitor cocktail and 1 mM phenylmethanesulfonyl fluoride 
(PMSF). The cells were lysed by sonication on ice, and the lysate was centrifuged 
at 13,900 RPM for 20 min at 4 °C. The supernatant was then incubated with Ni-
NTA resin (CV = 3 mL) for 1 - 2 h on ice. This slurry was loaded into a fritted 
column, and the liquid allowed to flow through. The resin was washed extensively, 
first with 15 mL of Buffer A (50 mM HEPES, pH 7.5), then twice with 10 mL of 
Buffer B (50 mM HEPES, 5 mM imidazole, pH 7.5). At this point, the protein can 
be eluted with 300 mM imidazole for off-column hydrolysis or can be incubated 
with βME for on-column hydrolysis.  
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Purification of MBP-π363-MxeCBD 
Cells (1 L expression) were harvested at 5,000 RPM using a GS3 rotor and 
Sorvall RC-5 centrifuge for 15 min at 4 °C. The supernatant was discarded, and 
the pellet was resuspended in 30 mL of resuspension buffer: 20 mM Tris, 500 mM 
NaCl, pH 7.5, protease inhibitor cocktail and 1 mM PMSF. After lysing the cells by 
sonication on ice, the lysate was centrifuged at 13,900 RPM for 20 min at 4 °C. 
The supernatant was incubated with chitin beads (CV = 3 - 4 mL) for 1 - 2 h on ice. 
This slurry was loaded into a fritted column, and the liquid allowed to flow through. 
The resin was washed extensively with 10 mL of 20 mM Tris, 500 mM NaCl, pH 
7.5 three times. Then, the bound protein was subjected to on-column hydrolysis.  
 
2.3.4 - General Procedure for On-Column Hydrolysis 
To the resin (either Ni-NTA or chitin beads) bound with the protein of 
interest, Buffer A (50 mM HEPES, pH 7.5) was added into the column such that 
the final volume (resin CV + buffer volume) was 10 mL. Then, 141 μL of βME stock 
(stock concentration = 14.2 M) was added such that the final concentration of βME 
was 200 mM, and the column was incubated for 16 – 24 h at the desired 
temperature, without shaking or on a tube rotisserie (gentle mixing). After overnight 
incubation, the flow-through was collected, dialyzed against 20 mM Tris, pH 8.0, 
and purified over HiTrap Q column using a 100 min NaCl gradient (0 to 0.5 M NaCl 
in 20 mM Tris, pH 8.0). The product fractions were pooled and dialyzed against 
the appropriate storage buffer and stored at - 80 °C until further use. Storage buffer 
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for αS and MBP: 20 mM Tris, 100 mM NaCl, pH 7.5. Storage buffer for holo CaM: 
6 mM CaCl2, 15 mM HEPES, 140 mM KCl, pH 6.7.  
 
2.3.5 - General Procedure for Off-column Hydrolysis. 
 The mature fusion protein was eluted from the Ni-NTA resin with 6 x 2 mL 
portions of elution buffer (50 mM HEPES, 300 mM imidazole, pH 7.5). The eluted 
fractions were combined, and βME stock was added such that the final 
concentration of βME was 200 mM. The protein solution was incubated for 16 – 24 
h at desired temperature without shaking or on a tube rotisserie (gentle mixing). 
The hydrolyzed protein was dialyzed against 20 mM Tris, pH 8.0 and incubated 
with Ni-NTA resin for 1 h on ice. The flow-through was collected and purified by 
HiTrap Q column as described above.  
 
2.3.6 - Comparison of On- and Off-Column Hydrolysis.  
After Ni-NTA purification, but before eluting the fusion protein with 
imidazole, 50% of the Ni-beads were transferred into another fritted column and 
then eluted with 50 mM HEPES, 300 mM imidazole, pH 8.0. Based on SDS PAGE 
analysis, clean fractions were pooled and treated with 200 mM βME without 
removal of imidazole. The other resin was brought up in 50 mM HEPES pH 8.0 in 
the column, to the same volume as the off-column fraction volume, and treated 
with 200 mM βME (Figure 2-1). Both batches were incubated at 4 °C or RT for 24 
h without shaking, producing the hydrolyzed product, αS-F*136-CO2H, in a similar 
91	
	
yield. However, one must be cautioned that the high concentration of βME may 
reduce the Ni2+ in the Ni-NTA, which can be observed by brown discoloration.  
 
Table	2-1: Calculated	and	Observed	Protein	Masses.	
	
Peptide Calculated m/z [M+H]+ Observed m/z [M+H]+ 
αS-F*136-MxeH6 (2-2a) 37328 37328 
αS-F*136-CO2H (2-7a) 14469 14469 
CaMF-F*139-MxeH6 (2-2b) 39560 39562 
CaMF-F*139-CO2H (2-7b) 16701 16703 
CaMF-d139-MxeH6 (2-2c) 39652 39653 
CaMF-d139-CO2H (2-7c) 16793 16793 
αS-B136-MxeH6 (2-2d) 37406 37406 
αS-B136-CO2H (2-7d) 14548 14548 
αS-Z136-MxeH6 (2-2e) 37345 37346 
αS-Z136-CO2H (2-7e) 14486 14488 
αS-ZRco136-CO2H (2-8e) 15175 15176 
MBP-p363-MxeH6 (2-2f) 67438 67445 
MBP-p363-CO2H (2-7f) 39597 39597 
MBP- pFaz363-CO2H (2-8f) 40171 40171 
 
The masses for full length MBP-π363-MxeH6 (68242 Da) and MBP-π363-CO2H 
(40401 Da) were not observed. Observed masses in the table above correspond 
to proteolyzed MBP8-367-π363-MxeH6 and MBP8-367-π363-CO2H consistent with the 
N-terminal cleavage of a ‘MKTEEGK’ fragment to reveal a N-terminal leucine. The 
mass of the Cu click reaction with Faz is consistent with this proteolysis event.  
 
 
 
 
92	
	
2.3.7 - Variation of Cleavage Conditions 
To analyze the effect of temperature on the protein splicing rate, the fusion 
protein, αS-F*136-MxeH6 (2-2a, 1 mg/mL, 100 μL) was incubated in the buffer (50 
mM HEPES, pH 7.5) supplemented with 200 mM of βME (3.5 μL of 14.2 M stock 
solution) at various temperatures (4 °C, 15 °C, RT, or 37 °C), without shaking. For 
βME concentration dependent analysis, βME was added to each protein solution 
(100 μL) such that the final concentration of βME was 25, 100, 200, 500, or 1000 
mM. The mixture was incubated at room temperature for 24 h without shaking. 
Lastly, to test the pH dependent hydrolysis rate, the fusion protein (250 μL in 50 
mM HEPES at pH 7.5) buffer was exchanged to 50 mM MES at pH 6.0, 50 mM 
HEPES at pH 7.0, 50 mM HEPES at pH 8.0, or 50 mM CHES at pH 9.0 using an 
Amicon (EMD Millipore) Ultra 0.5 mL 3 kDa spin column. The concentration of the 
buffer-exchanged protein was re-measured using a BCA assay and adjusted to ~ 
1 mg/mL. Each protein solution (100 μL) at various pHs was incubated with 200 
mM of βME at room temperature. As a control reaction, the protein solution (25 
μL) at various pHs was incubated without βME addition. The reactions were 
sampled at various times for PAGE analysis as described above.  
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Figure	2-5:	βME	Concentration	Dependence	of	the	rate	of	Splicing	of	Fusion	Protein	aS-F*136-MxeH6	(2a).	
Fusions	were	incubated	in	the	presence	of	varying	concentrations	of	βME	at	pH	7.5	at	22	°C.	PAGE	analysis	
was	used	to	monitor	cleavage	of	fusion	protein	2-2a	by	βME	to	give	intein	2-3a	and,	after	hydrolysis,	αS-
F*136-CO2H	(2-7a).		
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Figure S2. βME concentration dependence of the rate of splicing of fusion protein αS-F*136-MxeH6 (2a).  
Fusions were incubated in the presence of varying concentrations of βME at pH 7.5 at 22 °C.  PAGE 
analysis was used to monitor cleavage of fusion protein 2a by βME to give intein 3a and, after hydrolysis, 
αS-F*136-CO2H (7a). ! !
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Figure	2-6:	pH	Dependence	of	the	Rate	of	Splicing	of	Fusion	Protein	aS-F*136-MxeH6	(2-2a).	Fusions	were	
incubated	 in	 the	presence	of	200	mM	βME	at	22	°C	at	varying	pHs.	PAGE	analysis	was	used	to	monitor	
cleavage	of	fusion	protein	2-2a	by	βME	to	give	intein	2-3a	and,	after	hydrolysis,	αS-F*136-CO2H	(2-7a).		
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Figure S3. pH ependence of the rate of splicing of fusion p otein αS-F*136-MxeH6 (2 ).  Fusi ns were 
incubated in the pre ence f 200 mM βME at 22 °C at varying pHs.  PAGE analysis was used to monitor 
cleavage of fusion protein 2a by βME to give intein 3a and, after hydrolysis, αS-F*136-CO2H (7a). !  
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Figure	 2-7:	 Temperature	 Dependence	 of	 the	 Rate	 of	 Splicing	 of	 Fusion	 Protein	 aS-F*136-MxeH6	 (2-2a).	
Fusions	were	incubated	in	the	presence	of	200	mM	βME	at	pH	7.5	at	varying	temperatures.	PAGE	analysis	
was	used	to	monitor	cleavage	of	fusion	protein	2-2a	by	βME	to	give	intein	2-3a	and,	after	hydrolysis,	αS-
F*136-CO2H	(2-7a).		
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Figure S4. Temp rature depend nc  of the rate of splicing of fusion protein αS-F*136-MxeH6 (2a).  
Fusions were incubated in the pr sence of 200 mM βME at pH 7.5 at varying temperatures.  PAGE 
analysis was used to monitor cleavage of fusion protein 2a by βME to give intein 3a and, after hydrolysis, 
αS-F*136-CO2H (7a). !  
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2.3.8 - Analysis of Splicing Kinetics  
The intensities of the Coomassie-stained gel bands were quantified using 
ImageQuant TL software (GE Healthcare). The intensity of the fusion protein 2-2a 
at t = 0 was normalized to unity. The fractional intensity values were plotted as a 
function of time and fit to a pseudo first order kinetic model with KaleidaGraph 
(Synergy software; Reading, PA, USA) using the equation 2.1:  
y = y0 + A • exp (-kobst)             (2.1) 
Here, y is the fractional intensity of the fusion protein, t is the time in hours, A is a 
scaling factor for the fusion protein depletion (adjustable parameter), and y0 
indicates the fraction of the fusion protein remaining at the reaction endpoint 
(adjustable parameter). The rate data for cleavage reactions with varying βME 
concentrations (Figure 2-5), pHs (Figure 2-6), and temperatures (Figure 2-7) were 
all fit to equation (2.1). The observed rate constants at different concentrations of 
βME were then fit to equation 2.2 to obtain a second order rate constant (k) of 5.79 
x 10-4 M-1• s-1 (Figure 2-8). 
kobs = [βME] • k             (2.2) 
Rate constants obtained at different temperatures were fit to the Arhenius 
expression to determine the activation barrier (Ea) using equation (2.3), where R 
is the gas constant, T is temperature, and A is the pre-exponential factor (Figure 
2-8): 
ln(kobs) = -Ea/RT + ln(A)                       (2.3) 
A value of 10.6 kcal•mol-1 was obtained for Ea.  
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Figure	 2-8:	 Dependence	of	 Splicing	Rate	of	 Fusion	Protein	 2a	on	Reaction	Conditions.	 Plots	 of	 reaction	
progress	derived	from	densitometry	analysis	of	SDS	PAGE	gels	for	(a)	varying	βME	concentration	at	pH	7.5	
and	22	°C,	(b)	varying	pH	at	200	mM	βME	and	22	°C,	and	(c)	varying	temperature	at	200	mM	βME	and	pH	
7.5.	The	observed	rates	from	(a)	and	the	22	°C	data	from	(c)	can	be	fit	as	a	function	of	βME	concentration	
at	pH	7.5	and	22	°C	(d)	to	obtain	a	rate	constant	of	5.79	x	10-4	M-1•s-1.	The	activation	energy	for	cleavage,	
determined	from	an	Arhenius	plot	(e)	of	the	reactions	at	varying	temperature	(d),	is	10.6	kcal•mol-1.		
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Figure S5. Dependence of splicing rate of fusion protein 2a on reaction conditions.  Plots of reaction 
progress derived from densitometry analysis of SDS PAGE gels for (a) varying βME concentration at pH 
7.5 and 22 °C, (b) varying pH at 200 mM βME and 22 °C, and (c) varying temperature at 200 mM βME 
and pH 7.5.  The observed rates from (a) and the 22 °C data from (c) can be fit as a function of βME 
concentration at pH 7.5 and 22 °C (d) to obtain a rate constant of 5.79 x 10-4 M-1•s-1.  The activation 
energy for cleavage, determined from an Arhenius plot (e) of the reactions at varying temperature (d), is 
10.6 kcal•mol-1. !  
98	
	
2.3.9 – Analysis of Uaa Proteins 
Analysis of CaMF-δ139.  
After the Ni-NTA purification, 25% (v/v) of the beads were transferred to 
another fritted column and eluted with 300 mM imidazole for further analyses. The 
remaining 75% of the beads were incubated with 200 mM βME at 22 °C for 24 h. 
The flow-through was collected and purified by the procedure described above. 
The fluorescent gel was imaged using a UVP Model UVLS-28 long wave UV lamp 
and a Samsung Galaxy S4 13 megapixel camera.  
 
Analysis of αS-B136.  
After the Ni-NTA purification, 25% (v/v) of the beads were transferred to 
another fritted column and eluted with 300 mM imidazole for further analyses. The 
remaining 75% of the beads were incubated with 200 mM βME at 22 °C for 24 h. 
The flow-through was collected and purified by the procedure described above. 
Bzf is a light sensitive compound, thus direct exposure to light should be avoided. 
Total protein content was visualized using Coomassie brilliant blue.  
 
Labeling and Analysis of αS-Z136.  
After Ni-NTA purification, 25% (v/v) of the 2-2e beads were aliquotted to a 
fritted column and eluted with 300 mM imidazole for further analyses. The 
remaining 75% of the 2-2e beads were incubated with 200 mM βME at 22 °C for 
20 h. The flow- through was collected and purified by FPLC. 100 μL of Q-column 
purified αS-Z136 (2-7e, 1 mg/mL) was reacted with 10 eq. of tetramethylrhodamine 
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dibenzocyclooctyne (Rco) at 37 °C for 20 h. Excess dye was removed by buffer 
exchange using Amicon Ultra 3 kilodalton centrifugal filters and an Eppendorf 
5415R benchtop centrifuge. The gel fluorescence images and MALDI MS of the 
purified αS-ZRco136 (2-8e) confirmed the presence of the Azf and Rco labeled 
protein.  
 
Labeling and Analysis of MBP-π363.  
The Q-column purified MBP-π363-CO2H (12.5 μL; in 20 mM Tris, 250 mM 
NaCl, pH 8.0) was labeled with 0.5 μL fluorescent Rhodamine 110 azide (Faz, 10 
mM) using 2.5 μL of premixed catalyst solution, composed of THPTA (20.2 mM), 
CuSO4 (5.11 mM), and sodium ascorbate (53.77 mM), at 37 °C for 4 hours. The 
reactions were then boiled with a gel loading dye (5 μL) for 10 min at 95 °C and 
analyzed by SDS PAGE. Fluorescence images were obtained with a Typhoon FLA 
7000. Fluorescein was imaged using 473 nm excitation and a Y520 filter. Total 
protein content was visualized using Coomassie brilliant blue.  
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CHAPTER 3: 
 
SYNTHESIS AND CHARACTERIZATION OF THIOAMIDE CONTAINING PROTEINS 
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Reprinted (adapted) with permission from (Christopher R. Walters, D. Miklos 
Szantai-Kis, Yitao Zhang, Zachary Reinert, W. Seth Horne, David M. Chenoweth, 
and E. James Petersson) the Royal Society of Chemistry (Chem. Sci., 2017,8, 
2868-2877). Copyright (2017) Royal Society of Chemistry.256 
Section 3.1 – Introduction 
The incorporation of functional molecules for monitoring and manipulating 
protein folding has greatly facilitated studies of biochemical phenomena.257 The 
optimal choice of modification to a protein of interest depends on the type of 
process to be tracked, disrupted, strengthened, or isolated. Recently, there has 
been an emerging interest in making subtle alterations to the protein backbone to 
provide additional means to probe and mimic dynamic protein movements and 
interactions.98, 103, 258-260 In particular, substituting a thioamide peptide linkage at 
single or multiple positions provides a small but powerful means to influence and/or 
monitor protein dynamics or function.  
Thioamides (a.k.a. thionoamides, thioxoamides) have distinct properties 
from oxoamides, including a larger van der Waals radius, red shifted πàπ* and 
nàπ* transitions, lower oxidation potential, lower infrared (IR) stretching frequency 
and lower N–H pKa.261-265 These properties have allowed thioamides to be 
leveraged as photoswitches, Förster resonance energy transfer (FRET) acceptors, 
and photoinduced electron transfer quenchers, as well as IR and circular dichroism 
(CD) spectroscopic probes in biochemical systems.220, 221, 232, 234, 235, 237, 266-269 
Although thioamides have already proven to be valuable multifaceted probes, few 
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studies have sought to elucidate the energetic impacts they have on peptide or 
protein folding. This consideration is of the utmost importance in assessing the 
thioamide's potential as a “minimalist” spectroscopic label.  
Previous structural studies of thioamide substitutions largely relied upon 
short, isolated protein motifs in the absence of a tertiary structure context. In fact, 
when we began this work, there were no published studies of thioamides in 
proteins of defined tertiary structure. Fischer, Kiefhaber, and coworkers provided 
the most complete study of the effects of thioamides in α-helices, using model 
helical polyalanine peptides bearing thioalanine (AlaS, thioamide substitutions are 
denoted by superscript “S” throughout) substitutions.231 Their analysis revealed 
that the thioamide disrupts the helix if substituted at a central position, but is less 
destabilizing at the N-terminus. Their results suggest that the thioamide is similar 
to a glycine substitution at the same position in terms of helix disruption. 
Thioamides have also been incorporated into the 15-mer S peptide, which forms 
an α-helix upon binding to ribonuclease S.270 Substitutions were made throughout 
the helix and were destabilizing at every position, with varying ΔΔG values in 
comparison to the WT complex (0.6–4.7 kcal mol-1). However, in a different study, 
Miwa and coworkers observed that a LeuS substitution in the central region of an 
α-helical coiled-coil dimer gave a similarly helical structure to the oxoamide 
counterpart (as observed by CD) and increased the melting temperature by 10 
°C.221 This discrepancy, which likely arises from subtle geometric differences 
between an isolated a-helix and that in a coiled coil271, implies that tertiary structure 
may serve to lessen or even reverse destabilization by a thioamide.  
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In an alternate secondary structure context, the thioamide was found to be 
tolerated between residues i + 2 and i + 3 in a type II β-turn.220 Here, the 
thiocarbonyl is solvent-exposed, and the interior of the turn does not require any 
reorganization to accommodate the larger sulfur atom. Thioamide substitutions 
have been made in a tryptophan-rich β-hairpin to interrogate the role of hydrogen 
bond formation in the folding transition state.232 However, the results of this study 
may not be general to all b-sheets due to the highly engineered sequence of the 
tryptophan zipper peptide. Most recently, Raines and coworkers made thioamide 
substitutions in collagen model peptides (CMPs) to assess their impact in the Pro-
Pro-Gly (PPG) repeats of an all PPG polyproline type II (PPII) helix.233 It was found 
that incorporation of GlyS (i.e., PPGS) was significantly destabilizing, whereas 
substitution with ProS (i.e., PPSG) was slightly stabilizing to the triple helix.  
Taken together, the above studies present a limited understanding about 
where thioamides can be utilized most efficiently in biological systems. Thioamides 
are likely to have much more nuanced effects in proteins with complex tertiary folds 
and dynamic regions. Thus far, only three full-length thioamide proteins have been 
described in the literature: the semi-synthetic constructs a-synuclein and 
dihydrofolate reductase, and the natural protein methyl-coenzyme M reductase.153, 
226, 229 Consequently, there have been no systematic studies of thioamides in 
folded proteins, which will be essential to guiding their future use as spectroscopic 
probes or as modulators of protein structure and function.  
Herein, we describe an in-depth study of the effects of thioamide backbone 
substitution in two benchmark protein systems: (1) the C-terminal loop and helix of 
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calmodulin (CaM), an α-helical protein and (2) the β-sheet of the B1 domain of 
protein G (GB1), a compact α/β tertiary structure. For each protein, we performed 
CD spectroscopy studies to elucidate the structural and thermodynamic stability 
changes resulting from thioamide insertion. The two systems represent new hosts 
for examination of the effects of thioamides on protein secondary structure in a 
tertiary fold context. Overall, the findings reported here lay the groundwork for the 
rational implementation of thioamides as biophysical probes in diverse protein 
systems.  
 
Figure	 3-1:	 Top:	 NCL	 synthesis	 of	 CaM	 thioproteins.	 Cys135	 is	 masked	 as	 glutamine	 by	 alkylation	 with	
iodoacetamide.	 Bottom:	 Synthesis	 of	 GB1	 thioproteins	 by	 hydrazide	 ligation.	 Cys24	 undergoes	
desulfurization	to	the	native	residue	Ala24.		
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Section 3.2 – Results and Discussion 
 
3.2.1 – Design and Semisynthesis of CaM Thioproteins 
 
CaM is a 148 amino acid, α-helical calcium signaling protein that is 
ubiquitous in eukaryotes. It is comprised of two structurally similar domains (N- and 
C-terminal), each containing two calcium binding sites.272 Upon binding calcium, 
CaM undergoes a conformational change to expose a trans-domain helix, which 
acts as a binding platform for many of its regulatory target proteins.273, 274 
Previously, a semisynthesis of CaM was performed to modify the C-terminal EF-
hand.275 Since these authors observed some destabilization of CaM, we decided 
to limit thioamide substitutions in our investigations to the C-terminal loop and 
helix, near the highest affinity calcium binding site. Thus, I performed native 
chemical ligation (NCL) reactions between the expressed fragment CaM1–134 and 
the synthetic fragment CaM135–148.  
An existing CaM intein fusion was modified to produce CaM1–134-GyrA-His6, 
which was expressed, purified, and cleaved with 2-mercaptoethanesulfonate 
(MES) to yield the C-terminal thioester CaM1–134-MES (Figure 3-1, Top).252 Each 
thiopeptide was made by solid phase peptide synthesis (SPPS) with the thioamide 
installed as previously described.222 NCL reactions were performed between the 
CaM135–148 fragment and CaM1–134-MES using published conditions optimized for 
thiopeptides.153 The native residue at position 135 in CaM is a Gln. Therefore, Cys 
at this position was masked after NCL to mimic Gln (denoted as CysQ) by 
iodoacetamide treatment. This process routinely yielded 1–2 mg quantities of 
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purified CaM (8–25% isolated yield with CaM1–134-MES protein as a limiting 
reagent).  
Positions for thioamide substitutions were selected with three criteria in 
mind: importance to local secondary structure, functional importance for Ca2+ 
binding, and ease of synthesis of peptides and thioamide precursors. Of particular 
interest were residues in the C-terminal helix of Ca2+-bound CaM (Tyr138, Glu139, 
Glu140, Phe141, and Val142). Glu140 is functionally important as it undergoes 
significant conformational change from the apo protein in order to directly chelate 
a Ca2+ ion in the holo protein.273 Tyr138, Glu139, Phe141, and Val142 reside in the N-
terminal and central portions of the helix. I hypothesized that thioamide substitution 
at these sites would be destabilizing due to the weaker hydrogen bond acceptor 
capacity of the thiocarbonyl. Two additional sites were chosen to assess the impact 
of substitutions in loops and solvent exposed areas proximal to this helix (Val136 
and Ala147, the penultimate residue in CaM).  
Proteins bearing each of these thioamide substitutions were synthesized 
using the MES thioester method described above and verified by MALDI-MS 
(Table 3-5). Wild-type (WT) CaM and a Cys135 mutant were expressed in E. coli as 
controls for proper refolding of the thioproteins. The Cys135 mutant was subjected 
to denaturing NCL conditions similar to the thioproteins and subsequently 
underwent the same purification and capping reaction.  
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3.2.2 – CaM Thioprotein Folding Thermodynamics 
Each CaM variant was characterized by CD spectroscopy under two 
different buffer conditions: one for the calcium-bound holo protein (10 mM Tris pH 
7.5, 2 mM CaCl2) and another for the calcium-free apo form (10 mM Tris pH 7.5, 
0.5 mM ethylenediaminetetraacetic acid, EDTA). CaM CD spectra show a 
prototypical α-helical signature with minima at 208 and 222 nm (Figure 3-2). 
Spectra for the thioprotein variants include a small minimum between 260 and 280 
nm resulting from the thioamide πàπ* transition. This peak is weaker than the 
comparable transition observed in GB1 and collagen (vide infra), or in previous 
reported small thiopeptides.220, 221, 234 The attenuation of the thiocarbonyl CD signal 
is likely an environmental and concentration based effect, as the thioamide in CaM 
is a small fraction of the overall amide content and the region containing the 
thioamide is destabilized in several variants. The thioamide nàπ* transition at 340 
nm is not visible in any of the CaM CD spectra.  
Among the holo proteins, the spectrum of CysQ135 is similar in shape and 
magnitude to that of WT CaM, indicating the side chain modification necessary to 
enable NCL has no significant effect on the fold (Figure 3-2, Top). Most of the 
thioamide substitutions appear well tolerated in the holo protein; however, the 
TyrS138 and PheS141 modifications considerably alter the folded state, with a nearly 
three-fold decrease in molar residue ellipticity (MRE, θ) at 222 and 208 nm. These 
mutants show a similar helical signature to the N-terminal truncation mutant CaM1–
71, suggesting that the C-terminal domain may be completely disordered as a result 
of thioamide incorporation (Figure 3-3). To understand more about the nature of 
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each thioamide substitution, I subjected the CaM variants to thermal denaturation. 
Like WT CaM, each of the thioamide variants and the CysQ135 oxo control have 
melting temperatures greater than 80 °C in the presence of Ca2+ (Figure 3-4).  
Upon the removal of calcium by EDTA, CaM reverts to the apo structure, 
which lacks the stable transdomain helix and open EF hands observed in the holo 
form.276, 277 I hypothesized that the substantial structural differences between the 
apo and holo folds may lead a thioamide at a given site to have distinct effects in 
those two contexts. Thus, I carried out an analogous series of CD experiments to 
characterize folding in the apo CaM variants. Surprisingly, the CysQ135 modification 
appears to be significantly perturbing to the apo form, reducing helicity by half 
relative to apo WT CaM (Figure 3-2, Bottom). While the origins of the effect of side 
chain modification at residue 135 are not clear, we used the data observed for the 
CysQ135 oxo control as a benchmark to probe the impact of thioamide incorporation 
on the apo fold.  
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Figure	3-2:	Holo	(top)	and	apo	(bottom)	θMRE	spectra	for	the	WT,	CysQ135,	and	all	thioCaM	variants.	TyrS138,	
GluS140,	and	PheS141	show	the	largest	disruptions	in	helicity.	
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Figure	3-3:	Molar	ellipticity	(θn)	of	holo	CaM	truncations	(top)	and	apo	CaM	truncations	(top).	TyrS138	and	
PheS141	modifications	are	more	disruptive	than	losing	the	C-terminal	helix	(CaM1-134),	but	not	as	disruptive	
as	removal	of	the	C-terminal	domain	(CaM1-71)	in	the	apo	structure.	
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Figure	3-4:	Thermal	melting	profiles	of	holo	CaM	variants	plotted	as	θMRE	transformed	data.	
 
Each of the apo proteins show complete unfolding transitions over the 
temperature range of 5 to 95 °C. Initial apo thermal melts were performed on WT 
CaM and the CysQ135 control. The melting temperature for the WT CaM sample is 
lower than values previously reported in literature,278-281 likely due to different 
buffer conditions. Although I attempted to fit our data to a two-state model (Table 
3-9, Figures 3-18 through 3-21), I ultimately chose to analyze our results using a 
three-state model. The three-state model has been rigorously tested for CaM and 
has shown residuals that are more random and have smaller variance than those 
from two-state model, indicating that CaM unfolding proceeds through a semi-
stable intermediate.281 Additionally, the enthalpy and melting temperature values 
obtained in two-state fitting had higher error values, suggesting that the three-state 
fitting procedure was superior for our analysis. Therefore, I report thermodynamic 
data for each transition (TM1, ΔH1, TM2, and ΔH2) and an overall ΔGU that is the 
sum of the individual unfolding free energies for each transition calculated at 25 °C 
(Table 3-1).  
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For comparison of three-state CaM unfolding to the two-state unfolding of 
GB1, I generated pseudo fraction folded (Ff*) plots based on this three-state model, 
where the intermediate state makes a weighted contribution to the total fraction of 
folded protein (Figure 3-5). I denote the half-point of these weighted unfolding 
curves as TM*. Using this fitting model, I determined that CysQ135 CaM is slightly 
less stable than WT CaM in TM* and ΔGU; however, this minor change in stability 
should not prevent it from serving as an appropriate control to study the effects of 
the thioamide substitutions.  
 
Figure	 3-5:	 Thermal	 Stability	 of	 CaM	 Thioamide	 Variants.	 CD	 thermal	 melts	 of	 stabilizing	 and	
destabilizing	apo	CaM	variants	plotted	as	fraction	folded	(Ff*)	fits	showing	a	weighted	contribution	
of	 the	 intermediate	 to	 the	 folded	 state	 as	 discussed	 above.	 Melting	 curves	 were	 obtained	 by	
measuring	the	θ222	at	1	°C	increments	in	10	mM	Tris,	0.5	mM	EDTA	pH	7.5.	Transformation	of	raw	
CD	signal	to	MRE	values	and	three-state	fitting	procedures	were	performed	as	described	in	Section	
3.3.	
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Table	3-1:	Apo	CaM	thermodynamic	values.	
 
 
Using the CysQ135 protein as a basis for comparison, AlaS147 slightly 
destabilizes the apo fold, lowering ΔGU by 0.4 kcal mol-1. In agreement with the 
CD spectra, TyrS138 and GluS140 appear to be the most destabilizing mutations, 
decreasing ΔGU by 1.8 and 2.0 kcal mol-1, respectively. ValS142 is well tolerated, 
giving rise to a ΔGU within error of the oxoamide. Unexpectedly, both ValS136 and 
GluS139 show elevated melting temperatures and an increase of ΔGU by 0.5 kcal 
mol-1. The unstable PheS141 construct was prone to aggregation during thermal 
denaturation, precluding rigorous thermodynamic analysis. Nevertheless, the 
thioamide substitutions that I could study span a range of thermodynamic effects, 
which we can interpret in terms of known structures.  
The analysis of the thioamide substitutions in apo CaM is limited by the 
small number of high-resolution structures available. Here, the analysis will focus 
on structures of the apo protein from Rattus norvegicus (crystal, PDB entry 1QX5) 
and Xenopus laevis (NMR, PDB entry 1CFD).276, 277 While the differences in these 
two structures are valuable in considering the dynamics of apo CaM, it should be 
CaM	
Variant	
TM1												
(°C)	
ΔH1																	
(kcal	mol-1)	
TM2																		
(°C)	
ΔH2												
(kcal	mol-1)	
TM*															
(°C)	
ΔTm*	
(°C)	
ΔGU																
(kcal	mol-1)	
ΔΔGU	
(kcal	mol-1)	
WT	 43.5	±	0.6	 33.1	±	0.8	 48.6	±	0.6	 60.5	±	0.7	 46.8	±	0.3	 ---	 6.4	±	0.2	 ---	
CysQ135	Oxo	 38.9	±	0.8	 30.2	±	0.9	 48.8	±	0.7	 61.7	±	0.8	 45.5	±	0.4	 ---	 5.9	±	0.1	 ---	
ValS	136	 39.6	±	0.5	 36.7	±	0.6	 55.3	±	0.8	 52.0	±	0.5	 48.6	±	0.7	 3.2	 6.5	±	0.1	 0.6	
TyrS138	 34.7	±	0.8	 39.7	±	0.7	 43.0	±	0.9	 51.1	±	1.0	 39.3	±	0.8	 -6.2	 4.1	±	0.2	 -1.8	
GluS139	 40.7	±	0.7	 40.1	±	0.4	 51.9	±	0.6	 53.9	±	0.9	 47.0	±	0.1	 1.6	 6.4	±	0.1	 0.5	
GluS140	 33.9	±	1.1	 34.5	±	0.6	 45.5	±	0.8	 45.9	±	1.0	 40.4	±	0.8	 -5.1	 3.9	±	0.2	 -2.0	
ValS142	 36.4	±	0.6	 35.5	±	0.8	 48.4	±	0.8	 62.9	±	0.9	 44.0	±	0.7	 -1.5	 5.8	±	0.2	 -0.1	
AlaS147	 37.2	±	0.9	 32.1	±	0.2	 47.0	±	0.6	 63.2	±	1.3	 43.7	±	0.7	 -1.8	 5.5	±	0.2	 -0.3	
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noted that crystal packing in the 1QX5 structure gives rise to non-native 
intermolecular interactions. However, these are analogous to intramolecular 
interactions observed in the NMR structure (Figure 3-6 and described in detail in 
Figures 3-27 through 3-30). As detailed below, both structures provide valuable 
insight into the effects of the thioamide substitutions.  
Based on comparison to the CysQ135 control, AlaS147 is mildly destabilizing. 
This is somewhat surprising as the thioamide in question is located at the C-
terminal end of the helix and therefore should serve as an N–H hydrogen bond 
donor with the thiocarbonyl sulfur oriented into solvent (Figures 3-27 and 3-28). 
ValS142 shows only a minimal reduction in TM (Figure 3-5). In both the NMR and X-
ray structure, the C--O/N distance for the hydrogen bond that the ValS142 
thiocarbonyl would make with Thr146 is somewhat long (3.1 Å and 3.3 Å, 
respectively), so the thiocarbonyl could reasonably be accommodated there 
(Figure 3-29). Placing a thioamide near the start of the C-terminal helix (TyrS138 or 
GluS140) is highly destabilizing, presumably due to disruption of backbone hydrogen 
bonding. Both these residues have relatively short C--O/N hydrogen bond 
distances and also interact with neighboring loops or helices (Figure 3-6 Right, 
Figure 3-30 and Table 3-10).  
Two thioamide variants were significantly stabilized relative to the 
oxoamide: ValS136 and GluS139. In both cases, the stabilization appears to arise 
from a combination of a location sterically tolerant to the thioamide carbonyl and a 
strengthening of hydrogen bonds involving the thioamide N–H. In the 1CFD 
structure, the C--O/N distance for the hydrogen bond that the ValS136 thiocarbonyl 
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would make with Ile100 is 3.4 Å and the C--O/N angle is 137°. In the 1QX5 structure, 
this carbonyl makes an intermolecular hydrogen bond with another CaM molecule 
in the crystal lattice (Figure 3-6 Left, Figure 3-29, and Table 3-10). Thus, the longer 
thiocarbonyl could certainly be accommodated in this flexible region of apo CaM 
and might even make for a more favorable interaction. In the 1QX5 structure, the 
GluS139 carbonyl C--O/N distance from the Val142/Gln143 amide N–H is 3.0 Å and 
the C--O/N angle is 144°, making it seemingly unfavorable for thioamide 
substitution. However, in the 1CFD NMR structure, this distance and angle are 3.4 
Å and 145°, respectively, indicating sufficient flexibility in this region to 
accommodate the thiocarbonyl (Figure 3-6 and Table 3-10).  
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Figure	 3-6:	 Structural	 Analysis	 of	 CaM	 Thioamide	 Variants.	 Top	 Left:	 Potential	 hydrogen	 bonding	
interactions	for	stabilization	observed	in	ValS136	and	GluS139	substitutions.	Right:	Neutral	(ValS142	and	AlaS147)	
and	destabilizing	(TyrS138,	GluS140,	and	PheS141)	substitutions.	Destabilization	of	CaM	by	PheS141	and	TyrS138	
and	may	be	due	to	disruption	in	the	packing	of	the	helix.	GluS140	disrupts	hydrogen	bond	acceptance	without	
making	a	compensatory	hydrogen	bond	donor	interaction.	Increased	C=O---N	distance	(3.1	Å)	in	the	turn	of	
the	helix	at	ValS142	may	allow	for	better	accommodation	of	the	thioamide	sulfur.	AlaS147	is	the	penultimate	
C-terminal	residue	and	only	serves	as	a	hydrogen	bond	donor.	Structures	rendered	from	PDB	entry	1QX5	
chains	D	(yellow)	and	R	(green)	and	from	PDB	entry	1CFD	(orange,	only	N-terminal	region	shown).277,	282	
 
 
For both ValS136 and GluS139, there is also a potential to acquire a new 
favorable thioamide N–H interaction. In the 1QX5 structure, the Glu140 N–H (part 
of a thioamide in GluS139) is positioned ideally in the plane of the backbone carbonyl 
of Asn137 with a 3.3 Å N/O--C hydrogen bond length (Figure 3-6, Left). Alternatively, 
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in the 1CFD structure, the GluS139 thioamide N–H makes a hydrogen bond with the 
sidechain carbonyl of Asn137 (Figure 3-29). Although this region of CaM is dynamic, 
both structures offer plausible explanations for the increased stability of the GluS139 
variant. On the other hand, for ValS136, the explanation is less clear-cut. In the 
1QX5 structure, the distance from the side chain carbonyl of Glu140 to the 
backbone nitrogen of Asn137 is 4.2 Å and the carbonyl is out of plane from the N–
H bond (Figure 3-29). No interaction of this N–H with Glu140 is apparent in the 
1CFD structure. Nonetheless, the side chain of Glu140 appears to be highly mobile 
(average B-factor of 86.5 Å2 in 1QX5) and reorientation of the side chain to favor 
this hydrogen bond may be possible. Although previously unappreciated, these 
interactions may be responsible for the positioning of the C-terminal helix for 
correct folding of the helix-loop-helix motif in the EF-hand. However, it is 
impossible to know the exact details of how each thioamide is changing the local 
and distal dynamics of the protein without high-resolution structural studies.  
3.2.3 – 1H – 15N Heteronuclear Correlated Single Quantum Coherence 
Nuclear Magnetic Resonance Studies of CaM 
 
 15N isotopically labeled proteins have been traditionally used to enable two-
dimensional NMR studies of proteins to inform upon changes in the environment 
of single amino acid residues in distinct conformers. In particular, acquisition of 
heteronuclear single quantum coherence (HSQC) spectra have been used to great 
effect in the study of CaM conformational changes and protein-protein 
interactions.283-286 Because of the wealth of previous CaM NMR experiments in the 
literature, NMR was an attractive target as a high-resolution technique by which to 
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study the thioamide’s effects on the C-terminal domain of CaM. To begin 
preliminary investigations into the site-specific effects of thioamide incorporation, I 
modified the CaM semisynthesis to allow for isotopic labeling of residues 1-134. 
Although this will not provide complete coverage of the entire CaMS thioprotein 
structure, this partially isotopically labeled system can be used as a model for 
future NMR studies of the protein. Additionally, this system will provide insight into 
how distal sites that are not proximal to the thioamide are perturbed by its inclusion. 
Figure	3-7:	Scheme	for	generating	CaMS	proteins	that	contain	15N	isotopically	 labeled	residues	1-134	for	
HSQC	NMR	structural	studies.  
 
To initiate NMR studies of the protein, I slightly modified the growth 
conditions of the CaM1-134-GyrA fusion protein so that the 15N isotope can be 
incorporated into the protein. Minimal M9 media was prepared that was devoid of 
any nitrogen sources other than 15NH4Cl (see Section 3.3.3). E. coli containing the 
appropriate plasmid for CaM1-134-GyrA were grown in this media and protein 
production was induced through the addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG). From a 1 L expression, I estimate a yield of ~30 mg 
CaM1-134-GyrA is produced from which approximately 25-28 mg of CaM1-134-MES 
can be isolated after MESNa cleavage (dry weight calculation). 
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 I initially began these studies by synthesizing a CysQ135 oxo control as well 
as ValS136 and TyrS138 single thioamide constructs. These constructs were prepared 
with yields similar to those of the proteins used for CD studies, but expressions 
were performed a much larger scale to produce quantities sufficient for NMR 
studies (5-8 mg). After NCL, purification, and capping each Cys135 residue with 
iodoacetamide, the proteins were frozen in liquid nitrogen and lyophilized to a 
powder. Dried protein stocks were then dissolved in 475 μL of holo NMR buffer 
(100 mM KCl, 6 mM CaCl2, 0.02 % NaN3, 10 mM d4-imidazole, pH 6.5). However, 
it was found that dried CaM proteins did not completely dissolve in NMR buffer as 
they did previously with CD sample buffers. This lead to insufficient quantities of 
15N-labeled CaM in solution for HSQC spectra acquisition. Therefore, the CysQ oxo 
control and the ValS136 constructs were synthesized again and after a final FPLC 
purification, buffer exchanged into minimal Tris buffer instead of lyophilizing them 
to a solid. Each protein’s buffer was then exchanged into holo NMR buffer and the 
volume reduced to ~500 μL using Amicon 3K MWCO spin filters. By keeping the 
protein in solution during NMR sample preparation, I found that the insolubility 
issues encountered through the previously attempted preparation could be 
avoided. However, the protein samples (~0.2 mM) were still lower than the target 
concentration for HSQC acquisition (0.5 mM). Nonetheless, each sample had D2O 
added to a final concentration of 5% v/v to enable shimming of the magnet, and 
HSQC acquisition was attempted. Although the samples may be insufficiently 
concentrated to acquire all desired chemical shifts, the data set obtained provided 
an initial hint of the residue specific structural changes that arise from inserting a 
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thioamide at the ValS136 position, and provided a basis by which future NMR HSQC 
experiments are designed and implemented. 
 
 
Figure	3-8:	NMR	HSQC	(1H-15N)	spectra.	Each	protein	displays	characteristic	folded	CaM	features	such	as	
the	1H	downfield	chemical	shift	of	the	EF	Hand	glycine	residues	25,	61,	98,	and	134.	Leu116	and	Thr117	both	
show	small	changes	in	the	chemical	shift	compared	to	the	CysQ	oxo	protein.		
 
 
HSQC spectra were acquired by Dr. Kathy Valentine (Professor Josh 
Wand’s laboratory) using previously described methods for CaM NMR 
acquisition.285, 286 Although definitive assignments cannot be made on the basis of 
the collection performed here, a spectra of the 100 % homologous Xenopus laevis 
(frog) CaM from Kainosho et al.284 can be used as reference data set to make 
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tentative resonance peak assignments and comparisons between the oxo control 
and ValS136.  
 As shown in Figure 3-8, the CysQ135 and ValS136 proteins have overlapping 
resonances for the majority of peaks that can be detected for the ~0.2 mM 
samples. Additionally, these spectra have several characteristics that indicate that 
the proteins are well folded compared to the reference spectrum from X. laevis 
CaM. One such characteristic is a distinct grouping of glycine amide resonances 
(observed in both samples), one from each of the EF hands responsible for binding 
Ca2+ ions (residues 25, 61, 98, and 134). Gly134 is proximal to the ValS136 thioamide 
substitution and shows an identical chemical shift to oxo control, indicating that the 
domain architecture of this EF hand may be intact. This is also corroborated by the 
similarity to the chemical shift observed in Kainosho et al.’s HSQC data.284 
However, there are two notable differences in individually assigned residues based 
on the X. laevis spectra. The first distinct change comes at the resonance centered 
around the coordinates (1H: 9.2 ppm, 15N: 115 ppm). For the CysQ135, this 
resonance overlays exactly with the Thr117 in the reference spectrum. However, 
the ValS136 spectrum shows an upfield chemical shift for each axis. The resonance 
corresponding to the Leu116 residue (1H: 8.8 ppm, 15N: 125 ppm) also shows a 
similar difference from the CysQ spectrum. These two residues are present in the 
loop of the second EF hand in the C-terminal domain (see Figure 3-9) and directly 
precede the second helix of this helix-loop-helix motif. These residues are 
approximately 17-20 Å away from the site of modification (measurement from 
1UP5 and 1J7P), indicating that a thioamide modification, such as ValS136, can 
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have long range effects on the chemical environment of residues in other calcium 
binding domains.  
 
Figure	 3-9:	 Left:	 Crystal	 structure	 of	 CaM	 showing	 the	 positions	 of	 the	 thioamide	 substitution	 (ValS136)	
relative	to	the	two	perturbed	residues	(Leu116	and	Thr117).	Right:	NMR	solution	phase	structure	of	the	C-
terminal	 domain	 of	 CaM	 showing	 an	 identical	 relationship	 between	 the	 two	 highlighted	 regions.	 The	
approximate	 distance	 between	 Val136	 and	 Leu116/Thr117	 is	 17	 Å	 as	 measured	 in	 Pymol	 (PDB	 accession	
numbers	1UP5	and	1J7P)283,	287.	
 
Although the samples used in this preliminary study are under-
concentrated, and not every resonance can be detected and assigned in the 
spectra, these data suggest that the thioamide modification can have long-range 
effects on the structural dynamics of proteins. This structural modulation could be 
useful in engineering protein structure or in the disruption of protein-protein 
interactions. However, the syntheses of these proteins must be optimized to 
produce larger quantities of protein so that an increased signal-to-noise ratio can 
be obtained during HSQC spectra acquisition. Therefore, it may be more 
advantageous to screen crystallization conditions for CaMS in the pursuit of high 
resolution X-ray crystal structures of thioamides embedded in secondary and 
tertiary folds. 
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3.2.4 – Design and Synthesis of GB1 Thioproteins 
The immunoglobulin-binding B1 domain of protein G from Streptococcus 
bacteria is 56 amino acids in length and has a tertiary structure comprised of three 
of the most common secondary structural motifs in proteins.288 The compact GB1 
fold consists of a protein-spanning α-helix packed against a four-stranded β-sheet 
with both parallel and anti-parallel strands, making it an ideal model to study local 
folding dynamics in a tertiary structure context. Indeed, NMR, X-ray 
crystallography, and an array of computational studies have been used to great 
effect in understanding the order in which individual secondary structure elements 
fold to form the final tertiary structure of GB1.289, 290 More recently, various 
unnatural backbone substitutions have been examined in GB1.291-293 While these 
substitutions were thermodynamically destabilizing to the folded state, many of the 
proteins showed a native-like fold by X-ray crystallography and CD. Given these 
precedents, GB1 is an excellent platform to examine effects of thioamides on 
folding in a β-sheet, a structural motif not yet studied in detail with thioamide 
substitutions.  
GB1 and three thioamide variants were synthesized using a combination of 
automated and manual SPPS, followed by NCL (work by D. Miklos Szantai-Kis). 
We originally intended to synthesize thioamide GB1 through SPPS only, but 
encountered low yields due to suboptimal coupling reactions after thioamide 
insertion and Edman degradation-type cleavage of the amide bond C-terminal to 
the thioamide under acidic deprotection conditions. Thioprotein production by NCL 
allowed us to work with shorter thiopeptide fragments where the number of 
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couplings subsequent to thioamide insertion and the length of the deprotection 
reactions can be limited. In the synthesis of GB1 and variants, D.Miklos Szantai-
Kis performed a ligation between a thioamide containing GB11–23 thioester and 
GB124–56Cys24. After desulfurization of Cys24 using VA-044 and sacrificial 
thioacetamide, thioamide GB1 constructs were obtained with no trace of the 
ligation point and yields ranging between 10 and 20 % (Figure 3-1, Bottom).218 
Using this NCL and desulfurization strategy, we synthesized three GB1 
variants with single thioamide substitutions at Leu5, Ile6, or Leu7 (synthesis 
performed by D. Miklos Szantai-Kis). The Leu5 residue acts as a hydrogen bond 
acceptor in an anti-parallel β-sheet interaction and as a hydrogen bond donor in a 
parallel β-sheet interaction. In contrast, Ile6 acts as a hydrogen bond acceptor in a 
parallel β-sheet interaction and as a hydrogen bond donor in an anti-parallel β-
sheet interaction. The hydrogen bonding pattern of Leu7 is similar to that of Leu5 
(anti-parallel acceptor, parallel donor), but the carbonyl points outward slightly, 
increasing the hydrogen bond distance by 0.2 Å and placing it out of plane with 
respect to its partner in the sheet. Thus, we anticipated that the increased size and 
C==X bond length of the thiocarbonyl might be better accommodated at Leu7 than 
at Leu5 or Ile6. These three substitutions, while not comprehensive, provide 
examples of how thioamides may be accommodated into both types of b-sheet 
folds within the context of a complex tertiary domain.  
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3.2.5 – GB1 Thioprotein Folding Thermodynamics 
GB1 CD spectra typically contain a broad minimum between 208 and 222 
nm with few defined features in this range due to the combination of the α-helical 
and β-sheet contributions to the signal. The LeuS5 and IleS6 substitutions have 
nearly identical spectra and maintain similar curve features as the GB1 Oxo 
control, but with significantly reduced MRE values (Figure 3-10). It is likely that the 
internal hydrogen bonding networks are perturbed by these substitutions, leading 
to a disruption in the packing of the tertiary structure. LeuS7 seems to be the most 
tolerated thioamide substitution with a CD signature closest in magnitude to the 
control at 208 nm. However, the MRE values are still significantly reduced across 
the entire set of spectra.  
 
Figure	3-10:	CD	scans	of	GB1	Oxo	and	GB1	thioproteins.	Each	of	the	thioproteins	displays	the	characteristic	
minimum	centered	at	270	nm	from	the	thioamide	absorbance.	
For GB1, the thermal denaturation curves (See Section 3.3, Figures 3-35 
and 3-36) fit well to a two-state unfolding model. The TM of GB1 Oxo is 78.2 °C 
and includes a sharp unfolding transition that is preceded by only a modest initial 
unfolding event occurring gradually between 5 and 65 °C (Figure 3-11). The 
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thermodynamic differences for each thioamide substitution track with the changes 
in signal observed in the wavelength scans. IleS6 leads to a 9.5 °C destabilization 
in melting temperature while LeuS5 leads to an even greater destabilization of 12.6 
°C. LeuS7 is the least destabilizing thioamide substitution with a melting 
temperature only 2.3 °C lower than WT GB1. The corresponding unfolding free 
energies (ΔΔGU), show that LeuS7 is destabilized by only 0.5 kcal mol-1. Thus, I 
have demonstrated that the precise context of thioamide substitution is also 
important for β-sheet systems.  
 
 
Figure	3-11:	 	Thermal	Stability	of	GB1	Thioamide	Variants.	CD	thermal	melts	of	GB1	variants	plotted	as	
fraction	 folded	 values	 generated	 from	 a	 two-state	 fitting	 model.	 Melting	 curves	 were	 obtained	 by	
measuring	the	θ220	at	1	°C	increments	in	20	mM	Na2HPO4	pH	7.0.	Transformation	of	raw	CD	signal	to	MRE	
values	and	two-state	fitting	procedures	were	performed	as	described	in	Section	3.3.	
 
 
	
Table	3-2:		GB1	Thermodynamic	Values.	
GB1	Variant	 Tm																																						(°C)	
ΔTM 																										
(°C)	
ΔΔGU												
(kcal	mol-1)	
Oxo	 78.2	±	0.0	 ---	 ---	
LeuS5	 65.6	±	1.6	 -12.6	 -2.5	±	0.3	
IleS6	 68.7	±	0.5	 -9.5	 -1.9	±	0.1	
LeuS7	 75.9	±	1.2		 -2.3	 -0.5	±	0.2	
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In GB1, the thermodynamic and structural changes from thioamide 
incorporation can be readily rationalized based on existing structural data (PDB 
entry 2QMT).290 LeuS5 thiocarbonyl substitution likely disrupts the hydrogen bond 
with the N–H of Thr16, altering packing of only the outer strand of the β-sheet 
(Figure 3-12). The LeuS5 thioamide N–H should maintain the hydrogen bond to the 
Phe52 carbonyl in the core parallel β-sheet interface and might even strengthen 
this interaction. Computational modeling indicates that Leu5 forms part of the 
folding nucleus of GB1,289 so perhaps it is not surprising that the Leu5 substitution 
has the most significant effect on the TM and reduced the cooperativity of the 
folding transition. IleS6 reverses this hydrogen bonding pattern, maintaining the N–
H hydrogen bond to the carbonyl of Gly14 in the outer strand and disrupting 
hydrogen bonding with the Val54 amide N–H in the core strand. Disturbance of the 
core of the β-sheet region would explain why the IleS6 substitution induces such a 
significant change in the TM. LeuS7 causes almost no disruption in folding as 
determined by CD. It seems that the longer hydrogen bond distance (3.1 Å to the 
Lys13/Gly14 amide N) and out-of-plane orientation of the Leu7 carbonyl are 
permissive of the sulfur substitution, as I anticipated. If there is any minor 
disturbance, it could be compensated for by the increased strength of the LeuS7 
thioamide N–H hydrogen bond with the carbonyl of Val54. Taken together, these 
analyses reinforce my observation that the effects of thioamide incorporation in β-
sheets can depend dramatically on the location of the substitution (Table 3-2).  
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Figure	3-12:	Structural	Analysis	of	GB1	Thioamide	Variants.	Left:	Overall	structure	of	GB1	with	modeled	
thioamide	substitutions.	Each	thioamide	substitution	is	poised	to	make	two	hydrogen	bonding	interactions	
with	opposing	strands.	Right:	Zoomed	in	region	showing	that	the	LeuS7	thiocarbonyl	is	skewed	out	of	the	
plane	of	the	anti-parallel	β-sheet	(C=O---N	angle	=	134°),	providing	a	potential	explanation	for	why	it	is	less	
destabilizing	than	LeuS5	or	IleS6.	Structures	rendered	from	PDB	entry	2QMT.294	
 
3.2.6 – Outlook and Conclusions 
Collaborative work by Dr. Yitao Zhang and Professor David Chenoweth 
gave us a third protein system (collagen) to examine thioamide backbone 
substitutions and compare our results in CaM and GB1. To probe the effect of the 
thioamide on collagen model peptide (CMP) self-assembly, they installed the 
moiety near the central positions of the 21-mer host system Ac-
(POG)3(XYG)(POG)3-NH2. Peptides were synthesized through SPPS, coupling 
Fmoc-POG-OH trimers at all but the central POG subunit (the ‘O’ denotes 2S,4R-
4-hydroxyproline or Hyp). Here, individual residues were installed, including the 
suitable building block for incorporation of the thioamide. Analysis of thioamide 
substitutions in PPG and POG CMPs illustrates the three fundamental effects that 
thioamides are expected to have on proteins. In PSPG, the combination of weaker 
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hydrogen bonding and steric clashes due to the larger van der Waals radius of 
sulfur and longer C=S bond length significantly destabilizes (ΔTM = -25.7 °C) the 
protein (Figure 3-13). In contrast, both PPSG and POSG collagen peptides are 
moderately stabilized compared to their oxoamide counterparts. At the Yaa 
position, the thioamide N–H can form a stabilizing inter-strand hydrogen bond, 
while the thiocarbonyl projects into solvent. Thus, thioamide substitution at the Yaa 
position confers the energetic benefits of the stronger hydrogen bond donor 
without the penalties of the weaker acceptor or steric clashes. The disruption 
introduced by the PPGS thioamide is not as drastic as the PSPG replacement 
because it does not pack against the core of the triple helix, but it may provide 
general steric interference with neighboring strand contacts. The POSG and POGS 
peptides recapitulate the positional effects of the thioamide while retaining the 
stabilizing effects of Hyp. The additivity of the backbone and sidechain 
substitutions supports the idea that the conformations of the thioamide collagen 
variants are similar to the parent collagen model peptides (with the exception of 
PSPG, for which few conclusions can be drawn). In this regard, our data shows 
that a thioamide substitution can act synergistically with a proline ring substitution 
for potential applications in thiopeptide based collagen materials.  
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Figure	3-13:	 Structural	 analysis	 of	 CMP	 thioamide	 variants.	 ProSProGly	 and	ProProGlyS	 have	buried	 and	
partially	buried	sulfur	atoms,	respectively	(Top	and	Middle),	accounting	for	the	disruptions	observed	in	the	
CD	experiments.	The	ProProSGly	(Bottom)	sulfur	atom	is	fully	solvent	exposed	and	the	N–H	of	the	thioamide	
forms	a	hydrogen	bond	with	the	strand	shown	in	grey	(inset),	accounting	for	the	stabilization	observed	in	
the	CD	experiments.	Structures	rendered	from	PDB	entry	2CUO.	295	
	
 
 
 
CMPs range between 4–6%. To analyze the thioamide impact on
structure, thermodynamics, and kinetics of folding, we sub-
jected each CMP variant to CD scans, thermal melts, and kinetic
refolding experiments.
Collagen model thiopeptide folding thermodynamics
CD scans of each thioamide variant display a characteristic
collagen spectrum with a minimum at 198 nm and maximum
around 225 nm, along with a broad minimum centered around
265 nm, representing the p/ p* contribution from the thio-
amide. The magnitude of the minima at 198 nm and 265 nm
depend upon the position of the thioamide, with the PSPG
substitution leading to the greatest loss inMRE signal (Fig. S27–
S31†). Unsurprisingly, the PSPG replacement massively desta-
bilizes the protein (Fig. 6 and Table 3), likely because the sulfur
points inward towards the core of the trimer, imposing a steric
obstacle to the packing of the strands (Fig. 7). Additionally, the
lower electronegativity of the elongated carbon–sulfur bond
weakens key interchain H-bonding between the glycine N–H
and the C]O of the Xaa proline. The PPSG modication shows
a stabilization of the triple helix with a signicant increase in
Tm and 0.4 kcal mol!1 increase in DGU, while PPGS shows
a moderate destabilization, in agreement with previous
studies.24 Hysteresis studies showed that the free energy
diﬀerences are in good agreement with the melting temperature
proles (Fig. S32–S36†). Additionally, each thioamide CMP fol-
ded on a similar timescale to the PPG control, demonstrating
that the kinetics of folding are not altered by thioamide
substitution.
To assess thioamide backbone compatibility with substitu-
tions at the 4 position of the pyrrolidine ring in proline, we
incorporated Hyp into the Yaa position. This POG mutant is
well known to stabilize collagen triple helices through stereo-
electronic eﬀects and hydrogen bonding.62–66 Results show that
peptides POSG and POGS exhibit TM increases of 2.5 and 4.2 "C,
respectively, relative to their corresponding Pro congeners.
Interestingly, the stabilizing eﬀects from the Hyp substitution
and thioamide appear additive when compared to appropriate
PPG and POG controls. Thioamide substitution at the central
Yaa position contributes about 0.5 kcal mol!1 of stability and
Hyp substitution contributes about 1.3 kcal mol!1. Further-
more, the POSG substitution leads to faster folding compared to
that of any thioamide variant or control peptide examined here.
Like for CaM and GB1, thioamide substitutions in collagen have
eﬀects that strongly depend on the position of incorporation.
Fig. 6 Thermal stability of CMP thioamide variants. CD thermal melts
of collagen plotted as fraction folded (Ff) values generated from the ﬁt.
Melting curves were obtained bymeasuring the q224 at 1 "C increments
in PBS buﬀer. Transformation of raw CD signal to MRE values is
described in eqn (S1)† and ﬁtting procedures were as previously
described.52,60,61
Table 3 CMP thermodynamic and kinetic values
Collagen variant TM ("C) DGUa DDGUa t1/2 (min)
Pro-Pro-Gly Oxo 36.7 # 0.4 10.8 32.5 # 2.0
ProS-Pro-Gly 11.0 # 0.9 5.1 !5.7 25.0 # 4.5
Pro-ProS-Gly 38.5 # 0.5 11.2 0.4 35.3 # 5.2
Pro-Pro-GlyS 30.3 # 0.5 9.2 !1.6 40.3 # 7.6
Pro-Hyp-Gly Oxo 39.9 # 0.5 12.0 24.0 # 4.5
Pro-HypS-Gly 41.0 # 0.2 12.6 0.6 17.7 # 4.0
Pro-Hyp-GlyS 34.5 # 0.0 11.1 !0.9 23.8 # 2.8
a Unfolding free energy in kcal mol!1, calculated as described in the ESI.
Fig. 7 Structural analysis of CMP thioamide variants. ProSProGly and
ProProGlyS have buried and partially buried sulfur atoms, respectively
(Top and Middle), accounting for the disruptions observed in the CD
experiments. The ProProSGly (Bottom) sulfur atom is fully solvent
exposed and the N–H of the thioamide forms a hydrogen bond with
the strand shown in grey (inset), accounting for the stabilization
observed in the CD experiments. Structures rendered from PDB entry
2CUO.67
This journal is © The Royal Society of Chemistry 2017 Chem. Sci.
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ΔΔG = -5.7 kcal mol-1
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Thioamides have the potential to be one of the most multifunctional probes 
in the large repertoire of unnatural amino acid substitutions available for protein 
labeling. They can be used as functional handles in IR, CD, or fluorescence 
spectroscopy, as photoswitches, or as perturbants in structure/ function studies. 
With thioamide substitutions across three protein systems, CaM, GB1, and 
collagen model peptides (work by Dr. Yitao Zhang and Professor David 
Chenoweth), the data set amassed in our recent publication represents the most 
comprehensive study to date bearing on the question of how thioamides affect 
protein thermostability.256 While virtually all previous reports of thioamides in 
secondary structure contexts have found the modification to be disruptive, I have 
shown that, within CaM, the replacement is tolerated in some positions within the 
C-terminal α-helix as well as the preceding loop. While all thioamide substitutions 
in the β-sheet of GB1 were destabilizing, at one position the impact was minimal. 
The CMP (Zhang and Chenoweth) results are consistent with findings by Newberry 
et al,233 and although high resolution structures have not yet been obtained, the 
additive stabilizing effects of thioamidation and proline hydroxylation suggests that 
these CMPs adopt a fold consistent with structures like PDB entry 2CUO.  
Overall, our analysis based on existing crystal and NMR structures allows 
us to rationalize many of our findings in terms of the physical properties of the 
thioamide bond, and to consider how both perturbing and non-perturbing thioamide 
locations might be useful. Thioamide incorporation in the first turn of an a-helix is 
a strong helix breaker, and it is disruptive in sheets where it replaces a short 
hydrogen bond that is in the plane of the sheet. These findings can be explained 
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by the longer C=S bond length and larger van der Waals radius of sulfur, and 
highlight the potential of thioamides as tools to modulate protein folding. 
Thioamides can be tolerated in helices where the substituted amide oxygen 
participates in longer H-bonds and in sheets where the carbonyl bond is at a more 
acute angle. I have also seen that thioamides are tolerated, or even stabilizing, 
when the disruptive effect of the thiocarbonyl is compensated by the stronger 
hydrogen bond donation of the thioamide N–H. Minimally perturbing substitutions 
are ideal for fluorescence studies using the thioamide as a quenching moiety. 
Increased thermal stability of ValS136 and GluS139 in CaM highlight the fact that 
thioamides can serve as stabilizing backbone replacements for interrogating 
hydrogen bonding networks.  
The results reported here have set a foundation for rational thioprotein 
design to realize the above benefits to biophysics and protein engineering. A 
growing database of thioamide “mutants” could, in conjunction with appropriate 
computational models, allow one to predict the effects of thioamide substitution to 
achieve the desired destabilizing, neutral, or stabilizing effects on a protein of 
interest. Efforts are underway to obtain high resolution structural and dynamic 
information on the thioamide substitution. In addition to the generation of thioamide 
proteins by NCL, Hecht's recent co-translational incorporation of thioamide 
dipeptides using mutant ribosomes offers a potentially more facile semisynthetic 
route to thioproteins.229 Deciphering the mechanism of incorporation of the natural 
thioglycine residue in the archael methyl-coenzyme M reductase could also permit 
the in vivo biosynthetic incorporation of backbone thioamides.226 As thioamide 
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proteins become more synthetically accessible, the results reported here should 
provide valuable insights into the design of appropriate thioproteins for diverse 
applications.  
 
Section 3.3 – Materials and Methods 
3.3.1 – Materials 
Fmoc protected amino acids and peptide coupling reagents as well 2-
chlorotrityl resins were purchased from EMD Millipore (Billerica, MA, USA). 
Hydrazide hydrate solution was purchased from Oakwood Chemical (Estill, SC, 
USA). Piperidine was purchased from American Bioanalytical (Natick, MA, USA). 
VA-044 was purchased from Wako Pure Chemical Industries (Osaka, Japan). 
Triisopropylsilane (TIPS) was purchased from Santa Cruz Biotechnology, Inc 
(Dallas, TX, USA). GB124-56 A24C was purchased from Genscript (Piscataway, NJ, 
USA). Restriction enzymes and chitin purification resin were purchased from New 
England Biolabs (Ipswich, MA, USA) and Pfu Turbo DNA Polymerase was 
purchased from Agilent Technologies (Santa Clara, CA, USA). DNA oligomers 
were purchased from Integrated DNA Technologies, Inc (Coralville, IA, USA). The 
pTXB1 plasmid containing CaM1-116 S17C, was a gift from the Linse Laboratory of 
the Department of Biochemistry and Structural Biology at Lund University. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased from LabScientific, 
Inc (Highlands, NJ, USA). Protease inhibitor tablets were purchased from Roche 
Boehringer Mannheim (Indianapolis, IN, USA). Amicon Ultra centrifugal filter units 
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were purchased from EMD Millipore (Billerica, MA, USA). Sodium 2-
mercaptoethanelsulfonate (MES•Na) was purchased from TCI America (Portland, 
OR, USA). β-mercaptoethanol (βME) was purchased from Bio-Rad Laboratories 
(Hercules, CA, USA). FPLC purification of proteins was performed on an AKTA 
system with HiTrap Q columns (GE Healthcare Bio-Sciences, Pittsburgh, PA, 
USA), while peptide HPLC was performed on a Varian Prostar system (currently 
Agilent Technologies, Santa Clara, CA, USA) for CaM and GB1 peptides. 
Thiopropyl sepharose 6b resin was also purchased from GE Healthcare 
(Princeton, NJ, USA). Cuvettes for CD spectroscopy were purchased from Hellma 
Analytics USA (Plainview, NY, USA). All other reagents, solvents, and materials 
were purchased from either Fisher Scientific (Pittsburgh, PA, USA) or Sigma-
Aldrich (St. Louis, MO, USA) unless otherwise specified. CMPs were designed, 
synthesized, and analyzed by Dr. Yitao Zhang in Professor David Chenoweth’s 
laboratory. GB1 constructs were synthesized by D. Miklos Szantai-Kis. Matrix 
assisted laser desorption/ionization mass spectrometry (MALDI) was performed 
on a Bruker Ultraflex III mass spectrometer (Billerica, MA). High Resolution Mass 
Spectrometry (HRMS) for small molecules were obtained on a Waters LCT 
Premier XE LC/MS system (Milford, MA, USA). Nuclear magnetic resonance 
spectra were obtained on a Bruker DRX 500 MHz instrument. HSQC spectra were 
obtained by Dr. Kathleen Valentine in Professor Josh Wand’s laboratory. Common 
abbreviations for all other chemicals are as follows: 1-
[Bis(dimethylamino)methylene]-1H-1,2,3- triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU), 2-(1H-benzotriazol-1-yl)- 1,1,3,3-
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tetramethyluronium hexafluorophosphate (HBTU), O-(1H-6-Chlorobenzotriazole-
1-yl)- 1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU), N-
methylmorpholine (NMM), isobutyl chloroformate (ICBF), N,N-
diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), 1,2-ethanedithiol (EDT), 
hydroxybenzotriazole (HOBt), 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid 
(HEPES), tris(2-carboxyethyl)phosphine (TCEP), and guanidinium hydrochloride 
(Gdn•HCl).  
3.3.2 – Chemical Synthesis of Thioacylating Monomers 
The below route was adapted from Shalaby et al.296 Abbreviations for 
reagents can be found in the general information section. The syntheses of Ala, 
Phe, Glu, Val, Pro, and Leu thioamide precursors have been reported 
previously.132, 153, 218, 266, 297, 298 
 
Figure	3-14:	Scheme	outlining	the	synthesis	of	thioacylating	monomers.	
 
 
 
Synthesis and Purification of Thiotyrosine (Fmoc-TyrS-NBt) Precursor 
 
(9H-fluoren-9-yl)methyl (S)-(1-((2-amino-5-nitrophenyl)amino)-3-(4-(tert-
butoxy)phenyl)-1- oxopropan-2-yl)carbamate (3-1). Fmoc-Tyr(t-Bu)-OH (1.49 
g, 3.25 mmol) was dissolved in 25 mL of tetrahydrofuran (THF) under argon flow 
with stirring. The solution was then cooled to -10 °C in a 1:3 NaCl/ice bath. To this 
solution, 2 equiv of N-methylmorpholine (6.25 mmol, 0.71 mL) and 1.1 equivalents 
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of isobutyl chloroformate (3.58 mmol, 0.464 mL) were added dropwise, 
respectively. The reaction was then allowed to stir at -10 °C for 15 min. Next, 1.1 
equivalents of 4-nitro-o-phenylenediamine (3.58 mmol, 0.55 g) was added to the 
reaction. The reaction was then stirred for 2 h at -10 °C and then stirred at room 
temperature (RT) overnight under Ar. The resulting solution turned orange 
overnight. The reaction was then removed from argon flow and the solvent was 
removed under reduced pressure. The resulting orange solid was dissolved in N,N- 
dimethylformamide (DMF, 20 mL) and added to a saturated aqueous potassium 
chloride solution (200 mL) to precipitate the desired product. This precipitate was 
removed from solution by vacuum filtration with a Büchner funnel and washed with 
cold water. The solid was then allowed to air dry for 2 h before being dried under 
vacuum. The resulting solid was still judged impure by thin layer silica 
chromatography (TLC) and purified further by flash chromatography by dissolving 
the solid in THF (5 mL) and loading it on silica (500 mL bed volume in 45:55 ethyl 
acetate:hexane). Compound 3-1 eluted with an Rf of 0.5 and was dried by rotary 
evaporation, washed with chloroform, and dried under high vacuum overnight. 
Compound 3-1 was obtained in 71.4 % yield (1.38 g, 2.32 mmol). HRMS (ESI) m/z 
calculated for C34H34N4O6Na [M+Na]+ is 617.2376, found 617.2379. 1H NMR (500 
MHz, C2D6OS): δ 9.44 (1 H, s), 8.13 (1 H, s), 7.88 (4 H, d, J = 7.5), 7.71 (2 H, d, J 
= 7.4), 7.41 (2 H, t, J = 7.4), 7.32 (2 H, q, J = 7.4), 7.25 (2 H, d, J = 8.6), 6.87 (2 H, 
d, J = 8.5), 6.78 (1 H, d, J = 9.1), 6.39 (2 H, s), 4.45 (1 H, d, J = 7.5), 4.28 – 4.15 
(3 H, m), 3.13 – 2.89 (2 H, m), 2.80, 1.22 (9 H, s). 13C NMR (126 MHz, C2D6OS): 
δ 171.1, 162.3, 156.1, 153.56, 149.3, 143.7, 140.7, 135.5, 132.2, 129.8, 127.6, 
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127.0, 125.3, 123.4, 123.4, 123.2, 121.8, 120.1, 113.6, 77.6, 65.8, 56.7, 46.6, 39.5, 
36.7, 28.5. 
 
(9H-fluoren-9-yl)methyl (S)-(1-((2-amino-5-nitrophenyl)amino)-3-(4-(tert-
butoxy)phenyl)-1-thioxopropan-2-yl)carbamate (3-2). Sodium carbonate 
(0.246 g, 2.32 mmol) and phosphorus pentasulfide (1.03 g, 2.32 mmol) were added 
to THF (20 mL) in an oven-dried round bottom flask and allowed to stir under Ar at 
RT until the phosphorus pentasulfide was completely dissolved (30 min). Then the 
solution was cooled to 0 °C in an ice bath and 3-1 was dissolved in minimal THF 
and added to the reaction. The reaction was then monitored by TLC with a mobile 
phase of 2:3 ethyl acetate/hexanes. The product has an Rf of 0.4. After 4 h, the 
starting material was mostly consumed and a small amount of the benzimidazole 
byproduct had been formed, therefore the reaction was judged to be at completion. 
The reaction was condensed to dark yellow oil by rotary evaporation. This oil was 
then dissolved in minimal ethyl acetate and was loaded onto silica plug (bed 
volume approximately 400 mL in ethyl acetate) to remove the phosphorus 
pentasulfide. The crude product was eluted in ethyl acetate as a dark yellow band. 
This solution was dried by rotary evaporation and redissolved in 2:3 ethyl 
acetate/hexanes (5 mL). This mixture was purified by flash chromatography on 
silica with a running solvent of 2:3 ethyl acetate/hexanes. The product eluted as a 
yellow solution and solvent was removed under reduced pressure. The resulting 
yellow solid was washed with dichloromethane and chloroform, then dried under 
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high vacuum overnight. Compound 3-2 was obtained in 71.1% yield (1.01 g, 1.65 
mmol).  HRMS (ESI) m/z calculated for C34H35N4O5S [M+H]+ is 611.2328, found 
611.2339. 1H NMR (500 MHz, C2D6OS): δ 11.24 (1 H, s), 8.37 – 8.25 (1 H, m), 
8.10 (1 H, d, J = 6.6), 7.94 (1 H, dd, J = 9.1, 2.7), 7.89 (2 H, d, J = 7.6), 7.73 (2 H, 
dd, J = 13.1, 7.5), 7.65 (1 H, d, J = 2.7), 7.42 (1 H, t, J = 7.5), 7.36 – 7.30 (1 H, m), 
7.29 (2 H, d, J = 8.5), 6.91 (2 H, d, J = 8.4), 6.77 (1 H, d, J = 9.0), 6.25 (2 H, s), 
4.68 (1 H, q, J = 7.2), 4.35 – 4.25 (1 H, m), 4.21 (2 H, q, J = 7.5), 3.14 (1 H, dd, J 
= 13.4, 7.2), 3.05 (1 H, dd, J = 13.4, 7.6), 1.26 (9 H, s). 13C NMR (126 MHz, 
C2D6OS): δ 206.8, 156.2, 153.8, 150.5, 143.8, 143.6, 140.7, 135.3, 131.8, 130.0, 
127.6, 127.0, 125.4, 125.3, 124.9, 124.4, 123.3, 122.2, 120.1, 113.8, 79.2, 77.7, 
65.9, 62.6, 46.6, 39.5, 28.5. 
 
(9H-fluoren-9-yl)methyl (S)-(3-(4-(tert-butoxy)phenyl)-1-(6-nitro-1H-
benzo[d][1,2,3]triazol-1-yl)-1-thioxopropan-2-yl)carbamate (3-3, Fmoc-TyrS-
NBt). Compound 3-2 (1.01 g, 1.65 mmol) was dissolved in glacial acetic acid 
diluted with 5% water (15 mL) and allowed to stir while cooling to 0 °C in an ice 
bath. After 5 min, 1.25 equiv of NaNO2 (0.142 g, 2.06 mmol) was added slowly to 
the reaction. The reaction was monitored by TLC using 2:3 ethyl acetate in 
hexanes as the mobile phase; compound 3-3 has an Rf of 0.7. After 30 min, no 
starting material remained by TLC and the reaction became thick with an orange 
precipitate. Cold Milli-Q water (100 mL) was added to the reaction to precipitate 
the remaining product. The resulting orange precipitate was filtered on a Büchner 
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funnel, washed with additional cold Milli-Q water, allowed to air dry for 20 min, and 
then dried under high vacuum overnight. The product was then lyophilized due to 
residual water remaining after high vacuum. The crude yield of the reaction was 
82% (0.836 g, 1.35 mmol) and was used directly in solid phase peptide synthesis 
without further purification. HRMS (ESI) m/z calculated for C34H31N5O5S [M-H]- is 
621.2046, found 621.2055. 1H NMR (500 MHz, CDCl3): δ 9.62 (1 H, s), 8.44 (1 H, 
d, J = 8.6), 8.28 (1 H, d, J = 8.8), 7.77 (2 H, d, J = 6.9), 7.61 – 7.53 (3 H, m), 7.47 
– 7.36 (4 H, m), 7.36 – 7.28 (3 H, m), 7.05 (2 H, d, J = 7.7), 6.82 (2 H, d, J = 7.8), 
6.59 (1 H, d, J = 7.2), 5.74 (1 H, d, J = 8.9), 4.51 – 4.40 (2 H, m), 4.39 – 4.33 (1 H, 
m), 4.20 (1 H, s), 3.33 (1 H, dd, J = 13.5, 5.7), 3.15 (1 H, dd, J = 13.6, 7.5), 1.25 
(9 H, s). 13C NMR (126 MHz, CDCl3): δ 208.4, 155.6, 154.9, 149.7, 149.2, 143.8, 
141.5, 131.8, 129.9, 127.9, 127.2, 125.1, 124.3, 122.35, 121.7, 120.2, 112.7, 
100.1, 78.6, 77.4, 77.2, 76.9, 67.3, 62.4, 47.3, 42.6, 28.9. 
 
Synthesis and Purification of Thioisoleucine (Fmoc-IleS-NBt) Precursor 
 
(9H-fluoren-9-yl)methyl ((2S,3S)-1-((2-amino-5-nitrophenyl)amino)-3-methyl-
1-oxopentan-2-yl)carbamate (3-4). Fmoc-Ile-OH (3.53 g, 10.0 mmol) was 
dissolved in anhydrous THF (90 mL). N-methylmorpholine (2.20 mL, 20.0 mmol) 
was added and the reaction was cooled to -10 °C while the flask was purged with 
argon. Isobutyl chloroformate (1.30 mL, 10.0 mmol) was added dropwise while 
stirring. The reaction mixture was stirred for 15 min at -10 °C, then 4-nitro-o-
phenylenediamine (1.53 g, 10.0 mmol) was added. The reaction was stirred under 
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argon for 2 hours at -10 °C, then at room temperature overnight. After removing 
the solvent in vacuo, the residue was dissolved in DMF (50 mL). Upon addition of 
saturated aqueous KCl (250 mL) solution and Milli-Q water (250 mL), a yellow solid 
precipitated. The solid was filtered, washed with Milli-Q water and dried under 
vacuum. Compound 3-4 was isolated in 78.5% yield (3.84 g, 7.85 mmol) and 
79.4% purity, as determined by HPLC. HRMS (ESI) m/z calculated for C27H28N4O5 
[M+H]+ is 489.2138, found 489.2130. 1H NMR (500 MHz, C2D6OS): δ 9.54 (s, 1H), 
8.29 (d, J = 2.7 Hz, 1H), 7.91 – 7.83 (m, 3H), 7.80 – 7.72 (m, 3H), 7.41 (t, J = 7.2 
Hz, 4H), 7.32 (t, J = 7.5 Hz, 2H), 6.79 (d, J = 9.1 Hz, 1H), 6.52 (s, 2H), 4.35 – 4.20 
(m, 4H), 4.09 (t, J = 8.2 Hz, 1H), 1.90 (ddt, J = 12.4, 8.5, 4.2 Hz, 1H), 1.56 (ddd, J 
= 13.7, 7.4, 3.3 Hz, 1H), 1.30 – 1.17 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H), 0.88 (t, J = 
7.4 Hz, 3H). 13C NMR (126 MHz, C2D6OS): δ 171.2, 156.4, 148.8, 143.7, 140.7, 
135.5, 127.6, 127.0, 125.3, 122.9, 121.2, 121.1, 120.1, 113.7, 65.8, 59.8, 46.7, 
35.8, 24.7, 15.4, 10.7. 
 
(9H-fluoren-9-yl)methyl ((2S,3S)-1-((2-amino-5-nitrophenyl)amino)-3-methyl-
1-thioxopentan-2-yl)carbamate (3-5). Anhydrous Na2CO3 (0.239 g, 2.25 mmol) 
and P4S10 (1.00 g, 2.25 mmol) were suspended in anhydrous THF (30 mL) in an 
oven-dried round bottom flask and stirred under argon for 30 minutes until solution 
became clear. Compound 3-4 (1.10 g, 3.00 mmol) was added and the reaction 
stirred over night at room temperature under argon. The next day the solvent was 
removed in vacuo. The resulting residue was resuspended in ethyl acetate and 
filtered over a pad of Celite® (Sigma-Aldrich, St. Louis, MO) to remove insoluble 
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P4S10 adducts. The filtrate was washed twice with 5% NaHCO3 and once with 
brine. The aqueous layer was acidified with HCl and back extracted twice with ethyl 
acetate. The combined organic layers were dried over MgSO4, filtered and the 
solvent was removed in vacuo. The crude product was redissolved in 
dichloromethane and purified over silica to afford pure product as a yellow foam in 
50.8% yield (0.770 g, 1.52 mmol). Rf = 0.5 in ethyl acetate/hexanes (1:1). HRMS 
(ESI) m/z calculated for C27H28N4O4S [M+H]+ is 505.1910, found 505.1909. 1H 
NMR (500 MHz, CDCl3) δ 9.57 (s, 1H), 7.98 (s, 1H), 7.95 (d, J = 8.9 Hz, 1H), 7.77 
– 7.70 (m, 2H), 7.49 (d, J = 7.5 Hz, 1H), 7.44 (d, J = 7.4 Hz, 1H), 7.42 – 7.33 (m, 
2H), 7.27 (s, 2H), 7.30 – 7.20 (m, 2H), 6.58 (d, J = 9.0 Hz, 1H), 5.70 (s, 1H), 4.27 
(d, J = 7.7 Hz, 3H), 4.14 (t, J = 7.1 Hz, 1H), 2.10 – 2.02 (m, 1H), 1.29 – 1.20 (m, 
2H), 1.02 (d, J = 6.7 Hz, 3H), 0.97 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ 206.2, 157.4, 148.5, 143.3, 141.3, 138.4, 128.1, 128.0, 127.4, 127.3, 125.6, 
125.0, 125.0, 124.9, 122.3, 120.3, 120.2, 115.3, 77.4, 67.6, 66.89, 47.0, 39.1, 
29.83, 15.9, 11.1. 
 
(9H-fluoren-9-yl)methyl ((2S,3S)-3-methyl-1-(6-nitro-1H-
benzo[d][1,2,3]triazol-1-yl)-1-thioxopentan-2-yl)carbamate (3-6, Fmoc-IleS-
NBt). Compound 3-5 (0.770 g, 1.52 mmol) was dissolved in 95% glacial acetic acid 
diluted with 5 % water (20 mL). The solution was cooled to 0 °C and NaNO2 (156 
mg, 2.26 mmol) was added slowly. Upon complete addition, the reaction mixture 
was stirred for 30 min at 0 °C, after which cold Milli-Q water (125 mL) was added. 
The precipitated orange solid was filtered, washed with cold Milli-Q water and dried 
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in vacuo. The crude yield of the reaction was 57.7% (0.453 g, 0.88 mmol) and was 
used directly in solid phase peptide synthesis without further purification. Rf = 0.45 
in dichloromethane. HRMS (ESI) m/z calculated for C27H25N5O4S [M+Na]+ is 
538.1525, found 538.1508.  1H NMR (500 MHz, CDCl3) δ 9.70 (s, 1H), 8.46 (d, J 
= 8.7 Hz, 1H), 8.32 (d, J = 8.9 Hz, 1H), 7.76 (d, J = 7.6 Hz, 2H), 7.60 (d, J = 7.5 
Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.31 (q, J = 8.1 Hz, 2H), 6.22 (dd, J = 9.9, 6.2 Hz, 
1H), 5.70 (d, J = 9.9 Hz, 1H), 4.49 (dd, J = 10.9, 6.9 Hz, 1H), 4.41 (dd, J = 10.9, 
6.8 Hz, 1H), 4.22 (t, J = 6.9 Hz, 1H), 2.13 – 2.04 (m, 1H), 1.72 – 1.61 (m, 1H), 1.30 
– 1.19 (m, 1H), 1.03 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 209.5, 156.0, 149.5, 149.0, 143.6, 143.6, 141.3, 131.7, 127.7, 
127.0, 127.0, 125.0, 124.9, 122.2, 121.5, 119.9, 112.8, 66.9, 65.7, 47.2, 41.1, 24.1, 
16.2, 11.2.  
 
Synthesis and Purification of Thioglutamate (Fmoc-GluS-NBt), 
Thiophenylalnine (Fmoc-PheS-NBt), Thioalanine (Fmoc-AlaS-NBt), 
Thioleucine (Fmoc-LeuS-NBt), Thioproline (Fmoc-ProS-NBt), Thioglycine 
(Fmoc-GlyS-NBt), and Thiovaline (Fmoc-ValS-NBt) Precursors. Each of these 
precursors were synthesized using modified synthesis from Shalaby et al. and 
have been reported previously.132, 153, 222, 237, 296, 297 
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3.3.3 – Calmodulin Synthesis and Analysis 
Peptide Synthesis of CaM135-148 Cys135 PheS138  
The first CaM thiopeptide construct made was CaM135-148Cys135PheS138. 
Residue 138 is a tyrosine in the native sequence, but PheS was used for the initial 
method development as it had been previously synthesized and used in our lab for 
ligation. Solid phase peptide synthesis (SPPS) of CaM135-148 Cys135 PheS138 (H2N-
CVNFSEEFVQMMTAK-OH) was performed on 2-chlorotrityl resin (100-200 mesh) 
on a 50 μmol scale. The peptide was elongated up to the thioamide position using 
standard SPPS protocols by adding 5 equiv of amino acid, HBTU, and DIPEA in 
DMF (2 mL) and stirring each coupling for 40 min at RT. Fmoc removal was 
performed by stirring the resin in 20% piperidine in DMF (5 mL) for 20 min at RT. 
It should be noted that each amino acid coupling was performed twice to improve 
isolated peptide yields (data not shown). Prior to the thioamide coupling, the resin 
was washed with dry dichloromethane (DCM, obtained by drying over molecular 
sieves; washed 2 x 4 mL). Fmoc-PheS-NBt (1.5 eq.) was then added to the vessel 
with DIPEA (1.5 equiv) in DCM (1.5 mL) and the reaction was stirred at RT for 30 
min. The vessel was then drained and the resin washed with dry DCM (2 x 4 mL) 
before repeating the thioamide coupling. At completion of the second coupling, the 
resin was washed with DCM, then DMF (2 x 4 mL each) and standard SPPS was 
used to add the remaining amino acids. After the Fmoc deprotection of Cys135, the 
resin was washed with DMF and DCM, before being dried by vacuum for 10 min. 
A cleavage cocktail was prepared with 24:16:1:1:1 
DCM:TFA:TIPS:EDT:Thioanisole (total volume of 4.3 mL). This was added to the 
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dried resin and allowed to stir at RT for 1 h before being drained and collected. 
DCM (4 mL) was added to the resin to wash out any remaining peptide and the 
collected solution was dried to a yellow oil by rotary evaporation. This oil was 
washed with DCM (3 x 5 mL) to remove any excess organic reagents. The crude 
peptide product was then precipitated by adding cold diethyl ether (10 mL) and 
vortexing vigorously. The resulting precipitate was centrifuged to a pellet and the 
supernatant was discarded. Crude peptide was stored under argon at 4 °C until 
purification by HPLC could proceed. 
 
HPLC Purification of CaM135-148 Cys135 PheS138 
The crude white solid was dissolved in 35% v/v acetonitrile in Milli-Q water 
with 0.1 % TFA. The peptide was purified by reverse phase HPLC using a binary 
solvent system (Buffer A: water with 0.1% TFA; Buffer B: acetonitrile with 0.1% 
TFA). A Grace Vydac C18 Preparatory column was used with the gradient in Table 
3-3 to purify CaM135-148-Cys135 PheS138. 
Table	3-3:	Solvent	gradient	used	for	HPLC	purification.	
	
Time (min) Buffer A (%) 
0:00 98 
5:00 98 
10:00 75 
34:00 62 
35:00 2 
40:00 2 
41:00 98 
46:00 98 
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Synthesis of Remaining CaM Thiopeptides  
Synthesis of each CaM thiopeptide was performed as described above. 
MALDI (Table 3-4) and MALDI tandem MS/MS (data not shown) analysis was used 
to confirm the mass and intact thioamide presence in each peptide. We routinely 
obtained 2-6 mg (2-7% yield) of thiopeptide with these syntheses. 
	
	
Table	3-4:	Calculated	and	observed	m/z	for	isolated	CaM	thiopeptides.	
CaM135-148 Sequence Calculated m/z [M+H]+  Observed m/z 
H2N-CVSNYEEFVQMMTAK-OH 1708.72 1709.94 
H2N-CVNFSEEFVQMMTAK-OH 1693.73 1693.74 
H2N-CVNYSEEFVQMMTAK-OH 1708.72 1710.25 
H2N-CVNYESEFVQMMTAK-OH 1708.72 1709.47 
H2N-CVNYEESFVQMMTAK-OH 1708.72 1709.21 
H2N-CVNYEEFSVQMMTAK-OH 1708.72 1710.28 
H2N-CVNYEEFVSQMMTAK-OH 1708.72 1709.37 
H2N-CVNYEEFVQMMTASK-OH 1708.72 1710.19 
 
 
Expression and Purification of WT and Cys135 CaM  
Expression (1 L in LB media) and purification of these CaM constructs were 
done as previously reported.237 Yields for each protein totaled ~20 mg/L and each 
protein was stored as a lyophilized powder prior to further processing and 
preparation for CD measurements.  
 
Cloning of CaM1-134-GyrA-H6  
Full-length CaM was previously cloned into the pTXB1 vector containing the 
MxeGyrA intein and a six residue histidine tag for Ni-NTA purification.252 The 14 
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amino acid deletion was carried out in four rounds of QuikChangeÒ PCR using the 
following four sets of primers. Deletions were confirmed by DNA sequencing with 
T7 promoter and terminator primers.  
 
 
i. Deletion of CaM146-148 
Forward: 5’-GAAGAGTTTGTACAGATGATGTGCATCACGGGAGAT-3’ 
Reverse: 5’-ATCTCCCGTGATGCACATCATCTGTACAAACTCTTC-3’ 
ii. Deletion of CaM142-145 
Forward: 5’-CAAGATAACTATGAAGAGTTTTGCATCACGGGAGAT-3’ 
Reverse: 3’-ATCTCCCGTGATGCAAAACTCTTCATAGTTTACTTG-3’ 
iii. Deletion of CaM138-141 
Forward: 5’-GATGGTGATGGTCAAGTAAACTGCATCACGGGAGAT-3’ 
Reverse: 5’-ATCTCCCGTGATGCAGTTTACTTGACCATCACCATC-3’ 
iv. Deletion of CaM135-137 
Forward: 5’-GACATTGATGGTGATGGTTGCATCACGGGAGAT-3’ 
Reverse: 5’-ATCTCCCGTGATGCAACCATCACCATCAATGTC-3’ 
 
Original Protein Sequence: 
 
(M)ADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMI
NEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELR
HVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVQMMTAKCITGDALVALP
EGESVRIADIVPGARPNSDNAIDLKVLDRHGNPVLADRLFHSGEHPVYTVRTVE
GLRVTGTANHPLLCLVDVAGVPTLLWKLIDEIKPGDYAVIQRSAFSVDCAGFAR
GKPEFAPTTYTVGVPGLVRFLEAHHRDPDAQAIADELTDGRFYYAKVASVTDA
GVQPVYSLRVDTADHAFITNGFVSHATGLTGLKLHHHHHH      
 
Resulting Protein Sequence:  
 
(M)ADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMI
NEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELR
HVMTNLGEKLTDEEVDEMIREADIDGDGCITGDALVALPEGESVRIADIVPGARP
NSDNAIDLKVLDRHGNPVLADRLFHSGEHPVYTVRTVEGLRVTGTANHPLLCLV
DVAGVPTLLWKLIDEIKPGDYAVIQRSAFSVDCAGFARGKPEFAPTTYTVGVPG
LVRFLEAHHRDPDAQAIADELTDGRFYYAKVASVTDAGVQPVYSLRVDTADHA
FITNGFVSHATGLTGLKLHHHHHH      
 
The sequence in black is the WT calmodulin sequence. The portion in blue is the 
deleted sequence to be added by NCL with Cys in place of Gln at the ligation site. 
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The sequence in green is the Mxe GyrA intein followed by the His6 tag in red. The 
initial methionine (M) is removed during expression by an endogenous Escherichia 
Coli methionine aminopeptidase. 
 
CaM1-134-GyrA-H6 Expression  
CaM1-134-GyrA was transformed into BL21-Gold (DE3) E. Coli cells and 
grown against ampicillin (100 μg/mL) on an LB-agar plate. Single colonies were 
picked and grown in liquid LB media (3 x 5 mL, 100 μg/mL ampicillin) with shaking 
(250 RPM) at 37 °C until saturation. Each primary culture was then added to a 
secondary culture of autoclaved LB media (1 L, 100 μg/mL ampicillin) and grown 
at 37 °C, with shaking (250 RPM) until OD600= 0.8-1.0 (3-4 h). IPTG was then 
added (final concentration = 1 mM) and the temperature and shaking speed were 
reduced to 25 °C and 225 RPM respectively for 16 h of additional incubation. 
  
Expression of 15N Isotopically Enriched CaM1-134-GyrA-H6  
The plasmid encoding CaM1-134-GyrA was transformed into BL21-Gold 
(DE3) E. Coli cells and grown against ampicillin (100 μg/mL) on an LB-agar plate. 
A single colony was picked and grown in liquid LB media (5 mL, 100 μg/mL 
ampicillin) with shaking (250 RPM) at 37 °C until saturation. The bacteria were 
then pelleted by centrifugation and resuspended in a sterile 50 % solution of 
glycerol in water (1 mL) and flash frozen in liquid nitrogen prior to being stored at 
-80 °C. This glycerol stock will be used directly in culture growth and protein 
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expression.  For bacterial culture growth, a minimal media was prepared as 
follows. First, a 10 x stock of M9 salts was prepared by dissolving Na2HPO4 (90 
g), KH2PO4 (45 g), and NaCl (7.5 g) in 1 L of Milli-Q water. A 50 mL and a 1 L 1x 
M9 media were prepared by making a ten-fold dilution in Milli-Q water and were 
autoclaved for sterilization. Next, a master mix of additives and nutrients were 
prepared by dissolving 15NH4Cl (1 g), glucose (2 g), MgSO4 (0.24 g), CaCl2 (0.15 
g), yeast extract (0.2 g), and ampicillin (0.1 g) in 20 mL of sterile (autoclaved) Milli-
Q water in a sterile 50 mL falcon tube. 1 mL of master mix was then added to the 
50 mL aliquot of media and the remaining master mix was added to the 1 L media 
portion. To each was added FeSO4 (15 mg/mL stock) and ZnCl2 (15 mg/mL) to a 
final concentration 0.1 % v/v. The 50 mL M9 1x is used primary culture for protein 
expression. To begin bacterial growth, 20 μL of CaM1- 134-GyrA BL21 glycerol stock 
was added to the starter culture flask and the culture was grown at 37 °C (250 
RPM) until saturation (~8 hours). Once at saturation, this 50 mL culture was added 
to the 1 L 1x M9 secondary culture and was grown at 37 °C (250 RPM) until OD600 
= 0.8 (~3-4 hours). Then protein expression was induced by adding IPTG to a final 
concentration of 1 mM and the culture was grown an additional 20 hours at 25 °C 
with shaking (225 RPM). Purification then proceeded as described below. 
 
CaM1-134-GyrA-H6 Purification  
Cells (3 x 1 L expression) were harvested by centrifugation at 5,000 RPM 
in a GS3 rotor and Sorvall RC-5 centrifuge for 10 min at 4 °C. The supernatant 
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was discarded and the cell pellet was suspended in 25 mL lysis buffer (50 mM 
HEPES, pH 7.5) containing two broad spectrum protease inhibitor tablets. 
Resuspended cells were then lysed on ice by sonication (30 amps power, 1 second 
pulse, 1 second rest, 2 minute total sonication time) and then pelleted at 13,000 
RPM in an SS-34 rotor (Sorvall RC-5 centrifuge) for 15 min at 4 °C. The 
supernatant was collected and incubated with Ni2+-NTA resin (4 mL column 
volume) for 1 h on ice with shaking. The slurry was then added to a fritted column 
and the liquid was allowed to flow through. The resin was then washed with 3 x 10 
mL of buffer (50 mM HEPES, pH 7.5) and 3 x 10 mL of wash buffer (50 mM 
HEPES, 10 mM imidazole, pH 7.5).  CaM1-134-GyrA was then eluted from the resin 
in 5 fractions each containing 5 mL of elution buffer (50 mM HEPES, 300 mM 
imidazole, pH 7.5). The pooled fractions were dialyzed against MES•Na cleavage 
buffer (20 mM Tris, pH 7.3) overnight at 4 °C. 
 
CaM1-134-GryA-H6 MES•Na Intein Cleavage and Purification of CaM1-134-MES 
Thioester  
 
MES•Na (200 mM final concentration) was added to 25 mL of the solution 
containing CaM1-134-GyrA in MES•Na cleavage buffer and allowed to incubate with 
stirring for 16 h at 4 °C. After 16 h, a 1:30 dilution in water of the cleavage solution 
was analyzed by MALDI-MS and the reaction appeared to be at completion. The 
cleavage reaction was dialyzed against 20 mM Tris, pH 8.0 at RT for 2 h to remove 
the remaining MES•Na from solution. CaM1-134-MES was purified in three batches 
over a HiTrap Q column using a 120 min NaCl gradient (0.1 M to 0.8 M NaCl in 20 
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mM Tris, pH 8.0). The desired product partially coelutes with the impurity CaM1-
135-OH, a hydrolytic byproduct of the intein cleavage reaction, which can be 
resolved after ligation. This eluent was collected in 6 x 1.5 mL fractions (product 
presence confirmed by MALDI-MS). The pooled fractions were dialyzed against 
Milli-Q water at 4 °C overnight before being flash frozen with liquid nitrogen and 
lyophilized to a solid. Total yield from a 3 x 1 L expression is approximately 30 mg 
of 90% pure CaM1-134-MES. 
 
Purification of CaM1-134-OH  
CaM1-134-GyrA-H6 was expressed as above. After Ni2+-NTA purification, the 
eluent was dialyzed against 20 mM Tris pH 7.3 (2 L) overnight at 4 °C. CaM1-134-
GyrA-H6 was then treated with βME (200 mM) to cleave the intein and reveal CaM1-
134-OH. This cleavage process is discussed elsewhere.252 This protein was then 
purified by anion exchange over a HiTrap Q column as described above for CaM1-
134-MES. The protein was sufficiently pure after one round of FPLC purification and 
was dialyzed against Milli-Q water overnight at 4 °C before being frozen in liquid 
nitrogen and lyophilized to a white powder. The total isolated yield of CaM1-134-OH 
was 8 mg per L of culture. 
 
Expression and Purification of CaM1-71-OH  
CaM1-71-GyrA-CBD was transformed into BL21-Gold (DE3) E. coli cells and 
grown on an LB-agar plate with ampicillin (100 μg/mL). A single colony was picked 
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and grown in liquid LB media (5 mL, 100 μg/mL ampicillin) with shaking (250 RPM) 
at 37 °C until saturation. The primary culture was then added to a secondary 
culture of sterile Terrific Broth media299 (1 L, 100 μg/mL ampicillin) and grown at 
37 °C, shaking (250 RPM) until OD600= 0.8-1.0 (3-4 h). IPTG was then added (final 
concentration = 1 mM) and the temperature and shaking speed were reduced to 
25 °C and 225 RPM. The culture was allowed to grow for 16 h. Cells were 
harvested by centrifugation at 5,000 RPM in GS3 rotor and Sorvall RC-5 centrifuge 
for 10 min at 4 °C. The supernatant was discarded and the cell pellet was 
resuspended in 10 mL lysis buffer (20 mM Tris, pH 8.0) containing one broad 
spectrum protease inhibitor tablet. Resuspended cells were then lysed on ice by 
sonication (30 amps power, 1 second pulse, 1 second rest, 2 minute total 
sonication time) and spun down at 13,000 RPM in an SS-34 rotor in a Sorvall RC-
5 centrifuge for 15 min at 4 °C. The supernatant was collected and incubated with 
chitin beads (5 mL column volume, CV) for 1 h on ice with shaking. The slurry was 
then added to a fritted column and the liquid was allowed to flow through. The 
beads were washed with 10 x CV of 20 mM Tris pH 8.0. Intein cleavage buffer (20 
mM Tris, 200 mM βME, pH 7.5, 10 mL) was then added to the beads and incubated 
on a rotisserie at RT for 16 h. The column was then drained and the flow through 
collected. The eluent was dialyzed against 20 mM Tris, pH 8.0 to remove any 
excess βME and purified by FPLC using anion exchange as described above. The 
protein was pure after one round of FPLC purification and was dialyzed against 
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Milli-Q water overnight at 4 °C before being frozen in liquid nitrogen and lyophilized 
to white powder. The total isolated yield was 6 mg per L of culture. 
 
Native Chemical Ligation (NCL) for Synthesis of Thioamide CaM Constructs 
The following general protocol was used for the synthesis of all thioamide 
containing constructs. Ligation buffer (2 mL) was prepared fresh prior to each 
reaction by adding NaH2PO4 (0.2 M), Gdn•HCl (6 M), TCEP•HCl (20 mM) and 
thiophenol (2% v/v) to 1.7 mL of water and adjusting the pH to 7.3 followed by the 
volume to 2 mL. Approximately 10 mg (660 nmol) of CaM1-134-MES of was weighed 
out using an analytical balance and added to an Eppendorf tube. To this tube, 
ligation buffer (500 μL) was added and the tube was vortexed to ensure all dried 
protein dissolved and then incubated at RT for 2 min to allow the more electrophilic 
CaM1-134-SPh to form by transthioesterification of the MES thioester with 
thiophenol (see Figure 3-15). Thiopeptide (2 equiv) was then weighed out into a 
separate Eppendorf tube and ligation buffer (500 μL) was added. This tube was 
then vortexed to ensure that all of the thiopeptide dissolved. The thiopeptide was 
then added to the tube containing the CaM1-134-SPh protein and incubated at 37 
°C with constant shaking (500 RPM) for 20 h. The reaction was monitored by 
MALDI for product formation and it should be noted that additional CaM1-134-OH 
byproduct was formed during the reaction. At reaction completion, the mixture was 
diluted to 3 mL with Milli-Q water and dialyzed against 20 mM Tris pH 8.0 overnight 
at 4 °C in preparation for FPLC purification. 
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Figure	3-15:	NCL	methodology	used	to	generate	all	CaM	thiproteins.	Transthioesterification	of	CaM1-134-
MES	with	thiophenol,	followed	by	ligation	to	CaM135-148-Cys135	thiopeptide.	
 
NCL Control for CaM Cys135 
The expressed CaM Cys135 protein was subjected to NCL conditions by 
incubating it with ligation buffer for 20 h with constant shaking (500 RPM) at 37 °C. 
This protein was then subjected to the same purification and alkylating protocols 
as the thioamide CaM mutants. 
 
Purification of Thioamide CaM NCL Reactions  
The dialysate from the crude reaction was filtered and treated with TCEP 
Bond-Breaker™ (5 μL) prior to being manually loaded onto a 4 mL bed volume 
HiTrap Q column. The purification proceeded using the same gradient as the 
CaM1-134-MES thioester purification. The full-length CaM thioprotein elutes over 5 
fractions with CaM1-134-OH but the two proteins cannot be completely separated 
using any gradient on anion exchange. To remove the impurity, a cysteine capture 
thiopropyl sepharose 6b resin is used. The NCL product containing a cysteine will 
form a covalent disulfide bond with the thiopropyl group while the impurity CaM1-
134-OH will flow through the resin. Prior to purification by this resin, the fractions 
from anion exchange purification were dialyzed against 2 L thiopropyl binding 
buffer (20 mM Tris, 1 mM EDTA pH 7.5) overnight at 4 °C. The resin (0.6 g, 1.5 
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mL CV) is prepared by washing it with 50 x CV of Mili-Q water, followed by 10 x 
CV of binding buffer. The dialysate is then added to the slurry and incubated on a 
rotisserie for 1 h at RT. The flow through is collected and analyzed by MALDI to 
ensure that the thioamide CaM bound to the resin. The resin was then washed 
with 10 x CV of binding buffer, 25 x CV of wash buffer (20 mM Tris, 100 mM NaCl, 
1 mM EDTA, pH 7.5), and again with 10 x CV binding buffer. Elution buffer is 
prepared by adding βME to a final concentration of 30 mM in 6 mL binding buffer. 
Elution buffer (4 mL) is then added to the resin and incubated on a rotisserie for 
20 min at RT. The eluent is collected and the resin washed with the remaining 2 
mL of elution buffer, followed by 3 mL of binding buffer to elute the remaining 
protein. The presence of thioamide CaM is determined by MALDI by observing the 
mass of the βME disulfide adduct (M+76 Da). This solution is then dialyzed against 
2 L of capping buffer (20 mM Tris, pH 8.3) for 2 h at RT before proceeding to the 
alkylation of Cys135. 
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Figure	3-16:	MALDI	mass	spectra	analysis	of	purification	of	CaM-Cys135PheS138	by	thiopropyl	sepharose	resin.	
(A)	 Mixture	 of	 CaM1-134	 (*)	 and	 CaM1-148-Cys135PheS138	 (*)	 prior	 to	 resin	 incubation.	 (B)	 Flow	 through	
containing	only	CaM1-134	(calculated	m/z	[M+H]+	=	15008	Da;	observed	15008	Da)	after	resin	incubation.	(C)	
Elution	containing	only	the	desired	CaM1-148-Cys135PheS138	NCL	product	(calculated	m/z	[M+H]+	=	16682	Da;	
observed	16682	Da).	Masses	corresponding	 to	 (M+2)/2	 (half-mass)	and	M+206	Da	 (adduct	 formed	with	
sinapic	acid	matrix	for	depositing	samples)	are	commonly	observed	in	each	spectrum.	
 
Alkylation of Cys135 with Iodoacetamide 
The dialysate from the previous step was added to a 15 mL Falcon tube 
and incubated with TCEP Bond-Breaker™ (10 mM) for 2 min. Next, iodoacetamide 
(final concentration = 200 mM) was added and the solution was vortexed slowly 
until all of the iodoacetamide was dissolved. The reaction was incubated at RT for 
five min and the presence of singly alkylated thioamide CaM or CaM-Cys135 was 
confirmed by MALDI-MS (Table 3-5). This solution was then dialyzed against 2 L 
of water for 2 h, followed by a second round of dialysis overnight at 4 °C to remove 
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the excess TCEP and iodoacetamide. The resulting solution was flash frozen in 
liquid nitrogen and lyophilized to a fine white powder. For 15N isotopically enriched 
samples, at completion of the capping reactions, the samples were dialyzed in two 
rounds (2 L for 2 hours each at room temperature) against 20 mM Tris pH 8.0. The 
samples were then subjected to FPLC purification if any impurities persisted using 
the previously described procedure. Samples were again dialyzed against 20 mM 
Tris pH 8.0 and were then concentrated and buffer exchanged using the protocol 
outlined below (see NMR sample preparation).  
Table	3-5:	Calculated	and	observed	protein	m/z.	All	CaM	thioproteins	routinely	fly	as	[M+Na]+.		
 
CaM Variant 
Calculated m/z 
[M+H]+  
Calculated m/z 
[M+Na]+  Observed m/z 
WT 16708 16730 16705 
CaM1-134-OH 15008 15030 15007 
CaM1-134-MES 15130 15152 15130 
CaM1-71 7832 7854 7832 
CaM-CysQ135 16740 16762 16740 
CaM-CysQ135ValS136 16756 16778 16777 
CaM-CysQ135PheS138 16740 16762 16762 
CaM-CysQ135TyrS138 16756 16778 16777 
CaM-CysQ135GluS139 16756 16778 16778 
CaM-CysQ135GluS140 16756 16778 16775 
CaM-CysQ135PheS141 16756 16778 16778 
CaM-CysQ135ValS142 16756 16778 16775 
CaM-CysQ135AlaS147 16756 16778 16777 
 
Table	3-6:	Calculated	and	observed	protein	m/z	for	15N	isotopically	labeled	proteins.	
CaM Variant 
Calculated 
m/z [M+H]+  
Calculated m/z 
[M+Na]+  Observed m/z 
CaM1-134-MES (15N1-134) 15290 15312 15290 
CaM-CysQ135 (15N1-134) 16899 16921 16920 
CaM-CysQ135ValS136 (15N1-134) 16915 16937 16936 
CaM-CysQ135TyrS138 (15N1-134) 16915 16937 16935 
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Trypsin Digest of CaM-CysQ135 AlaS147  
To a 5 μL aliquot of sequencing grade trypsin (0.1 mg/mL), 50 μL of a 25 
μM stock of CaM-CysQ135AlaS147 was added. This mixture was incubated at 37 °C 
for 16 h. The resulting tryptic peptide mixture was analyzed by MALDI. The desired 
[M+Na]+ (expected: 2561.8 Da, observed: 2561.2 Da) was detected for the peptide 
H2N-EADIDGDGCQVNYEEFVQMMTASK-OH obtained from the cut site at Arg126. 
The spectrum was absent of any peaks indicating multiple or missed alkylations 
by iodoacetamide. To ensure that Cys135 was alkylated while leaving the thioamide 
sulfur intact, MALDI-MS/MS of this peptide was performed. The resulting mass 
spectrum could be assigned for fragmentation to the x-, y-, b- and a-series of this 
peptide (Figure 3-17 and 3-18). Fragments could be unambiguously assigned to a 
peptide containing the alkylated CysQ and unmodified AlaS147 without any 
detectable missed or aberrant alkylations, respectively (Table 3-7). 
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Figure	 3-17:	 Top:	 Trypsin	 digest.	 The	 blue	 box	 indicates	 the	 desired	 peak	 selected	 for	 MS/MS	
([M+Na]+expected:	 2561.8	 Da,	 observed:	 2561.2	 Da).	 Bottom:	 MS/MS	 spectrum	 of	 fragmented	 tryptic	
peptide.	Ions	from	the	a-,b-,x-	and	y-series	are	observed.	
 
 
 
159	
	
 
Figure	3-18:	Fragmentation	patterns	of	the	H2N-EADIDGDGCQVNYEEFVQMMTASK-OH	tryptic	peptide.	
	
Table	3-7:	Expected	(black)	and	observed	(red)	MS/MS	fragment	m/z	(a-,	b-,	x-	and	y-	series	ions)	for	the	
tryptic	 peptide	 H2N-EADIDGDGCQVNYEEFVQMMTASK-OH.	 Nearly	 complete	 coverage	 of	 the	 peptide	 is	
observed.	
 
 
 
 
 
H2N-E-A-D-I-D-G-D-G-CQ-V-N-Y-E-E-F-V-Q-M-M-T-AS-K-COOH
O
NH2
O
HO
O
N
H
O
H
N
O
OH O
N
H
O
H
N
O
OH O
N
H
O
H
N
O
OH O
N
H
O
H
N
S
O
N
H
O
H
N
O
NH2 O
N
H
OH
O
H
N
O OH
O
N
H
O OH
O
H
N
O
N
H
O
H
N
O
O
N
H
S
O
H
N
S
O
N
H
HO
S
H
N
O
N
H
NH2
OH
NH2
O
NH2
y-series
b-series
x-series
a-series
Sequence Observed Series a (m/z) Obs a (m/z) b (m/z) Obs b (m/z) x (m/z) Obs x (m/z) y (m/z) Obs y (m/z)
E b 102.113 130.123 129.031 --- 2539.811
A a,b,x,y 173.192 175.091 201.202 200.068 2436.690 2437.508 2410.696 2412.637
D a,b 288.280 288.113 316.290 316.115 2365.611 2339.617
I a,b 401.440 401.163 429.450 429.166 2250.522 2224.528
D b 516.528 544.538 547.022 2137.363 2111.369
G a 573.580 571.227 601.590 2022.274 1996.280
D a 688.669 690.220 716.679 1965.222 1939.228
G b 745.721 773.731 773.218 1850.134 1824.140
C a,b 905.899 930.107 933.909 934.077 1793.082 1767.088
V a 1005.032 1005.909 1033.042 1632.903 1606.909
N --- 1119.136 1147.146 1533.771 1507.776
Y b 1282.312 1310.322 1308.626 1419.667 1393.672
E b,x 1411.427 1439.437 1452.515 1256.491 1258.493 1230.496
E --- 1540.543 1568.553 1127.375 1101.381
F --- 1687.719 1715.729 998.260 972.266
V a 1786.852 1785.055 1814.862 851.083 825.089
Q x 1914.983 1942.993 751.951 773.218 725.956
M y 2046.175 2074.185 623.820 597.826 598.194
M --- 2177.368 2205.378 492.627 495.222 466.633
T x,y 2278.473 2306.483 361.435 361.199 335.441 334.140
A a,x,y 2365.612 2387.506 2393.622 260.330 261.142 234.335 235.096
K a,x,y 2493.786 2495.692 2521.796 173.191 175.091 147.197
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Figure	3-19:	MALDI	MS	spectra	showing	CaM	proteins	(WT	CaM,	CysQ135,	ValS136,	TyrS138,	GluS139,	and	GluS140;	
see	Table	3-5	for	observed	and	expected	molecular	weights)	without	any	impurities.	Masses	corresponding	
to	(M+2)/2	(half-mass)	and	M+206	Da	(adduct	formed	with	sinapic	acid	matrix	for	depositing	samples)	are	
commonly	observed	in	each	spectrum.	
 
Observed: 16705 Da 
Observed: 16777 Da 
Observed: 16778 Da 
Observed: 16740 Da 
Observed: 16777 Da 
Observed: 16775 Da 
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Figure	 3-20:	MALDI	 MS	 spectra	 showing	 CaM	 proteins	 (PheS141,	 ValS142,	 and	 AlaS147;	 see	 Table	 3-5	 for	
observed	and	expected	molecular	weights)	without	any	impurities.	Masses	corresponding	to	(M+2)/2	(half-
mass)	 and	 M+206	 Da	 (adduct	 formed	 with	 sinapic	 acid	 matrix	 for	 depositing	 samples)	 are	 commonly	
observed	in	each	spectrum.	
 
 
 
 
 
Observed: 16778 Da 
Observed: 16777 Da 
Observed: 16775 Da 
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Figure	3-21:	MALDI	MS	spectra	showing	segmental	(residues	1-134)	15N	isotopically	labeled	CaM	proteins	
(CysQ	oxo,	ValS136,	and	TyrS138).	Isolated	yields	were	not	calculated	for	these	proteins	but	final	concentration	
of	each	sample	prior	to	NMR	spectra	acquisition	was	estimated	based	upon	UV	absorption	at	276	nm.	
 
	
Table	3-8:	 Synthesized	CaM	variants	 for	CD	and	 their	 yields	based	upon	BCA	quantification	prior	 to	CD	
measurements.	
CaM Variant Percent Yield 
CaM-CysQ135ValS136 7.0% 
CaM-CysQ135TyrS138 13.9% 
CaM-CysQ135GluS139 7.6% 
CaM-CysQ135GluS140 13.0% 
CaM-CysQ135PheS141 8.2% 
CaM-CysQ135ValS142 24,8% 
CaM-CysQ135AlaS147 11.2% 
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Preparation of Samples for Circular Dichroism (CD) Measurements 
For each pure CaM variant, the lyophilized powder was dissolved in 2 mL 
of holo CD buffer (10 mM Tris, 2 mM CaCl2, pH 7.5) and incubated for 10 min at 
RT to anneal the protein. This solution was then aliquoted into 2 x 1 mL samples. 
The holo aliquot for Ca2+ bound CaM measurements was dialyzed once more 
against 2 L of holo buffer for 2 h at RT to ensure any remaining iodoacetamide or 
TCEP salt from the capping reaction was removed. The apo aliquot for Ca2+ free 
CaM measurements was dialyzed against 2 L of calcium stripping buffer (10 mM 
Tris, 1 mM EDTA, pH 7.5) for 2 h at RT before an additional round of dialysis 
against 2 L of apo CD buffer (10 mM Tris, 0.5 mM EDTA, pH 7.5) for 2 h at RT. 
The dialysis buffers were saved to be used for further dilutions of the samples as 
well as background measurements in CD spectra acquisition. 
 
Preparation of Samples for HSQC NMR Acquisition  
Samples were concentrated and buffer exchanged into NMR buffer (100 
mM KCl, 6 mM CaCl2, 0.02 % NaN3, 10 mM d4-imidazole, pH 6.5) through Amicon 
3 kDa MWCO spin filters (spun at 13,200 RPM for 5 minutes each round). 
Approximately 10 rounds of centrifugation were needed to concentrate the 
samples and another 10 rounds of buffer exchange was performed by adding 400 
μL of NMR buffer to the spin-filter tube and spinning at 13, 200 RPM for 5 minutes 
in an Eppendorf 5415r benchtop centrifuge (4 °C) for each round. Sample volume 
was then adjusted to 475 μL and 25 μL of D2O was added to a final concentration 
of 5 % v/v. These samples were then used directly in HSQC NMR data acquisition. 
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HSQC NMR Acquisition and Data Analysis  
NMR data was obtained by a collaborator (Dr. Kathy Valentine and 
Professor Josh Wand; University of Pennsylvania) on a Bruker 500 MHz 
instrument at 30 °C. The raw HSQC spectra was processed in Bruker TopSpin 
(Billerica, MA). The raw data was individually phase adjusted using the commands 
‘abs1’ and ‘abs2’ and then overlaid to compare chemical shifts. The phase 
adjusted spectra were manually contour adjusted until negative resonances were 
no longer visible. CaM reference HSQC data from X. laevis were downloaded from 
the biological magnetic resonance data bank (BMRB; accession number 6541) 
and analyzed using the DEVise plot plug-in.284 
 
Modified BCA Assay for Concentration Determination of CaM CD Samples 
A commercial Pierce™ Thermo Fisher Scientific BCA assay kit (Bellefonte, 
PA) was used to determine the concentration of each sample of CaM. However, 
the assay was modified slightly to give more consistent concentration readings 
amongst replicates of samples. BCA reagent was prepared as described by the 
commercial protocol. A set of standard bovine serum albumen (BSA) dilutions 
(1.25, 1.0, 0.75, 0.5, 0.25, and 0.125 mg/mL) were used as a calibration curve. A 
separate calibration curve was generated for holo and apo samples as each buffer 
affects the absorbance measurement differently. BCA reagent (200 μL) was added 
to each empty Eppendorf tube for standards and samples. A 0 mg/mL BSA control 
tube was also used. Then each standard and sample (25 μL) were added to their 
corresponding BCA reagent tubes. The 0 mg/mL sample received either holo or 
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apo CD buffer. The samples were then vortexed to mix and incubated at 37 °C for 
30 min. Each sample was then diluted with 1.2 mL of buffer and vortexed to mix. 
Absorbance at 562 nm (A562) was obtained by a HP 8452 UV/Vis 
spectrophotometer in a 1 cm path length cuvette. The A562 values were fit linearly 
and the fit was used to determine the concentration of the CaM samples. This 
method was compared to CaM quantification based upon the A276 and a previously 
published extinction coefficient (ε276 = 3006 M-1 cm-1) and was in good agreement 
for WT CaM samples.300 However, direct quantification by A276 for thioamide 
containing constructs using this method is not viable as the extinction coefficient 
in this absorbance region for each thioamide position in the context of the protein 
is unknown. 
 
CD Wavelength Measurements 
Based upon the concentrations obtained from the BCA assay, each holo 
and apo protein was divided into three aliquots and diluted to 10 μM in their 
respective buffers with the exception of TyrS138, which was diluted to 30 μM to 
obtain a sufficiently high signal-to-noise ratio for CD measurements. The 
wavelength measurements were taken in triplicate to average out any small error 
in the concentration measurements or dilutions. Each sample (300 μL) was added 
to a 1 mm path length Helma Analytics 110-QS CD cuvette and loaded into a Jasco 
J-1500 CD Spectrometer. CD wavelength scans were taken at 25 °C by scanning 
at a 1 nm step between 350 nm and 190 nm with a bandwidth of 1 nm and an 
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averaging time of 8 s per measurement. Background spectra were obtained by 
measuring the CD signal of the relevant buffer in each cuvette with an averaging 
time of 2 s. The raw signal (θd, mDeg) from each sample was background 
subtracted against the blanks and converted to molar residue ellipticity (θMRE) 
using  
 𝜃"#$ = 𝜃&/(𝑐𝑙𝑛#)           (3.1)  
where c is the concentration (M), 𝑙 is the path length (1 mm), and 𝑛# is the number 
of residues in the protein. The resulting averaged scans for each holo and apo 
protein along with a table of θ222 and θ208 values are shown in Figure 3-2 and Table 
3-9. Plots showing non-residue adjusted molar ellipticity (θn) for holo and apo 
CaM1-135 and CaM1-71 truncations, as well as selected thioproteins, are shown in 
Figure 3-3. 
Table	3-9:	Average	values	for	θ222	(holo	and	apo)	and	θ208	(holo)	MREs	from	three	replicate	spectra.	The	
ratio	between	θ222	and	θ208	is	only	given	for	the	holo	proteins	due	to	the	shift	in	global	minima	from	208	to	
205	nm	between	holo	and	apo	CaM.		
 
CaM 
Variant Holo θ222  Holo θ208 Holo θ222/θ208 Apo θ222  
WT  -13.40 -13.74 0.98 -13.20 
CysQ135 -11.73 -11.85 0.99 -7.39 
ValS136 -12.31 -13.07 0.94 -6.89 
TyrS138 -4.77 -5.91 0.81 -4.92 
GluS139 -13.36 -14.63 0.91 -4.98 
GluS140 -10.80 -12.55 0.86 -3.99 
PheS141 -4.80 -5.22 0.92 -3.52 
ValS142 -13.56 -15.24 0.89 -6.33 
AlaS147 -12.03 -13.39 0.90 -5.52 
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Thermal Denaturation of CaM Measured by CD 
Thermal denaturation was performed by monitoring θd at 222 nm over a 
temperature range of 5 to 95 °C. The temperature increase was set to 0.5 °C per 
min with an equilibration time of 10 s. Measurements were made with an averaging 
time of 8 s per sample and a bandwidth of 1 nm. All holo samples did not 
completely melt over this temperature range and have melting temperatures (TM) 
greater than 85 °C (Figure 3-4). All apo proteins melted over this temperature 
range with significant initial transitions prior to global unfolding. Fitting procedures 
for raw apo melting data are described in the following sections.  
 
Two State Fit of Apo CaM CD Data  
The two state model assumes that there is a single transition between the 
folded and unfolded states, with no intermediate state populated. For this model, 
the folded and unfolded linear baselines were fit between 5 to 20 °C and 65 to 80 
°C, respectively, by using the low temperature (𝜃- = 𝑚-𝑇 +	𝑏-) and high 
temperature (𝜃3 = 𝑚3𝑇 +	𝑏3) equations. The entire data set was then fit to   𝜃-45 = 𝜃- 𝑇 1 − 𝐹9:;9 +	𝜃3 𝑇 𝐹9:;9  𝐹9:;9 = <=(>?@A>B)/CADE<=(>?@A>B)/CA     (3.2) 
where ΔH and ΔS are adjustable parameters and R = 1.9872 cal•mol-1•K-1. The 
fraction unfolded curve is generated by minimizing the root mean square difference 
(RMSD) between 𝐹9:;9 and the experimental fraction unfolded (𝐹<FG, calculated 
from the experimental θMRE using equation 3.3) against the parameters listed 
above over the entire temperature range.  
168	
	
𝐹<FG = IJCKLIMINLIM             (3.3) 
The 𝐹9:;9 fits of the θMRE data and fraction folded (1 − 𝐹9:;9; 𝐹-) plots for all controls 
and mutants can be seen in Figures 3-22 through 3-25. The TMs were calculated 
by 𝑇" = PQPR , assuming the free energy ΔGU = 0 at the midpoint of the transition. 
The free energy at 25 °C (ΔGU(25)) was determined by 𝛥𝐺 = 𝛥𝐻 − 𝑇𝛥𝑆	using the 𝛥𝐻 and 𝛥𝑆 calculated from the fits and T = 298.15 K.  All data fitting was performed 
using the solver function in Microsoft Excel (Redmond, WA) and the plots were 
rendered in GraphPad Prism (LaJolla, CA).  We note that although the ΔΔGU(25) 
values obtained from these two state fits are unreasonably low, using the simple 
analysis based on ΔTM values in equation 3.8, we obtain ΔΔGU* values that are in 
reasonable agreement with the three state unfolding data given in Table 3-1 in the 
main text. 
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Figure	3-22:	Plots	generated	using	the	two	state	fitting	method	for	WT,	CysQ135,	and	ValS136	.	Left:	For	each	
CaM	variant	a	single	set	of	raw	data	(θMRE)	and	fits	from	equations	for	θfit,	θf,	and	θu.	Right:	The	averaged	
fraction	folded	plots	(1-Fcalc)	from	three	replicated	melts.	
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Figure	3-23:	Plots	generated	using	the	two	state	fitting	method	for	TyrS138,	GluS139,	and	GluS140.	Left:	For	
each	 CaM	 variant	 a	 single	 set	 of	 raw	data	 (θMRE)	 and	 fits	 from	equations	 for	 θfit,	 θf,	 and	 θu.	 Right:	 The	
averaged	fraction	folded	plots	(1-Fcalc)	from	three	replicated	melts.	
0 20 40 60 80
-5
-4
-3
-2
-1
0
TyrS138
Temp (°C)
θ M
R
E 
x1
0-
3 
(d
eg
  c
m
2  d
m
ol
-1
) θMRE
θfit
θf
θu
0 20 40 60 80
-8
-6
-4
-2
0
GluS139
Temp (°C)
θ M
R
E 
x1
0-
3 
(d
eg
  c
m
2  d
m
ol
-1
) θMRE
θfit
θf
θu
0 20 40 60 80
-5
-4
-3
-2
-1
0
GluS140
Temp (°C)
θ M
R
E 
x1
0-
3 
(d
eg
  c
m
2  d
m
ol
-1
) θMRE
θfit
θf
θu
0 10 20 30 40 50 60 70 80
0.0
0.5
1.0
Ff TyrS138
Temp (°C)
Fr
ac
tio
n 
Fo
ld
ed
0 10 20 30 40 50 60 70 80
0.0
0.5
1.0
Ff GluS139
Temp (°C)
Fr
ac
tio
n 
Fo
ld
ed
0 10 20 30 40 50 60 70 80
0.0
0.5
1.0
Ff GluS140
Temp (°C)
Fr
ac
tio
n 
Fo
ld
ed
171	
	
 
Figure	3-24:	Plots	generated	using	the	two	state	fitting	method	for	ValS142,	AlaS147,	and	CaM1-134.	Left:	For	
each	 CaM	 variant	 a	 single	 set	 of	 raw	data	 (θMRE)	 and	 fits	 from	equations	 for	 θfit,	 θf,	 and	 θu.	 Right:	 The	
averaged	fraction	folded	plots	(1-Fcalc)	from	three	replicated	melts.	
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Figure	3-25:	Overlay	of	average	fraction	unfolded	(Fcalc)	plots	generated	from	the	two	state	fitting	analysis.	
Left:	CysQ135,	ValS136,	TyrS138,	and	GluS139.	Right:	WT,	GluS140,	ValS142,	and	AlaS147.	
 
Table	3-10:	Average	values	for	the	thermodynamic	parameters	determined	from	the	two	state	fits	of	Fcalc.	
ΔTM	and	ΔΔGU	are	values	relative	to	the	CysQ135	control.		
 
CaM 
Variant 
TM  
(°C) 
ΔTM 
(°C) 
ΔH  
(kcal mol-1) 
ΔGU(25) 
(kcal mol-1) 
ΔΔGU(25) 
(kcal mol-1) 
ΔΔGU* 
(kcal mol-1) 
WT 46.0 ± 0.1 --- 41.9 ± 1.1 2.74 ± 0.08 ---  
CaM1-134 48.7 ± 0.3 --- 48.5 ± 5.7 3.54 ± 0.43 ---  
CysQ135 44.1 ± 0.2 --- 31.5 ± 2.2 1.88 ± 0.15 ---  
ValS 136 50.6 ± 0.6 +6.5 24.3 ± 0.3 1.91 ± 0.05 +0.03 -0.71 
TyrS138 40.1 ± 0.6 -4.0 40.9 ± 0.3 1.95 ± 0.09 +0.07 0.44 
GluS139 46.8 ± 1.7 +2.7 24.5 ± 2.7 1.70 ± 0.31 -0.18 -0.29 
GluS140 40.8 ± 0.7 -3.3 29.5 ± 1.8 1.47 ± 0.08 -0.41 0.36 
ValS142 42.7 ± 0.4 -1.4 30.7 ± 2.0 1.70 ± 0.09 -0.18 0.15 
AlaS147 41.8 ± 0.8 -2.3 35.9 ± 2.0 1.90 ± 0.18 +0.02 0.25 
 
* Calculated from ΔTM using equation 3.8 in Section 3.3.4 
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Three State Fit of Apo CaM Data 
In this model, the protein undergoes two transitions: F®I and I®U, where 
F, I, and U are the folded, intermediate, and unfolded states, respectively. This fit 
is more intuitive for CaM as the N- and C-terminal domains behave almost 
independently and have different melting temperatures.278, 280, 281 The equations 
used here are adopted from Sorensen et al.281 The folded, intermediate, and 
unfolded baselines were fit to 𝜃- = 𝑚-𝑇 +	𝑏-, 𝜃4 = 𝑚4𝑇 +	𝑏4, and 𝜃3 = 𝑚3𝑇 +	𝑏3, 
respectively. In this case, 𝑚4 was constrained to the average of 𝑚- and 𝑚3 as 
previously described.281 The full data set was then fit to  
 𝜃-45 = (𝜃-) 𝐹- + (𝜃4)(𝐹4) + (𝜃3)(𝐹3)         (3.4) 
 𝐹3 = WXWYDEWXEWXWY 𝐹4 = WXDEWXEWXWY 𝐹- = 1 − 𝐹4 − 𝐹3     (3.5) 
 𝐾[ = 𝑒LP]^/#_           (3.6) 
 𝛥𝐺[ 𝑇 = 𝛥𝐻[ 1 − __J^ + 𝛥𝐶G^ 𝑇 − 𝑇"^ − 𝑇 𝐿𝑛 __J^ 	     (3.7) 
where K1 and K2 are the equilibrium constants for the transitions F®I and I®U, 
respectively. 𝐹-, 𝐹4, and 𝐹3 are the calculated fractions of the total population that 
the folded, intermediate, and unfolded states make up at any given temperature. 
The heat capacity 𝛥𝐶G^ for each transition is set to zero in accordance with 
previous analyses of CaM unfolding.281 𝛥𝐻[ and 𝑇"^ are adjustable parameters for 
each transition. The RMSD between the observed θMRE and 𝜃-45 (equation 3.4) was 
minimized against these adjustable parameters. A weighted fraction folded value 	𝐹-∗ = 𝐹- + 𝑛𝐹4 was generated to account for the contributions of both C- and N-
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terminal unfolding to the overall unfolding transition. Here, 𝑛 is a weighting factor 
held constant to 𝑛 = 0.5 to reflect the weighted contribution of 𝑚4 in 𝜃-45. A weighted 
average melting temperature of the two transitions (TM*) is generated by finding 𝑇 
such that 𝛥𝐺D(𝑇) + 𝛥𝐺f(𝑇) = 0. TM* corresponds to the midpoint of the 𝐹-∗	unfolding curve.  ΔGU(25) for the total transition of F®U was calculated as a 
sum of ΔG1(298.15) and ΔG2(298.15). Plots for each mutant and control are shown 
in Figures 3-22 through 3-25. Comparison of the fits from the two state (Ff) and the 
three state (Ff*) fitting methods is shown in Figures 3-29 and 3-30. 
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Figure	3-26:	Plots	generated	using	the	three	state	fitting	method	for	WT,	CysQ135,	and	ValS136.	Left:	For	each	
CaM	variant	a	single	set	of	raw	data	(θMRE)	and	fits	generated	from	θfit,	θf,	and	θu.	Right:	The	averaged	Ff	
(purple),	Fi	(green),	and	Fu	(blue)	plots	from	the	three	replicates.	
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Figure	3-27:	Plots	generated	using	the	three	state	fitting	method	for	TyrS138,	GluS139,	and	GluS140.	Left:	For	
each	CaM	variant	a	single	set	of	raw	data	(θMRE)	and	fits	generated	from	θfit,	θf,	and	θu.	Right:	The	averaged	
Ff	(purple),	Fi	(green),	and	Fu	(blue)	plots	from	the	three	replicates.	
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Figure	3-28:	Plots	generated	using	the	three	state	fitting	method	for	ValS142	and	AlaS147.	Left:	For	each	CaM	
variant	a	single	set	of	raw	data	(θMRE)	and	fits	generated	from	θfit,	θf,	and	θu.	Right:	The	averaged	Ff	(purple),	
Fi	(green),	and	Fu	(blue)	plots	from	the	three	replicates.	
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Figure	3-29:	Overlay	of	Ff	(dotted	lines)	and	Ff*	(solid	lines)	from	three	state	fits.	Top:	CysQ135,	ValS136,	TyrS138,	
and	GluS139.	Bottom:	WT,	GluS140,	ValS142,	and	AlaS147.	
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Figure	3-30:	Overlay	of	Ff	(dotted	lines)	from	two	state	fits	and	Ff*	(solid	lines)	from	three	state	fits.	Top:	
CysQ135,	ValS136,	TyrS138,	and	GluS139.	Bottom:	WT,	GluS140,	ValS142,	and	AlaS147.	
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Figure	3-31:	Apo	CaM	structures.	Overlay	of	C-terminal	helix	of	1CFD	NMR	structure	with	corresponding	
helix	in	chainR	of	1QX5	crystal	structure	showing	alignment	of	residues	118-148.		Twisting	about	the	114-
117	segment	prevents	simultaneous	alignment	of	the	rest	of	the	CaM	sequence.		Residues	81-101	in	chainD	
of	1QX5	structure	make	intermolecular	contacts	similar	to	the	intramolecular	contacts	of	residues	81-101	
in	 1CFD.	 	 Left	 Inset:	 All	 eight	 chains	 in	 1QX5	 structure	 aligned,	 showing	 identical	 folds.	 	 Right	 Inset:	 C-
terminal	helices	of	1CFD	and	1QX5	structures.	
 
	
Table	 3-11:	 Distances	 and	 angles	 for	 hydrogen	 bonds	 at	 sites	 of	 thioamide	 substitution	 in	 apo	 CaM	
structures	from	PDB	entries	1CFD	and	1QX5.		1QX5	distances	are	averages	of	distances	in	all	8	chains.		X	
denotes	site	of	thioamide	insertion.		Hydrogen	bonding	partners	can	be	seen	in	Figures	3-32	through	3-34.	
 
 C=X--N Dist. (Å) C=X--N Angle (º) NX--O=C Dist. (Å) NX--O=C Angle (º) 
Residue 1CFD 1QX5 1CFD 1QX5 1CFD 1QX5 1CFD 1QX5 
ValS136 3.4 3.1 137 151 --- --- --- --- 
TyrS138 2.6 3.1 165 157 ---   2.8* ---   123* 
GluS139 3.4 3.0 145 144   3.3* ---   130* --- 
GluS140 3.4 3.0 150 147 --- --- --- --- 
PheS141 3.3 3.0 145 158 2.6 3.0 165 156 
ValS142 3.3 3.3 160 152 3.4 3.0 150 147 
AlaS147 --- --- --- --- 3.4 3.2 150 115 
*Asn137 sidechain forms hydrogen bonds with either Tyr138 or Glu139. 
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Figure	3-32:	Hydrogen	bonding	of	ValS136.		In	the	1QX5	structure,	Val136	accepts	a	hydrogen	bond	from	IleS100	
in	another	chain.	
 
 
 
 
Figure	3-33:	Hydrogen	bonding	of	GluS139,	ValS142,	AlaS147.	The	1CFD	structure	shows	the	potential	stabilizing	
hydrogen	bond	from	the	N-H	of	the	GluS139	thioamide	to	the	sidechain	carbonyl	of	Asn137.	
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Figure	 3-34:	 Hydrogen	 bonding	 of	 TyrS138	 and	 PheS141.	 1QX5	 structure	 shows	 the	 potential	 stabilizing	
hydrogen	bond	from	the	N-H	of	the	TyrS138	thioamide	to	the	sidechain	carbonyl	of	Asn137.	
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3.3.4 – Analysis of GB1 Thioproteins 
 
Sample Preparation for CD 
Dried peptides were dissolved in 500 μL ligation Buffer (200 mM Na2HPO4, 
6 M GnHCl, pH 7.0) and dialyzed against 2 L 20 mM Na2HPO4, pH 7.0. The dialysis 
buffer was exchanged for fresh buffer twice over a period of 24 hours. After 
dialysis, samples were concentrated to 300-400 uL, using Amicon Ultra centrifugal 
filter units (3 kDa MWCO).  
 
Concentration Determination of GB1 
The absorbance for each GB1 sample was measured at 274 nm and Beer’s 
law was used to determine the concentration of each sample by using extinction 
coefficients of ε274 = 9567 M-1 cm-1 and ε274 = 19736 M-1 cm-1 for the GB1 Oxo and 
GB1 thioamide proteins, respectively.  
 
CD Wavelength Measurements 
Each sample (300 μL) was added to a 1 mm path length Helma Analytics 
110-QS CD cuvette and loaded into a Jasco J-1500 CD Spectrometer. CD 
wavelength scans were taken at 25 °C by scanning at a 1 nm step between 350 
nm and 190 nm with a bandwidth of 1 nm and an averaging time of 8 s per 
measurement. Blank spectra were obtained by measuring the CD signal of the 
relevant buffer in each cuvette with an averaging time of 2 s. The raw signal (θd, 
mDeg) from each sample was background subtracted against the blank buffer 
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spectrum and converted to molar residue ellipticity (θMRE) using equation 3.1. The 
resulting averaged scans for each GB1 variant are shown in Figure 3-10.  
 
CD Thermal Melts 
Thermal denaturation was performed by monitoring θd at 220 nm over a 
temperature range of 5 to 95 °C. The temperature increase was set to 0.2 °C per 
min with an equilibration time of 10 s. Measurements were made with an averaging 
time of 8 s per sample and a bandwidth of 1 nm.  
 
Two-State Fitting of GB1 Thermal Melts 
The two state fitting procedure described in the above CaM section was 
used to fit all GB1 melting profiles with a few minor changes. The linear folded and 
unfolded baselines for GB1 Oxo were fit from 5 to 60 °C and 90 to 95 °C, 
respectively. The thioprotein folded and unfolded baselines were fit from 5 to 50 
°C and 85 to 95 °C, respectively.  These changes reflect the elevated melting 
temperature observed in GB1 compared to CaM. Changes in free energy of 
unfolding between GB1 Oxo and the thioprotein variants were calculated using 
equation 3.8 as described by Becktel et al and previously used in GB1 studies.292, 
301 
 𝛥𝛥𝐺 = 	 P_J∙PQhih_J,hih            (3.8)  
Here, ΔHoxo and TM, oxo are values for GB1 Oxo that are obtained from the two state 
fits discussed above. ΔTM is the difference in melting temperatures between GB1 
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Oxo and a particular thioprotein analogue. These calculations are made under the 
assumption that a single amino acid change only provides a small perturbation to 
the system and that the structural and functional characteristics of the system 
largely remain intact.301 
 
 
Figure	3-35:	Plots	generated	using	the	two	state	fitting	method	for	GB1	Oxo	and	LeuS5.	Left:	For	each	GB1	
variant,	a	single	set	of	raw	data	(θMRE)	and	fits	from	equations	for	θfit,	θf,	and	θu.	Right:	The	averaged	fraction	
folded	plots	(1-Fcalc)	from	two	replicated	melts.	
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Figure	3-36:	 	 Plots	 generated	using	 the	 two	 state	 fitting	method	 for	 IleS6	 and	 LeuS7.	 Left:	 For	 each	GB1	
variant,	a	single	set	of	raw	data	(θMRE)	and	fits	from	equations	for	θfit,	θf,	and	θu.	Right:	The	averaged	fraction	
folded	plots	(1-Fcalc)	from	two	replicated	melts.	
 
Table	3-12:	Distances	and	angles	for	hydrogen	bonds	at	sites	of	thioamide	substitution	in	GB1	from	PDB	
entry	2QMT.	X	denotes	site	of	thioamide	insertion.	
 
Residue C=X--N Dist. (Å) C=X--N Angle (º) N
X--O=C Dist. (Å) NX--O=C Angle (º). 
LeuS5 3 154 2.8 152 
IleS6 3 175 2.8 147 
LeuS7 3.1 134 2.8 177 
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CHAPTER 4: 
 
IMPROVED FMOC DEPROTECTION CONDITIONS FOR THE SYNTHESIS OF 
THIOAMIDE CONTAINING PEPTIDES AND PROTEINS 
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Reprinted (adapted) with permission from (Christopher R. Walters, D. Miklos 
Szantai-Kis, Taylor M. Barrett, Eileen M. Hoang, and E. James Petersson) the 
Thieme Publishing Group; Synlett (DOI: 10.1055/s-0036-1589027). Copyright 
(2017) Thieme Publishing Group. 
Section 4.1 – Introduction 
 
As described in Section 3.1, thioamide substitutions in the backbone of 
peptides and proteins have been leveraged in many biophysical studies due to 
their distinct physiochemical properties as compared to their native oxoamide 
counterpart.	220, 221, 232, 234, 235, 237, 266-269 For these and other types of applications, 
site-specific incorporation of thioamides into peptides is required. This is generally 
achieved by synthesizing thioamide precursor monomers that can then be 
incorporated into peptides using fluorenylmethyloxycarbonyl (Fmoc)-based solid 
phase peptide synthesis (SPPS). The activated precursors can be synthesized 
from Fmoc protected amino acids in three steps (Figure 4-1) based on a 
nitrobenzyltriazolide (Nbt) route developed by Shalaby et al.296  
Thioamides are generally compatible with the reagents used in SPPS 
including bases, activators, cleavage additives and trifluoroacetic acid (TFA). 
However, there are three side reactions that can often occur with thioamide 
containing peptides. First, prolonged exposure to high TFA concentrations during 
cleavage of the peptide from resin can lead to an Edman degradation-type reaction 
resulting in backbone cleavage at the n+1 position.302 Therefore, one must 
consider a tradeoff between complete removal of acid-labile protecting groups and 
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degradation of the thiopeptide (especially in long peptides) when determining the 
duration of TFA exposure. Second, our laboratory as well as Mukherjee et al. 
reported that thioamide precursors can react with residual amounts of water during 
coupling, leading to the exchange of sulfur for oxygen.222, 266 The use of anhydrous 
CH2Cl2 greatly reduced the formation of the undesired oxoamide. Last, 
epimerization can occur at the α-carbon of the thioamino acid (pKa ~13).303-307  
Prolonged exposure to base during Fmoc deprotection can catalyze this 
epimerization reaction. Recently, it was reported that lowering the concentration of 
piperidine and shortening Fmoc deprotection times to 1 minute resulted in less 
epimerization of thioamides.308 However, since the half-life of the Fmoc group 
under these conditions is 20-45 seconds, this approach significantly decreases the 
yield of isolated protein.309 
 
Figure	4-1:	Scheme	for	the	synthesis	of	Fmoc-TyrS(tBu)-NBt	using	the	route	from	Shalaby	et	al.296	Thioamino	
acid	 NBt	 derivatives	 can	 be	 used	 directly	 in	 a	 thioacylation	 reaction	 for	 incorporation	 of	 backbone	
thioamides	in	SPPS.	
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A 20% (v/v) solution of piperidine in dimethylformamide (DMF) is the most 
commonly used solution for Fmoc deprotection in SPPS, but there are alternatives: 
a 50% (v/v) solution of morpholine in DMF is considered a milder condition and is 
often used for sensitive glycopeptides.310 In contrast, a 2% (v/v) solution of 1,8-
diazabicyclo[5.4.0]-undec-7-ene (DBU) is considered a harsher deprotection 
condition.311 Unlike piperidine or morpholine, DBU is a non-nucleophilic base and 
is not able to scavenge the reactive dibenzofulvene group resulting from the Fmoc 
deprotection.311 Therefore, either a nucleophile needs to be added as a scavenger, 
or reaction times must be kept short and the resin washed extensively after 
deprotection. 
Here, I demonstrate that for the synthesis of thiopeptides, the use of 2% 
(v/v) DBU in DMF as an Fmoc deprotection solution is superior to 20% (v/v) 
piperidine in DMF. I, in conjunction with colleague Taylor Barrett, synthesized 
several thiopeptides with both of the aforementioned deprotection solutions and 
observed that peptides synthesized with 2% DBU typically exhibited a lower 
percentage of epimerization than those synthesized with 20% piperidine. 
Additionally, we typically observe a higher isolated yield and increased purity of 
thiopeptide using 2% DBU as a deprotection reagent. Thus, DBU deprotections 
are generally superior to piperidine deprotections for backbone thioamides. 
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Section 4.2 – Results and Discussion 
 
I designed a set of model peptides containing a mixture of non-polar (Phe 
and Ala) and polar (Lys and Glu) amino acids (Table 4-1). For each sequence, 7-
methoxycoumarin-4-yl-alanine (Mcm or μ) was installed as the first amino acid on 
2-chlorotrityl resin. This chromophore has an absorption maximum at 325 nm and 
allows for facile tracking of the peptides by analytical HPLC. Thioamides also have 
a shifted absorption maximum (272 nm) relative to oxoamides (215 nm), which can 
be used to characterize the thiopeptides. To discriminate between genuine L-
thiaomino acid peptides and their D-epimers, we synthesized both L- and D-
thionitrobenzyltriazolide monomers (Fmoc-alaS-NBt and Fmoc-pheS-NBt, using 
the lower-case letter convention for D-amino acids) for inclusion into the model 
peptides. The retention times for the authentic D-thioamino acid peptides were 
used as standards for each of the first four sets of thiopeptides. Additionally, a 
separate assay was performed to assess how each condition affected yield. In 
these experiments, 7-methoxycoumarin-4-acetic acid (Mca) was added to each 
peptide sample to a final concentration of 500 μM, representing the maximum 
theoretical yield of peptide in each HPLC sample. The integration value of this 
standard peak was compared to the integration of the product peak in each 
chromatogram (at 325 nm) to calculate the yield. 
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Figure	 4-2:	 General	 scheme	 for	 deprotection	 reactions	 on	 thiopeptides.	 DBU	 leads	 to	 a	 decrease	 in	
epimerization	as	observed	by	analytical	HPLC.	
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piperidine deprotections. In addition, the yield was increased from 30% to 36% 
when DBU was used (Table 4-1). Oxoamide controls for the L- and D-peptides 
were also synthesized using piperidine as the deprotection reagent and no 
epimerization was observed for these peptides (Figure 4-5). 
 
 
Table	4-1:	Comparison	of	yield	and	percent	epimerization	between	peptides	synthesized	with	either	DBU	
or	piperidine.	
 
	
Peptidea % Epimerization 
%  
Purity 
% 
Yield 
KAFSAKμ (4-1) – Piperidine 16.1 56.2 29.9 
KAFSAKμ (4-1)  – DBU 9.1 61.6 35.9 
FSAKAKμ (4-2) – Piperidine 1.0 89.0 44.3 
FSAKAKμ (4-2) – DBU 0.0 88.5 51.3 
FASKAKμ (4-3) – Piperidine 3.2 68.5 44.0 
FASKAKμ (4-3) – DBU 1.0 67.3 44.7 
FAKASKμ (4-4) – Piperidine/DBU n/db n/db n/db 
FAESAKμ (4-5) – Piperidine 5.6 71.5 18.2 
FAESAKμ (4-5) – DBU 1.0 71.6 22.7 
CVNYSEEFVQMMTAK (4-6) - Piperidine 49.9 14.9 n/dc 
CVNYSEEFVQMMTAK (4-6) - DBU 9.3 22.0 n/dc 
CVNYEEFSVQMMTAK (4-7) - Piperidine 28.1 37.0 n/dc 
CVNYEEFSVQMMTAK (4-7) - DBU 7.0 28.6 n/dc 
Graph:	Example	chromatogram	for	epimer	quantification	and	yield	determination.	L-	and	D-	denote	epimers	
of	4-1,	KAFSAKμ	and	KAfSAKμ,	respectively,	#	denotes	KAAKμ,	the	product	of	failed	FS	coupling.		
^	denotes	Mca	standard	used	to	quantify	yield.	
aPeptides	in	one-letter	code.	Superscript	S	denotes	thioamino	acids.	μ	=	7-Methoxycoumarin-4-yl-alanine;	
bL-	 and	 D-	 epimers	 were	 not	 resolvable	 on	 analytical	 HPLC;	 cNo	 external	 standard	 added	 for	 yield	
quantification.	
 
 
 
4-1
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Encouraged by these results, we synthesized four additional peptide series 
(2-5) with L- and D-thioamino acids. Series 4-2 changes the sequence to put the 
PheS linkage at the N-terminus of the peptide, allowing us to quantify the 
epimerization effects from a single deprotection reaction. Only 1% epimerization 
was detected with piperidine; epimerization was undetectable with DBU 
conditions. This result indicates that the initial deprotection step may not have a 
significant effect and implies that the thioamino acid is vulnerable to epimerization 
at each subsequent deprotection step.  The epimerization of thiopeptides may also 
depend upon local sequence or the identity of the thioamino acid. Therefore, we 
synthesized peptides 4-3 and 4-4 with AlaS at each Ala position within the same 
sequence as peptide 4-2. We detected 3% epimerization with piperidine and 1% 
epimerization with DBU for peptide 4-3. This is in agreement with the expected 
additive effects of multiple piperidine treatments. Unfortunately, the L- and D-
epimers of peptide 4-4 were not separable by analytical HPLC. This highlights the 
need for Fmoc removal conditions that minimize epimerization of thioamino acid 
positions, as epimerization byproducts may not always be chromatographically 
distinguishable from the desired product. 
The peptides synthesized thus far contained non-polar thioamino acids, 
therefore we synthesized peptide 4-5 containing a GluS linkage to verify that 
epimerization can be suppressed independent of sidechain identity (although % 
epimerization may vary depending on amino acid identity). In agreement with the 
effects discussed in peptides 4-1 to 4-3, DBU treatments for peptide 4-5 decreased 
epimerization from 6% to 1%. The peak area percentage was calculated for 
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peptides 4-1 to 4-3 and 4-5 in order to quantify the effects of DBU deprotections 
on the purity of the products. In each case, the purity of the desired L-peptide was 
similar across methods, with the exception of peptide 4-1, where purity was 
increased using the DBU method (Figure 4-3). In samples containing the Mca 
standard discussed above, the yield of desired L-product was either maintained or 
increased through use of DBU, with the most significant increases in yield 
observed in peptides 4-1 and 4-2 (29.9% to 35.9% and 44.3% to 51.3%, 
respectively). Taken together, these results indicate that in sequences where there 
are several deprotections after the thioamide installation, it is beneficial to use DBU 
as a deprotection method to reduce epimerization and even increase yield and 
purity of the desired L-thiopeptide product. 
To extend these results to a longer, more sequence diverse system, I 
synthesized a peptide derived from the C-terminus of the calcium-binding protein 
calmodulin (CaM).272 I have described the synthesis and characterization of 
CaM135-148-Cys135 including many thioamide substitutions recently(see Section 
3.2)256, and I wished to see what improvements could be made by using DBU 
deprotection conditions. I established two target sites at N-terminal and central 
positions within the 14-mer peptide (CaM135-148-Cys135TyrS138 and CaM135-148-
Cys135PheS141, 4-6-L and 4-7-L respectively). Each peptide was synthesized on a 
50 μmol scale on 2-chlorotrityl resin with either piperidine or DBU deprotection 
conditions. Thiopeptide products were detected by their characteristic absorbance 
at 272 nm and percent epimerization calculated for each peptide based on the 
retention times of an authentic D-thioamino acid peptide (CaM135-148-
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Cys135pheS141, 4-7-D) and MALDI-MS analysis of the peaks from analytical HPLC 
chromatograms (4-6 and 4-7). In each of the CaM thiopeptides, the epimerization 
with piperidine is more exaggerated than with any of the model peptides discussed 
thus far (50% and 28% for 4-6 and 4-7, respectively). As expected, DBU 
deprotection decreased the observed epimerization percentages for peptides 4-6 
and 4-7 to 9% and 7%, respectively. These results highlight the positional and 
sequence variability in the amount of epimerization observed with piperidine-based 
Fmoc removal, as well as the net positive effects that DBU deprotections can have 
in all cases observed here. However, by chromatographic peak area percentage 
analysis, DBU does appear to decrease the overall purity in 4-7 as it may lead to 
additional byproducts that we were unable to assign by MALDI-MS analysis. I hope 
to further improve our methodology by using an additive during Fmoc-deprotection 
in order to decrease the formation of undesired byproducts. Nevertheless, DBU 
deprotections did lead to a 7% increase in peak area percentage for 4-6.  
 Finally, we compared our DBU protocol to the protocol used in Mukherjee 
et al., which also reported reduced epimerization during thiopeptide synthesis.308 
Peptide 4-1 was synthesized up to the coupling of PheS3, and then the resin was 
split. For one half of the resin, the peptide was elongated using 2 x 1 minute Fmoc 
deprotections with 10% piperidine, as in Mukherjee et al. For the other half of the 
resin, the peptide was elongated using our procedure of 3 x 2 minute deprotections 
with 2% DBU. We observed similar purity (63% vs. 61% with DBU), but a higher 
degree of epimerization (7% vs. 1% with DBU) in the synthesis using 10% 
piperidine. I also synthesized the longer peptide 4-7 using the same split-resin 
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approach for direct comparison of the two methods. Here, I observed somewhat 
lower purity (14% vs. 17% with DBU) with significantly higher epimerization (23% 
vs. 2% with DBU) in the synthesis using 10% piperidine. Thus, we find that 
although the two methods give peptides of comparable overall purity, the lower 
levels of epimerization seen with DBU represent a significant advantage for our 
method, as peptide epimers may not always be separable by HPLC (as seen for 
peptide 4-4). 
With the preparation of each backbone thiopeptide system, we have 
demonstrated reduction of epimerization at the thioamino acid α-carbon by 
performing Fmoc deprotection reactions with DBU in the place of piperidine. 
Although only four different amino acids were tested (AlaS, PheS, GluS, and TyrS), 
the positional and sequence variability with which this effect is demonstrated 
provides strong evidence that this result is general. Furthermore, we demonstrated 
that in at least one sidechain thioamide case, the use of DBU as the deprotection 
reagent was superior to piperidine or morpholine (work discussed elsewhere by D. 
Miklos Szantai-Kis). While we have not yet observed a piperidine adduct in a 
backbone thioamide, it may occur at sterically-accessible sites such as GlyS 
residues. Such adducts would presumably not be stable, but could lead to Edman-
type degradation, as well as hydrolysis of the peptide backbone or oxoamide 
formation by reaction with water under the acidic resin cleavage conditions.  All of 
these side reactions would be avoided by using DBU for Fmoc-deprotections 
during peptide synthesis. I expect that these synthetic developments will help to 
improve the accessibility of thioamide containing peptides and proteins, further 
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enabling the broad spectrum of biophysical and biochemistry experiments made 
possible by this versatile functional group. 
 
Section 4.3 – Materials and Methods 
 
4.3.1 – General Information 
Piperidine was purchased from AmericanBio (Natick, MA). Triisopropylsilane 
(TIPS) was purchased from Santa Cruz Biotechnology, Inc (Dallas, TX). All Fmoc 
protected amino acids and peptide synthesis reagents were purchased from EMD 
Millipore (Billerica, MA). All other reagents and solvents were purchased from 
Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO) unless otherwise 
specified. Peptides 4-1 through 4-5 were synthesized and injected onto the 
analytical HPLC by Taylor Barrett. 
High resolution electrospray ionization mass spectra (ESI-HRMS) were 
collected with a Waters LCT Premier XE liquid chromatograph/mass spectrometer 
(Milford, MA). Low resolution electrospray ionization mass spectra (ESI-LRMS) 
were obtained on a Waters Acquity Ultra Performance LC connected to a single 
quadrupole detector (SQD) mass spectrometer. UV-Vis absorption spectra were 
acquired on a Hewlett-Packard 8452A diode array spectrophotometer (Agilent 
Technologies, Santa Clara, CA). Nuclear magnetic resonance (NMR) spectra were 
obtained on a Bruker DRX 500 MHz, Bruker DRX 600 MHz and Bruker AVIII 
500MHz instruments (Billerica, MA). Matrix assisted laser desorption/ionization 
with time-of-flight detector (MALDI-TOF) mass spectra were acquired on a Bruker 
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Ultraflex III instrument (Billerica, MA). Analytical HPLC was performed on an 
Agilent 1100 Series HPLC system (Santa Clara, CA). HPLC columns were 
purchased from or Phenomenex (Torrence, CA). 
 
4.3.2 – Synthesis and Epimerization Analysis of Thiopeptides 
 
Synthesis of Thioamino Acid Precursors (Fmoc-AaS-NBt) 
All L- and D-thioamino acid precursors were synthesized as Fmoc-
thionitrobenzotriazolide monomers (Fmoc-AaS-NBt) by starting with commercially 
available Fmoc protected amino acids and using a route modified from Shalaby et 
al.217 Each thioamino acid precursor used in our studies has been previously 
synthesized and characterized296, with the exception of Fmoc-alaS-NBt and Fmoc-
pheS-NBt (lower case naming convention denotes D-amino acids), which were 
synthesized using the same routes as their L-counterparts and are detailed below. 
 
(9H-fluoren-9-yl)methyl(R)-(1-((2-amino-5-nitrophenyl)amino)-1-oxo-3-
phenylpropan-2-yl)carbamate (4-8). Fmoc-phe-OH (1.29 mmol, 500 mg) was 
dissolved in 15 mL of tetrahydrofuran (THF) and stirred under argon. The solution 
was then cooled to -10 °C in a 1:3 NaCl: ice bath. To this solution, 2 equivalents 
of N-methylmorpholine (2.58 mmol, 0.284 mL) was slowly added in dropwise. Next, 
1.1 equivalents of isobutyl chloroformate (1.42mmol, 0.186mL) was slowly added 
in dropwise.  The reaction was then stirred at -10 °C for 15 minutes. Then, 1.1 
equivalents of 4-nitro-o-phenylenediamine (1.42 mmol, 217.50 mg) was added to 
the reaction. The reaction was then stirred for 2 hours at -10 °C and taken out of 
200	
	
the ice bath to be stirred at room temperature (RT) overnight under argon.  The 
resulting reaction mixture formed a thick, yellow precipitate. The reaction was then 
removed from argon and the solvent was removed under reduced pressure. The 
yellow solid that formed was dissolved in N,N-dimethylformamide (DMF, 20 mL) 
and added to 100mL of saturated aqueous potassium chloride solution in order to 
precipitate the desired product out of solution.  This precipitate was removed from 
solution by vacuum filtration with a Büchner funnel and washed with cold water 
and diethyl ether.  The solid was then allowed to air dry for two hours before being 
dried under vacuum overnight. Compound 4-8 (1.13 mmol, 589 mg) was obtained 
in a crude yield of 87.4% and used, crudely, in the following thionation reaction. 
 
(9H-fluoren-9-yl)methyl(R)-(1-((2-amino-5-nitrophenyl)amino)-3-phenyl-1-
thioxopropan-2-yl)carbamate (4-9). Sodium carbonate (1.13 mmol, 119.8 mg) 
and phosphorus pentasulfide (1.13 mmol, 501.7 mg) were added to 20 mL of THF 
in an oven-dried round bottom flask and allowed to stir under argon at room 
temperature until the phosphorus pentasulfide was completely dissolved (30 
minutes). Then the solution was cooled to 0°C in an ice bath and 4-8 (1.13 mmol, 
589 mg) was dissolved in minimal THF (10mL) and added to the reaction. The 
reaction was then monitored by thin layer chromatography (TLC) with a mobile 
phase of 2:3 ethyl acetate:hexanes.  After 1.5 hours, the starting material was 
mostly consumed and a small amount of byproduct had been formed, therefore 
the reaction was judged to be at completion. The reaction was condensed to dark 
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yellow oil by rotary evaporation.  This oil was then dissolved in minimal ethyl 
acetate and was loaded onto silica plug (bed volume approximately 400 mL in ethyl 
acetate) to remove the phosphorus pentasulfide. The column was run in DCM, and 
then the crude product was eluted in neat ethyl acetate as a bright yellow band. 
This solution was dried by rotary evaporation and redissolved in 1:1 ethyl 
acetate:hexanes (3 mL). This mixture was purified by flash chromatography on 
silica with a running solvent of 1:1 ethyl acetate:hexanes. Product eluted as a 
yellow solution and solvent was removed under reduced pressure. The resulting 
yellow solid was washed with dichloromethane and chloroform, then dried under 
high vacuum overnight. The product was obtained at a 54.2% (0.612 mmol, 329.6 
mg) yield and used in the following step after characterization by 1H NMR. 1H NMR 
(500 MHz, CDCl3): δ 9.07 (s, 1H), 7.90 (dd, J = 9.0, 2.6 Hz, 1H), 7.73 (dd, J = 10.6, 
7.5 Hz, 2H), 7.58 (s, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.41 – 7.32 (m, 3H), 7.30 – 7.17 
(m, 9H), 6.48 (d, J = 9.0 Hz, 1H), 5.78 (s, 1H), 4.86 (s, 1H), 4.10 (dt, J = 16.7, 8.3 
Hz, 5H), 3.21 (d, J = 9.2 Hz, 0H), 1.59 (s, 1H), 1.36 – 1.04 (m, 1H). 
 
(9H-fluoren-9-yl)methyl(R)-(1-(6-nitro-1H-benzo[d][1,2,3]triazol-1-yl)-3-
phenyl-1-thioxopropan-2-yl)carbamate (4-10). Compound 4-9 (0.612 mmol, 330 
mg) was dissolved in glacial acetic acid diluted with 5% water (10 mL) and allowed 
to stir while cooling to 0°C in an ice bath. After 5 minutes, 1.25 equivalents of 
NaNO2 (0.765 mmol, 52.8 mg) was added slowly to the reaction. After thirty 
minutes, no starting material remained by TLC and the reaction became thick with 
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an orange precipitate. Cold Milli-Q water (100 mL) was added to the reaction to 
precipitate the remaining product and the resulting orange precipitate was filtered 
on a Büchner funnel, washed with additional cold Milli-Q water, dried on a watch 
glass overnight, and lyophilized to remove access acetic acid. The crude yield of 
the reaction was 84.0% (0.514 mmol, 256 mg) and was used directly in solid phase 
peptide synthesis without further purification. 1H NMR (500 MHz, Chloroform-d, 
major rotamer only) δ 9.61 (s, 1H), 8.44 (d, J = 8.9 Hz, 1H), 8.29 (d, J = 8.9 Hz, 
1H), 7.74 (d, J = 7.6 Hz, 2H), 7.52 (t, J = 6.9 Hz, 2H), 7.38 (t, J = 7.6 Hz, 2H), 7.28 
(q, J = 8.0 Hz, 2H), 7.23 – 7.13 (m, 5H), 6.56 (d, J = 7.4 Hz, 1H), 5.66 (d, J = 9.3 
Hz, 1H), 4.46 – 4.35 (m, 1H), 4.33 (t, J = 9.0 Hz, 1H), 3.40 (dd, J = 14.0, 5.4 Hz, 
1H), 3.10 (dd, J = 13.8, 8.0 Hz, 1H).  ESI+-HRMS: calculated for C30H23N5O4S+: 
550.1549; found [M+H]+: 550.1550. 
 
Synthesis and Purification of Fmoc-alaS-NBt Precursor 
Starting with Fmoc-ala-OH (3.21mmol, 1.00g), (9H-fluoren-9-yl)methyl(R)-
(1-(6-nitro-1H-benzo[d][1,2,3]triazol-1-yl)-1-thioxopropan-2-yl)carbamate (4-11) 
was synthesized as described elsewhere298. Compound 4-11 was obtained in 
26.6% yield (0.942 mmol, 446 mg) after three steps. 1H NMR (500 MHz, 
Chloroform-d, major rotamer only) δ 9.68 – 9.62 (m, 1H), 8.47 – 8.41 (m, 1H), 8.30 
(d, J = 8.9 Hz, 1H), 7.76 (d, J = 7.6 Hz, 2H), 7.62 (t, J = 6.9 Hz, 2H), 7.40 (t, J = 
6.2 Hz, 2H), 7.35 – 7.28 (m, 2H), 6.26 (h, J = 6.8 Hz, 1H), 5.77 (d, J = 9.0 Hz, 1H), 
4.57 – 4.32 (m, 2H), 4.22 (t, J = 6.9 Hz, 1H), 1.69 (d, J = 6.6 Hz, 3H). ESI+-HRMS: 
calculated for C24H19N5O4S+: 474.1236; found [M+H]+: 474.1248. 
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Synthesis of Thiopeptides with Piperidine Deprotections 
SPPS of thiopeptides 4-1 through 4-7 was performed on 2-chlorotrityl resin 
(100-200 mesh, 10 μmol scale) in 6 mL fritted syringes. The resin was swelled in 
DMF (6 mL, 30 minutes) while stirring. The syringe was then drained and to it was 
added Fmoc-β-(7-methoxy-coumarin-4-yl)-alanine (Fmoc-Mcm-OH, 2 
equivalents) and DIPEA (4 equivalents) in DMF (2 mL). This initial loading reaction 
stirred for 30 minutes at room temperature (RT) before being drained, washed with 
DMF (2 x 4 mL) and repeated. Fmoc removal was performed by adding to the resin 
a solution of 20 % v/v piperidine in DMF (2 mL total volume) and stirring for 20 
minutes at RT. The vessel was then drained and the resin washed with DMF, 
followed by DCM (1 x 4 mL DMF, 2 x 4 mL DCM, then 2 mL DMF). The peptide 
was then elongated up to the thioamide position using standard SPPS protocols 
by adding 5 equivalents of amino acid, HBTU, and 10 equivalents of DIPEA in DMF 
(2 mL) and stirring each coupling for 45 minutes at RT. Prior to the thioamide 
coupling, the resin was washed with dry DCM (obtained by drying over 4 Å 
molecular sieves, washed 2 x 4 mL). Fmoc-AaS-NBt (2 equiv.) was then added to 
the vessel with DIPEA (2 equiv.) in DCM (2 mL) and the reaction was stirred at RT 
for 30 minutes. The vessel was then drained and the resin washed with dry DCM 
(2 x 4 mL) before the thioamide coupling was repeated. At completion of the 
second coupling, the resin was washed with DCM then DMF (2 x 4 mL) and Fmoc 
deprotection via piperidine treatment proceeded as described above. Standard 
SPPS was used to add the remaining amino acids. After the last Fmoc group was 
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removed, the resin was washed with DMF, followed by DCM (2 x 4 mL each). A 
cleavage cocktail was prepared with 12:6:1:1 DCM:TFA:TIPS:H2O. This was 
added to the resin and allowed to stir at RT for 30 minutes before being drained 
and collected. DCM (3 mL) was added to the resin to wash out any remaining 
peptide and the collected solution was dried to a colorless oil by rotary evaporation. 
The crude peptide product was then precipitated by adding cold diethyl ether (12 
mL) and vortexing vigorously. The resulting precipitate was dried and stored under 
argon at -20 °C until HPLC analysis proceeded. The oxo controls for peptide 4-1 
were synthesized by standard SPPS described above without any special coupling 
conditions for the oxo Fmoc-Phe-OH. 
 
Synthesis of Thiopeptides with DBU Deprotections 
SPPS for thiopeptides 4-1 through 4-7 proceeded as described above until 
deprotection following thioamide installation. After thioamide coupling was 
complete for each peptide, subsequent Fmoc deprotections were done using the 
alternative base DBU. For each deprotection the resin was treated with 2 % v/v 
DBU in DMF (2 mL total volume) for 2 minutes while stirring at RT. The vessel was 
then drained and the resin washed with DMF and DCM (1 x 4 mL DMF, 1 x 4 mL 
DCM, then 2 mL DMF). This procedure was repeated twice before proceeding to 
the next amino acid coupling reaction. At peptide completion, cleavage and 
precipitation proceeded as described in the above section. 
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Synthesis of Thiopeptides 4-1 and 4-7 with 10% Piperidine Deprotections 
Peptides 4-1 and 4-7 were synthesized as described in the previous section 
with the following differences. After thioamide coupling, the resin was split into two 
equal portions (10 μmol each for 4-1, 25 μmol each for 4-7). This will ensure that 
the starting material is identical for direct comparison between 2% DBU and 
shortened 10% piperidine deprotections. One of the aliquots had the remaining 
Fmoc deprotections performed with 2% DBU in DMF as described in the previous 
section (3 x 2 mL, 2 minutes per deprotection). The other aliquot had the remaining 
deprotections performed with 10% piperidine in DMF with shortened deprotection 
times (2 x 2 mL, 30 seconds per deprotection) as outlined in Mukherjee et al.223 
Table	4-2:		Peptide	Purification/Characterization	Methods	and	Retention	Time. 
Peptide Gradient Retention Time Column 
KAFSAKμ-OH (4-1-L) 2 18.2 min Phenomenex Luna C8 
KAfSAKμ-OH (4-1-D) 2 21.0 min Phenomenex Luna C8 
KAFAKμ-OH (4-1-Oxo) 2 16.6 min Phenomenex Luna C8 
FSAKAKμ-OH (4-2-L) 2 16.0 min Phenomenex Luna C8 
fSAKAKμ-OH (4-2-D) 2 18.7 min Phenomenex Luna C8 
FASKAKμ-OH (4-3-L) 2 17.2 min Phenomenex Luna C8 
FaSKAKμ-OH (4-3-D) 2 18.6 min Phenomenex Luna C8 
FAKASKμ-OH (4-4-L) 2 16.3 min Phenomenex Luna C8 
FAKaSKμ-OH (4-4-D) 2 16.4 min Phenomenex Luna C8 
FAESAKμ-OH (4-5-L) 2 18.2 min Phenomenex Luna C8 
FAeSAKμ-OH (4-5-D) 2 19.2 min Phenomenex Luna C8 
CVNYSEEFVQMMTAK-OH (4-6-L) 3 33.7 min Phenomenex Luna C8 
CVNySEEFVQMMTAK-OH (4-6-D) 3 29.0 min Phenomenex Luna C8 
CVNYEEFSVQMMTAK-OH (4-7-L) 3 32.4 min Phenomenex Luna C8 
CVNYEEfSVQMMTAK-OH (4-7-D) 3 28.8 min Phenomenex Luna C8 
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Table	4-3:	HPLC	Gradients	for	small	molecule/peptide	purification	and	characterization.	
No. Time (min) %B  No. Time (min) %B 
2 0:00 2  3 0:00 2 
 5:00 2   5:00 2 
 10:00 20   10:00 20 
 35:00 35   40:00 40 
 38:00 100   43:00 100 
 40:00 100   48:00 100 
 42:00 2   50:00 2 
 Solvent A: 0.1% trifluoroacetic acid in water; Solvent B: 0.1% trifluoroacetic acid in acetonitrile 
	
	
Table	4-4:	MALDI-TOF	MS	Characterization	of	Purified	Peptides. 
Peptide 
[M + H]+ 
Calculated Found 
KAFSAKμ-OH (4-1-L) 825.39 825.76 
KAfSAKμ-OH (4-1-D) 825.39 825.70 
KAFAKμ-OH (4-1-Oxo) 809.41 810.26 
FSAKAKμ-OH (4-2-L) 825.39 825.82 
fSAKAKμ-OH (4-2-D) 825.39 825.74 
FASKAKμ-OH (4-3-L) 825.39 826.48 
FaSKAKμ-OH (4-3-D) 825.39 826.01 
FAKASKμ-OH (4-4-L) 825.39 826.01 
FAKaSKμ-OH (4-4-D) 825.39 825.94 
FAESAKμ-OH (4-5-L) 826.84 827.04 
FAeSAKμ-OH (4-5-D) 826.84 827.00 
CVNYSEEFVQMMTAK-OH (4-6-L) 1709.72 1709.53 
CVNySEEFVQMMTAK-OH (4-6-D) 1709.72 1709.50 
CVNYEEFSVQMMTAK-OH (4-7-L) 1709.72 1709.87 
CVNYEEfSVQMMTAK-OH (4-7-D) 1709.72 1709.94 
   
μ = 7-methoxycoumarinylalanine 
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Analytical HPLC Peptides 4-1 through 4-5  
Stock solutions of all the peptides were made by dissolving the solid peptide 
precipitate in 50% (v/v) CH3CN in H2O (with 0.1% TFA) and vortexing to fully 
dissolve the peptide. Next, 100 μL of the stock solution were diluted to 1 mL total 
volume with water containing 0.1% TFA. Peptide samples were analyzed by 
reverse phase HPLC using gradient 2 on a Phenomenex Luna C8 column with a 
flow rate of 1 mL/min. The absorbance was monitored at 214 nm (amide bond), 
272 nm (thioamide bond), and 325 nm (methoxycoumarin) and peaks were 
analyzed by MALDI MS to confirm their identity (See Table 4-4). Integration values 
for peak area percentage and yield determination were calculated using the 
HPCORE ChemStation software from Agilent Technologies. Percent epimerization 
was calculated by dividing the peak area (325 nm) of the L-thiopeptide by the total 
peak area of the observed L- and D-thiopeptides. 
For quantification of peptide yields, 7-methoxycoumarin-4-acetic acid (Mca) 
can be used as an internal standard for each peptide sample. A stock of Mca was 
made in 1 mL of 1:1 CH3CN:H2O with dropwise DMSO added until all Mca 
solubilized. The concentration was determined by diluting the sample by a factor 
of 2000 in Milli-Q water and measuring the absorbance at 324 nm (ε=11,820 M-1 
cm-1; stock concentration was 22.1 mM). A 1 mL HPLC sample was then prepared 
by adding 50 μL of stock peptide solution (2 mL stock volume; described above) 
to a 500 μM solution of Mca in Milli-Q H2O containing 0.1% TFA. The maximum 
theoretical concentration of peptide in solution should be 500 μM and is 
represented by the Mca added to each sample. Samples were prepared in 
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triplicate and yield was calculated by dividing the peptide product peak integration 
(325 nm) by the Mca standard peak integration (325 nm). 
 
 
 
 
 
Figure	4-3:	Analytical	HPLC	of	peptide	4-1	showing	PheS	spectra	at	272	nm	(thioamide	absorbance,	left)	and	
325	nm	(Mcm	absorbance,	right).	The	L-epimer	(L)	and	D-epimer	(D)	are	denoted	for	each	spectrum.	The	
peak	marked	with	(#)	corresponds	to	peptide	product	where	thiophenylalanine	was	not	coupled.	
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Figure	4-4:	Analytical	HPLC	of	peptide	4-1	showing	pheS	spectra	at	272	nm	(thioamide	absorbance,	left)	and	
325	nm	(Mcm	absorbance,	right).	The	L-epimer	(L)	and	D-epimer	(D)	are	denoted	for	each	spectrum.	The	
peak	marked	with	(#)	corresponds	to	peptide	product	where	thiophenylalanine	was	not	coupled.	
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Figure	4-5:	 	Analytical	HPLC	of	peptide	4-1	 (oxo)	 showing	 spectra	at	325	nm	 (Mcm	absorbance).	The	L-
epimer	(L)	and	D-epimer	(D)	are	denoted	for	each	spectrum.	No	epimerization	was	observed	for	either	the	
L-	or	D-oxo	amino	acid	standards.	
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Figure	 4-6:	 Analytical	 HPLC	 of	 peptide	 4-1	 from	 direct	 comparison	 of	 2%	 DBU	 to	 10%	 piperidine	
deprotections.	Chromatograms	of	 the	PheS	spectra	at	272	nm	(thioamide	absorbance,	 left)	and	325	nm	
(Mcm	absorbance,	 right).	 The	 L-epimer	 (L)	 and	D-epimer	 (D)	 are	denoted	 for	 each	 spectrum.	 The	peak	
marked	with	(#)	corresponds	to	peptide	product	where	thiophenylalanine	was	not	coupled.	Retention	times	
differ	 from	 Figure	 4-3	 due	 to	 changes	 in	 HPLC	 instrumentation	 however,	 relative	 retention	 time	 shifts	
between	#,	L,	and	D	are	consistent.	
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Figure	4-7:	Analytical	HPLC	of	peptide	4-2	showing	PheS	spectra	at	272	nm	(thioamide	absorbance,	left)	and	
325	nm	(Mcm	absorbance,	right).	The	L-epimer	(L)	and	D-epimer	(D)	are	denoted	for	each	spectrum.	The	
peak	marked	with	(#)	corresponds	to	peptide	product	where	thiophenylalanine	was	not	coupled.	
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Figure	4-8:	Analytical	HPLC	of	peptide	4-2	showing	pheS	spectra	at	272	nm	(thioamide	absorbance,	left)	and	
325	nm	(Mcm	absorbance,	right).	The	L-epimer	(L)	and	D-epimer	(D)	are	denoted	for	each	spectrum.	The	
peak	marked	with	(#)	corresponds	to	peptide	product	where	thiophenylalanine	was	not	coupled.	
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Figure	4-9:	Analytical	HPLC	of	peptide	4-3	showing	AlaS	spectra	at	272	nm	(thioamide	absorbance,	left)	and	
325	nm	(Mcm	absorbance,	right).	The	L-epimer	(L)	and	D-epimer	(D)	are	denoted	for	each	spectrum.	The	
peak	marked	with	(#)	corresponds	to	peptide	product	where	thioalanine	was	not	coupled.	
 
 
 
 
 
 
 
 
 
 
 
 
0 10 20 30 40
Peptide 3 (AlaS, Piperidine)
Time (min)
m
A
U
 (2
72
 n
m
)
L
D
#
0 10 20 30 40
Peptide 3 (AlaS, Piperidine)
Time (min)
m
A
U
 (3
25
 n
m
) #
L
D
0 10 20 30 40
Peptide 3 (AlaS, DBU)
Time (min)
m
A
U
 (2
72
 n
m
)
#
L
D
0 10 20 30 40
Peptide 3 (AlaS, DBU)
Time (min)
m
A
U
 (3
25
 n
m
)
# L
D
215	
	
 
 
Figure	4-10:	Analytical	HPLC	of	peptide	4-3	showing	alaS	spectra	at	272	nm	(thioamide	absorbance,	left)	and	
325	nm	(Mcm	absorbance,	right).	The	L-epimer	(L)	and	D-epimer	(D)	are	denoted	for	each	spectrum.	The	
peak	marked	with	(#)	corresponds	to	peptide	product	where	thioalanine	was	not	coupled.	
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Figure	4-11:	Analytical	HPLC	of	peptide	4-4	showing	AlaS	spectra	at	272	nm	(thioamide	absorbance,	left)	
and	325	nm	(Mcm	absorbance,	right).	The	L-epimer	(L)	and	D-epimer	(D)	are	denoted	for	each	spectrum,	
although	 they	 cannot	 be	 separated	 for	 this	 peptide.	 The	 peak	marked	with	 (#)	 corresponds	 to	 peptide	
product	where	thioalanine	was	not	coupled.	
 
 
 
 
 
 
 
 
 
 
0 10 20 30 40
Peptide 4 (AlaS, Piperidine)
Time (min)
m
A
U
 (2
72
 n
m
)
LD
#
0 10 20 30 40
Peptide 4 (AlaS, Piperidine)
Time (min)
m
A
U
 (3
25
 n
m
)
#
LD
0 10 20 30 40
Peptide 4 (AlaS, DBU)
Time (min)
m
A
U
 (2
72
 n
m
)
#
LD
0 10 20 30 40
Time (min)
m
A
U
 (3
25
 n
m
)
Peptide 4 (AlaS, DBU)
#
LD
217	
	
 
 
Figure	4-12:	Analytical	HPLC	of	peptide	4-4	showing	alaS	spectra	at	272	nm	(thioamide	absorbance,	left)	and	
325	 nm	 (Mcm	 absorbance,	 right).	 The	 L-epimer	 (L)	 and	 D-epimer	 (D)	 are	 denoted	 for	 each	 spectrum,	
although	 they	 cannot	 be	 separated	 for	 this	 peptide.	 The	 peak	marked	with	 (#)	 corresponds	 to	 peptide	
product	where	thioalanine	was	not	coupled.	
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Figure	4-13:	Analytical	HPLC	of	peptide	4-5	showing	GluS	spectra	at	272	nm	(thioamide	absorbance,	left)	
and	325	nm	(Mcm	absorbance,	right).	The	L-epimer	(L)	and	D-epimer	(D)	are	denoted	for	each	spectrum.	
The	peak	marked	with	(#)	corresponds	to	peptide	product	where	thioglutamate	was	not	coupled.	Some	
conversion	of	the	thiopeptide	to	oxopeptide	is	observed	(denoted	by	“O”)	as	a	byproduct	of	prolonged	TFA	
exposure	during	cleavage	from	the	2-chlorotrityl	resin.	
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Figure	4-14:	Analytical	HPLC	of	peptides	4-1	through	4-5	containing	the	internal	Mca	standard	(Piperidine,	
left;	DBU,	right).	The	L-epimer	(L)	and	internal	Mca	standard	(^)	are	denoted	for	each	spectrum. 
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Table	4-5:	Peak	area	and	integration	values	for	the	MCA	assay	used	to	quantify	peptide	yields.	
 
 
 
 
 
 
 
 
 
 
Trial	1 Trial	2 Trial	3 Average Std.	Dev.
Peptide	4-1	Piperidine	Peak	Area 9171.8 9069.7 9048.9 9096.8 65.8
MCA	Peak	Area 30679.8 30563.2 30131.0 30458.0 289.1
Peptide	4-1	Piperidine	%	Yield 29.9 29.7 30.0 29.9 0.2
Peptide	4-1	DBU	Peak	Area 11008.1 10851.2 11045.3 10968.2 103.0
MCA	Peak	Area 30888.1 30286.8 30427.9 30534.3 314.4
Peptide	4-1	DBU	%	Yield 35.6 35.8 36.3 35.9 0.3
Peptide	4-2	Piperidine	Peak	Area 13795.1 14006.5 13968.3 13923.3 112.7
MCA	Peak	Area 31730.6 30989.6 31594.8 31438.3 394.5
Peptide	4-2	Piperidine	%	Yield 43.5 45.2 44.2 44.3 0.9
Peptide	4-2	DBU	Peak	Area 15826.5 16119.3 15740.6 15895.5 198.5
MCA	Peak	Area 31478.0 30749.3 30728.3 30985.2 426.9
Peptide	4-2	DBU	%	Yield 50.3 52.4 51.2 51.3 1.1
Peptide	4-3	Piperidine	Peak	Area 15119.9 12930.9 13185.9 13745.6 1197.0
MCA	Peak	Area 31879.6 30879.1 30868.7 31209.1 580.7
Peptide	4-3	Piperidine	%	Yield 47.4 41.9 42.7 44.0 3.0
Peptide	4-3	DBU	Peak	Area 13585.3 13747.5 13787.7 13706.8 107.2
MCA	Peak	Area 30547.3 30827.3 30651.5 30675.4 141.5
Peptide	4-3	DBU	%	Yield 44.5 44.6 45.0 44.7 0.3
Peptide	4-5	Piperidine	Peak	Area 5573.9 5612.5 5574.4 5586.9 22.1
MCA	Peak	Area 30473.7 30581.9 31179.6 30745.1 380.2
Peptide	4-5	Piperidine	%	Yield 18.3 18.4 17.9 18.2 0.3
Peptide	4-5	DBU	Peak	Area 6951.6 6971.3 6970.6 6964.5 11.2
MCA	Peak	Area 30477.2 30456.8 30999.1 30644.4 307.4
Peptide	4-5	DBU	%	Yield	 22.8 22.9 22.5 22.7 0.2
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Analytical HPLC of Thiopeptides 4-6 and 4-7 
Stock solutions of all the peptides were made by dissolving the solid peptide 
precipitate in 50% (v/v) CH3CN in H2O (with 0.1% TFA) and vortexing to fully 
dissolve the peptide. Next, 100 μL of the stock solution was diluted to 1 mL total 
volume with water containing 0.1% TFA. Peptide samples were analyzed using 
reverse-phase HPLC at a flow rate of 1 mL/min using gradient 3. The absorbance 
was monitored at 214 nm (amide bond) and 272 nm (thioamide bond) and peaks 
were analyzed by MALDI MS to confirm their identity (See Table 4-4). Integration 
values for peak area percentage were calculated using the HPCORE ChemStation 
software from Agilent Technologies. As there is no Mcm present in this peptide, 
Mca could not be used as an internal standard to quantify yield. Percent 
epimerization was calculated by dividing the peak area (272 nm) of the L-
thiopeptide by the total peak area of the observed L- and D-thiopeptides. 
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Figure	4-15:	Analytical	HPLC	of	peptide	4-6	showing	TyrS	spectra	at	272	nm	(thioamide	absorbance,	left)	
and	215	nm	(amide	absorbance,	right).	The	L-epimer	(L)	and	D-epimer	(D)	are	denoted	for	each	spectrum.	
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Figure	4-16:	 Top	and	Middle:	Analytical	HPLC	of	peptide	4-7	 showing	PheS	and	pheS	 spectra	at	272	nm	
(thioamide	absorbance,	left)	and	215	nm	(amide	absorbance,	right).	The	L-epimer	(L)	and	D-epimer	(D)	are	
denoted	for	each	spectrum.	Bottom:	The	authentic	pheS	peptide	4-7	was	synthesized	as	a	standard	using	
both	the	piperidine	(Left)	and	DBU	(Right)	deprotection	conditions	(spectra	monitored	a	272	nm	shown).	
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Figure	 4-17:	 Analytical	 HPLC	 of	 peptide	 4-7	 from	 direct	 comparison	 of	 2%	 DBU	 to	 10%	 piperidine	
deprotections.		Chromatograms	showing	PheS	spectra	at	272	nm	(thioamide	absorbance,	left)	and	215	nm	
(amide	absorbance,	 right).	The	L-epimer	 (L)	and	D-epimer	 (D)	are	denoted	for	each	spectrum.	The	peak	
labeled	 “T”	 is	 thioanisole	 from	 the	 TFA	 deprotection	 cocktail.	 Small	 changes	 in	 retention	 time	 due	 to	
changes	in	HPLC	instrumentation	as	compared	to	Figure	4-16.	
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CHAPTER 5: 
 
DITHIOAMIDE PROTEIN SEMISYNTHESIS FOR THERMODYNAMIC 
ANALYSIS AND FLUORESCENCE QUENCHING STUDIES 
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Section 5.1- Introduction 
 
Incorporation of multiple thioamides within a single protein may confer 
advantages over their single thioamide counterparts in biophysical studies. This is 
especially true in their capacity as fluorescence quenchers; dithioamides show 
increased fluorescence quenching relative to monothioamide analogs in model 6-
mer peptides containing Pro, Ala, and Gly.298 Furthermore, additive stabilization or 
destabilization of protein secondary and tertiary structure may be possible with 
dithioamide substitutions, based upon the observations made with single 
thioamide substitutions in prior studies (see Chapter 3).256 Yet the solid phase 
synthesis of sequence-diverse dithioamide peptides and their stability during TFA 
cleavage from resin, HPLC purification, and NCL, remains essentially untested.222 
In order to identify conditions for dithiopeptide synthesis and compatibility with 
NCL, I used a previously established CaM NCL semi-synthetic scheme (See 
Section 3.2).256 This section describes the syntheses of six distinct dithioamide 
containing peptides and proteins with varying thioamide positioning (See Figure 5-
1).  Each of these syntheses was achieved without any additional complications 
with respect to single thioamide ligations. Thioamide substitution positions were 
chosen to assess if dithioamide containing CaM variants (dithioCaM, CaMSS) can 
fold properly when accommodating multiple backbone substitutions. Furthermore, 
using CD thermal denaturation experiments, I determined the impact that these 
substitutions have on the thermostability of CaM. Sites for thioamide incorporation 
were chosen to assess if the stabilizing effects observed in single thioamide 
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substitutions can be additive. Additionally, I investigated whether a destabilizing 
mutation can be negated by a predicted stabilizing mutation.  
The second part of this work focuses on the study of the fluorescence 
quenching properties dithioamides have in a dynamic protein system such as CaM. 
These experiments employ a previously described CaM-peptide binding assay that 
utilizes a peptide (denoted ‘FRRIAR’) derived from an olfactory cyclic nucleotide 
gated ion channel.132 In the modified system described herein, the peptide contains 
a  tryptophan fluorophore (denoted as WRRIAR), which can be quenched by 
thioamides.235  Taken together, these studies of dithioproteins will inform the usage 
of next-generation, multiply thioamidated peptides and proteins for use as 
enhanced fluorescence quenchers and structural modulators.  
 
 
Figure	 5-1:	 Dithioamide	 substitutions	 in	 CaM.	 	 Top:	 NCL	 scheme	 for	 the	 semi-synthesis	 of	 dithioCaM	
following	the	same	general	procedure	outlined	in	Section	3.2.	Bottom:	Table	describing	the	sequences	of	
dithioamide	substitutions	and	the	corresponding	single	thioamide	effects	observed	in	Section	3.2.	
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Section 5.2- Synthesis and CD Characterization of Dithioamide Containing 
Calmodulin (CaMSS) 
 
 In my initial designs, I was interested in placing the thioamides in positions 
which, relative to one another, may provide the highest potential for degradation 
during SPPS extension and cleavage. For example, placing the thioamide at the i 
and i + 1 position may lead to an increase in Edman-like degradation of the 
thioamide, thereby leading to truncated peptide products (See Figure 5-2).312 
Additionally, i and i + 1 sites may also lead to enhanced n à π* interactions, which 
may be observed by near-UV absorption studies such as CD and 
spectrophotometry, even within the context of an α-helix.313 I have previously 
studied the structural and thermodynamic impacts of single thioamide substitutions 
in the context of the C-terminal loop and helix of CaM. With rationale for how the 
CaM fold accommodates each single thioamide, this same portion of CaM provides 
an established platform by which to explore multiply thioamidated proteins. The 
placement of two thioamides within the helix may change the periodicity of the 
helix, and allow for complementary inclusion of previously unaccommodated 
thioamide substitutions. Thus, I began my studies by synthesizing the two 
dithioamide peptides CaM135-148-Cys135TyrS138ValS142 and CaM135-148-
Cys135PheS141ValS142 by manual SPPS using modified thioamide coupling 
procedures from Section 3.2 and DBU deprotections as discussed in 4.2. It should 
be noted that the use of DBU as an alternative Fmoc deprotection reagent is 
especially advantageous for peptides containing two or more thioamides. This is 
due to the suppression of multiple epimerization reactions (at each thioamide α-
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carbon), thereby eliminating the formation of a multitude of byproducts. After two 
rounds of HPLC purification, pure CaM135-148-Cys135TyrS138ValS142 (5-1) and 
CaM135-148-Cys135PheS141ValS142 (5-2) were each obtained in 1.2% isolated yields 
(1.5 mg each). 
 
Figure	5-2:		Proposed	mechanism	of	Edman	degradation-like	backbone	cleavage	of	i	and	i+1	dithiopeptides	
under	acidic	conditions. 
 
These dithiopeptides were each used in a ligation with CaM1-134-MES in the 
presence of denaturant (Gdn) and thiophenol as the catalyst. The reactions were 
monitored by MALDI-MS for formation of CaM1-148-Cys135TyrS138ValS142 and CaM1-
148-Cys135PheS141ValS142. Each ligation generated no observable thio- to oxo-amide 
exchange or degradation products other than the typical CaM1-134-OH hydrolysis 
byproduct previously observed in these syntheses (see Section 3.3). To remove 
this byproduct, the crude reaction was subjected to anion exchange purification by 
FPLC, followed by Cys capture and release purification using thiopropyl sepharose 
resin as before.256 The site of the ligation (Cys135) is a glutamine residue in the 
native CaM sequence and in past preparations, I have alkylated this Cys with 
iodoacetamide to create a nearly isosteric Gln mimic (denoted “CysQ”). The 
dithioproteins were therefore treated with 100 mM iodoacetamide in capping buffer 
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(20 mM Tris, 0.5 mM TCEP, pH 8.3) and only singly alkylated proteins were 
detected by MALDI, with no observable thioamide sulfur modifications in 
agreement with past preparations of CaM thioproteins (CaMS). CaM1-148-
CysQ135TyrS138ValS142 and CaM1-148-CysQ135PheS141ValS142 were obtained in 
isolated yields of 5.1% and 5.9%, respectively. Although these yields are lower 
than previously reported syntheses of CaMS (typically 10-20% yield), this 
methodology certainly provides evidence that dithioproteins can be synthesized 
using NCL and our newly developed SPPS protocols.314 The low yield for these 
constructs may be due in part to poor solubility of the protein after lyophilization. 
Nonetheless, these CaM dithioproteins were obtained in quantities sufficient to 
acquire CD spectra of the Ca2+-bound and Ca2+-free structures. Each of the 
spectra show significantly diminished helicity when compared to a CysQ control 
protein, in agreement with the destabilization observed for each monothioamide 
substitution (Figure 5-3). Unfortunately, each of these constructs were prone to 
aggregation, as observed previously for the PheS141 single thioamide mutant. 
Therefore, we were unable to effectively monitor the thermal unfolding transitions 
of these dithioamide constructs.  
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Figure	5-3:	CD	wavelength	scans	of	initial	dithioamide	CaM	constructs	(PheS141/ValS142	and	TyrS138/ValS142)	
tested	for	compatibility	with	NCL.	Each	protein	shows	significantly	reduced	MRE	compared	to	CysQ.	
 
With the preliminary success of the synthesis of CaMSS, I turned my 
attention to other constructs that may be more amenable to CD studies in order to 
learn more about the effects of dithioamide substitutions in a helix-loop-helix motif 
(see Figure 5-1). The first thioamide positions, ValS136 and GluS139, were chosen to 
assess if single stabilizing mutations can work synergistically to provide greater 
gains in thermostability for the protein. Surprisingly, the MRE of both the holo and 
apo forms of the protein were significantly reduced relative to the CysQ and single 
thioamide ValS136 and GluS139 controls. Melting temperature (TM*) and free energy 
of unfolding (ΔGU) were determined by performing CD thermal melts monitoring 
the helicity of the protein via the CD signal at 222 nm as temperature was 
increased. As previously noted, holo CaM constructs do not unfold completely (TM 
> 80 °C) during thermal denaturation and all holo CaMSS proteins discussed here 
also do not unfold in the temperature range studied (5 to 95 °C). However, in 
agreement with the CD wavelength scans, apo CaM ValS136/GluS139 showed 
thermodynamic parameters that indicate destabilization compared to the CysQ 
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control (ΔTM = -2.9 °C, ΔΔGU = -1.1 kcal   mol-1). Although this is a counterintuitive 
result, this destabilization may indicate that the remodeling of the loop-helix 
hydrogen bonding network by ValS136 alters the structural dynamics of the helix. A 
change in the periodicity of the helix could, hypothetically, lead to poorer 
accommodation of the GluS139 thioamide sulfur by shrinking the hydrogen bond 
distance with the next helical turn (C=X--N distance is 3.4 Å), although higher 
resolution studies to support this hypothesis have not yet been performed.276 
 
Figure	 5-4:	 CD	wavelength	 scans	 for	 dithioproteins	 each	 containing	 at	 least	 one	 predictively	 stabilizing	
mutation.	Single	thioamide	protein	wavelength	scans	are	also	shown	for	direct	comparison.	A	significantly	
increased	πàπ*	single	(centered	at	270	nm)	is	observed	in	the	ValS136/TyrS138	protein	(blue).		
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Figure	5-5:	CD	wavelength	scans	of	each	CaMSS	protein	(holo	and	apo)	plotted	with	their	respective	single	
thioamide	scans	from	Section	3.2.	Increased	absorbance	at	270	nm	(thioamide	CD	signature)	is	observed	
for	both	ValS136/ValS142	and	ValS136/TyrS138	proteins. 
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With the intriguing, non-additive effects of the thioamide substitutions in 
CaM ValS136/GluS139, I wished to determine whether stabilizing effects of the ValS136 
mutation could be maintained with a second thioamide (ValS142), which was 
previously found to be a near neutral mutation (TM comparable to the CysQ control). 
However, I was again surprised to find that this CaMSS construct showed a 
decrease in MRE signal compared to each single thioamide control in the CD 
wavelength scans. However, CaM ValS136/ValS142 showed a similar melting 
temperature to the CysQ control (see Table 5-1), yet underwent a significantly less 
cooperative unfolding transition (ΔΔGU = -1.0 kcal mol-1). The stabilization provided 
to CaM by ValS136 (ΔTM = +3.1 °C) appears to have negated the slight perturbation 
observed in ValS142 (ΔTM = -1.5 °C), yet the two effects are not a sum of these 
individual values. Taken together, these two CaMSS proteins indicate that the effect 
multiple thioamides have on the thermostability and structural elements of a protein 
may be difficult to predict from the effects of single thioamides. Nevertheless, I 
continued my exploration of dithioamide substitutions in this region by combining 
one of the two singly stabilizing mutations (ValS136 or GluS139) with the destabilizing 
mutation TyrS138.  
Based on the results achieved in the ValS136/ValS142 protein, I hypothesized 
that one of the stabilizing mutations may be able to rescue some of the protein 
structure and thermostability that is compromised by TyrS138. For CaM 
TyrS138/GluS139, some of the global thermostability was recovered with respect to 
the TyrS138 single mutant (ΔTM = + 4.0 °C relative to TyrS138), however, it does not 
return the protein to the levels of thermostability of CysQ (ΔTM = -2.2 °C, ΔΔGU = -
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1.3 kcal mol-1). Curiously, there still appears to be significant structural perturbation 
when examining the CD wavelength scans; CaM TyrS138/GluS139 shows significant 
reduction in helical signature at 208 and 222 nm in both the holo and apo forms of 
the protein. In fact, the Apo form shows a MRE value at 222 nm that is consistent 
with the destabilizing TyrS138 single mutation. These results are again difficult to 
interpret, but it is most likely that together, the two thioamide mutations are driving 
the protein towards an alternative fold where some of destabilizing character of the 
TyrS138 can be recovered. However, the dithioamide protein shows distinct 
structural properties that do not completely agree with what would be expected 
from the net effects of both the previously published single mutations.  
 
 
Figure	5-6:	Left:	Holo	dithioCaM	MRE	values	plotted	as	a	function	of	temperature.	All	dithioproteins	have	
TM	values	greater	than	80	°C,	in	agreement	with	oxo	and	single	thioamide	controls.	Right:	Transformed	apo	
thermal	melts	 plotted	 as	 fraction	 folded	 (Ff*)	 fits	 that	 include	 a	weighted	 contribution	 from	 the	
intermediate	state	as	described	in	Section	3.2.	Melting	curves	were	obtained	by	measuring	the	θ222	
at	1	°C	 increments	 in	10	mM	Tris,	pH	7.5	with	either	0.5	mM	EDTA	 (apo)	or	2	mM	CaCl2	 (holo).	
Transformation	of	raw	CD	signal	to	MRE	values	and	three-state	fitting	procedures	were	performed	
as	described	in	Section	3.3.	
 
 
 
0 20 40 60 80 100
-15
-10
-5
0
DithioCaM Holo Thermal Melts
Temperature (°C)
θ M
R
E 
x1
0-
3 
(d
eg
  c
m
2  d
m
ol
-1
)
ValS136/Tyr
S
138
ValS136/Val
S
142
ValS136/Glu
S
139
TyrS138/Glu
S
139
0 10 20 30 40 50 60 70 80
0.0
0.5
1.0
Temperature (°C)
F f
*
DithioCaM Apo Thermal Melts
GluS139
CysQ135 Oxo
ValS136
TyrS138
ValS142
ValS136/Val
S
142
ValS136/Tyr
S
138
ValS136/Glu
S
139
TyrS138/Glu
S
139
236	
	
When performing the same set of experiments for CaM ValS136/TyrS138, I 
encountered an even more surprising result; the CD signature for CaM 
ValS136/TyrS138 matches identically to that of the ValS136 monothioamide protein. In 
addition, CaM ValS136/TyrS138 is more thermally stable during CD thermal melts 
when compared to the oxo control CysQ135 (ΔTM = 3.1 °C, ΔΔGU = 2.2 kcal mol-1) 
and shows a more cooperative transition during unfolding than that of either the 
TyrS138 or ValS136 thermal melting profiles (See Figure 5-6). To ensure that both 
thioamides were present in the protein and unmodified during iodoacetamide 
treatment, a trypsin digest was performed, followed by MALDI-TOF tandem 
MS/MS fragmentation analysis of the resulting tryptic dithioamide peptide. To my 
satisfaction, both thioamides are present in the fragmentation analysis (See 
Figures 5-11 and 5-12, and Table 5-6). The hypothesized hydrogen bond that 
ValS136 makes with the side-chain of GluS140 could change the periodicity of the C-
terminal helix, as with the ValS136/GluS139 mutant. However, in this case, the sulfur 
atom may be more readily accommodated into the inter-strand space due to an 
expansion in the first turn of the helix (TyrS138 sulfur accommodation normally 
forbidden; C=O--N distance of 2.6 Å). With the TyrS138 no longer being structurally 
perturbing in this conformation, the thioamide N-H may participate in a hydrogen 
bonding within the helix, thereby leading to increased stabilization.  
Although the structural and thermodynamic effects of dithioamide 
substitutions within CaM are not necessarily intuitive, TyrS138/GluS139 and 
ValS136/TyrS138 provide effects that can be rationalized within the context of the CaM 
C-terminal domain.  I am currently in pursuit of high-resolution studies of both 
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mono- and di-thioamide CaM through a combination of NMR and crystallography 
to provide more context for the effects, especially within the multiply thionated 
proteins discussed here.  
 
 
 
Figure	 5-7:	 Individual	 fraction	 folded	 (Ff*)	 plots	 for	 CaMSS	 thermal	 melts	 (from	 Figure	 5-5)	 showing	
corresponding	single	thioamide	thermal	melts	and	the	CysQ	oxo	and	wild	type	controls	(from	Section	3.2).	
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Table	5-1:	Thermodynamic	values	for	CaMSS	variants	compared	to	their	single	thioamide	congeners	from	
Section	3.2.	
 
 
 
Section 5.3 – Dynamic Fluorescence Quenching of Tryptophan in CaMSS 
 
 Calcium bound CaM is known to bind several peptide partners derived from 
various regulatory domains discussed in the literature.315 Upon binding these 
peptide sequences, CaM undergoes a structural change to produce a distinct 
conformation from that of the Ca2+-bound or Ca2+-free form. Our lab has previously 
used derivatized sequences of a peptide (denoted “FRRIAR”) taken from an 
olfactory cyclic nucleotide gated ion channel as a model system for studying 
distance dependent fluorescence quenching phenomena in CaM.132 In these 
experiments, FSRRIAR was used as a stoichiometric reporter for FRET quenching 
of Cnf placed at various sites within tyrosine-free CaM. In the following studies, we 
have used the inverse of this assay to place the thioamide within the context of the 
folded protein to observe quenching of an external fluorophore in a FRRIAR-like 
WT 43.5	±	0.6 33.1	±	0.8 48.6	±	0.6 60.5	±	0.7 46.8	±	0.3 --- 6.4	±	0.2 ---
CysQ135	Oxo 38.9	±	0.8 30.2	±	0.9 48.8	±	0.7 61.7	±	0.8 45.5	±	0.4 --- 5.9	±	0.1 ---
ValS	136 39.6	±	0.5 36.7	±	0.6 55.3	±	0.8 52.0	±	0.5 48.6	±	0.7 3.1 6.5	±	0.1 0.6
TyrS138 34.7	±	0.8 39.7	±	0.7 43.0	±	0.9 51.1	±	1.0 39.3	±	0.8 -6.2 4.1	±	0.2 -1.8
GluS139 40.7	±	0.7 40.1	±	0.4 51.9	±	0.6 53.9	±	0.9 47.0	±	0.1 1.6 6.4	±	0.1 0.5
ValS142 36.4	±	0.6 35.5	±	0.8 48.4	±	0.8 62.9	±	0.9 44.0	±	0.7 -1.5 5.8	±	0.2 -0.1
ValS	136/TyrS138 43.0	±	0.1 48.0	±	1.7 53.0	±	0.6 62.1	±	1.6 48.6	±	0.2 3.1 8.1	±	0.3 2.2
ValS	136/GluS139 37.4	±	1.0 36.0	±	1.5 46.4	±	0.8 50.5	±	2.7 42.6	±	0.1 -2.9 4.8	±	0.2 -1.1
ValS	136/ValS142 43.8	±	0.5 32.9	±	0.7 47.0	±	0.7 42.9	±	0.2 45.6	±	0.6 0.1 4.9	±	0.1 -1.0
TyrS	138/GluS139 38.8	±	0.0 36.3	±	1.9 47.6	±	0.1 43.4	±	2.0 43.6	±	0.2 -2.2 4.6	±	0.1 -1.3
ΔTm* ΔΔGU
(°C)
(kcal	
mol-1)
CysQ135	Oxo45.5	±	0.4 --- 5.9	±	0.1 ---
ValS	136 48.6	±	0.7 3.1 6.5	±	0.1 0.6
TyrS138 39.3	±	0.8 -6.2 4.1	±	0.2 -1.8
GluS139 47.0	±	0.1 1.6 6.4	±	0.1 0.5
ValS142 44.0	±	0.7 -1.5 5.8	±	0.2 -0.1
ValS	136/Tyr
S
13848.6	±	0.2 3.1 8.2	±	0.6 2.3
ValS	136/Glu
S
13941.9	±	0.4 -3.6 4.6	±	0.6 -1.3
ValS	136/Val
S
14238.0	±	0.0 -7.5 3.0	±	0.0 -2.9
TyrS	138/Glu
S
13941.6	±	1.2 -3.9 3.2	±	0.1 -2.7
ΔΔGU									
(kcal	mol-1)
ΔGUd																										
(kcal	mol-1)
CaM	Variant TM*																																			
(°C)
ΔGU																																
(kcal	
mol-1)
CaM	Variant TM1
a																					
(°C)
ΔH1																																
(kcal	mol-1)
TM2																																			
(°C)
ΔH2b																			
(kcal	mol-1)
TM*c																													
(°C)
ΔTm*	
(°C)
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peptide. Although Cnf is an attractive probe for FRET based quenching 
experiments, it cannot be used in CaM sequences that contain Tyr (all CaMS and 
CaMSS proteins contain a Tyr and position 99 and 138), due to the spectral overlap 
between Cnf emission and Tyr excitation. Therefore, a FRRIAR derivative 
containing an N-terminal fluorescent tryptophan residue (denoted WRRIAR) will 
be used as the fluorescent probe. The objective of these studies is threefold: (1) 
to establish that thioCaM and dithioCaM proteins are able to bind the peptide and 
undergo similar conformational changes observed in the WT controls, (2) to 
observe thioamides as fluorescence quenchers while embedded within folded 
secondary and tertiary elements of protein structure, and (3) to provide additional 
evidence of increased fluorescence quenching by dithioamides relative to their 
monothioamide counterparts. 
 The fluorescence experiments described in this section were designed by 
Chris Walters and John Ferrie and the fluorescence measurements were taken by 
John Ferrie, to be reported in total elsewhere. In order to qualitatively determine 
each CaMSS protein’s ability to bind WRRIAR, two ratios of CaMSS to WRRIAR 
were prepared (2:1 and 0.5:1 CaMSS:WRRIAR), with a 1 μM concentration of 
WRRIAR (125 μL final volume). The same ratiometric measurements were made 
with the single thioamide mutants ValS136, TyrS138, Glu139, and ValS142, to verify the 
potential additive quenching in dithioamide proteins. Fluorescence measurements 
with WRRIAR peptides were also performed on WT CaM and a CysQ135 oxoamide 
control protein to determine the maximum Trp fluorescence of CaM-bound 
WRRIAR. The concentrations of each protein used in these experiments were 
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determined by a FluoroProfile® (Sigma-Aldrich, St. Louis, MO) assay using a series 
of WT dilutions as standards. Excitation of tryptophan was performed at 295 nm 
and emission spectra were collected from 305 nm to 450 nm. A large peak 
centered at ~320 nm was detected in the buffer-only background spectra and can 
be attributed to the Raman scattering of the buffer. This peak is subtracted from 
all fluorescence spectra acquired for protein samples. Each experiment was 
replicated three times to ensure the precision of the data collected. 
The measurements collected were analyzed by John Ferrie (to be described 
in detail elsewhere) and based off of fits to each spectrum, the percent quenching 
of Trp and percent of peptide bound can be obtained for each CaM protein at each 
WRRIAR ratio. Quenching efficiency is calculated as the percent quenching 
divided by the percent peptide bound for each construct and ratiometric 
measurement. The ValS136/ValS142 CaM construct demonstrates the best example 
of the additive contributions each thioamide has on the quenching of Trp (see 
Figure 5-8). For each CaM:WRRIAR ratio, the single thioamide constructs ValS136 
and ValS142 provide Trp quenching in single contributions approximately equal to 
the total Trp quenching observed for the ValS136/ValS142. Fitting of the raw 
fluorescence spectra enables deconvolution of the amount of CaM-bound 
WRRIAR and free WRRIAR in solution. For ValS136/ValS142, this analysis indicates 
that 100 % of WRRIAR is bound at the 2:1 CaMSS:WRRIAR ratio. This is greater 
than the percent of WRRIAR bound for either of the single thioamide mutants and 
demonstrates similar binding capacity to that of the WT protein. Similar effects are 
demonstrated for the ValS136/Tyr138 protein, where, although the percent of 
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WRRIAR bound is not at WT levels for each ratiometric measurement, the CaMSS 
protein still shows higher quantities of peptide bound than its single thioamide 
counterparts at a 2:1 ratio of CaMSS to WRRIAR. Additionally, this dithioCaM 
construct restores much of the quenching efficiency lost in the single TyrS138 
mutant. More importantly, these results agree with the CD analysis that the 
stabilizing nature of the ValS136 mutation can act to recover the destabilizing TyrS138 
effects, even in the functional outcome of model protein-protein interactions with 
WRRIAR peptide binding. Both ValS136/GluS139 and TyrS138/GluS139 show a drastic 
increase in quenching efficiency, even though each construct appears to bind the 
peptide in lower quantities than each of their single thioamide controls. Although 
quantitative thermodynamic analysis was only performed on the calcium-free 
forms of these constructs, these peptide binding results are intuitive as these two 
CaMSS variants are significantly destabilized when compared to the CysQ135 
control.   
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Figure	5-8:	Individual	plots	of	CaM-WRRIAR	binding	experiments.	Left:	Efficiency	of	Trp	quenching	(percent	
Trp	quenched	divided	by	percent	peptide	bound)	by	each	thioamide	and	dithioamide	CaM	construct.	Right:	
Percent	of	WRRIAR	bound	to	each	protein	at	varying	stoichiometric	ratios	of	CaM:WRRIAR,	as	extracted	
from	the	fit.	
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Figure	5-9:	Calcium	bound	CaM	binding	a	WRRIAR-like	peptide	modeled	from	PDB	accession	1SY9.316	The	
expressed	 fragment	 of	 the	 protein	 is	 shown	 in	 blue,	 while	 the	 synthetic	 portion	 containing	 thioamide	
modifications	in	red.	The	green	helix	represents	the	bound	WRRIAR	peptide.	The	Ca2+-bound	CaM	structure	
is	taken	from	PDB	entry	1UP5.287	Inset:	Thioamide	substitutions	modeled	into	the	C-terminal	helix	of	CaM	
showing	their	potential	spatial	relationship	to	the	Trp	fluorophore	in	the	bound	WRRIAR	peptide.		
 
Discussion and Conclusion 
In this work, I have undertaken the initial steps towards understanding how 
to best utilize dithioamide substitutions in a full-length protein. The CD studies 
performed show that multiple thioamide substitutions within the same protein 
domain can have unexpected effects, such as the net stabilization observed when 
combining ValS136 (a stabilizing mutation) and TyrS138 (a massively destabilizing 
mutation). Although definitive rules cannot be parsed out from these pilot studies, 
it does appear that within the same helix (ValS136/GluS139 and TyrS138/GluS139), two 
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TyrS138
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Trp
Trp
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thioamide mutations cannot be incorporated without perturbing the structure and 
thermostability of the protein. However, as with ValS136/ValS142 and ValS136/Tyr138 
proteins, thioamide substitutions in the loop preceding the helix (ValS136) can work 
synergistically with thioamides embedded within the helix (TyrS138 and GluS139; see 
Figures 3-31 through 3-33).  
These dithioamide CaM variants were tested as fluorescence quenchers to 
monitor protein-peptide interactions with varying success. Most notably, the two 
most thermostable CaMSS variants (ValS136/ValS142 and ValS136/Tyr138) bound the 
fluorescent WRRIAR peptide in greater amounts than their single thioamide 
cognates, and showed an increased amount of Trp quenching. To our knowledge, 
these fluorescence studies show the first semisynthetic dithioprotein capable of 
performing native or near-native folding. Certainly, further high-resolution analyses 
must be done to directly observe the site-specific changes induced by multiply 
thioamidated CaM constructs. These experiments are paramount to maximizing 
the utility of the thioamide as a spectroscopic probe or modulator of the structure 
and function of protein targets. 
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Section 5.4 - Materials and Methods  
 
5.4.1- General Information  
 
Fmoc protected amino acids and peptide coupling reagents as well 2-
chlorotrityl resin were purchased from EMD Millipore (Billerica, MA, USA). 
Piperidine was purchased from American Bioanalytical (Natick, MA, USA). 
Triisopropylsilane (TIPS) was purchased from Santa Cruz Biotechnology, Inc 
(Dallas, TX, USA). Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased 
from LabScientific, Inc (Highlands, NJ, USA). Protease inhibitor tablets were 
purchased from Roche Boehringer Mannheim (Indianapolis, IN, USA). Sodium 2-
mercaptoethanelsulfonate (MES•Na) was purchased from TCI America (Portland, 
OR, USA). FPLC purification of proteins was performed on an ÄKTA system with 
HiTrap Q columns (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA), while 
peptide HPLC was performed on a Varian Prostar system (currently Agilent 
Technologies, Santa Clara, CA, USA) for CaM. Thiopropyl sepharose 6b resin was 
also purchased from GE Healthcare (Princeton, NJ, USA). Cuvettes for CD 
spectroscopy were purchased from Hellma Analytics USA (Plainview, NY, USA). 
All other reagents, solvents, and materials were purchased from either Fisher 
Scientific (Pittsburgh, PA, USA) or Sigma-Aldrich (St. Louis, MO, USA) unless 
otherwise specified. Matrix assisted laser desorption/ionization mass spectrometry 
(MALDI) was performed on a Bruker Ultraflex III mass spectrometer (Billerica, MA). 
Common abbreviations for all other chemicals are as follows: 2-(1H-benzotriazol-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), N,N-
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diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), 1,2-ethanedithiol (EDT), 
1,8-diazabicyclo(5.4.0)undec-7-ene (DBU),  4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), tris(2-carboxyethyl)phosphine (TCEP), 
and guanidinium hydrochloride (Gdn•HCl).  
 
5.4.2- Synthesis and Characterization of DithioCaM 
 
Synthesis of Thioamino Acid Precursors (Fmoc-AaS-NBt) 
All thioamino acid precursors were synthesized as Fmoc-
thionitrobenzotriazolide monomers (Fmoc-AaS-NBt) by starting with commercially 
available Fmoc protected amino acids and using a route modified from Shalaby et 
al.296 Each thioamino acid precursor used in these studies has been previously 
synthesized and characterized256, 296, as detailed in Section 3.4.2. 
 
Synthesis of Thioamide Containing Peptides for NCL 
SPPS of monothioamide and dithioamide peptides was performed on 2-
chlorotrityl resin (100-200 mesh) in 10 mL reaction vessels. The reaction scale was 
50 μmol for monothioamide peptides and 100 μmol for dithioamide peptides. The 
resin was swelled in DMF (6 mL, 1 hour) while stirring. The vessel was then drained 
and to it was added the first amino acid (Fmoc-Lys(Boc)-OH; 5 equivalents) and 
DIPEA (10 equivalents) in DMF (4 mL). This initial loading reaction stirred for 45 
minutes at room temperature (RT) before being drained, washed with DMF (2 x 4 
mL) and repeated. Fmoc removal prior to thioamide couplings was performed by 
adding to the resin a solution of 20 % v/v piperidine in DMF (5 mL total volume) 
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and stirring for 20 minutes at RT. The vessel was then drained and the resin 
washed with DMF, followed by DCM (2 x 4 mL DMF, 2 x 4 mL DCM, then 4 mL 
DMF). The peptide was then elongated up to the thioamide position using standard 
SPPS protocols by adding 5 equivalents of amino acid and HBTU, and 10 
equivalents of DIPEA in DMF (4 mL) and stirring each coupling for 45 minutes at 
RT. For thioamide couplings, each Fmoc-AaS-NBt (3 equivalents) precursor was 
added to the vessel with DIPEA (2 equivalents) in DCM (2 mL) and the reaction 
was stirred at RT for 30 minutes. The vessel was then drained and the resin 
washed with dry DCM (2 x 4 mL) before the thioamide coupling was repeated. At 
completion of the second coupling, the resin was washed with DCM then DMF (2 
x 4 mL) and Fmoc deprotection proceeded by adding to the resin a 2 % v/v DBU 
in DMF solution (2 mL total volume). This DBU deprotection reaction was stirred 
for 2 minutes at RT. Then, the vessel was drained and the resin washed with DMF 
and DCM (2 x 4 mL DMF, 2 x 4 mL DCM, then 4 mL DMF). This procedure was 
repeated twice more before proceeding to the next amino acid coupling reaction. 
All subsequent Fmoc deprotections were performed using this DBU method. 
Standard SPPS was used to add the remaining oxo amino acids, and in the case 
of the dithiopeptides, the second thioamino acid coupling was done as described 
above. After the last Fmoc group was removed, the resin was washed with DMF, 
followed by DCM (2 x 4 mL each). A cleavage cocktail was prepared with 
24:16:1:1:1 DCM:TFA:TIPS:EDT:Thioanisole (total volume of 4.3 mL). This was 
added to the resin and allowed to stir at RT for 1 hour before being drained and 
collected. DCM (6 mL) was added to the resin to wash out any remaining peptide 
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and the collected solution was dried to a colorless oil (or yellow oil in the case of 
TyrS containing peptides) by rotary evaporation. The crude peptide product was 
then precipitated by adding cold diethyl ether (20 mL) and vortexing vigorously. 
The resulting precipitate was dried and stored under argon at -20 °C until HPLC 
analysis proceeded.  
 
HPLC Purification of Thiopeptides 
Monothioamide peptides were purified as described in Section 3.4.256 
Dithioamide crude peptide samples were dissolved in 40 % acetonitrile in Milli-Q 
H2O with 0.1 % TFA (10 mL final volume). 5 μL of a 0.5 M solution of TCEP Bond 
Breaker™ was added to each sample to reduce any Cys disulfides that formed 
during deprotection and the sample was filtered through a 0.22 μm filter. HPLC 
purification was performed using a Grace VyDac C18 Preparatory column (flow 
rate of 12 mL/min) and the gradients listed in Table 5-2. Collected fractions were 
analyzed by MALDI-MS for the presence of the desired dithiopeptide mass (see 
Table 5-3). Additionally, MALDI-TOF tandem MS/MS fragmentation experiments 
and corresponding analysis was performed on each of the dithiopeptides to verify 
that both thioamides were intact. 
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Table	5-2:	HPLC	purification	gradients	for	CaM	dithiopeptides.	Buffer	A:	Milli-Q	H2O	with	0.1	%	TFA.	Buffer	
B:	Acetonitrile	with	0.1	%	TFA.	
	
	
	
	
	
	
	
Table	 5-3:	MALDI-MS	observed	masses	 for	 dithiopeptides	 and	 corresponding	 isolated	 yields	 after	HPLC	
purification.	
	
CaM135-148 Sequence Calculated m/z [M+H]+  
Observed 
m/z % yield 
H2N-CVNYEEFSVSQMMTAK-OH 1724.69 1724.74 1.2	
H2N-CVNYSEEFVSQMMTAK-OH 1724.69 1724.92 1.2	
H2N-CVSNYEEFVSQMMTAK-OH 1724.69 1723.33 8.3	
H2N-CVSNYSEEFVQMMTAK-OH 1724.69 1725.19 2.2	
H2N-CVSNYESEFVQMMTAK-OH 1724.69 1724.54 2.2	
H2N-CVNYSESEFVQMMTAK-OH 1724.69 1723.49 2.5	
	
 
 
 
 
 
Peptides Time (min) Buffer A (%) Time (min) Buffer A (%)
H2N-CVNYEEFSVSQMMTAK-OH 0 98 0 98
H2N-CVNYSEEFVSQMMTAK-OH 5:00 98 5:00 98
10:00 75 10:00 70
34:00 62 38:00 65
35:00 2 39:00 2
40:00 2 44:00 2
41:00 98 45:00 98
46:00 98 50:00 98
H2N-CVSNYEEFVSQMMTAK-OH 0 98 0 98
5:00 98 5:00 98
10:00 70 10:00 70
30:00 63 30:00 63
31:00 2 32:00 2
36:00 2 40:00 2
37:00 98 42:00 98
41:00 98 46:00 98
H2N-CVNYSESEFVQMMTAK-OH
Peptides
H2N-CVSNYSEEFVQMMTAK-OH
H2N-CVSNYESEFVQMMTAK-OH
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Synthesis, Purification, and Iodoacetamide Capping of CaM Dithioproteins  
 
Native chemical ligation reactions were run as described in Section 3.4 with 
no changes to protocol with respect to dithiopeptides. After 20 hours, reactions 
were quenched by adding 2 mL of Milli-Q water and dialyzing twice against 2 L of 
20 mM Tris pH 8.0 buffer (2 hours each) at room temperature in preparation for 
FPLC anion exchange chromatography using the gradient outlined in Table 5-4. It 
should be noted that the crude samples need to be treated with 15 μL of a 0.5 M 
solution of TCEP Bond Breaker™ to reduce disulfides prior to FPLC purification. 
Collected FPLC fractions were analyzed by MALDI-MS and fractions containing 
product were pooled and dialyzed against 20 mM Tris, 1 mM EDTA, pH 7.5 in 
preparation for thiopropyl sepharose purification. Using 0.75 g of dry thiopropyl 
sepharose for each CaMSS product, CaMSS was separated from the CaM1-134-OH 
hydrolysis byproduct as described in Section 3.4. The resulting pure eluent was 
dialyzed against 20 mM Tris pH 8.0 buffer (2 L) for 2 hours prior to capping with 
iodoacetamide. Capping reactions were run as in Section 3.4 with the exception 
that fewer equivalents of iodoacetamide were used (25 mM final concentration in 
each sample) to potentially avoid any thioamide alkylation. Reactions were 
incubated with agitation for ten minutes and monitored by MALDI. At completion, 
the reactions were dialyzed twice against water (2 L for 2 hours each) at room 
temperature before being flash frozen in liquid N2 and lyophilized to a powder.   
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Table	5-4:	Gradient	used	for	anion	exchange	purification	of	CaMSS	NCL	products.	Buffer	A:	20	mM	Tris,	pH	
8.0.	Buffer	B:	20	mM	Tris,	1	M	NaCl,	pH	8.0.	
	
Time (min) Buffer B (%) 
0:00 10 
10:00 10 
15:00 25 
70:00 40 
80:00 40 
80:01 100 
90:00 100 
	
Table	5-5:	Synthetic	yields	for	CaMSS	proteins.	
	
CaM Variant Percent Yield 
CysQ135TyrS138ValS142 5.1 % 
CysQ135PheS141ValS142 5.9 % 
CysQ135ValS136ValS142 3.3 % 
CysQ135ValS136GluS139 5.1 % 
CysQ135ValS136TyrS138 2.0 % 
CysQ135TyrS138GluS139 1.9 % 
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Figure	5-10:	MALDI-MS	traces	showing	pure	CaMSS	proteins	used	for	CD	and	fluorescence	experiments.		
 
 
 
 
Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16793
Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16793
Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16794
Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16794
Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16793
Expected [M+Na]+ = 16794
Observed [M+Na]+ = 16795
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Trypsin Digest of ValS136/TyrS138 CaM  
To ensure that the dithioamides are stable and unmodified during the entire 
purification and capping process, a trypsin digestion was performed on holo CaM-
CysQ135ValS136/TyrS138.  200 μL of the CaM sample used for CD spectra acquisition 
was incubated with 10 μL of 0.5 μg/mL sequencing grade trypsin at 37 °C for 20 
hours. The reaction was then analyzed by MALDI-MS and MALDI-TOF tandem 
MS/MS fragmentation. The parent mass and resulting fragmentation pattern are 
consistent with the presence of both intact thioamides and a singly alkylated Cys 
residue (see Figures 5-12 and 5-13 and Table 5-6).  
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Figure	5-11:	Top:	Trypsin	digest	of	CaM	ValS136/TyrS138	showing	the	mass	of	the	desired	fragment	containing	
the	both	thioamides	and	the	alkylated	CysQ	(expected	[M+H]+	=	2555.89	Da,	observed	2556.22	Da)	Bottom:	
Tandem	MS/MS	fragmentation	of	the	tryptic	peptide	corresponding	to	the	sequence	shown	in	Figure	5-13.	
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Figure	5-12:	Fragmentation	patterns	of	the	H2N-EADIDGDGCQVSNYSEEFVQMMTAK-OH	tryptic	peptide.	
 
Table	5-6:	Expected	(black)	and	observed	(red)	MS/MS	fragment	m/z	(a-,	b-,	x-	and	y-	series	ions)	for	the	
tryptic	 peptide	 H2N-EADIDGDGCQVSNYSEEFVQMMTAK-OH.	 Nearly	 complete	 coverage	 of	 the	 peptide	 is	
observed.	
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• 6167A trypsin doesn’t produce enough of the 
desired peptide mass to enable MS/MS analysis
• 6167B trypsin produces significantly more 
peptide (or it just flies better on MALDI), shows 
fragmentation consistent with OXO Val142. 
Sample is as labeled and shows a 
counterintuitive effect
Expected [M+H]+ = 2555.89 Da,
Observed = 2557.24 Da (RP method, but 
exact mass observed from MSMS)
Sequence Observed Series a (m/z) Obs a (m/z) b (m/z) Obs b (m/z) x (m/z) Obs x (m/z) y (m/z) Obs y (m/z) #	(+1)
E a,b 102.113 100.941 130.123 129.065 --- --- 2555.821 --- 22
A a,b,x 173.192 175.014 201.202 201.041 2452.699 2451.027 2426.706 --- 21
D a,b 288.280 288.021 316.290 316.039 2381.621 --- 2355.627 --- 20
I a,b 401.440 401.095 429.450 429.133 2266.532 --- 2240.538 --- 19
D b 516.528 --- 544.538 544.129 2153.373 --- 2127.379 --- 18
G --- 573.580 --- 601.590 --- 2038.284 --- 2012.290 --- 17
D x 688.669 --- 716.679 --- 1981.232 1979.720 1955.238 --- 16
G --- 745.721 --- 773.731 --- 1866.144 --- 1840.149 --- 15
CQ y 905.899 --- 933.909 --- 1809.092 --- 1783.098 1785.731 14
VS y 1004.395 --- 1049.057 --- 1647.668 --- 1622.959 1622.559 13
N b 1135.151 --- 1163.161 1162.947 1548.995 --- 1507.771 --- 12
YS b,y 1297.483 --- 1342.392 1343.922 1419.667 --- 1393.667 1391.709 11
E b 1443.497 --- 1471.507 1471.392 1255.516 --- 1214.436 --- 10
E y 1572.613 --- 1600.623 --- 1110.315 --- 1085.321 1084.365 9
F b,y 1719.789 --- 1747.799 1750.213 982.199 --- 956.206 955.283 8
V y 1818.922 --- 1846.932 --- 835.023 --- 809.029 808.179 7
Q x,y 1947.053 --- 1975.062 --- 735.891 733.961 709.896 709.140 6
M y 2078.245 --- 2106.255 --- 607.759 --- 581.766 581.112 5
M y 2209.438 --- 2237.448 --- 476.567 --- 450.573 450.990 4
T b,x,y 2310.543 --- 2338.552 2351.527 345.475 344.070 319.381 319.117 3
A x,y 2381.622 --- 2409.632 --- 244.269 243.032 218.275 218.041 2
K a,x,y 2509.796 2509.475 2537.806 --- 173.191 175.014 147.197 147.055 1
C obs Z obs
147.15336 2522.8
218.23216 218.1 2393.7
333.32076 334.1 2322.6
446.4802 446.2 2207.5
561.5688 2094.3
618.62072 1979.3
733.70932 1922.2
790.76124 1807.1
950.94004 1750.1
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Sample Fluorescence Fitting Data 
 Fluorescence data was collected as described in Section 5.4 and will be 
described in more detail by John Ferrie elsewhere. Below is a sample spectra 
(ValS136) of the raw fluorescence data and the fits used to extract the percent Trp 
quenched and percent WRRIAR bound values. 
 
Figure	5-13:	Fluorescence	spectra	of	CaM	ValS136	bound	to	the	WRRIAR	peptide	in	samples	with	ratios	of	
0.5:1	(Left)	and	2:1	(Right)	CaM	ValS136	to	WRRIAR.	Fits	were	performed	by	John	Ferrie	and	populations	of	
free	and	bound	WRRIAR	were	extracted	from	these	fits. 
	
 
CD Sample Preparation and Fitting Procedures 
 
CD samples were prepared as in Section 3.4 and CD spectra were acquired 
on samples with a final concentration between 10 and 15 μM (as determined by 
BCA assay). Each holo spectra and thermal melt was acquired as a single sample 
and apo spectra and thermal melt acquisition were performed in duplicate. Fitting 
procedures were performed via the three-state fit method described in Section 3.4. 
Initial guesses for ΔH1, ΔH2, ΤΜ1, and TM2 were taken from single thioamide thermal 
melts in Section 3.4 as starting values during the minimization of the root mean 
square deviation of θfit from θMRE. Representative traces of the raw data and fits, 
as well as the fractional population analysis, can be seen in Figure 5-13. 
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Figure	5-14:	Plots	generated	using	the	three	state	fitting	method	for	all	CaMSS	variants.	Left:	For	each	CaMSS	
variant,	a	representative	set	of	raw	data	(θMRE)	and	fits	generated	from	θfit,	θf,	and	θu.	Right:	The	averaged	
fraction	folded	(Ff,	purple),	fraction	intermediate	(Fi,	green),	and	fraction	unfolded	(Fu,	blue)	plots	from	the	
three	replicates.	
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CHAPTER 6: 
 
EXPANDING THE USAGE OF L/F-AMINOACYLTRANSFERASE FOR N-TERMINAL 
BIOCONJUGATION AND NATIVE CHEMICAL LIGATION REACTIONS 
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Section 6.1 – Introduction 
 The in vitro enzymatic modification of target proteins is an important 
contributor to the wide array of techniques for site-selectively incorporating 
unnatural amino acids (Uaas). Specifically, enzymatic modifications to isolated 
proteins can provide chemoselective and regioselective additions of Uaas in mild, 
aqueous conditions. This “downstream” approach to Uaa labeling can circumvent 
issues in the purification and yield of labeled proteins that are often encountered 
in genetic and synthetic incorporation methods.188, 257 Methods to engineer and 
expand the usage of these enzymes continue to improve and provide unique ways 
to change how researchers approach structural studies and functional modulation 
of proteins. One promising target for the enzymatic modification of the N-termini of 
target proteins is the enzyme Leucyl/Phenylalanyl Aminoacyl Transferase (AaT) 
from Escherichia Coli.197, 198, 317 In particular, this enzyme could be applied towards 
three distinct labeling strategies: (1) transfer of fluorescent molecules for use in 
biophysical studies of protein structure and function, (2) transfer of ‘click’ chemistry 
handles for chemoselective labeling reactions, and (3) addition of thiol bearing 
amino acids for use in the semisynthesis of proteins. 
  Endogenously, AaT functions in the N-end rule protein degradation 
pathway by adding Phe or Leu to the positively charged N-terminal Lys or Arg 
residues of a protein via a phenylalanyl- or leucyl-tRNA substrate that is generated 
by a synthetase (aaRS).193 AaT has strict fidelity to the N-terminal residues of a 
protein as it has not been observed to modify internal amino acids.317, 318 Recent 
work has demonstrated that a chemoenzymatic protocol with a simple aminoacyl 
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adenosine analogue of tRNA can be efficiently used as a minimalist substrate for 
AaT (Figure 6-1).319 Using either enzymatic (aaRS/tRNA) or chemoenzymatic 
transfer, AaT can conveniently modify the N-termini of peptides and proteins with 
residues useful for NCL. For example, homocysteine (Hcs) was transferred to the 
N-terminal Lys of a fragment of the protein α-synuclein, used in a NCL reaction 
with a fluorescently labeled peptide to generate labeled α-synuclein, and 
methylated, leaving Met at the ligation site.195 This “traceless” ligation allows for 
the inclusion of a synthetic probe without the need to introduce a Cys into the 
protein sequence, so that the protein may be studied in a near native state. 
 AaT has also been used to site-selectively introduce Uaas containing 
functional groups for ‘click’ chemistry applications.317 A preliminary study exploring 
the scope of Uaas containing either propargyl or azido groups that can be 
transferred by the enzyme showed that p-azidophenylalanine (Azf), 
azidohomoalanine (Aha), or homopropargylglycine (Hpg) can be transferred from 
an aminoacyl adenosine analogue (Figure 1-20).318, 320 Chemoselective labeling 
reactions can then be used to label these amino acids with a functional tag, such 
as biotin or fluorescent dyes. 
 Transfer of fluorescent dyes that require no additional ‘click’ chemistry 
functionalization would allow for fewer steps after enzymatic transfer to isolate the 
desired product.198 AaT has been screened against fluorescent amino acid 
substrates such as acridon-2-ylalanine and β-(7-methoxy-coumarin-4-yl)-alanine 
however, neither were transferred by the enzyme.318 In initial screening tests, a 
naphthalene containing amino acid (L-3-(2-naphthyl)-alanine) was transferred to a 
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short peptide substrate. However, no other polyaromatic amino acids have been 
successfully transferred by the wild type enzyme to date.  
 In the following sections, I will describe how the aforementioned usages of 
AaT have been rigorously tested for expansion. In initial pilot studies, the substrate 
scope of the wild type (WT) enzyme was probed to establish optimal conditions for 
the transfer of established, as well as novel, ‘click’ chemistry substrates and thiol 
bearing amino acids. These optimized conditions were then used in applications 
involving the protein calmodulin (CaM). The transfer of homocysteine by AaT was 
utilized in efforts to tracelessly construct CaM from three protein fragments, two 
expressed in E. coli and one synthesized by solid phase peptide synthesis (SPPS).  
 In a second vein of work, expansion of the substrate scope was explored. 
Based upon the crystal structures obtained by Watanabe et al., a library of mutants 
was generated to test for the transfer of thiol bearing and fluorescent amino acids 
for use in NCL and biophysical studies, respectively.197, 321 Additionally, AaT 
mutants were generated with the intent to expand the scope of N-terminal amino 
acids that AaT can recognize as substrates. Enabling AaT to accept N-terminal 
residues other than Arg or Lys would create a versatile enzyme for 
chemoenzymatic installations of NCL-capable or fluorogenic amino acids onto a 
larger variety of expressed proteins. Finally, at the exhaustion of our rationally 
designed mutant library, an AaT-Ice Nucleation Protein (AaT-INP) fusion was 
produced for use in a surface anchored variant of the enzyme in E. coli. This AaT-
INP conjugate was used in attempts to develop a high-throughput screening assay 
for rapid assessment of the activity of AaT mutants generated by saturation 
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mutagenesis. Although each of these AaT applications and technologies are still 
in development, this collection of studies has enabled a deeper understanding of 
the enzyme’s applications in bioconjugation and native chemical ligation. 
Section 6.2 – Transfer and Characterization of Natural and Unnatural Amino 
Acid Transfer by AaT 
 
Establishing a more complete characterization of the WT AaT enzyme’s 
substrate scope and transfer properties will enable a broader usage of the enzyme 
towards labeling proteins for biophysical studies. I began by examining the transfer 
of aromatic ‘click’ chemistry substrates that mimic the native substrate 
phenylalanine. With the report of O-propargyltyrosine (Ppy) incorporation into 
proteins via Uaa mutagenesis322, and the use of this probe in our lab to 
fluorescently label proteins via copper mediated ‘click’ chemistry323, I sought to 
establish if this Phe-like analogue could also be transferred by the WT enzyme.  
First, a small molecule adenosine donor bearing the Ppy amino acid (Ppy-
Ade) was synthesized using a modified method from Wagner et al. without 
complications (see Figure 6-7).318 Next, I tested the transfer of PpY to the N-
terminus of a short reporter peptide using the WT enzyme and a previously 
established analytical HPLC assay. In short, the enzyme (0.1 mg/mL) and Ppy-
Ade (1 mM) molecule were incubated in the presence of Lys-Ala-Coumarin peptide 
(0.1 mM; KACm, peptide 6-1, Figure 6-1) for four hours at 37 °C in aqueous 
transfer buffer. KACm and Ppy-Ade were incubated without AaT as a control to 
ensure that aminoacylation does not happen transiently in buffer. To establish 
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standards by which to compare Ppy, Phe and Azf transfer (using Phe-Ade and Azf-
Ade, respectively) were also tested using the WT enzyme.  
After incubation, the reactions were acidified through the addition of acetic 
acid and the proteins and salt were removed via acetone precipitation. The 
acetone was then removed by rotary evaporation and the resulting dry peptides 
dissolved in 1 mL Milli-Q H2O in preparation for analytical HPLC. Reactions were 
analyzed by injecting 100 μL of sample onto a Phenomenex Jupiter C18 column 
using a previously established gradient for the separation of N-terminally modified 
peptides from the KACm starting material (see Section 6.5).194 Percent transfer is 
represented by the peak area of the N-terminally modified peptide divided by the 
total peak area (represented by the peak area of the modified peptide and the 
KACm starting material) based upon absorbance of the coumarin dye in each 
peptide (325 nm). In an experiment with three replicates, the average level of N-
terminal modification of the KACM peptide with Ppy was calculated to be 20 % 
transfer (Figure 6-1). This is much lower in comparison to peak performance of the 
enzyme with the Phe-Ade (>90 % transfer) and the Azf-Ade analogue (>80 % 
transfer). This may be due to the propargyl group being sterically bulkier than Phe 
or Azf at the para position of the aromatic side chain. This steric bulk likely 
decreases the affinity of the enzyme for the Ppy-Ade substrate, leading to much 
lower efficiency of transfer by AaT. Nonetheless, these assays establish that the 
Ppy amino acid can be transferred by AaT for potential labeling applications via 
copper mediated ‘click’ chemistry with azide bearing biophysical probes.  
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Figure	6-1:	Top:	Scheme	for	the	transfer	of	amino	acids	to	the	N-terminus	of	the	short	reporter	peptide	
KACm	 (6-1)	 via	 aminoacylated	 adenosine	 donor	 molecules	 and	 AaT.	 Bottom:	 Analytical	 HPLC	
chromatograph	traces	 (325	nm)	demonstrating	transfer	of	Phe	(6-2),	Azf	 (6-3),	and	Ppy	(6-4).	Note:	The	
change	in	retention	time	of	6-1	in	the	Ppy	chromatogram	is	due	to	the	use	of	a	new	C18	column	for	that	
assay.	
	
 
In addition to exploring the permissivity of WT AaT for novel transfer 
substrates, it may be advantageous to screen its activity against buffer additives 
that can improve the accessibility of the N-terminal Lys or Arg amino acid on a 
protein substrate. When expanding the methodology of AaT labeling to protein 
targets, one must consider that the N-terminal region of the protein target may be 
folded and inaccessible to AaT.  Denaturants such as urea or guanidinium may 
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disrupt structural elements to make the N-terminal Lys or Arg solvent accessible, 
and therefore improve AaT access to the site of transfer. However, it is likely that 
high concentrations of denaturant will disrupt the native fold of AaT and lead to 
diminished transfer activity. Therefore, it is important to test the enzymatic activity 
of AaT at increasing concentrations of denaturant to establish a range at which 
these effects may improve the accessibility of the target substrate without 
significantly disrupting the enzyme’s catalytic activity. 
 To test AaT’s activity in denaturant, I relied upon the KACm assay described 
above. Here, KACm is treated with Phe-Ade and AaT in aqueous buffer with 
various concentrations of urea between 0 and 8 M. I chose urea for this experiment 
as it is a milder denaturant than guanidinium and it was previously shown that 
guanidinium significantly impacts the activity of the enzyme.318 Through analysis 
of the percent transfer of each assay, we found that the enzyme has >90 % transfer 
in concentrations of urea less than 2 M, and a half maximal inhibitory concentration 
(IC50) of 5.3 M urea. In contrast, at 1 M guanidinium, the same enzyme batch 
showed a 19 % transfer of Phe to KACm. Although guanidinium is a stronger 
denaturant than urea, it may also be acting as an inhibitor of AaT based off its 
functional similarity to the Arg sidechain, one of the two N-terminal amino acid 
substrates for AaT. Nonetheless, establishing a working range for urea should 
enable added accessibility of the N-termini of protein substrates without 
compromising transferase activity in future applications of this methodology. 
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Table	6-1:	Analytical	HPLC	Peak	Area	and	Percent	Transfer	Values	for	Phe	Transfer	to	KACm	in	Denaturant		
 Trial	1	 Trial	2	 Trial	3	 Average	
M	
Urea	
KACm	
Area	
Prod	
Area	
%	
Ligated	
KACm	
Area	
Prod	
Area	
%	
Ligated	
KACm	
Area	
Prod	
Area	
%	
Ligated	 Avg	 STDEV	
0	 29.0	 678.3	 95.9	 9.3	 672.5	 98.6	 14.5	 677.4	 97.9	 97.5	 1.42	
0.05	 22.9	 621.4	 96.4	 23.6	 580.5	 96.1	 28.1	 766.6	 96.5	 96.3	 0.21	
0.1	 22.2	 597.8	 96.4	 18.7	 576.2	 96.9	 24.1	 701.6	 96.7	 96.7	 0.22	
0.2	 26.9	 653.0	 96.0	 20.8	 688.8	 97.1	 48.2	 565.1	 92.1	 95.1	 2.60	
0.3	 27.9	 582.2	 95.4	 24.0	 644.7	 96.4	 17.9	 458.8	 96.2	 96.0	 0.53	
0.4	 11.6	 311.1	 96.4	 30.2	 819.5	 96.4	 12.5	 395.6	 96.9	 96.6	 0.30	
0.5	 15.1	 445.3	 96.7	 6.5	 582.0	 98.9	 6.1	 697.9	 99.1	 98.3	 1.33	
1.0	 26.0	 481.4	 94.9	 21.2	 620.9	 96.7	 9.9	 657.4	 98.5	 96.7	 1.83	
1.5	 33.1	 432.6	 92.9	 33.1	 557.5	 94.4	 33.1	 543.3	 94.3	 93.8	 0.82	
1.75	 30.2	 688.9	 95.8	 61.7	 523.3	 89.4	 60.7	 511.3	 89.4	 91.5	 3.69	
2.0	 98.7	 531.9	 84.3	 72.7	 549.4	 88.3	 74.1	 586.5	 88.8	 87.1	 2.44	
4.0	 244.5	 363.3	 59.8	 222.9	 322.4	 59.1	 295.7	 428.0	 59.1	 59.3	 0.37	
6.0	 494.3	 127.5	 20.5	 478.5	 132.0	 21.6	 150.0	 41.6	 21.7	 21.3	 0.67	
8.0	 4797.8	 41.1	 0.9	 4436.6	 32.7	 0.7	 4477.6	 33.2	 0.7	 0.8	 0.07	
	            
1M	
Gdn	 4833.2	 1126.7	 18.9	 4801.9	 1114.9	 18.8	 4741.4	 1122.8	 19.1	 19.0	 0.2	
 
 
	
Figure	6-2:	Dose	response	inhibitory	curve	for	the	determination	of	the	IC50	of	AaT	in	urea.	The	fit	was	
generated	using	GraphPad	Prism’s	non-linear	regression	fitting	using	the	log(inhibitor)	vs.	response-
Variable	slope	(four	parameter)	equation.	
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Section 6.3 – Rational Design of AaT Mutants for Substrate Scope Expansion 
To expand the usage of AaT to new classes of substrate amino acids and 
recognition elements beyond Arg or Lys, mutational screening must be performed. 
The target residues for transfer are polyaromatic fluorescent amino acids (Acd and 
Mcm) and β-thiol containing amino acids for NCL (penicillamine and β-
thiophenylalanine; see Figure 6-3). Additionally, one can envision reversing the 
‘polarity’ of the enzyme, where AaT recognizes the negatively charged residues 
Asp or Glu instead of positively charged residues (Lys or Arg). Moreover, π-
stacking interactions may also be able to initiate transfer to Phe or Trp as the N-
terminal recognition elements (Figure 6-3).   
The multiple structures from Tomita and coworkers allow for rational design 
of mutations to AaT to enlarge the substrate binding pocket (Figure 6-4).197, 321 The 
modeling of a Phe side chain into the active site shows that residues Leu67, Ile185, 
Phe177, Leu170, and Phe173 may sterically block the access of larger polyaromatic 
substrates.198  Additionally, Met148 and Met144 are primed to block the access of β-
branched amino acids that cannot be transferred by the WT enzyme. Finally, the 
negatively charged Glu156 (see Figure 6-5) residue has been noted as an important 
residue for the recognition of the positively charged N-terminal substrate amino 
acid (Lys or Arg) through electrostatic interactions. Mutations to this residue may 
enable transfer to proteins with N-terminal Glu or Asp. 
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Figure	6-3:	Ligation	of	fluorescent	amino	acids	(Z;	top)	or	β-thiol	amino	acids	(Z;	bottom)	to	the	exposed	N-
terminus	(X)	of	a	protein	by	aminoacyl	transferase	(AaT)	using	either	a	small	adenosine	donor	molecule	or	
aminoacyl	tRNA	generated	by	a	synthetase	(aaRS).		
 
 
 
Figure	6-4:	Crystal	structure	of	AaT	including	phenylalanine	as	it	enters	the	binding	site	and	potential	amino	
acid	targets	for	mutagenesis	experiments.	Crystal	structure	from	PDB	accession	2Z3O.321	
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As a proof-of-concept experiment to demonstrate that the enzyme is 
tolerant to mutations at these sites, alanine substitutions were made and these 
mutants were screened for activity in the transfer of Phe to KACm as in Section 
6.2. Additionally, other non-alanine mutations were made towards each of the 
previous goals as suggested from previous literature and unpublished 
computational modeling done by Professor Jeff Saven and coworkers at the 
University of Pennsylvania. Some of these mutations are previously untested, as 
they lead to a loss of soluble protein during purification, presumably due to 
destabilization of AaT. However, small modifications to the purification of these 
mutant AaT enzymes (see Section 6.5) provided several previously inaccessible 
enzyme constructs.  These mutations were screened for activity with Phe-Ade and 
a KACm acceptor peptide as well. 
 Expression yields for each of the single and double mutant AaT variants 
were determined by a previously described Bradford assay modified for AaT.318 In 
all cases, except for the C187A/L170A and C187A/F177A mutants, the expression of 
the protein in E. coli was sufficiently high to enable preliminary KACm assay 
reactions. All of the single point mutants (see Table 6-2), with the exception of 
F177A and I185A transfer Phe to the KACm peptide as determined by analytical 
HPLC.194 In fact, some of the mutations (C187A, L67M, and T194A) appear to be non-
perturbing to the enzyme’s function with similar Phe transfer percentages to the 
WT enzyme (98.8 %, 94.7%, and 83.4 % of WT activity, respectively). Mutations 
that altered the activity and stability of the enzyme the most were those intended 
to reduce steric bulk in the side-chain binding pocket (F177 and I185, see Figure 6-
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4). Many of the mutants containing two alterations significantly lowered the 
expression yield of AaT and few have the capabilities of transferring the Phe to the 
KACm reporter peptide (see Table 6-2). It should be noted that M144A, F177A, and 
I185A are were shown by Taki et al. to be able to transfer the fluorescent Acd amino 
acid when attached to tRNA (outlined in Figure 6-3).198 Therefore, an Acd-Ade 
small donor molecule was synthesized and tested with each of these mutants for 
transfer to the KACm reporter peptide. However, none of the mutants showed Acd 
transfer capabilities and the Acd-Ade molecule appeared to readily hydrolyze in 
aqueous buffer over the reaction time course (4 hours; mass of free Acd amino 
acid detected by LC-MS). The single mutants in Table 6-2 were also tested for 
their capabilities to transfer β-branched amino acids such as Val or Ile. These 
substrates would provide proof-of-concept data to support the notion that mutated 
AaT enzymes could transfer β-thiol containing amino acids for applications in EPL. 
Small molecule donors (Val-Ade and Ile-Ade) were synthesized using previously 
described procedures194 and again test reactions were performed using the KACm 
reporter peptide. Unfortunately, none of the mutants were capable of extending the 
substrate scope to the β-branched amino acids discussed here. In a final proof-of-
concept experiment, Glu156 was mutated to a Lys residue to potentially expand 
transfer to peptides bearing N-terminal Glu or Asp residues. This mutant was 
tested for Phe transfer using KACm reporter cognate peptides bearing either an 
N-terminal Asp or Glu (DACm and EACm, respectively). The rationally designed 
AaT mutant (E156K) showed no activity towards the intended target as determined 
by analytical HPLC.  
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Figure	6-5:	Crystal	structure	of	AaT	showing	Glu156	making	electrostatic	contact	with	a	peptide	substrate	
containing	an	N-terminal	Arg	residue.	PDB	accession	number	2Z3L.321	
 
 
Although many of the mutants screened could transfer the native substrate 
Phe, none of the mutants presented here could transfer the intended targets for 
expanding the scope of AaT. Rational design can be a tedious avenue for installing 
new enzymatic functions from a WT enzyme. Directed evolution can provide a 
more high-throughput method for screening enzyme mutants. Specifically, if one 
can perform iterative saturation mutagenesis, where a degenerate library of 
mutations is created for many sites within the protein, the enzyme can theoretically 
be evolved towards any target amino acid transfer (see review by Liu).324 However, 
purification protocols for recombinant expression and isolation of the AaT enzyme 
are lengthy and require multiple days to prepare the enzyme freshly for KACm 
assays. To eliminate the need for purification of the enzyme, we turned our 
attention towards surface display technologies. Surface display uses fusion protein 
Glu156
Arg
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tags encoded with the enzyme of interest to translocate the enzyme to the 
extracellular surface.325 Small scale cultures can be grown in in 96-well plates, 
where pelleted cells can be used directly in activity assays, thereby eliminating the 
need for lengthy purification protocols and large-scale (1 L) expressions. In E. coli 
surface display technologies, one of the most prominent protein translocation tags 
is the ice nucleation protein (INP) from Pseudomonas syringae.326-328 To test if the 
AaT enzyme can be used for surface display evolution of mutant enzymes, 
collaborator Professor Wilfred Chen’s lab (University of Delaware) generated a 
pET24a plasmid containing an expressible AaT-INP conjugate. However, in 
preliminary experiments, it was found that AaT was expressed in low levels on the 
surface of cells (determined by magneitcally-activated cell sorting). Additionally, 
when cells were treated with the KACm reporter peptide in the absence of any 
other reagents, the peptide was modified in quantities >80%, as determined by 
analytical HPLC. This modification was consistent with the transfer of Val to the 
peptide N-terminus. This background modification serves as a competing reaction, 
beyond which, it would be difficult to detect any activity by AaT.  
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Table	6-2:	Rationally	designed	AaT	mutants	with	their	respective	expression	yields	and	Phe	transfer	yields.	
Mutants	highlighted	in	red	were	predicted	by	Taki	et	al.	to	enable	polyaromatic	side	chain	transfer,	such	as	
Acd.198	
 
 
 The rational design or directed evolution of AaT mutants for the transfer of 
non-native substrates could be a promising avenue towards more ubiquitous post-
translational protein modification technology. However, none of the mutants 
explored in these pilot studies are capable of transferring unnatural amino acids or 
their cognates. Additionally, the initial tests in creating a high-throughput readout 
for AaT enzyme evolution showed that extracellular AaT may not be stable and 
small Lys-containing reporter peptides may not be viable in E. coli surface display 
assays. Experiments are ongoing to improve these technologies for applications 
of AaT to the transfer of new unnatural substrates. 
AaT Mutant ExpressionYield Phe Transfer % WT Activity
M144A 3 mg/L x 19.8
M158A 2 mg/L x 40.2
M158G 3 mg/L x 5.8
C187A 3 mg/L x 98.8
F177A <0.5 mg/L ---
L67M 2 mg/L x 94.7
L170A 0.5 mg/L x 70.1
T194A 2.5 mg/L x 83.4
I185A 1.0 mg/L ---
C187A/M158A 4.5 mg/L x 47.4
L170A/M158A 1.0 mg/L x 47.1
F177A/M144A 0.5 mg/L
F177A/F173A <0.5 mg/L
I185A/M144A 0.5 mg/L
C187A/M144A 0.5 mg/L x 47.4
C187A/L170A ---
C187A/F177A ---
C187A/I185A 0.5 mg/L
M144A/M158A 0.75 mg/L x 52.1
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Section 6.4 – AaT Applications in the Semisynthesis of Calmodulin 
 Using both synthetase and analogue donor molecule mediated transfer, 
AaT can conveniently be used to site-specifically modify the N-termini of peptides 
and proteins in vitro with the goal of installing residues capable of NCL at activated 
oxo- or thio-esters. This was demonstrated previously with α-synuclein, the 
intrinsically disordered protein implicated in Parkinson’s disease.195, 225 In one of 
these applications, a methionine surrogate, homocysteine, was transferred to a N-
terminal lysine of a Cnf containing α-synuclein. This residue was then used in a 
NCL reaction with a peptide containing a thioamide and a C-terminal thioester. 
Subsequent methylation of the protein was selective for homocysteine, thereby 
yielding a native methionine residue. The aminoacylated-tRNA substrate for AaT 
was generated using a mutant methionine synthetase (L13G MetRS) that permits 
the transfer of disulfide protected homocysteine to E. coli total tRNA extract. This 
traceless ligation allows for the inclusion of an unnatural probe in a minimally 
perturbing manner so that the protein may be studied in a near native state. To 
explore the potential applications of this methodology to larger, more ordered 
proteins, a three-part ligation of calmodulin (CaM) was envisioned.  
 CaM contains two large globular domains connected by a flexible linker 
region.283 Upon binding calcium in the globular domains, the protein undergoes a 
conformational change to yield a rigid trans-domain α-helix. The linker region 
contains several methionine residues that could be used for traceless 
homocysteine ligations, including one that is adjacent to a lysine residue, making 
it a convenient system for the application of our AaT ligation method (Figure 6-6). 
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To include an unnatural probe in the linker region, we have split the semi- synthesis 
of CaM into three fragments (see Figure 6-6). Using protein expression systems in 
E. coli, we have expressed and purified N-terminal and C-terminal fragments 
suitable for use in ligation reactions (unpublished work by Dr. Anne Wagner).329 
The N-terminal fragment (CaM1-71) contains a C-terminal GyrA intein and a chitin-
binding domain for chitin resin purification. The fragment can be purified from cell 
lysate by incubating it with chitin beads and cleaving the chitin bound intein from 
CaM1-71 with sodium 2-mercaptoethanelsulfonate (MESNa) to generate a C-
terminal thioester for NCL. The C-terminal fragment (CaM77-148) is generated by 
expressing CaM77-148 with an N-terminal histidine tag followed by a protease 
cleavage site. After Ni-NTA purification, the recombinant protein is treated with 
Factor Xa protease to cleave the purification tag and yield an N-terminal lysine 
(previously established by Dr. Anne Wagner). This protein is then mixed in a 
transfer reaction containing a L13G MetRS, which is used to generate the Hcm-
tRNA substrate in situ. S-(methylthio)-L-homocysteine (Hcm) is then transferred 
from the Hcm-tRNA to the Lys77 residue via AaT.330 In previous applications, 
transfer of Hcm to a Lys residue in α-synuclein was carried out with quantitative 
conversion. However, transfer to CaM proceeds with less than 10% transfer 
(approximated by FPLC purification chromatograms). Therefore, denaturant may 
be necessary to expose the N-terminal lysine for transfer to CaM77-148. It was 
previously determined that AaT could function in molar concentrations of urea (see 
Section 6.2). To ensure that the L13G MetRS is not inhibited by urea in the reaction 
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mixture, a concentration of 1 M urea was used for Hcm transfer reactions to Lys77, 
providing markedly improved yields of ~30% transfer.  
 The small, middle fragment (Hcy72-CaM72-75-N2H3, see Figure 6-6) was 
made via Fmoc solid phase peptide synthesis by using a hydrazine modified 2-
chlorotrityl resin to generate a C-terminal acyl hydrazide. Acyl hydrazide peptides 
have previously been used to generate acyl azides in situ to enable thioester 
formation for NCL reactions.165 The peptide synthesized for our scheme contained 
an unprotected homocysteine residue that was used to ligate the peptide to the 
CaM1-71 thioester in nearly quantitative yields. After purification, CaM1-75-N2H3 was 
oxidized to the acyl azide using ten equivalents of sodium nitrite followed by 
treatment with 4-mercaptophenylacetic acid (MPAA) to generate a reactive aryl 
thioester. CaM1-75-MPAA and Hcm76-CaM76-148 were then incubated in 6 M Gdn 
and 20 mM TCEP (to reduce Hcm to the reactive homocysteine residue) at 37 °C 
with shaking for 20 hours. Although both reactive species (CaM1-75-MPAA and -
Hcy76-CaM76-149) are present in the reaction mixture (confirmed by MALDI MS, see 
Table 6-5), the Hcy72,76-CaM1-148 product was not detected. This may be due to 
one of the fragments adopting a semi-stable conformation in which the reactive 
moiety is not accessible. Additionally, Hcs is generally less reactive than Cys 
residues, due to the formation of a six-membered ring as an intermediate 
(compared to a five-membered intermediate for Cys) during the SàN acyl shift.331  
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Figure	 6-6:	 Three-piece	 ligation	 scheme	 for	 AaT-EPL	 synthesis	 of	 CaM.	 Left:	 Generation	 of	 CaM1-71-SR	
through	 thiol	 cleavage	 of	 the	 CaM1-71-GyrA	 fusion	 protein.	 Middle:	 	 SPPS	 of	 Hcy72-CaM72-75-N2H3	 and	
subsequent	 ligation	 with	 CaM1-71-SR	 to	 generate	 CaM1-75-N2H3.	 The	 central	 fragment	 can	 contain	 any	
number	of	 synthetic	modifications,	 such	 as	 the	 thioamide	pictured	here.	Right:	AaT	 transfer	 of	Hcm	 to	
CaM77-148.	Bottom:	Generation	of	CaM1-75-MPAA	and	subsequent	reaction	with	Hcy76-CaM76-148,	followed	by	
alkylation	 of	 Hcy72	 and	 Hcy76	 to	 generate	 full-length	 CaM	without	 any	 NCL	 artifact	 residues.	 Fragment	
sequences	are	highlighted	with	their	corresponding	diagram	colors	(bottom	left).	The	black	‘M’	represents	
the	Met	residue	resulting	from	the	Hcm	transferred	by	AaT.	
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To test if ligation is possible between the two domains, a mutant Cys77-
CaM77-149 was used in a reaction with CaM1-75-MPAA. Yet, this test reaction did not 
yield ligation product in buffer containing 6 M guanidinium hydrochloride. However, 
in reactions with lower concentration of denaturant or no denaturant (3 or 0 M Gdn), 
product formation was observed by MALDI and SDS-PAGE. With confirmation that 
NCL reactions between the two domains are possible, reactions of CaM1-75-MPAA 
and Hcy76-CaM76-149 were pursued to generate Hcy72,76-CaM1-148, and 
subsequently WT CaM after alkylation of the Hcy residues with iodomethane. 
However, under conditions identical to the Cys-CaM model system, no Hcy72,76-
CaM1-148 full-length product was observed. The reaction was then tested for pH 
dependence (pH 6.8, 7.2, and 7.8) yet no product was observed in any of the 
reactions. Additives such as excess MPAA or thiophenol were added in an attempt 
catalyze the reaction through manipulation of the reactivity of the C-terminal 
thioester. Additionally, CaCl2 or ethylenediaminetetraacetic acid (EDTA) were also 
tested as reagents that could induce conformational changes in the C- and N-
terminal domains, thereby driving association and promoting reactivity between 
CaM1-75-MPAA and Hcy76-CaM76-149. Though tested at various concentrations, 
none of these additives have shown the potential to promote the reaction to form 
Hcy72,76-CaM1-148.  
Currently, efforts in using two expressed protein fragments for the AaT- 
mediated, NCL synthesis of CaM have been unsuccessful. It is possible that 
reactivity between the two fragments (CaM1-75-MPAA and Hcy72-CaM76-149) could 
be modified by using additional additives, such as alkyl thioesters, which may be 
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less sterically hindering than their aryl thioester counterparts. If this AaT-expressed 
protein ligation strategy is successful in future syntheses of CaM, it could enable 
access to substitutions in the central linker region between the N- and C-terminal 
domains of CaM. Inserting a thioamide in this region would enable additional 
studies to corroborate the structural effects of thioamides in α-helices that are 
described in chapter 3 (see Figure 6-6). Additionally, placement of fluorescent 
amino acids, such as Mcm, in this region would enable fluorescence studies to 
investigate the reorganization of CaM during the binding to one of its many 
regulatory targets. In conclusion, future improvements to the AaT-EPL 
methodology would increase the number of protein targets that could be 
synthesized tracelessly by EPL. These proteins could contain any number of 
unnatural amino acids to be used in biophysical studies to uncover previously 
unattainable information about protein structure and function. 
Section 6.5 – Materials and Methods 
6.5.1 – Materials 
 
Amino acids for use in synthesis of adenosine donor molecules were 
purchased from Acros organics (New Jersey, United States), with the exception of 
p-azidophenylalanine (Azf), which was purchased from Bachem (Torrance, CA). 
5’-DMT-riboadenosine was purchased from ChemGenes (Wilmington, MA). 
Bradford reagent assay kits were purchased from BioRad (Hercules, CA). All other 
reagents were purchased from either Fisher Scientific (Waltham, MA) or Sigma 
(St. Louis, MO). The CaM1-71-GyrA-CBD and CaM77-148 protein plasmids were 
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previously generated by Dr. Anne Wagner. MALDI MS was taken on a Bruker 
Ultraflex III instrument (Billerica, MA) and LC-MS was performed on a Waters 
acquity UPLC system with a SQD single quadrupole mass analyzer with 
electrospray ionization (Milford, MA). 
6.5.2- Methods 
 
Synthesis of Aminoacyl Adenosine Donor Molecules 
 Tert-butyloxycarbonyl (Boc) protections of each amino acid used for 
adenosine donor syntheses were carried out as follows. In a 250 mL round bottom 
flask, NaOH (40 mmol) is dissolved in 46 mL / 50 mL of dioxane / water and the 
solution is cooled to 0 °C in an ice bath. Free, unprotected amino acid (10 mmol) 
is then added to the solution. In a separate flask, di-tert-butyl dicarbonate (Boc2O, 
25 mmol) is dissolved in 1 mL dioxane. Next, the Boc2O solution is slowly added 
to the reaction flask containing the amino acid/NaOH solution. Reactions generally 
proceed for two hours, while allowing the flask to warm to room temperature and 
are monitored by TLC. At reaction completion, ethyl acetate (60 mL) is added and 
the solution is acidified with HCl to a final pH of approximately 2-3. The resulting 
mixture is extracted twice with ethyl acetate and the organic layer was washed with 
brine, dried over MgSO4, and the solvent removed under reduced pressure. 
Quantitative conversion is routinely observed and no further purification is 
necessary.  
 Boc protected amino acids can be used directly in the synthesis of any 
aminoacyl adenosine donor molecules using the scheme below and the methods 
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outlined in detail in Wagner et al.194 Phe-Ade, Val-Ade, Ile-Ade, and Azf-Ade have 
all been synthesized previously by Dr. Anne Wagner and others. For O-
propargyltyrosine (Ppy-Ade) and acridon-2-ylalanine (Acd-Ade) derivatives, Dr. 
John Warner and Itthipol Sungwienwong provided the free amino acids. Synthesis 
of these molecules follows the scheme outlined for the synthesis of the Phe-Ade 
molecule given in Wagner et al. without significant deviation (Figure 6-7).318 HPLC 
chromatograms detailing the purification of the final Ppy-Ade and Acd-Ade 
products and their corresponding masses (detected by either MALDI- or LC-MS) 
can be seen in Figures 6-8 and 6-9, respectively.  
 
Figure	6-7:	Synthesis	of	amino	acid	adenosine	donors.	Boc	protection	of	a	free	amino	acid	(Aa)	is	followed	
by	 activation	 of	 carboxy	 terminus	 by	 the	 addition	 of	 chloroacetonitrile	 to	 generate	 the	 activated	
cyanomethylester.	The	N-Boc-Aa-cyanomethylester	can	then	directly	be	used	to	esterify	the	2’	or	3’	alcohol	
of	the	5’dimethoxytrityl	(DMT)	protected	adenosine	molecule.	This	is	then	followed	by	removal	of	the	DMT	
and	 Boc	 groups	 through	 treatment	 with	 trifluoroacetic	 acid	 (TFA).	 Abbreviations	 are	 as	 follows:	
diisopropylethylamine	 (DIPEA),	 tertahydrofuran	 (THF),	 tetrabutylammonium	 acetate	 (TBAC),	 and	
triisopropylsilane	(TIPS).	
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Figure	6-8:	HPLC	chromatogram	for	the	purification	of	Ppy-Ade	showing	absorbance	at	215	nm	and	260	nm.	
The	peaks	marked	with	*	are	the	2’	and	3’	ester	products	of	Ppy-Ade.	The	presence	of	product	was	verified	
by	LC-MS	mass	analysis	(expected	[M+H]+	=	469.59	Da,	observed	=	469.52	Da)	
 
Figure	6-9:	HPLC	chromatogram	for	the	purification	of	Acd-Ade	showing	absorbance	at	260	nm	and	368	
nm.	The	peaks	marked	with	*	are	the	2’	and	3’	ester	products	of	Acd-Ade.	The	presence	of	product	was	
verified	by	MALDI	MS	mass	analysis	(expected	[M+H]+	=	532.53	Da,	observed	=	532.43	Da)	
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KACm Peptide Transfer Assays 
Assays were adapted from Connor et al. and Wagner et al. 317, 318, 320 In 
short, the KACm peptide (0.1 mM final concentration) and Phe-Ade (1 mM final 
concentration) substrates were added to a 1.5 mL Eppendorf tube containing 1x 
transferase buffer (50 mM HEPES, 150 mM KCL, 10 mM MgCl2, pH 8.0). Aat was 
added to the mixture last, to a final concentration of 0.1 mg/mL in the total reaction 
volume of 125 μL. This reaction was mixed by pipetting and incubated at 37 °C for 
four hours. The reaction was then quenched by adding 1% acetic acid (375 μL). 
Next, acetone (1.5 mL) was added to the reaction and the samples were stored at 
–20 °C for 1 hour to precipitate the AaT and buffer salts. The samples were then 
centrifuged at 13, 200 RPM in an Eppendorf 5415R Benchtop centrifuge. The 
supernatant was then added to a fresh Eppendorf tube and the acetone was 
evaporated under reduced pressure. The resulting solid was redissolved in 1.2 mL 
of water containing 0.1 % TFA. Analytical HPLC was then performed on an Agilent 
1100 HPLC by injecting 100 μL on to a Phenomenex Jupiter C18 column and 
running the gradient listed in Table 6-3 at a flow rate of 1 mL/min.  
 For KACm transfer assays to determine AaT’s tolerance to the denaturant 
urea, the reactions were run identically as described above with increasing 
concentrations of urea diluted from either an 8 M or 12 M stock of urea. The 
acetone precipitation procedure described above was sufficient in removing the 
urea from the reaction after completion. All AaT mutant transfer activities were 
assessed through the above standard assay. For Acd-Ade, Val-Ade, Azf-Ade, and 
Ppy-Ade transfer tests, each respective analogue was exchanged for Phe-Ade in 
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the standard reaction and added to a final concentration of 1 mM. The Ppy-KACm 
transfer product is previously undescribed, therefore the reaction was replicated 
three times. An analytical HPLC trace for this product is observed in Figure 6-1. 
The product peak containing Ppy-KACm has an average retention time of 14.49 
min, compared to the KACm peak, which has a retention time of 12.46 min. 
Table	6-3:	Analytical	HPLC	gradient	for	purification	of	KACm	reactions.	Buffer	A:	Milli-Q	H2O	with	0.1	%	TFA.	
Buffer	B:	Acetonitrile	with	0.1	%	TFA.	
Time (min) Buffer A (%) 
0 99 
5:00 99 
10:00 70 
15:00 60 
20:00 0 
25:00 0 
27:00 99 
30:00 99 
	
 
Expression of AaT and Mutant AaT Variants 
 Expression of AaT proteins was done as previously described318 with one 
important change: after sonication, the lysed cells were centrifuged at lower 
speeds (8,000 RPM) in a Sorvall SS34 centrifuge for 10 minutes at 4 °C. This 
small, but important, modification led to more soluble AaT mutant protein yields, 
as evidenced by SDS-PAGE analysis (see example SDS-PAGE in Figure 6-10). 
285	
	
 
Figure	6-10:	SDS-PAGE	analysis	of	AaT	C187A/M158A	mutant	purification.	Lower	centrifugation	speeds	(Right)	
lead	to	more	soluble	protein,	which	can	be	purified	by	Ni-NTA	affinity	purification	(AaT	contains	a	His10	tag	
for	purification).	Higher	centrifugation	speeds	(left)	show	lower	quantity	of	purified	protein	after	Ni-NTA	
resin	 purification.	 ‘M’	 is	 a	 molecular	 weight	 marker	 and	 lanes	 marked	 ‘E’	 correspond	 to	 Ni-NTA	 resin	
elutions	as	described	in	the	purification	protocol	from	Wagner	et	al.318	
	
Expression and Purification of CaM77-148 and Cys77-CaM77-148 
E. coli BL21-Gold cells were transformed with the pET15b-H10-CaM78-149 
that encodes ampicillin (Amp) resistance. Cells were grown on LB-Agar plates with 
ampicillin (100 μM) and single colonies were picked and grown in a 5 mL LB-Amp 
(100 μg/mL) starter culture at 37 °C for 12 hours. A secondary culture of 1 L of 
terrific broth media was inoculated with 5 mL of the starter culture and grown at 37 
°C  until OD600 = 0.8 at which point the culture was inoculated with 1 mL of 1 M 
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The 
culture was then grown at 25 °C, shaking at 225 rpm for 16 hours. After incubation, 
cells were pelleted at 5,000 RPM using a GS3 rotor and Sorvall RC-5 centrifuge 
for 10 minutes at 4 °C. The supernatant was discarded and the pellet was 
resuspended in 20 mL of lysis buffer: one Roche Boehringer Mannheim complete, 
mini, EDTA-free, protease inhibitor cocktail tablet dissolved in 20 mM Tris pH 8.0. 
M E1 E2 E3 E4 E5 E6 E7 E8 M E1 E2 E3 E4 E5 E6 E7 E8
AaT C187A/M158A	13,200	RPM	Centrifugation AaT C187A/M158A	8,000	RPM	Centrifugation
AaT
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The resuspended cells were lysed on ice using sonication (amplitude 30, 1 second 
on, 1 second off; 2 minute total cycle). The resulting solution was centrifuged at 
13,000 RPM in a sorvall ss34 rotor for 20 minutes at 4 °C.  The supernatant was 
incubated with Nickel-NTA resin (column volume = 3-4 mL) for 1-2 h on ice.  The 
slurry was loaded into a fritted column and the liquid solution allowed to flow 
through. The resin was washed in 3 column volumes of four wash buffers, each 
with increasing imidazole content (10 mM, 25 mM, 50 mM) in 20 mM Tris pH 8.0. 
Then the bound protein was eluted over 8 fractions (2 mL each) in 250 mM 
Imidazole, 20 mM Tris pH 8.0.  The eluent was dialyzed against Factor Xa buffer 
(50 mM Tris, 100 mM NaCl, 5 mM CaCl2 pH 8.0) overnight before being treated 
with 10 μL of  Factor Xa Protease (Hematologics, Seattle, WA). This proteolysis 
Cleavage of the H10-IEGR purification was incubated at 37 °C for 24 hours. The 
resulting solution was dialyzed against 20 mM Tris pH 8.0 for 12 hours before 
being filtered and purified via anion exchange chromatography on a AKTA FPLC 
system. Fractions containing the mass of CaM78-149 (confirmed by MALDI-TOF 
mass spectrometry) were pooled and dialyzed against water before being frozen 
and lyophilized for use in AaT-Hcm transfer reactions. 
 
Expression and Purification of CaM1-71-GyrA-CBD 
CaM1-71-GyrA-CBD was transformed into BL21-Gold (DE3) E. coli cells and 
grown on an LB-agar plate with ampicillin (100 μg/mL). A single colony was picked 
and grown in liquid LB media (5 mL, 100 μg/mL ampicillin) with shaking (250 RPM) 
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at 37 °C until saturation. The primary culture was then added to a secondary 
culture of sterile Terrific Broth media299 (1 L, 100 μg/mL ampicillin) and grown at 
37 °C, shaking (250 RPM) until OD600= 0.8-1.0 (3-4 h). IPTG was then added (final 
concentration = 1 mM) and the temperature and shaking speed were reduced to 
25 °C and 225 RPM. The culture was allowed to grow for 16 h. Cells were 
harvested by centrifugation at 5,000 RPM in GS3 rotor and Sorvall RC-5 centrifuge 
for 10 min at 4 °C. The supernatant was discarded and the cell pellet was 
resuspended in 10 mL lysis buffer (20 mM Tris, pH 8.0) containing one broad 
spectrum protease inhibitor tablet. Resuspended cells were then lysed on ice by 
sonication (30 amps power, 1 second pulse, 1 second rest, 2 minute total 
sonication time) and spun down at 13,000 RPM in an SS-34 rotor in a Sorvall RC-
5 centrifuge for 15 min at 4 °C. The supernatant was collected and incubated with 
chitin beads (5 mL column volume, CV) for 1 h on ice with shaking. The slurry was 
then added to a fritted column and the liquid was allowed to flow through. The 
beads were washed with 10 x CV of 20 mM Tris pH 8.0. Intein cleavage buffer (20 
mM Tris, 0.5 NaCl, 200 mM MESNa, pH 7.5, 10 mL) was then added to the beads 
and incubated on a rotisserie at room temperature for 16 h. The column was then 
drained and the flow through collected. The eluent was dialyzed against 20 mM 
Tris, pH 8.0 to remove any excess MES and purified using a HiTrap Q column on 
a 120 min NaCl gradient (0.1 M to 0.8 M NaCl in 20 mM Tris, pH 8.0). The protein 
was pure after one round of FPLC purification (see MALDI MS in Table 6-6) and 
was dialyzed against Milli-Q water overnight at 4 °C before being frozen in liquid 
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nitrogen and lyophilized to white powder. The total isolated yield was ~8 mg per L 
of culture. 
Solid Phase Peptide Synthesis of Hcy72-CaM72-75-N2H3 
2-chlorotrityl resin (100-200 mesh, 50 μmol scale) was swelled in DMF (4 
mL, 30 minutes) while stirring. Treatment with hydrazine hydrate in DMF (5 % v/v) 
using the protocol set forth by Zheng et al. yielded the hydrazine resin used in the 
peptide synthesis described here.165 Fmoc-Lys(Boc)-OH (5 equivalents), 2-(1H-
benotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU; 5 
equivalents), diisopropylethylamine (DIPEA; 10 equivalents) in N,N-
dimethylformamide (DMF; 4 mL) was added to the resin. This solution was allowed 
to stir for 45 minutes at room temperature. After completion of the coupling 
reaction, the vessel was drained and the resin was washed with DMF (2 x 2 mL), 
then the coupling was repeated once more. After draining and washing the resin 
again, the Fmoc protecting group was removed by treatment with a 20% v/v 
solution of piperidine in DMF. The vessel was then drained and the resin was 
washed with DMF (2 x 2 mL), dichloromethane (2 x 2 mL), and DMF again (1 x 4 
mL). All subsequent Fmoc deprotections were performed using this method. All 
subsequent amino acid (Fmoc-Aa-OH) coupling reactions were performed by 
using a solution of Fmoc-Aa-OH (5 equivalents), 2-(1H-benotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU; 5 equivalents), and DIPEA (10 
equivalents) in DMF (2 mL), with the exception of Fmoc-Hcy(Trt)-OH, for which 3 
equivalents of amino acid and HBTU are used. After the last Fmoc group was 
removed, the resin was washed with DMF, followed by DCM (2 x 4 mL each). The 
289	
	
resin was then dried for 30 minutes under vacuum. A cleavage cocktail (8 mL total 
volume) was prepared with 90:5:5 of TFA:TIPS:H2O. This was added to the resin 
and allowed to stir at RT for 1 hour before being drained and collected. DCM (3 
mL) was added to the resin to wash out any remaining peptide and the collected 
solution was dried under rotary evaporation. The crude peptide product was then 
precipitated by adding cold diethyl ether (15 mL) and vortexing vigorously. The 
precipitate was pelleted by centrifugation and the ether supernatant was 
discarded. The resulting precipitate was dried and stored at -20 °C until HPLC 
purification could proceed.  
Table	6-4:	Preparatory	HPLC	gradient	for	purification	of	Hcy72-CaM72-75-N2H3.	Buffer	A:	Milli-Q	H2O	with	0.1	
%	TFA.	Buffer	B:	Acetonitrile	with	0.1	%	TFA.	
Time (min) Buffer A (%) 
0 98 
4:00 98 
25:00 60 
27:00 2 
32:00 2 
35:00 98 
37:00 98 
 
HPLC Purification of Hcy72-CaM72-75-N2H3 
The crude precipitate from above was dissolved in 50 % v/v acetonitrile in 
H2O with 0.1 % TFA (10 mL). Purification was performed by reverse phase HPLC 
on a Waters Sunfire Preparatory C18 column (12 mL/min flow rate) using the 
binary gradient described in Table 6-4. Fractions were collected and the product 
peak identified by LC-MS (see Table 6-6). The collected fractions were frozen in 
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liquid N2 and lyophilized to white powder for use in CaM NCL experiments as 
follows. The isolated yield of this peptide synthesis was 94.6% (23.9 mg). 
 
Native Chemical Ligation Reaction of CaM1-71-MES with Hcy72-CaM72-75-N2H3 
Ligation buffer (2 mL) was prepared fresh prior to each reaction by adding 
NaH2PO4 (0.1 M), Gdn•HCl (6 M), TCEP•HCl (20 mM) and thiophenol (2% v/v) to 
1.7 mL of water and adjusting the pH to 7.2, followed by the volume to 2 mL.     
Ligation buffer (460 μL) was added to an eppendorf tube containing CaM1-71-MES 
(17.4 mg, 2.18 μmol) and the tube was vortexed to ensure all dried protein 
dissolved. This solution was then incubated at RT for 5 min to allow the more 
electrophilic CaM1-134-SPh to form by transthioesterification of the MES thioester 
with thiophenol. The solution containing CaM1-71-SPh was then added to an 
Eppendorf tube containing Hcy72-CaM72-75-N2H3 (5 equiv) and the reaction was 
incubated at 37 °C with constant shaking (600 RPM) for 20 h. The reaction was 
monitored by MALDI for product formation (see Table 6-6). It should be noted that 
as the reaction proceeds, significant amounts of CaM1-71-OH byproduct forms as 
a result of the hydrolysis of the thioester. At reaction completion, the solution was 
diluted to 2 mL with Milli-Q water and dialyzed against 20 mM Tris pH 8.0 overnight 
at 4 °C in preparation for FPLC purification. FPLC purification proceeded using a 
HiTrap Q column and a 120 min NaCl gradient (0.1 M to 0.8 M NaCl in 20 mM Tris, 
pH 8.0). This eluent was collected in 6 x 1.5 mL fractions (product presence 
confirmed by MALDI-MS). The pooled fractions were dialyzed against Milli-Q water 
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at 4 °C overnight before being flash frozen with liquid nitrogen and lyophilized to a 
solid. Isolated yield of Hcy72-CaM1-75-N2H3 is 33.0% (0.72 μmol). 
 
Conversion of Hcy72-CaM1-75-N2H3 to Hcy72-CaM1-75-MPAA 
The following protocol is modified from Zheng et al.165 The Eppendorf tube 
containing dried Hcy72-CaM1-75-N2H3 (described above) had 400 μL of hydrazide 
ligation buffer A (0.2 M NaH2PO4, 6 M Gdn, pH 3.0) added to it. This protein sample 
was then cooled to -15 °C in a 1:3 NaCl:ice bath. A 0.5 M stock solution of sodium 
nitrite was then prepared by dissolving 17.3 mg (0.25 mmol) in 500 μL of ligation 
buffer A. This stock solution (14.4 μL, 10 equivalents) was then added to Hcy72-
CaM1-75-N2H3 to oxidize the acyl hydrazide to the acyl azide (Hcy72-CaM1-75-N3). 
This mixture stirred for 15 minutes at -15 °C. In a separate Eppendorf tube, 24.2 
mg of 4-mercaptophenylacetic acid (MPAA, 200 equivalents) were dissolved in 
400 μL of hydrazide ligation buffer B (200 mM NaH2PO4, 6.0 M guanidinium 
hydrochloride, pH 6.7). This mixture was then added to Hcy72-CaM1-75-N3 and the 
pH was adjusted to 6.9 using 1 M NaOH. The reaction was then stirred for 2 hours 
and monitored by MALDI MS. After 1 hour, the reaction was quenched with 1 mL 
of water and 5 μL of TCEP BondBreaker™, before being dialyzed against 2 L of 
water 2 x 2 hours at 4 °C. The resulting dialysate was flash frozen in liquid N2 and 
lyophilized to a brown powder for use in the ligation reactions with Hcm76-CaM76-
148. 
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AaT Transfer of Hcm to CaM77-148  
An example set of reaction conditions, based on previously published 
conditions, with small modifications were performed as follows.195 Four reactions, 
each using an aliquot (1.2 mg) of CaM77-148, were intiated by mixing each reagent 
listed in Table 6-5 below. Stock solutions of each reagent were prepared as 
previously described. A methionine synthetase containing an L13G mutation has 
been previously described to aminoacylate tRNAMet from a commercially available 
E. coli total tRNA to generate the Hcm-tRNA substrate used by AaT for Hcm 
transfer.330 All reagents were mixed together in a 1.5 mL Eppendorf tube, with the 
freshly prepared L13G synthetase and AaT added last. A final concentration of 1 M 
urea was used to make the N-terminal Lys of CaM77-148 more accessible for 
transfer of Hcm. The final volume of the reaction was 0.5 mL and 1x transfer buffer 
is 50 mM HEPES, 150 mM KCL, 10 mM MgCl2, pH 8.0. Reactions were incubated 
for 20 hours at 37 °C before being quenched by dialyzing against 20 mM Tris pH 
8.0 and purified by FPLC-anion exchange over a 120 min gradient (0.1 M to 0.8 M 
NaCl in 20 mM Tris, pH 8.0). The starting material CaM78-148 and product Hcm76-
CaM76-148 do not completely separate during FPLC purification. Therefore, product 
of the transfer reaction (Hcm76-CaM76-148) that was greater than 80% pure (by 
FPLC peak area and MALDI MS confirmation) was collected with CaM78-148 as an 
impurity. These FPLC fractions were then dialyzed against twice against MilliQ 
water (2 L) at room temperature for 2 hours. The dialysate was then flash frozen 
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in liquid N2 and lyophilized to a brown powder for use in the ligation reactions with 
Hcy72-CaM1-75-MPAA. 
Table	6-5:	Reagents	and	associated	reaction	concentrations	and	volumes	added	to	the	above	Hcm	transfer	
reaction.	
 
 
 
Native Chemical Ligation of Cys77-CaM77-148 to Hcy72-CaM1-75-MPAA 
To test ligation conditions for Hcy based NCL reactions with Hcy72-CaM1-75-
MPAA, the variant Cys77-CaM77-148 was used. Here, three reaction conditions were 
used: ligation buffer A (0.2 M NaH2PO4, 20 mM TCEP•HCl, pH 7.3), ligation buffer 
B (0.2 M NaH2PO4, 3 M Gdn•HCl, 20 mM TCEP•HCl, pH 7.3) and ligation buffer 
C (0.2 M NaH2PO4, 6 M Gdn•HCl, 1 mM EDTA, 20 mM TCEP•HCl, pH 7.3). For 
each reaction, an aliquot of Hcy72-CaM1-75-MPAA (1 mg) was dissolved in one of 
the above buffers (136 μL). Next, 136 μL of corresponding ligation buffer was 
added to an aliquot containing three equivalents of solid Cys77-CaM77-148. The two 
reactants were then mixed in a single Eppendorf tube and incubated at 37 °C for 
20 hours while shaking at 500 RPM. The reactions were monitored by MALDI MS 
for the formation of the full-length CaM-like product (with the noted absence of 
Reagent Final Concentration Volume (μL)
CaM77-148  protein 2.4 mg/mL ---
10x Transfer Buffer 1x 50.0
E. coli total tRNA (10 mg/mL) 2 mg/mL 100.0
ATP (50 mM, dissolved in water) 2.5 mM 25.0
Hcm (52.8 mM, dissolved in water) 1.0 mM 9.5
L13G (1.52 mg/mL) 0.1 mg/mL 32.9
AaT (.44 mg/mL) 0.1 mg/mL 113.6
Water --- 106.5
Urea (12 M) 1 M 62.5
294	
	
Met78). The correct product mass (see Table 6-6) was observed in the reactions 
using ligation buffer A and B from above.   
Table	6-6:	CaM	masses	calculated	for	each	of	the	fragments	used	for	NCL	reactions.	The	full	length	Hcy72,76-
CaM1-148	product	was	not	observed	for	any	reaction	condition.	
	
 
 
Native Chemical Ligation of Hcm76-CaM76-148 to Hcy72-CaM1-75-MPAA 
NCL reactions for Hcm76-CaM76-148 ligation to Hcy72-CaM1-75-MPAA were 
performed using the identical reaction conditions and stoichiometry (1:3 of Hcy72-
CaM1-75-MPAA to Hcm76-CaM76-148) from buffer A and buffer B conditions (see 
above). It should be noted that the buffer contains TCEP, which will reduce the 
Hcm residue to the active, nucleophilic Hcy residue for NCL to proceed (this 
reduction confirmed by monitoring the reaction with MALDI MS; see Table 6-6). 
However, under identical reaction conditions as the above Cys77-CaM77-148 ligation, 
no product was formed. An increase in pH may be necessary to form more of the 
nucleophilic thiolate species on Hcy for the reaction to proceed. Therefore, the 
NCL reaction was set up again using buffer B with a modified pH of 7.8. Again, 
CaM Variant Calculated m/z [M+H]+ Observed m/z
CaM1-71-MES 7955 7977 ([M+Na]
+)
Hcy72-CaM72-75-N2H3 505.65 505.44
Hcy72-CaM1-75-N2H3 8318 8318
Hcy72-CaM1-75-MPAA 8454 8453
CaM77-148 8277 8277
Cys77-CaM77-148 8251 8251
Hcm76-CaM76-148 8440 8440
Hcy76-CaM76-148 8394 8396
Hcy72,76-CaM1-148 16679 Not Observed
ΔMet76, Hcy72, Cys77-CaM1-148 16537 16537
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after 20 hours, no product was observed by MALDI MS, despite the reactive 
species (Hcy72-CaM1-75-MPAA and Hcy76-CaM76-148) persisting in the reaction. In 
an attempt to change the conformation of CaM to potentially make the reactive 
sites more accessible, the reaction using buffer B were performed again, with 
either 100 mM CaCl2 or 10 mM EDTA. Again, no product was detected by MALDI 
MS. In a final test, buffer B had 2% v/v thiophenol added to it and the reaction was 
repeated. Thophenol may be able to serve as an added catalyst for the reaction 
and to suppress the hydrolysis of Hcy72-CaM1-75-MPAA. The reaction failed to yield 
full-length Hcy72,76-CaM1-148, as observed by MALDI MS. 
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